diff --git "a/data/tdr.csv" "b/data/tdr.csv"
deleted file mode 100644--- "a/data/tdr.csv"
+++ /dev/null
@@ -1,1213 +0,0 @@
-#,Journal,Year,Therapeutic Area,Paper Title,Paper Link,Study Protocol Link,Protocol+SAP / SAP Link,SAP Doc Type,Trial Design,NCT ID,PMID,Notes,Lead Sponsor,Sponsor Class,Collaborators,Keep?,Verified?,Statistician,Statistician Title,Statistician Employer,Statistician Profile URL,Statistician Confidence,Statistician Source,Statistician Notes
-1,NEJM,2026,Cardiovascular,Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease,https://doi.org/10.1056/nejmoa2511478,,https://cdn.clinicaltrials.gov/large-docs/68/NCT04078568/SAP_005.pdf,SAP,fixed_parallel_superiority,NCT04078568,41985133,Ph3 | single | treatment,Children's Hospital of Fudan University,Academic/Other,Jiangxi Province Children's Hospital; First People's Hospital of Hangzhou; Shengjing Hospital; The First Hospital of Jilin University; Chengdu Women's and Children's Central Hospital; (+9 more),?,Y,Yalan Dou,Trial Statistician,Children's Hospital of Fudan University,https://cdn.clinicaltrials.gov/large-docs/76/NCT04806776/SAP_000.pdf,High,Web-search,"Yalan Dou is explicitly listed as Trial Statistician in multiple clinical trial documents (SAP, protocols)."
-2,NEJM,2026,Infectious Disease,"Immunogenicity and Safety of vYF, a Yellow Fever Vaccine - A Phase 2 Trial",https://doi.org/10.1056/nejmoa2505665,https://cdn.clinicaltrials.gov/large-docs/10/NCT04942210/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/10/NCT04942210/SAP_001.pdf,SAP,noninferiority,NCT04942210,41950474,Ph2 | quadruple | prevention,"Sanofi Pasteur, a Sanofi Company",Industry,,?,Y,,,,,None,,
-3,NEJM,2026,Hematology,A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia,https://doi.org/10.1056/nejmoa2513120,https://cdn.clinicaltrials.gov/large-docs/24/NCT04278924/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/24/NCT04278924/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04278924,41950473,Ph2 | quadruple | treatment,Takeda,Industry,,?,Y,,,,,None,,
-4,NEJM,2026,Oncology,Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer,https://doi.org/10.1056/nejmoa2507874,https://cdn.clinicaltrials.gov/large-docs/59/NCT02912559/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/59/NCT02912559/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02912559,41880612,Ph3 | treatment,National Cancer Institute (NCI),NIH,,?,Y,Fang-Shu Ou ; Tyler Zemla,Biostatistics (per PubMed affiliation),"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN. ; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-5,NEJM,2026,Oncology,Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia,https://doi.org/10.1056/nejmoa2511882,https://cdn.clinicaltrials.gov/large-docs/77/NCT03362177/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/77/NCT03362177/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03362177,41812193,Ph3 | double | treatment,Amgen,Industry,,?,Y,Kejia Wang,Biostatistics (per PubMed affiliation),"Biostatistics, Amgen, Thousand Oaks, CA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-6,NEJM,2026,Neurology,An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1,https://doi.org/10.1056/nejmoa2407326,https://cdn.clinicaltrials.gov/large-docs/69/NCT05027269/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/69/NCT05027269/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05027269,41707138,Ph1/Ph2 | quadruple | treatment,"Avidity Biosciences, Inc.",Industry,,?,Y,,,,,None,,
-7,NEJM,2026,Oncology,"Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer",https://doi.org/10.1056/nejmoa2511218,https://cdn.clinicaltrials.gov/large-docs/85/NCT02947685/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/85/NCT02947685/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02947685,41604639,Ph3 | treatment,"Alliance Foundation Trials, LLC.",Academic/Other,"Pfizer; GBG Forschungs GmbH; Fondazione Michelangelo; PrECOG, LLC.; Breast Cancer Trials, Australia and New Zealand; (+3 more)",?,Y,Sumithra Mandrekar ; Travis Dockter,Biostatistics (per PubMed affiliation),"Alliance Foundation Trials Statistics and Data Center, Mayo Clinic, Rochester, MN. ; Alliance Foundation Trials Statistics and Data Center, Mayo Clinic, Rochester, MN.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-8,NEJM,2026,Neurology,Fremanezumab in Children and Adolescents with Episodic Migraine,https://doi.org/10.1056/nejmoa2504546,https://cdn.clinicaltrials.gov/large-docs/57/NCT04458857/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/57/NCT04458857/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT04458857,41534042,Ph3 | quadruple | treatment,"Teva Branded Pharmaceutical Products R&D, Inc.",Industry,,?,Y,Steve Barash,"Director, Global Statistics",Teva Pharmaceutical,https://www.zoominfo.com/p/Steve-Barash/-2042369296,High,Web-search,"Steve Barash is listed as Director, Global Statistics at Teva Pharmaceutical."
-9,NEJM,2026,Respiratory,Ketamine or Etomidate for Tracheal Intubation of Critically Ill Adults,https://doi.org/10.1056/nejmoa2511420,https://cdn.clinicaltrials.gov/large-docs/96/NCT05277896/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/96/NCT05277896/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT05277896,41369227,Ph4 | treatment,Vanderbilt University Medical Center,Academic/Other,"National Heart, Lung, and Blood Institute (NHLBI); Patient-Centered Outcomes Research Institute",?,Y,Brant Imhoff ; Li Wang,Biostatistics (per PubMed affiliation),"Department of Biostatistics, Vanderbilt University Medical Center, Nashville. ; Department of Biostatistics, Vanderbilt University Medical Center, Nashville.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-10,NEJM,2026,Cardiovascular,Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years,https://doi.org/10.1056/nejmoa2509766,https://cdn.clinicaltrials.gov/large-docs/14/NCT02675114/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/14/NCT02675114/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02675114,41144631,NA | treatment,Edwards Lifesciences,Industry,,?,Y,,,,,None,,
-11,NEJM,2026,Oncology,Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer,https://doi.org/10.1056/nejmoa2510310,https://cdn.clinicaltrials.gov/large-docs/37/NCT02319837/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/37/NCT02319837/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02319837,41124201,Ph3 | treatment,Pfizer,Industry,"Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",?,Y,,,,,None,,
-12,NEJM,2026,Oncology,Nivolumab for Resected Stage III or IV Melanoma at 9 Years,https://doi.org/10.1056/nejmoa2504966,https://cdn.clinicaltrials.gov/large-docs/06/NCT02388906/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/06/NCT02388906/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02388906,41124198,Ph3 | quadruple | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,,,,,None,,
-13,NEJM,2026,Oncology,Survival with Osimertinib plus Chemotherapy in <i>EGFR</i>-Mutated Advanced NSCLC,https://doi.org/10.1056/nejmoa2510308,https://cdn.clinicaltrials.gov/large-docs/86/NCT04035486/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/86/NCT04035486/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT04035486,41104938,Ph3 | treatment,AstraZeneca,Industry,,?,Y,Helen Mann,Biostatistics (per PubMed affiliation),"Oncology Biometrics, AstraZeneca, Cambridge, United Kingdom.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-14,NEJM,2025,Nephrology/Urology,Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN,https://doi.org/10.1056/nejmoa2501510,https://cdn.clinicaltrials.gov/large-docs/27/NCT05067127/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/27/NCT05067127/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05067127,41337715,Ph3 | triple | treatment,"Apellis Pharmaceuticals, Inc.",Industry,,?,Y,,,,,None,,
-15,NEJM,2025,Infectious Disease,Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model,https://doi.org/10.1056/nejmoa2500179,https://cdn.clinicaltrials.gov/large-docs/75/NCT05048875/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/75/NCT05048875/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT05048875,41297006,Ph2 | triple | prevention,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"Janssen, LP; National Institutes of Health (NIH)",?,Y,Liesbeth Van Wesenbeeck,,Johnson & Johnson,https://www.researchgate.net/publication/383430531_The_IL-6_Hypothesis_in_COVID-19_A_Phase_2_Randomised_Double-blind_Placebo-controlled_Study_to_Evaluate_the_Efficacy_and_Safety_of_Free_IL-6_Sequestration_by_the_Monoclonal_Antibody_Sirukumab_in_Severe,Medium,Web-search,"Liesbeth Van Wesenbeeck is listed alongside a statistician in a trial protocol snippet, suggesting a biostatistics role."
-16,NEJM,2025,Rheumatology/Immunology,A Randomized Trial of Physical Therapy for Meniscal Tear and Knee Pain,https://doi.org/10.1056/nejmoa2503385,,https://cdn.clinicaltrials.gov/large-docs/04/NCT03059004/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT03059004,41160820,NA | single | treatment,Brigham and Women's Hospital,Academic/Other,National Institutes of Health (NIH); State University of New York at Buffalo; The Cleveland Clinic; University of Pittsburgh; University of Melbourne; (+1 more),?,Y,,,,,None,,
-17,NEJM,2025,Infectious Disease,Mass Administration of Azithromycin to Infants in Mali to Reduce Mortality,https://doi.org/10.1056/nejmoa2504644,https://cdn.clinicaltrials.gov/large-docs/11/NCT04424511/Prot_SAP_ICF_002.pdf,https://cdn.clinicaltrials.gov/large-docs/11/NCT04424511/Prot_SAP_ICF_002.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04424511,41092331,Ph3 | quadruple | treatment,Tampere University,Academic/Other,"Center for Vaccine Development CVD-Mali, Bamako, Mali; University College London Hospitals; Tro Da Ltd, UK; Duke-NUS Graduate Medical School; Bill and Melinda Gates Foundation; (+1 more)",?,Y,,,,,None,,
-18,NEJM,2025,Infectious Disease,Randomized Trial of Targeted Indoor Spraying to Prevent Aedes-Borne Diseases,https://doi.org/10.1056/nejmoa2501069,https://cdn.clinicaltrials.gov/large-docs/21/NCT04343521/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/21/NCT04343521/Prot_SAP_001.pdf,Protocol+SAP,cluster,NCT04343521,41061233,NA | prevention,Emory University,Academic/Other,National Institute of Allergy and Infectious Diseases (NIAID),?,Y,Shirin Jabbarzadeh ; M Elizabeth Halloran,Biostatistics (per PubMed affiliation),"Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta. ; Department of Biostatistics, University of Washington, Seattle.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-19,NEJM,2025,Cardiovascular,Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis,https://doi.org/10.1056/nejmoa2508170,https://cdn.clinicaltrials.gov/large-docs/92/NCT04811092/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/92/NCT04811092/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04811092,41025556,Ph3 | double | treatment,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",Industry,,?,Y,Yaru Shi,"Principal Scientist, Biostatistics",Merck,https://www.linkedin.com/in/yaru-shi-4b5818bb,High,Web-search,"Yaru Shi is explicitly listed as Principal Scientist, Biostatistics at Merck. Wei Fu is also a Principal Scientist."
-20,NEJM,2025,Infectious Disease,Clesrovimab for Prevention of RSV Disease in Healthy Infants,https://doi.org/10.1056/nejmoa2502984,https://cdn.clinicaltrials.gov/large-docs/73/NCT04767373/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/73/NCT04767373/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04767373,40961446,Ph2/Ph3 | double | prevention,Merck Sharp & Dohme LLC,Industry,,?,Y,Radha A Railkar,"Sr. Director, Biostatistics",Merck,https://www.researchgate.net/profile/Radha-Railkar-2,High,Web-search,"Radha A Railkar is listed as Sr. Director, Biostatistics at Merck & Co. on ResearchGate."
-21,NEJM,2025,Oncology,Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer,https://doi.org/10.1056/nejmoa2504650,https://cdn.clinicaltrials.gov/large-docs/99/NCT02647099/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/99/NCT02647099/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT02647099,40961426,Ph3 | quadruple | treatment,Anna Martling,Academic/Other,Uppsala University Hospital; Skane University Hospital,?,Y,Henrik Grönberg ; Martin Eklund,Biostatistics (per PubMed affiliation),"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm. ; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-22,NEJM,2025,Endocrinology/Metabolism,Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity,https://doi.org/10.1056/nejmoa2500969,https://cdn.clinicaltrials.gov/large-docs/17/NCT05564117/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/17/NCT05564117/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05564117,40934115,Ph3 | quadruple | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-23,NEJM,2025,Oncology,Overall Survival with Amivantamab-Lazertinib in <i>EGFR</i>-Mutated Advanced NSCLC,https://doi.org/10.1056/nejmoa2503001,https://cdn.clinicaltrials.gov/large-docs/80/NCT04487080/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/80/NCT04487080/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04487080,40923797,Ph3 | triple | treatment,"Janssen Research & Development, LLC",Industry,,?,Y,Tao Sun,"Scientific Director, Biostatistics",Johnson & Johnson,https://www.linkedin.com/in/tao-sun-0853a8345,High,Web-search,"LinkedIn profile confirms Tao Sun is Scientific Director, Biostatistics at Johnson & Johnson."
-24,NEJM,2025,Cardiovascular,Home-Based Care for Hypertension in Rural South Africa,https://doi.org/10.1056/nejmoa2509958,https://cdn.clinicaltrials.gov/large-docs/55/NCT05492955/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/55/NCT05492955/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05492955,40888742,NA | treatment,Brigham and Women's Hospital,Academic/Other,,?,Y,,,,,None,,
-25,NEJM,2025,Respiratory,Apixaban for Extended Treatment of Provoked Venous Thromboembolism,https://doi.org/10.1056/nejmoa2509426,https://cdn.clinicaltrials.gov/large-docs/03/NCT04168203/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/03/NCT04168203/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04168203,40888734,Ph4 | quadruple | treatment,Brigham and Women's Hospital,Academic/Other,,?,Y,,,,,None,,
-26,NEJM,2025,Respiratory,Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis,https://doi.org/10.1056/nejmoa2410542,https://cdn.clinicaltrials.gov/large-docs/93/NCT04544293/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/93/NCT04544293/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04544293,40834301,Ph3 | quadruple | treatment,Savara Inc.,Industry,,?,Y,,,,,None,,
-27,NEJM,2025,Endocrinology/Metabolism,"Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes",https://doi.org/10.1056/nejmoa2505669,https://cdn.clinicaltrials.gov/large-docs/40/NCT05971940/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/40/NCT05971940/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05971940,40544435,Ph3 | double | treatment,Eli Lilly and Company,Industry,,?,Y,Sarah Eyde,Statistical Advisor,Eli Lilly and Company,https://rocketreach.co/sarah-eyde-email_558591165,High,Web-search,Sarah Eyde is a Statistical Advisor at Eli Lilly and was previously a Principal Biostatistician.
-28,NEJM,2025,Oncology,Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer,https://doi.org/10.1056/nejmoa2415434,https://cdn.clinicaltrials.gov/large-docs/18/NCT03765918/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/18/NCT03765918/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03765918,40532178,Ph3 | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Cole Manschot,Biostatistician,Merck,https://www.linkedin.com/in/cole-manschot-46832690,High,Web-search,"Cole Manschot is a Biostatistician at Merck, confirmed by LinkedIn and multiple publications."
-29,NEJM,2025,Respiratory,Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation,https://doi.org/10.1056/nejmoa2505708,https://cdn.clinicaltrials.gov/large-docs/92/NCT02447692/Prot_003.pdf,https://cdn.clinicaltrials.gov/large-docs/92/NCT02447692/SAP_006.pdf,SAP,fixed_parallel_superiority,NCT02447692,40513024,NA | supportive care,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,Academic/Other,Canadian Institutes of Health Research (CIHR); Medtronic; Canadian Critical Care Trials Group,?,Y,Kevin E Thorpe,Biostatistics (per PubMed affiliation),"Biostatistics Division, Dalla Lana School of Public Health, University of Toronto, Toronto.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-30,NEJM,2025,Oncology,Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy,https://doi.org/10.1056/nejmoa2502099,https://cdn.clinicaltrials.gov/large-docs/66/NCT05740566/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/66/NCT05740566/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05740566,40454646,Ph3 | treatment,Amgen,Industry,,?,Y,Tony Jiang,Director of Biostatistics,Amgen,https://theorg.com/org/astellas-pharma/org-chart/tony-jiang,High,Web-search,Tony Jiang is identified as a Director of Biostatistics at Amgen.
-31,NEJM,2025,Oncology,"Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer",https://doi.org/10.1056/nejmoa2505725,https://cdn.clinicaltrials.gov/large-docs/23/NCT05654623/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/23/NCT05654623/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05654623,40454645,Ph3 | treatment,Pfizer,Industry,"Arvinas Estrogen Receptor, Inc.",?,Y,Dongrui R Lu,Biostatistics,Pfizer,https://pubmed.ncbi.nlm.nih.gov/39072356/,Medium,Web-search,Dongrui R Lu's affiliation is listed as Biostatistics at Pfizer Inc.
-32,NEJM,2025,Oncology,Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer,https://doi.org/10.1056/nejmoa2502931,https://cdn.clinicaltrials.gov/large-docs/28/NCT02998528/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/28/NCT02998528/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02998528,40454642,Ph3 | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,Lily Wang,Division of Biostatistics,Bristol Myers Squibb,https://pubmed.ncbi.nlm.nih.gov/39815633/,High,Web-search,Lily Wang is listed as being in the Division of Biostatistics at Bristol Myers Squibb in a recent publication.
-33,NEJM,2025,Oncology,Overall Survival with Inavolisib in <i>PIK3CA</i>-Mutated Advanced Breast Cancer,https://doi.org/10.1056/nejmoa2501796,https://cdn.clinicaltrials.gov/large-docs/99/NCT04191499/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/99/NCT04191499/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04191499,40454641,Ph2/Ph3 | double | treatment,Hoffmann-La Roche,Industry,,?,Y,,,,,None,,
-34,NEJM,2025,Oncology,Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer,https://doi.org/10.1056/nejmoa2415566,https://cdn.clinicaltrials.gov/large-docs/96/NCT05587296/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/96/NCT05587296/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05587296,40454634,Ph3 | double | treatment,Bayer,Industry,,?,Y,Nazanin Haseli-Mashhadi,MSc(Statistics),Bayer,https://pmc.ncbi.nlm.nih.gov/articles/PMC11342219/,High,Web-search,Nazanin Haseli Mashhadi is listed as MSc(Statistics) and affiliated with Statistics and Data at Bayer.
-35,NEJM,2025,Oncology,Structured Exercise after Adjuvant Chemotherapy for Colon Cancer,https://doi.org/10.1056/nejmoa2502760,https://cdn.clinicaltrials.gov/large-docs/08/NCT00819208/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/08/NCT00819208/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT00819208,40450658,NA | other,Canadian Cancer Trials Group,Network/Cooperative,"Survivorship Research Group; Queen's University, Belfast",?,Y,,,,,None,,
-36,NEJM,2025,Respiratory,As-Needed Albuterol-Budesonide in Mild Asthma,https://doi.org/10.1056/nejmoa2504544,https://cdn.clinicaltrials.gov/large-docs/34/NCT05505734/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/34/NCT05505734/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05505734,40388330,Ph3 | double | treatment,Bond Avillion 2 Development LP,Industry,Parexel,?,Y,Lynn Dunsire,Statistical Science Director,AstraZeneca,https://rocketreach.co/lynn-dunsire-email_3917951,High,Web-search,Lynn Dunsire is a Statistical Science Director at AstraZeneca.
-37,NEJM,2025,Respiratory,Nerandomilast in Patients with Progressive Pulmonary Fibrosis,https://doi.org/10.1056/nejmoa2503643,https://cdn.clinicaltrials.gov/large-docs/82/NCT05321082/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/82/NCT05321082/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05321082,40388329,Ph3 | quadruple | treatment,Boehringer Ingelheim,Industry,,?,Y,Hui Gu ; Florian Voss,Biostatistics (per PubMed affiliation),"Global Biostatistics and Data Sciences, Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT. ; Global Biostatistics and Data Sciences, Boehringer Ingelheim Pharma, Ingelheim am Rhein, Germany.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-38,NEJM,2025,Respiratory,Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis,https://doi.org/10.1056/nejmoa2414108,https://cdn.clinicaltrials.gov/large-docs/69/NCT05321069/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/69/NCT05321069/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05321069,40387033,Ph3 | quadruple | treatment,Boehringer Ingelheim,Industry,,?,Y,Daniel Wachtlin ; Yi Liu,Biostatistics (per PubMed affiliation),"Department of Biostatistics and Data Sciences, Boehringer Ingelheim Pharma, Ingelheim am Rhein, Germany. ; Department of Biostatistics and Data Sciences, Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-39,NEJM,2025,Rheumatology/Immunology,"Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1",https://doi.org/10.1056/nejmoa2405847,https://cdn.clinicaltrials.gov/large-docs/03/NCT05687903/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/03/NCT05687903/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05687903,40367374,Ph2 | double | treatment,Takeda,Industry,,?,Y,,,,,None,,
-40,NEJM,2025,Cardiovascular,Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk,https://doi.org/10.1056/nejmoa2415820,https://cdn.clinicaltrials.gov/large-docs/22/NCT05142722/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/22/NCT05142722/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05142722,40337982,Ph3 | quadruple | treatment,NewAmsterdam Pharma,Industry,,?,Y,Violeta Balinskaite,Senior Biostatistician,Medpace,https://uk.linkedin.com/in/violetabalinskaite,High,Web-search,LinkedIn and Medpace blog confirm Violeta Balinskaite is a Senior Biostatistician at Medpace.
-41,NEJM,2025,Infectious Disease,BCG Revaccination for the Prevention of &lt;i&gt;Mycobacterium tuberculosis&lt;/i&gt; Infection,https://doi.org/10.1056/nejmoa2412381,https://cdn.clinicaltrials.gov/large-docs/61/NCT04152161/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/61/NCT04152161/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04152161,40334156,Ph2 | triple | prevention,Gates Medical Research Institute,Academic/Other,,?,Y,,,,,None,,
-42,NEJM,2025,Respiratory,Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype,https://doi.org/10.1056/nejmoa2413181,https://cdn.clinicaltrials.gov/large-docs/09/NCT04133909/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/09/NCT04133909/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04133909,40305712,Ph3 | double | treatment,GlaxoSmithKline,Industry,"PPD Development, LP",?,Y,Bhabita Mayer,Biostatistics (per PubMed affiliation),"Biostatistics, GSK, London.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-43,NEJM,2025,Infectious Disease,Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza,https://doi.org/10.1056/nejmoa2413156,https://cdn.clinicaltrials.gov/large-docs/12/NCT03969212/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/12/NCT03969212/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03969212,40267424,Ph3 | double | treatment,Hoffmann-La Roche,Industry,,?,Y,Corrado Bernasconi,Senior Biostatistician,F. Hoffmann-La Roche,https://indivi.io/for-professionals,High,Web-search,Corrado Bernasconi is explicitly listed as Head of Biostatistics and former Senior Biostatistician at F. Hoffmann-La Roche.
-44,NEJM,2025,Respiratory,Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis,https://doi.org/10.1056/nejmoa2411664,https://cdn.clinicaltrials.gov/large-docs/69/NCT04594369/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/69/NCT04594369/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04594369,40267423,Ph3 | double | treatment,Insmed Incorporated,Industry,,?,Y,,,,,None,,
-45,NEJM,2025,Infectious Disease,Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo,https://doi.org/10.1056/nejmoa2412439,https://cdn.clinicaltrials.gov/large-docs/99/NCT05559099/Prot_003.pdf,https://cdn.clinicaltrials.gov/large-docs/99/NCT05559099/SAP_005.pdf,SAP,fixed_parallel_superiority,NCT05559099,40239067,Ph2 | quadruple | treatment,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo",?,Y,,,,,None,,
-46,NEJM,2025,Neurology,Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis,https://doi.org/10.1056/nejmoa2415988,https://cdn.clinicaltrials.gov/large-docs/41/NCT04411641/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/41/NCT04411641/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04411641,40202696,Ph3 | triple | treatment,Sanofi,Industry,,?,Y,,,,,None,,
-47,NEJM,2025,Neurology,Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis,https://doi.org/10.1056/nejmoa2415985,https://cdn.clinicaltrials.gov/large-docs/78/NCT04410978/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/78/NCT04410978/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT04410978, NCT04410991",40202623,Ph3 | triple | treatment,Sanofi,Industry,,?,Y,Yixin Chen,"Director, Senior Statistical Project Leader",Sanofi,https://www.linkedin.com/in/yixin-chen-02360b57,High,Web-search,"Yixin Chen is Director, Senior Statistical Project Leader at Sanofi."
-48,NEJM,2025,Other,A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis,https://doi.org/10.1056/nejmoa2501561,https://cdn.clinicaltrials.gov/large-docs/73/NCT04524273/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/73/NCT04524273/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04524273,40202593,Ph3 | quadruple | treatment,Amgen,Industry,,?,Y,,,,,None,,
-49,NEJM,2025,Cardiovascular,A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis,https://doi.org/10.1056/nejmoa2413449,https://cdn.clinicaltrials.gov/large-docs/02/NCT03725202/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/02/NCT03725202/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03725202,40174237,Ph3 | quadruple | treatment,AbbVie,Industry,,?,Y,Peter A Merkel,Biostatistics (per PubMed affiliation),"Division of Rheumatology, Department of Medicine, and the Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-50,NEJM,2025,Cardiovascular,Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death,https://doi.org/10.1056/nejmoa2415160,https://cdn.clinicaltrials.gov/large-docs/08/NCT04896008/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/08/NCT04896008/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04896008,40167274,Ph3 | triple | treatment,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",Industry,,?,Y,Yaru Shi,"Principal Scientist, Biostatistics",Merck,https://www.linkedin.com/in/yaru-shi-4b5818bb,High,Web-search,Yaru Shi is a Principal Scientist in Biostatistics at Merck. Barry Miller is also a biostatistician at Merck.
-51,NEJM,2025,Cardiovascular,Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a),https://doi.org/10.1056/nejmoa2415818,https://cdn.clinicaltrials.gov/large-docs/42/NCT05565742/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/42/NCT05565742/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT05565742,40162643,Ph2 | double | treatment,Eli Lilly and Company,Industry,,?,Y,Kathy Wolski,Lead Biostatistician,Cleveland Clinic,https://www.linkedin.com/in/kathy-wolski-97842226,High,Web-search,Kathy Wolski is listed as Lead Biostatistician at Cleveland Clinic. Qiuqing Wang is also a Lead Biostatistician.
-52,NEJM,2025,Cardiovascular,Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes,https://doi.org/10.1056/nejmoa2501006,https://cdn.clinicaltrials.gov/large-docs/26/NCT03914326/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/26/NCT03914326/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03914326,40162642,Ph3 | quadruple | treatment,Novo Nordisk A/S,Industry,,?,Y,Scott S Emerson,Biostatistics (per PubMed affiliation),"Department of Biostatistics, University of Washington, Seattle.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-53,NEJM,2025,Cardiovascular,Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation,https://doi.org/10.1056/nejmoa2500366,https://cdn.clinicaltrials.gov/large-docs/85/NCT04696185/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/85/NCT04696185/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04696185,40162639,Ph4 | single | treatment,Spanish Society of Cardiology,Academic/Other,Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III,?,Y,,,,,None,,
-54,NEJM,2025,Other,Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps,https://doi.org/10.1056/nejmoa2414482,https://cdn.clinicaltrials.gov/large-docs/64/NCT04851964/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/64/NCT04851964/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04851964,40106374,Ph3 | quadruple | treatment,AstraZeneca,Industry,Amgen,?,Y,Claudia Chen ; Åsa Hellqvist,Biostatistics (per PubMed affiliation),"Biometrics, Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD. ; Biometrics, Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-55,NEJM,2025,Endocrinology/Metabolism,A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes,https://doi.org/10.1056/nejmoa2415948,https://cdn.clinicaltrials.gov/large-docs/32/NCT05785832/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/32/NCT05785832/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT05785832,40105270,NA | treatment,"Tandem Diabetes Care, Inc.",Industry,Jaeb Center for Health Research,?,Y,,,,,None,,
-56,NEJM,2025,Dermatology,Remibrutinib in Chronic Spontaneous Urticaria,https://doi.org/10.1056/nejmoa2408792,https://cdn.clinicaltrials.gov/large-docs/11/NCT05030311/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/11/NCT05030311/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT05030311, NCT05032157",40043237,Ph3 | quadruple | treatment,Novartis Pharmaceuticals,Industry,,?,Y,Karine Lheritier,Statistician,Novartis,https://www.researchgate.net/profile/Karine-Lheritier,High,Web-search,Karine Lheritier is explicitly listed as a Statistician at Novartis on ResearchGate and LinkedIn.
-57,NEJM,2025,Infectious Disease,Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis,https://doi.org/10.1056/nejmoa2410965,https://cdn.clinicaltrials.gov/large-docs/77/NCT04221477/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/77/NCT04221477/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04221477,39927615,Ph3 | double | treatment,Hoffmann-La Roche,Industry,,?,Y,,,,,None,,
-58,NEJM,2025,Cardiovascular,Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation,https://doi.org/10.1056/nejmoa2406674,https://cdn.clinicaltrials.gov/large-docs/83/NCT04755283/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/83/NCT04755283/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04755283,39842011,Ph2 | triple | supportive care,"Anthos Therapeutics, Inc.",Industry,Novartis Pharmaceuticals,?,Y,,,,,None,,
-59,NEJM,2025,Oncology,Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer,https://doi.org/10.1056/nejmoa2406070,https://cdn.clinicaltrials.gov/large-docs/72/NCT01772472/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/72/NCT01772472/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT01772472,39813643,Ph3 | treatment,Hoffmann-La Roche,Industry,NSABP Foundation Inc; GBG Forschungs GmbH,?,Y,,,,,None,,
-60,NEJM,2025,Oncology,Imlunestrant with or without Abemaciclib in Advanced Breast Cancer,https://doi.org/10.1056/nejmoa2410858,https://cdn.clinicaltrials.gov/large-docs/08/NCT04975308/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/08/NCT04975308/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04975308,39660834,Ph3 | treatment,Eli Lilly and Company,Industry,,?,Y,,,,,None,,
-61,NEJM,2025,Oncology,Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma,https://doi.org/10.1056/nejmoa2409029,https://cdn.clinicaltrials.gov/large-docs/20/NCT03301220/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/20/NCT03301220/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03301220,39652675,Ph3 | treatment,"Janssen Research & Development, LLC",Industry,,?,Y,Linlin Sha,Senior Biostatistician,The Janssen Pharmaceutical Companies of Johnson & Johnson,https://stat.fsu.edu/alumni,High,Web-search,Linlin Sha is listed as a Senior Biostatistician at Janssen on the FSU alumni page.
-62,NEJM,2025,Infectious Disease,Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons,https://doi.org/10.1056/nejmoa2411858,https://cdn.clinicaltrials.gov/large-docs/52/NCT04925752/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/52/NCT04925752/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04925752,39602624,Ph3 | double | prevention,Gilead Sciences,Industry,,?,Y,,,,,None,,
-63,NEJM,2025,Cardiovascular,Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity,https://doi.org/10.1056/nejmoa2410027,https://cdn.clinicaltrials.gov/large-docs/57/NCT04847557/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/57/NCT04847557/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04847557,39555826,Ph3 | double | treatment,Eli Lilly and Company,Industry,,?,Y,,,,,None,,
-64,NEJM,2025,Other,Inebilizumab for Treatment of IgG4-Related Disease,https://doi.org/10.1056/nejmoa2409712,https://cdn.clinicaltrials.gov/large-docs/97/NCT04540497/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/97/NCT04540497/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04540497,39541094,Ph3 | quadruple | treatment,Amgen,Industry,,?,Y,Yanping Wu,Senior Director Biostatistics (Rare Disease),Amgen,https://www.signalhire.com/profiles/tadcha-nujak%27s-email/190526384,High,Web-search,Yanping Wu is Senior Director Biostatistics (Rare Disease) at Amgen. Xinxin Dong is also a biostatistician at Amgen.
-65,NEJM,2025,Endocrinology/Metabolism,Tirzepatide for Obesity Treatment and Diabetes Prevention,https://doi.org/10.1056/nejmoa2410819,https://cdn.clinicaltrials.gov/large-docs/22/NCT04184622/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/22/NCT04184622/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04184622,39536238,Ph3 | double | treatment,Eli Lilly and Company,Industry,,?,Y,Shuyu Zhang,statistician,Eli Lilly,https://www.sciencedirect.com/science/article/pii/S1526590010003871,High,Web-search,Shuyu Zhang is explicitly identified as 'the company statistician' at Eli Lilly in a publication.
-66,NEJM,2025,Cardiovascular,Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease,https://doi.org/10.1056/nejmoa2409183,https://cdn.clinicaltrials.gov/large-docs/10/NCT03594110/Prot_006.pdf,https://cdn.clinicaltrials.gov/large-docs/10/NCT03594110/SAP_008.pdf,SAP,fixed_parallel_superiority,NCT03594110,39453837,Ph3 | double | treatment,Boehringer Ingelheim,Industry,University of Oxford; Eli Lilly and Company,?,Y,Sibylle J Hauske,Global Biostatistics & Data Sciences,Boehringer Ingelheim,https://www.kireports.org/article/S2468-0249(24)00255-9/fulltext,Medium,Web-search,Sibylle Hauske is affiliated with Global Biostatistics & Data Sciences at Boehringer Ingelheim.
-67,NEJM,2025,Oncology,Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors,https://doi.org/10.1056/nejmoa2403991,https://cdn.clinicaltrials.gov/large-docs/20/NCT03375320/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/20/NCT03375320/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03375320,39282913,Ph3 | double | treatment,National Cancer Institute (NCI),NIH,,?,Y,Susan Geyer ; Tyler Zemla,Biostatistics (per PubMed affiliation),"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN. ; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-68,NEJM,2025,Gastroenterology/Hepatology,Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk,https://doi.org/10.1056/nejmoa2409368,https://cdn.clinicaltrials.gov/large-docs/84/NCT05089084/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/84/NCT05089084/SAP_002.pdf,SAP,factorial,NCT05089084,39225259,Ph3 | quadruple | treatment,Arrowhead Pharmaceuticals,Industry,,?,Y,,,,,None,,
-69,NEJM,2025,Cardiovascular,Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy,https://doi.org/10.1056/nejmoa2409134,https://cdn.clinicaltrials.gov/large-docs/49/NCT04153149/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/49/NCT04153149/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT04153149,39213194,Ph3 | quadruple | treatment,Alnylam Pharmaceuticals,Industry,,?,Y,,,,,None,,
-70,NEJM,2024,Infectious Disease,Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B,https://doi.org/10.1056/nejmoa2405485,https://cdn.clinicaltrials.gov/large-docs/15/NCT04225715/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/15/NCT04225715/SAP_001.pdf,SAP,platform,NCT04225715,39774313,Ph2 | treatment,Hoffmann-La Roche,Industry,,?,Y,,,,,None,,
-71,NEJM,2024,Oncology,Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer,https://doi.org/10.1056/nejmoa2402141,https://cdn.clinicaltrials.gov/large-docs/30/NCT04008030/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/30/NCT04008030/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04008030,39602630,Ph3 | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,,,,,None,,
-72,NEJM,2024,Oncology,Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer,https://doi.org/10.1056/nejmoa2401497,https://cdn.clinicaltrials.gov/large-docs/65/NCT01224665/Prot_SAP_ICF_000.pdf,https://cdn.clinicaltrials.gov/large-docs/65/NCT01224665/Prot_SAP_ICF_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01224665,39589370,NA | treatment,SWOG Cancer Research Network,Network/Cooperative,National Cancer Institute (NCI),?,Y,,,,,None,,
-73,NEJM,2024,Other,Middle Meningeal Artery Embolization for Nonacute Subdural Hematoma,https://doi.org/10.1056/nejmoa2401201,https://cdn.clinicaltrials.gov/large-docs/45/NCT04700345/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/45/NCT04700345/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04700345,39565989,NA | treatment,Huashan Hospital,Academic/Other,Shanghai Municipal Health Commission; Shanghai Shen Kang Hospital Development Center,?,Y,,,,,None,,
-74,NEJM,2024,Rheumatology/Immunology,Total Hip Replacement or Resistance Training for Severe Hip Osteoarthritis,https://doi.org/10.1056/nejmoa2400141,,https://cdn.clinicaltrials.gov/large-docs/27/NCT04070027/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT04070027,39476341,NA | double | treatment,Vejle Hospital,Academic/Other,Odense University Hospital; Naestved Hospital; Aarhus University Hospital; The Danish Rheumatism Association; Region of Southern Denmark; (+2 more),?,Y,,,,,None,,
-75,NEJM,2024,Oncology,Inavolisib-Based Therapy in &lt;i&gt;PIK3CA&lt;/i&gt;-Mutated Advanced Breast Cancer,https://doi.org/10.1056/nejmoa2404625,https://cdn.clinicaltrials.gov/large-docs/99/NCT04191499/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/99/NCT04191499/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04191499,39476340,Ph2/Ph3 | double | treatment,Hoffmann-La Roche,Industry,,?,Y,,,,,None,,
-76,NEJM,2024,Endocrinology/Metabolism,Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis,https://doi.org/10.1056/nejmoa2403664,https://cdn.clinicaltrials.gov/large-docs/35/NCT05064735/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/35/NCT05064735/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT05064735,39476339,Ph3 | triple | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-77,NEJM,2024,Oncology,Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma,https://doi.org/10.1056/nejmoa2405888,https://cdn.clinicaltrials.gov/large-docs/88/NCT03907488/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/88/NCT03907488/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03907488,39413375,Ph3 | treatment,National Cancer Institute (NCI),NIH,,?,Y,,,,,None,,
-78,NEJM,2024,Oncology,Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis,https://doi.org/10.1056/nejmoa2314076,https://cdn.clinicaltrials.gov/large-docs/97/NCT04996797/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/97/NCT04996797/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04996797,39321363,Ph2 | quadruple | treatment,"Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",Industry,,?,Y,,,,,None,,
-79,NEJM,2024,Other,Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia,https://doi.org/10.1056/nejmoa2312749,https://cdn.clinicaltrials.gov/large-docs/44/NCT03910244/Prot_004.pdf,https://cdn.clinicaltrials.gov/large-docs/44/NCT03910244/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03910244,39292928,Ph2 | quadruple | treatment,The Cleveland Clinic,Academic/Other,RTI International,?,Y,,,,,None,,
-80,NEJM,2024,Hematology,Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease,https://doi.org/10.1056/nejmoa2401537,https://cdn.clinicaltrials.gov/large-docs/76/NCT04710576/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/76/NCT04710576/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04710576,39292927,Ph2 | treatment,Syndax Pharmaceuticals,Industry,,?,Y,,,,,None,,
-81,NEJM,2024,Oncology,Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer,https://doi.org/10.1056/nejmoa2408154,https://cdn.clinicaltrials.gov/large-docs/77/NCT03732677/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/77/NCT03732677/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03732677,39282910,Ph3 | treatment,AstraZeneca,Industry,,?,Y,,,,,None,,
-82,NEJM,2024,Oncology,Ponsegromab for the Treatment of Cancer Cachexia,https://doi.org/10.1056/nejmoa2409515,https://cdn.clinicaltrials.gov/large-docs/76/NCT05546476/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/76/NCT05546476/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05546476,39282907,Ph2 | quadruple | treatment,Pfizer,Industry,,?,Y,,,,,None,,
-83,NEJM,2024,Oncology,Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer,https://doi.org/10.1056/nejmoa2407086,https://cdn.clinicaltrials.gov/large-docs/25/NCT04494425/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/25/NCT04494425/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT04494425,39282896,Ph3 | treatment,AstraZeneca,Industry,Daiichi Sankyo,?,Y,,,,,None,,
-84,NEJM,2024,Oncology,Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer,https://doi.org/10.1056/nejmoa2404873,https://cdn.clinicaltrials.gov/large-docs/97/NCT03703297/Prot_003.pdf,https://cdn.clinicaltrials.gov/large-docs/97/NCT03703297/SAP_004.pdf,SAP,fixed_parallel_superiority,NCT03703297,39268857,Ph3 | triple | treatment,AstraZeneca,Industry,,?,Y,,,,,None,,
-85,NEJM,2024,Respiratory,Long-Term Oxygen Therapy for 24 or 15 Hours per Day in Severe Hypoxemia,https://doi.org/10.1056/nejmoa2402638,,https://cdn.clinicaltrials.gov/large-docs/04/NCT03441204/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT03441204,39254466,Ph4 | treatment,Skane University Hospital,Academic/Other,Lund University; Blekinge County Council Hospital,?,Y,,,,,None,,
-86,NEJM,2024,Respiratory,Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype,https://doi.org/10.1056/nejmoa2406673,https://cdn.clinicaltrials.gov/large-docs/32/NCT04719832/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/32/NCT04719832/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT04719832, NCT04718103",39248309,Ph3 | double | treatment,GlaxoSmithKline,Industry,IQVIA Pty Ltd,?,Y,,,,,None,,
-87,NEJM,2024,Cardiovascular,Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke,https://doi.org/10.1056/nejmoa2314779,https://cdn.clinicaltrials.gov/large-docs/79/NCT03735979/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/79/NCT03735979/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03735979,39231343,Ph3 | double | treatment,Washington University School of Medicine,Academic/Other,National Institute of Neurological Disorders and Stroke (NINDS),?,Y,,,,,None,,
-88,NEJM,2024,Neurology,A Monoclonal Antibody to PACAP for Migraine Prevention,https://doi.org/10.1056/nejmoa2314577,https://cdn.clinicaltrials.gov/large-docs/23/NCT05133323/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/23/NCT05133323/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05133323,39231342,Ph2 | double | prevention,H. Lundbeck A/S,Industry,,?,Y,,,,,None,,
-89,NEJM,2024,Cardiovascular,Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction,https://doi.org/10.1056/nejmoa2407107,https://cdn.clinicaltrials.gov/large-docs/26/NCT04435626/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/26/NCT04435626/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04435626,39225278,Ph3 | quadruple | treatment,Bayer,Industry,,?,Y,Brian Claggett,chief statistician,Brigham and Women's Hospital,https://learn.hms.harvard.edu/about/leadership-faculty/faculty/brian-claggett,High,Web-search,Brian Claggett is explicitly identified as the chief statistician for the Cardiac Imaging Core Laboratory at Brigham.
-90,NEJM,2024,Oncology,Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma,https://doi.org/10.1056/nejmoa2313906,https://cdn.clinicaltrials.gov/large-docs/50/NCT04195750/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/50/NCT04195750/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04195750,39167807,Ph3 | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,,,,,None,,
-91,NEJM,2024,Infectious Disease,Azithromycin to Reduce Mortality - An Adaptive Cluster-Randomized Trial,https://doi.org/10.1056/nejmoa2312093,https://cdn.clinicaltrials.gov/large-docs/87/NCT04224987/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/87/NCT04224987/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04224987,39167806,Ph4 | quadruple | treatment,"University of California, San Francisco",Academic/Other,"Bill and Melinda Gates Foundation; Ministry of Health, Niger",?,Y,,,,,None,,
-92,NEJM,2024,Oncology,Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults,https://doi.org/10.1056/nejmoa2312948,https://cdn.clinicaltrials.gov/large-docs/22/NCT02003222/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/22/NCT02003222/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02003222,39047240,Ph3 | treatment,National Cancer Institute (NCI),NIH,Canadian Cancer Trials Group,?,Y,,,,,None,,
-93,NEJM,2024,Infectious Disease,Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women,https://doi.org/10.1056/nejmoa2407001,https://cdn.clinicaltrials.gov/large-docs/09/NCT04994509/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/09/NCT04994509/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04994509,39046157,Ph3 | double | prevention,Gilead Sciences,Industry,,?,Y,,,,,None,,
-94,NEJM,2024,Infectious Disease,Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19,https://doi.org/10.1056/nejmoa2309002,https://cdn.clinicaltrials.gov/large-docs/01/NCT05047601/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/01/NCT05047601/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05047601,39018532,Ph2/Ph3 | quadruple | prevention,Pfizer,Industry,,?,Y,,,,,None,,
-95,NEJM,2024,Oncology,Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer,https://doi.org/10.1056/nejmoa2313811,https://cdn.clinicaltrials.gov/large-docs/28/NCT04697628/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/28/NCT04697628/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04697628,38959480,Ph3 | treatment,"Seagen, a wholly owned subsidiary of Pfizer",Industry,Genmab,?,Y,,,,,None,,
-96,NEJM,2024,Oncology,Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i>-Mutated Advanced NSCLC,https://doi.org/10.1056/nejmoa2403614,https://cdn.clinicaltrials.gov/large-docs/80/NCT04487080/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/80/NCT04487080/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04487080,38924756,Ph3 | triple | treatment,"Janssen Research & Development, LLC",Industry,,?,Y,,,,,None,,
-97,NEJM,2024,Gastroenterology/Hepatology,Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis,https://doi.org/10.1056/nejmoa2313318,https://cdn.clinicaltrials.gov/large-docs/09/NCT04543409/Prot_004.pdf,https://cdn.clinicaltrials.gov/large-docs/09/NCT04543409/SAP_005.pdf,SAP,fixed_parallel_superiority,NCT04543409,38924732,Ph3 | triple | treatment,AstraZeneca,Industry,,?,Y,,,,,None,,
-98,NEJM,2024,Gastroenterology/Hepatology,Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age,https://doi.org/10.1056/nejmoa2312282,https://cdn.clinicaltrials.gov/large-docs/51/NCT04394351/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/51/NCT04394351/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT04394351,38924731,Ph3 | quadruple | treatment,Regeneron Pharmaceuticals,Industry,Sanofi,?,Y,,,,,None,,
-99,NEJM,2024,Respiratory,Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity,https://doi.org/10.1056/nejmoa2404881,https://cdn.clinicaltrials.gov/large-docs/04/NCT05412004/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/04/NCT05412004/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05412004,38912654,Ph3 | double | treatment,Eli Lilly and Company,Industry,,?,Y,,,,,None,,
-100,NEJM,2024,Oncology,Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma,https://doi.org/10.1056/nejmoa2404139,https://cdn.clinicaltrials.gov/large-docs/83/NCT01682083/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/83/NCT01682083/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT01682083,38899716,Ph3 | double | treatment,Novartis Pharmaceuticals,Industry,,?,Y,,,,,None,,
-101,NEJM,2024,Infectious Disease,Community-Based Cluster-Randomized Trial to Reduce Opioid Overdose Deaths,https://doi.org/10.1056/nejmoa2401177,https://cdn.clinicaltrials.gov/large-docs/39/NCT04111939/Prot_003.pdf,https://cdn.clinicaltrials.gov/large-docs/39/NCT04111939/SAP_001.pdf,SAP,cluster,NCT04111939,38884347,NA | health services research,RTI International,Academic/Other,Boston Medical Center; Columbia University; Ohio State University; University of Kentucky; National Institute on Drug Abuse (NIDA); (+1 more),?,Y,,,,,None,,
-102,NEJM,2024,Infectious Disease,Stress Ulcer Prophylaxis during Invasive Mechanical Ventilation,https://doi.org/10.1056/nejmoa2404245,https://cdn.clinicaltrials.gov/large-docs/00/NCT03374800/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/00/NCT03374800/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03374800,38875111,Ph3 | quadruple | prevention,McMaster University,Academic/Other,"Canadian Institutes of Health Research (CIHR); Canadian Critical Care Trials Group; Australian and New Zealand Intensive Care Society Clinical Trials Group; National Health and Medical Research Council, Australia",?,Y,,,,,None,,
-103,NEJM,2024,Respiratory,Noninvasive Ventilation for Preoxygenation during Emergency Intubation,https://doi.org/10.1056/nejmoa2313680,https://cdn.clinicaltrials.gov/large-docs/52/NCT05267652/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/52/NCT05267652/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT05267652,38869091,NA | treatment,Vanderbilt University Medical Center,Academic/Other,"University of Colorado, Denver",?,Y,,,,,None,,
-104,NEJM,2024,Infectious Disease,Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis,https://doi.org/10.1056/nejmoa2401943,https://cdn.clinicaltrials.gov/large-docs/73/NCT04166773/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/73/NCT04166773/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04166773,38856224,Ph2 | double | treatment,Eli Lilly and Company,Industry,,?,Y,,,,,None,,
-105,NEJM,2024,Infectious Disease,A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis,https://doi.org/10.1056/nejmoa2401755,https://cdn.clinicaltrials.gov/large-docs/73/NCT04771273/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/73/NCT04771273/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04771273,38847460,Ph2 | quadruple | treatment,Boehringer Ingelheim,Industry,,?,Y,,,,,None,,
-106,NEJM,2024,Infectious Disease,Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D,https://doi.org/10.1056/nejmoa2314134,https://cdn.clinicaltrials.gov/large-docs/33/NCT03852433/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/33/NCT03852433/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03852433,38842520,Ph2 | treatment,Gilead Sciences,Industry,,?,Y,,,,,None,,
-107,NEJM,2024,Neurology,Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia,https://doi.org/10.1056/nejmoa2404656,https://cdn.clinicaltrials.gov/large-docs/15/NCT04490915/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/15/NCT04490915/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04490915,38828955,Ph3 | triple | treatment,Neurocrine Biosciences,Industry,,?,Y,,,,,None,,
-108,NEJM,2024,Oncology,"Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma",https://doi.org/10.1056/nejmoa2403407,https://cdn.clinicaltrials.gov/large-docs/23/NCT04484623/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/23/NCT04484623/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04484623,38828951,Ph3 | treatment,GlaxoSmithKline,Industry,,?,Y,,,,,None,,
-109,NEJM,2024,Oncology,Osimertinib after Chemoradiotherapy in Stage III &lt;i&gt;EGFR&lt;/i&gt;-Mutated NSCLC,https://doi.org/10.1056/nejmoa2402614,https://cdn.clinicaltrials.gov/large-docs/54/NCT03521154/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/54/NCT03521154/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03521154,38828946,Ph3 | double | treatment,AstraZeneca,Industry,,?,Y,,,,,None,,
-110,NEJM,2024,Neurology,Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia,https://doi.org/10.1056/nejmoa2404655,https://cdn.clinicaltrials.gov/large-docs/51/NCT04806451/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/51/NCT04806451/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04806451,38828945,Ph3 | triple | treatment,Neurocrine Biosciences,Industry,,?,Y,,,,,None,,
-111,NEJM,2024,Oncology,"Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma",https://doi.org/10.1056/nejmoa2405090,https://cdn.clinicaltrials.gov/large-docs/47/NCT04246047/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/47/NCT04246047/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04246047,38828933,Ph3 | treatment,GlaxoSmithKline,Industry,,?,Y,,,,,None,,
-112,NEJM,2024,Oncology,Asciminib in Newly Diagnosed Chronic Myeloid Leukemia,https://doi.org/10.1056/nejmoa2400858,https://cdn.clinicaltrials.gov/large-docs/26/NCT04971226/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/26/NCT04971226/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04971226,38820078,Ph3 | treatment,Novartis Pharmaceuticals,Industry,,?,Y,,,,,None,,
-113,NEJM,2024,Other,Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks,https://doi.org/10.1056/nejmoa2314192,https://cdn.clinicaltrials.gov/large-docs/17/NCT05259917/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/17/NCT05259917/SAP_001.pdf,SAP,crossover,NCT05259917,38819658,Ph3 | double | treatment,"KalVista Pharmaceuticals, Ltd.",Industry,,?,Y,,,,,None,,
-114,NEJM,2024,Pediatrics,Efficacy and Safety of Donidalorsen for Hereditary Angioedema,https://doi.org/10.1056/nejmoa2402478,https://cdn.clinicaltrials.gov/large-docs/10/NCT05139810/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/10/NCT05139810/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT05139810,38819395,Ph3 | quadruple | treatment,"Ionis Pharmaceuticals, Inc.",Industry,,?,Y,,,,,None,,
-115,NEJM,2024,Endocrinology/Metabolism,"Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia",https://doi.org/10.1056/nejmoa2404147,https://cdn.clinicaltrials.gov/large-docs/71/NCT04832971/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/71/NCT04832971/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04832971,38809174,Ph2 | quadruple | treatment,Arrowhead Pharmaceuticals,Industry,,?,Y,,,,,None,,
-116,NEJM,2024,Endocrinology/Metabolism,"Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia",https://doi.org/10.1056/nejmoa2404143,https://cdn.clinicaltrials.gov/large-docs/01/NCT04998201/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/01/NCT04998201/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04998201,38804517,Ph2 | quadruple | treatment,Arrowhead Pharmaceuticals,Industry,,?,Y,,,,,None,,
-117,NEJM,2024,Cardiovascular,Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes,https://doi.org/10.1056/nejmoa2403347,https://cdn.clinicaltrials.gov/large-docs/53/NCT03819153/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/53/NCT03819153/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03819153,38785209,Ph3 | quadruple | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-118,NEJM,2024,Respiratory,Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation,https://doi.org/10.1056/nejmoa2401304,https://cdn.clinicaltrials.gov/large-docs/73/NCT04456673/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/73/NCT04456673/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04456673,38767614,Ph3 | quadruple | treatment,Sanofi,Industry,Regeneron Pharmaceuticals,?,Y,,,,,None,,
-119,NEJM,2024,Oncology,Perioperative Nivolumab in Resectable Lung Cancer,https://doi.org/10.1056/nejmoa2311926,https://cdn.clinicaltrials.gov/large-docs/79/NCT04025879/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/79/NCT04025879/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04025879,38749033,Ph3 | double | treatment,Bristol-Myers Squibb,Industry,,?,Y,,,,,None,,
-120,NEJM,2024,Cardiovascular,Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage,https://doi.org/10.1056/nejmoa2313040,https://cdn.clinicaltrials.gov/large-docs/28/NCT03661528/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/28/NCT03661528/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03661528,38749032,Ph4 | single | treatment,"Alexion Pharmaceuticals, Inc.",Industry,,?,Y,Lizhen Xu,Statistician,Population Health Research Institute,https://www.researchgate.net/profile/Lizhen-Xu,High,Web-search,Lizhen Xu (L.X.) is explicitly identified as a Statistician at the Population Health Research Institute.
-121,NEJM,2024,Cardiovascular,Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy,https://doi.org/10.1056/nejmoa2401424,https://cdn.clinicaltrials.gov/large-docs/18/NCT05186818/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/18/NCT05186818/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05186818,38739079,Ph3 | double | treatment,Cytokinetics,Industry,Corxel Pharmaceuticals,?,Y,,,,,None,,
-122,NEJM,2024,Pediatrics,Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura,https://doi.org/10.1056/nejmoa2314793,https://cdn.clinicaltrials.gov/large-docs/75/NCT03393975/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/75/NCT03393975/SAP_001.pdf,SAP,crossover,NCT03393975,38692292,Ph3 | prevention,Baxalta now part of Shire,Industry,"Takeda Development Center Americas, Inc.",?,Y,,,,,None,,
-123,NEJM,2024,Infectious Disease,Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria,https://doi.org/10.1056/nejmoa2312775,https://cdn.clinicaltrials.gov/large-docs/11/NCT05304611/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/11/NCT05304611/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT05304611,38669354,Ph2 | triple | prevention,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"National Institutes of Health (NIH); Malaria Research and Training Center, Bamako, Mali; University of the Sciences, Techniques and Technologies of Bamako; University of Washington; Harvard School of Public Health (HSPH); (+1 more)",?,Y,,,,,None,,
-124,NEJM,2024,Oncology,Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma,https://doi.org/10.1056/nejmoa2312695,https://cdn.clinicaltrials.gov/large-docs/34/NCT03142334/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/34/NCT03142334/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03142334,38631003,Ph3 | quadruple | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,,,,,None,,
-125,NEJM,2024,Oncology,Alectinib in Resected <i>ALK</i>-Positive Non-Small-Cell Lung Cancer,https://doi.org/10.1056/nejmoa2310532,https://cdn.clinicaltrials.gov/large-docs/76/NCT03456076/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/76/NCT03456076/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03456076,38598794,Ph3 | treatment,Hoffmann-La Roche,Industry,,?,Y,,,,,None,,
-126,NEJM,2024,Cardiovascular,Pragmatic Trial of Hospitalization Rate in Chronic Kidney Disease,https://doi.org/10.1056/nejmoa2311708,https://cdn.clinicaltrials.gov/large-docs/36/NCT02587936/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/36/NCT02587936/Prot_SAP_001.pdf,Protocol+SAP,cluster,NCT02587936,38598574,NA | other,University of Texas Southwestern Medical Center,Academic/Other,Parkland Center for Clinical Innovation; Parkland Health and Hospital System; Texas Health Resources; Connecticut Center for Primary Care; Dallas VA Research Corporation; (+4 more),?,Y,,,,,None,,
-127,NEJM,2024,Infectious Disease,Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19,https://doi.org/10.1056/nejmoa2309003,https://cdn.clinicaltrials.gov/large-docs/13/NCT05011513/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/13/NCT05011513/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05011513,38598573,Ph2/Ph3 | quadruple | treatment,Pfizer,Industry,,?,Y,,,,,None,,
-128,NEJM,2024,Cardiovascular,Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus,https://doi.org/10.1056/nejmoa2312573,https://cdn.clinicaltrials.gov/large-docs/50/NCT04722250/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/50/NCT04722250/SAP_001.pdf,SAP,noninferiority,NCT04722250,38587261,NA | treatment,Medtronic Cardiovascular,Industry,,?,Y,,,,,None,,
-129,NEJM,2024,Cardiovascular,Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction,https://doi.org/10.1056/nejmoa2400969,https://cdn.clinicaltrials.gov/large-docs/23/NCT03473223/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/23/NCT03473223/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03473223,38587254,Ph3 | quadruple | prevention,CSL Behring,Industry,,?,Y,,,,,None,,
-130,NEJM,2024,Cardiovascular,Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk,https://doi.org/10.1056/nejmoa2402309,https://cdn.clinicaltrials.gov/large-docs/02/NCT05355402/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/02/NCT05355402/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT05355402,38587249,Ph2 | quadruple | treatment,"Ionis Pharmaceuticals, Inc.",Industry,,?,Y,,,,,None,,
-131,NEJM,2024,Gastroenterology/Hepatology,"Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome",https://doi.org/10.1056/nejmoa2400201,https://cdn.clinicaltrials.gov/large-docs/34/NCT04568434/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/34/NCT04568434/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04568434,38587247,Ph3 | double | treatment,"Ionis Pharmaceuticals, Inc.",Industry,,?,Y,,,,,None,,
-132,NEJM,2024,Cardiovascular,Empagliflozin after Acute Myocardial Infarction,https://doi.org/10.1056/nejmoa2314051,https://cdn.clinicaltrials.gov/large-docs/74/NCT04509674/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/74/NCT04509674/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04509674,38587237,Ph3 | quadruple | treatment,Boehringer Ingelheim,Industry,Eli Lilly and Company,?,Y,,,,,None,,
-133,NEJM,2024,Infectious Disease,RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes,https://doi.org/10.1056/nejmoa2305478,https://cdn.clinicaltrials.gov/large-docs/59/NCT04605159/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/59/NCT04605159/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04605159,38477988,Ph3 | quadruple | prevention,GlaxoSmithKline,Industry,,?,Y,,,,,None,,
-134,NEJM,2024,Oncology,Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer,https://doi.org/10.1056/nejmoa2312117,https://cdn.clinicaltrials.gov/large-docs/56/NCT04223856/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/56/NCT04223856/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04223856,38446675,Ph3 | treatment,"Astellas Pharma Global Development, Inc.",Industry,Merck Sharp & Dohme LLC; Seagen Inc.,?,Y,,,,,None,,
-135,NEJM,2024,Oncology,Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer,https://doi.org/10.1056/nejmoa2308900,https://cdn.clinicaltrials.gov/large-docs/30/NCT01658930/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/30/NCT01658930/SAP_001.pdf,SAP,noninferiority,NCT01658930,38416430,NA | treatment,Canadian Cancer Trials Group,Network/Cooperative,Gynecologic Cancer Intergroup (GCIG); Canadian Institutes of Health Research (CIHR); Korean Gynecologic Oncology Group; Dutch Gynaecological Oncology Group; Cancer Trials Ireland; (+8 more),?,Y,,,,,None,,
-136,NEJM,2024,Pediatrics,Omalizumab for the Treatment of Multiple Food Allergies,https://doi.org/10.1056/nejmoa2312382,https://cdn.clinicaltrials.gov/large-docs/96/NCT03881696/Prot_003.pdf,https://cdn.clinicaltrials.gov/large-docs/96/NCT03881696/SAP_004.pdf,SAP,fixed_parallel_superiority,NCT03881696,38407394,Ph3 | triple | treatment,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"Genentech, Inc.; Novartis Pharmaceuticals; Rho Federal Systems Division, Inc.",?,Y,,,,,None,,
-137,NEJM,2024,Rheumatology/Immunology,Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis,https://doi.org/10.1056/nejmoa2311155,https://cdn.clinicaltrials.gov/large-docs/48/NCT04157348/Prot_012.pdf,https://cdn.clinicaltrials.gov/large-docs/48/NCT04157348/SAP_013.pdf,SAP,noninferiority,NCT04157348,38393328,Ph3 | triple | treatment,AstraZeneca,Industry,,?,Y,,,,,None,,
-138,NEJM,2024,Gastroenterology/Hepatology,A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis,https://doi.org/10.1056/nejmoa2312100,https://cdn.clinicaltrials.gov/large-docs/33/NCT04620733/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/33/NCT04620733/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04620733,38381664,Ph3 | double | treatment,Gilead Sciences,Industry,,?,Y,,,,,None,,
-139,NEJM,2024,Infectious Disease,Cefepime-Taniborbactam in Complicated Urinary Tract Infection,https://doi.org/10.1056/nejmoa2304748,https://cdn.clinicaltrials.gov/large-docs/48/NCT03840148/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/48/NCT03840148/SAP_001.pdf,SAP,noninferiority,NCT03840148,38354140,Ph3 | double | treatment,"Venatorx Pharmaceuticals, Inc.",Industry,,?,Y,,,,,None,,
-140,NEJM,2024,Neurology,Inhibition of CD40L with Frexalimab in Multiple Sclerosis,https://doi.org/10.1056/nejmoa2309439,https://cdn.clinicaltrials.gov/large-docs/28/NCT04879628/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/28/NCT04879628/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04879628,38354138,Ph2 | quadruple | treatment,Sanofi,Industry,,?,Y,,,,,None,,
-141,NEJM,2024,Cardiovascular,Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection,https://doi.org/10.1056/nejmoa2310392,https://cdn.clinicaltrials.gov/large-docs/78/NCT03785678/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/78/NCT03785678/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03785678,38329148,Ph3 | quadruple | treatment,"Genentech, Inc.",Industry,,?,Y,,,,,None,,
-142,NEJM,2024,Dermatology,An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis,https://doi.org/10.1056/nejmoa2308713,https://cdn.clinicaltrials.gov/large-docs/68/NCT05223868/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/68/NCT05223868/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05223868,38324484,Ph2 | double | treatment,"Janssen Research & Development, LLC",Industry,,?,Y,,,,,None,,
-143,NEJM,2024,Infectious Disease,Skin Antisepsis before Surgical Fixation of Extremity Fractures,https://doi.org/10.1056/nejmoa2307679,https://cdn.clinicaltrials.gov/large-docs/62/NCT03523962/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/62/NCT03523962/SAP_001.pdf,SAP,crossover;cluster,NCT03523962,38294973,Ph4 | single | treatment,"University of Maryland, Baltimore",Academic/Other,McMaster University; Patient-Centered Outcomes Research Institute,?,Y,,,,,None,,
-144,NEJM,2024,Pediatrics,Azithromycin during Routine Well-Infant Visits to Prevent Death,https://doi.org/10.1056/nejmoa2309495,https://cdn.clinicaltrials.gov/large-docs/64/NCT03676764/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/64/NCT03676764/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03676764,38231623,Ph4 | quadruple | prevention,"University of California, San Francisco",Academic/Other,"Centre de Recherche en Sante de Nouna, Burkina Faso; Bill and Melinda Gates Foundation",?,Y,,,,,None,,
-145,NEJM,2024,Cardiovascular,Testosterone Treatment and Fractures in Men with Hypogonadism,https://doi.org/10.1056/nejmoa2308836,https://cdn.clinicaltrials.gov/large-docs/34/NCT03518034/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/34/NCT03518034/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03518034,38231621,Ph4 | quadruple | treatment,AbbVie,Industry,"Endo Pharmaceuticals; Acerus Pharmaceuticals Corporation; Allergan Sales, LLC; Upsher-Smith Laboratories",?,Y,,,,,None,,
-146,NEJM,2024,Cardiovascular,Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy,https://doi.org/10.1056/nejmoa2305434,https://cdn.clinicaltrials.gov/large-docs/35/NCT03860935/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/35/NCT03860935/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03860935,38197816,Ph3 | quadruple | treatment,"Eidos Therapeutics, a BridgeBio company",Industry,,?,Y,,,,,None,,
-147,NEJM,2024,Obstetrics/Gynecology,Effects of Cooking with Liquefied Petroleum Gas or Biomass on Stunting in Infants,https://doi.org/10.1056/nejmoa2302687,,https://cdn.clinicaltrials.gov/large-docs/82/NCT02944682/SAP_010.pdf,SAP,fixed_parallel_superiority,NCT02944682,38169489,NA | prevention,Emory University,Academic/Other,"National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI); Bill and Melinda Gates Foundation; Berkeley Air Monitoring Group; Colorado State University; (+14 more)",?,Y,,,,,None,,
-148,NEJM,2024,Infectious Disease,Liquefied Petroleum Gas or Biomass Cooking and Severe Infant Pneumonia,https://doi.org/10.1056/nejmoa2305681,,https://cdn.clinicaltrials.gov/large-docs/82/NCT02944682/SAP_010.pdf,SAP,fixed_parallel_superiority,NCT02944682,38169488,NA | prevention,Emory University,Academic/Other,"National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI); Bill and Melinda Gates Foundation; Berkeley Air Monitoring Group; Colorado State University; (+14 more)",?,Y,,,,,None,,
-149,NEJM,2024,Oncology,"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma",https://doi.org/10.1056/nejmoa2312054,https://cdn.clinicaltrials.gov/large-docs/03/NCT03710603/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/03/NCT03710603/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03710603,38084760,Ph3 | treatment,Stichting European Myeloma Network,Network/Cooperative,"Janssen Research & Development, LLC",?,Y,,,,,None,,
-150,NEJM,2024,Gastroenterology/Hepatology,Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis,https://doi.org/10.1056/nejmoa2306185,https://cdn.clinicaltrials.gov/large-docs/65/NCT04526665/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/65/NCT04526665/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04526665,37962077,Ph3 | quadruple | treatment,Ipsen,Industry,,?,Y,,,,,None,,
-151,NEJM,2024,Oncology,A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy,https://doi.org/10.1056/nejmoa2305635,https://cdn.clinicaltrials.gov/large-docs/85/NCT04287985/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/85/NCT04287985/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT04287985,37916620,Ph2 | quadruple | treatment,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Industry,,?,Y,,,,,None,,
-152,NEJM,2024,Cardiovascular,Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease,https://doi.org/10.1056/nejmoa2305637,https://cdn.clinicaltrials.gov/large-docs/99/NCT04227899/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/99/NCT04227899/SAP_003.pdf,SAP,noninferiority,NCT04227899,37888915,NA | single | treatment,Abbott Medical Devices,Industry,,?,Y,,,,,None,,
-153,NEJM,2023,Infectious Disease,Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants,https://doi.org/10.1056/nejmoa2309189,https://cdn.clinicaltrials.gov/large-docs/10/NCT05437510/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/10/NCT05437510/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05437510,38157500,Ph3 | prevention,"Sanofi Pasteur, a Sanofi Company",Industry,AstraZeneca,?,Y,,,,,None,,
-154,NEJM,2023,Infectious Disease,Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in Women,https://doi.org/10.1056/nejmoa2304007,https://cdn.clinicaltrials.gov/large-docs/40/NCT04050540/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/40/NCT04050540/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04050540,38118022,Ph4 | prevention,University of Washington,Academic/Other,"Kenya Medical Research Institute; Kenya National AIDS & STI Control Programme; University of California, San Francisco; National Institute of Allergy and Infectious Diseases (NIAID)",?,Y,,,,,None,,
-155,NEJM,2023,Oncology,"Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer",https://doi.org/10.1056/nejmoa2309169,https://cdn.clinicaltrials.gov/large-docs/55/NCT04209855/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/55/NCT04209855/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04209855,38055253,Ph3 | treatment,AbbVie,Industry,Gynecologic Oncology Group; European Network of Gynaecological Oncological Trial Groups (ENGOT),?,Y,,,,,None,,
-156,NEJM,2023,Cardiovascular,Intravenous Levothyroxine for Unstable Brain-Dead Heart Donors,https://doi.org/10.1056/nejmoa2305969,https://cdn.clinicaltrials.gov/large-docs/58/NCT04415658/Prot_003.pdf,https://cdn.clinicaltrials.gov/large-docs/58/NCT04415658/Prot_SAP_005.pdf,Protocol+SAP,noninferiority,NCT04415658,38048188,Ph3 | treatment,Washington University School of Medicine,Academic/Other,Mid-America Transplant,?,Y,,,,,None,,
-157,NEJM,2023,Neurology,Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease,https://doi.org/10.1056/nejmoa2304430,https://cdn.clinicaltrials.gov/large-docs/70/NCT03444870/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/70/NCT03444870/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT03444870, NCT03443973",37966285,Ph3 | double | treatment,Hoffmann-La Roche,Industry,,?,Y,,,,,None,,
-158,NEJM,2023,Cardiovascular,Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia,https://doi.org/10.1056/nejmoa2307983,https://cdn.clinicaltrials.gov/large-docs/07/NCT02981407/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/07/NCT02981407/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT02981407,37952133,Ph3 | single | treatment,"Rutgers, The State University of New Jersey",Academic/Other,"University of Pittsburgh; National Heart, Lung, and Blood Institute (NHLBI)",?,Y,,,,,None,,
-159,NEJM,2023,Cardiovascular,Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes,https://doi.org/10.1056/nejmoa2307563,https://cdn.clinicaltrials.gov/large-docs/97/NCT03574597/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/97/NCT03574597/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03574597,37952131,Ph3 | quadruple | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-160,NEJM,2023,Oncology,Osimertinib with or without Chemotherapy in <i>EGFR</i>-Mutated Advanced NSCLC,https://doi.org/10.1056/nejmoa2306434,https://cdn.clinicaltrials.gov/large-docs/86/NCT04035486/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/86/NCT04035486/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT04035486,37937763,Ph3 | treatment,AstraZeneca,Industry,,?,Y,,,,,None,,
-161,NEJM,2023,Pediatrics,Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis,https://doi.org/10.1056/nejmoa2308550,https://cdn.clinicaltrials.gov/large-docs/85/NCT03493685/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/85/NCT03493685/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03493685,37921461,Ph3 | double | treatment,"Travere Therapeutics, Inc.",Industry,,?,Y,,,,,None,,
-162,NEJM,2023,Dermatology,Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis,https://doi.org/10.1056/nejmoa2301333,https://cdn.clinicaltrials.gov/large-docs/79/NCT04501679/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/79/NCT04501679/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04501679,37888917,Ph3 | double | treatment,Galderma R&D,Industry,,?,Y,,,,,None,,
-163,NEJM,2023,Cardiovascular,Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis,https://doi.org/10.1056/nejmoa2300757,https://cdn.clinicaltrials.gov/large-docs/83/NCT03997383/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/83/NCT03997383/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03997383,37888916,Ph3 | quadruple | treatment,Alnylam Pharmaceuticals,Industry,,?,Y,,,,,None,,
-164,NEJM,2023,Cardiovascular,Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years,https://doi.org/10.1056/nejmoa2307447,https://cdn.clinicaltrials.gov/large-docs/14/NCT02675114/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/14/NCT02675114/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02675114,37874020,NA | treatment,Edwards Lifesciences,Industry,,?,Y,,,,,None,,
-165,NEJM,2023,Oncology,Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions,https://doi.org/10.1056/nejmoa2306441,https://cdn.clinicaltrials.gov/large-docs/64/NCT04538664/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/64/NCT04538664/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04538664,37870976,Ph3 | treatment,"Janssen Research & Development, LLC",Industry,,?,Y,,,,,None,,
-166,NEJM,2023,Oncology,First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion-Positive NSCLC,https://doi.org/10.1056/nejmoa2309457,https://cdn.clinicaltrials.gov/large-docs/44/NCT04194944/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/44/NCT04194944/SAP_001.pdf,SAP,crossover,NCT04194944,37870973,Ph3 | treatment,Eli Lilly and Company,Industry,"Loxo Oncology, Inc.",?,Y,,,,,None,,
-167,NEJM,2023,Oncology,Phase 3 Trial of Selpercatinib in Advanced <i>RET</i>-Mutant Medullary Thyroid Cancer,https://doi.org/10.1056/nejmoa2309719,https://cdn.clinicaltrials.gov/large-docs/37/NCT04211337/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/37/NCT04211337/SAP_001.pdf,SAP,crossover,NCT04211337,37870969,Ph3 | treatment,"Loxo Oncology, Inc.",Industry,Eli Lilly and Company,?,Y,,,,,None,,
-168,NEJM,2023,Oncology,Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma,https://doi.org/10.1056/nejmoa2304753,https://cdn.clinicaltrials.gov/large-docs/92/NCT03070392/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/92/NCT03070392/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03070392,37870955,Ph2 | treatment,Immunocore Ltd,Industry,,?,Y,,,,,None,,
-169,NEJM,2023,Oncology,Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma,https://doi.org/10.1056/nejmoa2309863,https://cdn.clinicaltrials.gov/large-docs/98/NCT03036098/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/98/NCT03036098/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03036098,37870949,Ph3 | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,,,,,None,,
-170,NEJM,2023,Oncology,Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma,https://doi.org/10.1056/nejmoa2308849,https://cdn.clinicaltrials.gov/large-docs/04/NCT03390504/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/04/NCT03390504/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03390504,37870920,Ph3 | treatment,"Janssen Research & Development, LLC",Industry,,?,Y,,,,,None,,
-171,NEJM,2023,Endocrinology/Metabolism,Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes,https://doi.org/10.1056/nejmoa2308743,https://cdn.clinicaltrials.gov/large-docs/29/NCT03875729/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/29/NCT03875729/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03875729,37861217,Ph3 | quadruple | treatment,"Provention Bio, Inc.",Industry,,?,Y,,,,,None,,
-172,NEJM,2023,Oncology,Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer,https://doi.org/10.1056/nejmoa2303974,https://cdn.clinicaltrials.gov/large-docs/37/NCT02319837/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/37/NCT02319837/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02319837,37851874,Ph3 | treatment,Pfizer,Industry,"Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",?,Y,,,,,None,,
-173,NEJM,2023,Infectious Disease,Decolonization in Nursing Homes to Prevent Infection and Hospitalization,https://doi.org/10.1056/nejmoa2215254,https://cdn.clinicaltrials.gov/large-docs/32/NCT03118232/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/32/NCT03118232/Prot_SAP_000.pdf,Protocol+SAP,cluster,NCT03118232,37815935,Ph4 | prevention,"University of California, Irvine",Academic/Other,"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; University of Massachusetts, Amherst; Agency for Healthcare Research and Quality (AHRQ)",?,Y,,,,,None,,
-174,NEJM,2023,Psychiatry/Mental Health,Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression,https://doi.org/10.1056/nejmoa2304145,https://cdn.clinicaltrials.gov/large-docs/21/NCT04338321/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/21/NCT04338321/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04338321,37792613,Ph3 | treatment,Janssen-Cilag International NV,Industry,,?,Y,,,,,None,,
-175,NEJM,2023,Other,Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper,https://doi.org/10.1056/nejmoa2303452,https://cdn.clinicaltrials.gov/large-docs/18/NCT03600818/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/18/NCT03600818/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03600818,37792612,Ph3 | quadruple | treatment,Sanofi,Industry,Regeneron Pharmaceuticals,?,Y,,,,,None,,
-176,NEJM,2023,Infectious Disease,Ceftobiprole for Treatment of Complicated &lt;i&gt;Staphylococcus aureus&lt;/i&gt; Bacteremia,https://doi.org/10.1056/nejmoa2300220,https://cdn.clinicaltrials.gov/large-docs/33/NCT03138733/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/33/NCT03138733/SAP_001.pdf,SAP,noninferiority,NCT03138733,37754204,Ph3 | quadruple | treatment,Basilea Pharmaceutica,Industry,Department of Health and Human Services,?,Y,,,,,None,,
-177,NEJM,2023,Oncology,Dabrafenib plus Trametinib in Pediatric Glioma with <i>BRAF</i> V600 Mutations,https://doi.org/10.1056/nejmoa2303815,https://cdn.clinicaltrials.gov/large-docs/58/NCT02684058/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/58/NCT02684058/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT02684058,37733309,Ph2 | treatment,Novartis Pharmaceuticals,Industry,,?,Y,,,,,None,,
-178,NEJM,2023,Infectious Disease,Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19,https://doi.org/10.1056/nejmoa2209421,https://cdn.clinicaltrials.gov/large-docs/30/NCT04885530/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/30/NCT04885530/Prot_SAP_000.pdf,Protocol+SAP,platform,NCT04885530,37733308,Ph3 | double | treatment,"Susanna Naggie, MD",Academic/Other,National Center for Advancing Translational Sciences (NCATS); Vanderbilt University Medical Center,?,Y,,,,,None,,
-179,NEJM,2023,Hematology,Phase 3 Trial of Concizumab in Hemophilia with Inhibitors,https://doi.org/10.1056/nejmoa2216455,https://cdn.clinicaltrials.gov/large-docs/81/NCT04083781/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/81/NCT04083781/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04083781,37646676,Ph3 | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-180,NEJM,2023,Cardiovascular,Optical Coherence Tomography-Guided versus Angiography-Guided PCI,https://doi.org/10.1056/nejmoa2305861,https://cdn.clinicaltrials.gov/large-docs/77/NCT03507777/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/77/NCT03507777/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03507777,37634188,NA | double | treatment,Abbott Medical Devices,Industry,Abbott,?,Y,,,,,None,,
-181,NEJM,2023,Cardiovascular,Ferric Carboxymaltose in Heart Failure with Iron Deficiency,https://doi.org/10.1056/nejmoa2304968,https://cdn.clinicaltrials.gov/large-docs/31/NCT03037931/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/31/NCT03037931/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03037931,37632463,Ph3 | double | treatment,"American Regent, Inc.",Industry,Duke Clinical Research Institute,?,Y,,,,,None,,
-182,NEJM,2023,Cardiovascular,Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity,https://doi.org/10.1056/nejmoa2306963,https://cdn.clinicaltrials.gov/large-docs/11/NCT04788511/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/11/NCT04788511/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT04788511,37622681,Ph3 | double | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-183,NEJM,2023,Cardiovascular,Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes,https://doi.org/10.1056/nejmoa2303062,https://cdn.clinicaltrials.gov/large-docs/77/NCT02618577/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/77/NCT02618577/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02618577,37622677,Ph3 | double | prevention,Atrial Fibrillation Network,Academic/Other,"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company; Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)",?,Y,,,,,None,,
-184,NEJM,2023,Oncology,Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression,https://doi.org/10.1056/nejmoa2300184,https://cdn.clinicaltrials.gov/large-docs/33/NCT00958633/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/33/NCT00958633/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT00958633,37530824,Ph3 | double | treatment,University of British Columbia,Academic/Other,Canadian Institutes of Health Research (CIHR); GlaxoSmithKline; Lundbeck Canada Inc.; Lupin Limited,?,Y,,,,,None,,
-185,NEJM,2023,Surgery/Critical Care,Selective Inhibition of Na<sub>V</sub>1.8 with VX-548 for Acute Pain,https://doi.org/10.1056/nejmoa2209870,https://cdn.clinicaltrials.gov/large-docs/36/NCT04977336/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/36/NCT04977336/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT04977336, NCT05034952",37530822,Ph2 | quadruple | treatment,Vertex Pharmaceuticals Incorporated,Industry,,?,Y,,,,,None,,
-186,NEJM,2023,Gastroenterology/Hepatology,Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1,https://doi.org/10.1056/nejmoa2301940,https://cdn.clinicaltrials.gov/large-docs/60/NCT04096560/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/60/NCT04096560/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT04096560, NCT04820842",37494485,Ph2 | quadruple | treatment,Takeda,Industry,,?,Y,,,,,None,,
-187,NEJM,2023,Cardiovascular,Pitavastatin to Prevent Cardiovascular Disease in HIV Infection,https://doi.org/10.1056/nejmoa2304146,https://cdn.clinicaltrials.gov/large-docs/90/NCT02344290/Prot_ICF_003.pdf,https://cdn.clinicaltrials.gov/large-docs/90/NCT02344290/SAP_005.pdf,SAP,fixed_parallel_superiority,NCT02344290,37486775,Ph3 | quadruple | prevention,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"National Heart, Lung, and Blood Institute (NHLBI); Kowa Pharmaceuticals America, Inc.; Gilead Sciences; Massachusetts General Hospital; NEAT ID Foundation",?,Y,,,,,None,,
-188,NEJM,2023,Neurology,Trial of Solanezumab in Preclinical Alzheimer's Disease,https://doi.org/10.1056/nejmoa2305032,https://cdn.clinicaltrials.gov/large-docs/57/NCT02008357/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/57/NCT02008357/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02008357,37458272,Ph3 | quadruple | treatment,Eli Lilly and Company,Industry,Alzheimer's Therapeutic Research Institute,?,Y,,,,,None,,
-189,NEJM,2023,Infectious Disease,Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis,https://doi.org/10.1056/nejmoa2207940,https://cdn.clinicaltrials.gov/large-docs/86/NCT03518086/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/86/NCT03518086/SAP_003.pdf,SAP,fixed_parallel_superiority,"NCT03518086, NCT03524092",37379135,Ph3 | double | treatment,Eli Lilly and Company,Industry,,?,Y,,,,,None,,
-190,NEJM,2023,Endocrinology/Metabolism,Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial,https://doi.org/10.1056/nejmoa2301972,https://cdn.clinicaltrials.gov/large-docs/60/NCT04881760/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/60/NCT04881760/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04881760,37366315,Ph2 | double | treatment,Eli Lilly and Company,Industry,,?,Y,,,,,None,,
-191,NEJM,2023,Endocrinology/Metabolism,Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin,https://doi.org/10.1056/nejmoa2303208,https://cdn.clinicaltrials.gov/large-docs/85/NCT04460885/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/85/NCT04460885/SAP_001.pdf,SAP,noninferiority,NCT04460885,37356066,Ph3 | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-192,NEJM,2023,Infectious Disease,"Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH",https://doi.org/10.1056/nejmoa2304286,https://cdn.clinicaltrials.gov/large-docs/83/NCT04929483/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/83/NCT04929483/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04929483,37356033,Ph2 | quadruple | treatment,"89bio, Inc.",Industry,,?,Y,,,,,None,,
-193,NEJM,2023,Endocrinology/Metabolism,Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity,https://doi.org/10.1056/nejmoa2302392,https://cdn.clinicaltrials.gov/large-docs/79/NCT05051579/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/79/NCT05051579/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05051579,37351564,Ph2 | double | treatment,Eli Lilly and Company,Industry,,?,Y,,,,,None,,
-194,NEJM,2023,Infectious Disease,"A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D",https://doi.org/10.1056/nejmoa2213429,https://cdn.clinicaltrials.gov/large-docs/19/NCT03852719/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/19/NCT03852719/SAP_006.pdf,SAP,fixed_parallel_superiority,NCT03852719,37345876,Ph3 | treatment,Gilead Sciences,Industry,,?,Y,,,,,None,,
-195,NEJM,2023,Oncology,Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis,https://doi.org/10.1056/nejmoa2215943,https://cdn.clinicaltrials.gov/large-docs/41/NCT03959241/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/41/NCT03959241/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT03959241,37342922,Ph3 | prevention,Medical College of Wisconsin,Academic/Other,"National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI); National Marrow Donor Program",?,Y,,,,,None,,
-196,NEJM,2023,Respiratory,Video versus Direct Laryngoscopy for Tracheal Intubation of Critically Ill Adults,https://doi.org/10.1056/nejmoa2301601,https://cdn.clinicaltrials.gov/large-docs/95/NCT05239195/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/95/NCT05239195/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05239195,37326325,NA | treatment,Vanderbilt University Medical Center,Academic/Other,"University of Colorado, Denver",?,Y,,,,,None,,
-197,NEJM,2023,Cardiovascular,Cardiovascular Safety of Testosterone-Replacement Therapy,https://doi.org/10.1056/nejmoa2215025,https://cdn.clinicaltrials.gov/large-docs/34/NCT03518034/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/34/NCT03518034/SAP_001.pdf,SAP,noninferiority,NCT03518034,37326322,Ph4 | quadruple | treatment,AbbVie,Industry,"Endo Pharmaceuticals; Acerus Pharmaceuticals Corporation; Allergan Sales, LLC; Upsher-Smith Laboratories",?,Y,,,,,None,,
-198,NEJM,2023,Other,Transplantation Outcomes with Donor Hearts after Circulatory Death,https://doi.org/10.1056/nejmoa2212438,https://cdn.clinicaltrials.gov/large-docs/48/NCT03831048/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/48/NCT03831048/SAP_001.pdf,SAP,noninferiority,NCT03831048,37285526,NA | treatment,TransMedics,Industry,,?,Y,,,,,None,,
-199,NEJM,2023,Oncology,Overall Survival with Osimertinib in Resected <i>EGFR</i>-Mutated NSCLC,https://doi.org/10.1056/nejmoa2304594,https://cdn.clinicaltrials.gov/large-docs/06/NCT02511106/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/06/NCT02511106/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02511106,37272535,Ph3 | triple | treatment,AstraZeneca,Industry,,?,Y,,,,,None,,
-200,NEJM,2023,Oncology,Preoperative Treatment of Locally Advanced Rectal Cancer,https://doi.org/10.1056/nejmoa2303269,https://cdn.clinicaltrials.gov/large-docs/87/NCT01515787/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/87/NCT01515787/Prot_SAP_000.pdf,Protocol+SAP,noninferiority,NCT01515787,37272534,Ph2/Ph3 | treatment,Alliance for Clinical Trials in Oncology,Academic/Other,National Cancer Institute (NCI); Canadian Cancer Trials Group,?,Y,,,,,None,,
-201,NEJM,2023,Oncology,Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma,https://doi.org/10.1056/nejmoa2301665,https://cdn.clinicaltrials.gov/large-docs/66/NCT03391466/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/66/NCT03391466/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03391466,37272527,Ph3 | treatment,"Kite, A Gilead Company",Industry,,?,Y,,,,,None,,
-202,NEJM,2023,Respiratory,Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,https://doi.org/10.1056/nejmoa2303951,https://cdn.clinicaltrials.gov/large-docs/32/NCT03930732/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/32/NCT03930732/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03930732,37272521,Ph3 | quadruple | treatment,Sanofi,Industry,Regeneron Pharmaceuticals,?,Y,,,,,None,,
-203,NEJM,2023,Oncology,Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma,https://doi.org/10.1056/nejmoa2304194,https://cdn.clinicaltrials.gov/large-docs/01/NCT04164901/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/01/NCT04164901/SAP_001.pdf,SAP,crossover,NCT04164901,37272516,Ph3 | quadruple | treatment,Institut de Recherches Internationales Servier,Academic/Other,,?,Y,,,,,None,,
-204,NEJM,2023,Oncology,Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer,https://doi.org/10.1056/nejmoa2302983,https://cdn.clinicaltrials.gov/large-docs/43/NCT03425643/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/43/NCT03425643/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03425643,37272513,Ph3 | double | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,,,,,None,,
-205,NEJM,2023,Oncology,Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma,https://doi.org/10.1056/nejmoa2303379,https://cdn.clinicaltrials.gov/large-docs/27/NCT04181827/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/27/NCT04181827/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04181827,37272512,Ph3 | treatment,"Janssen Research & Development, LLC",Industry,,?,Y,,,,,None,,
-206,NEJM,2023,Oncology,Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer,https://doi.org/10.1056/nejmoa2214131,https://cdn.clinicaltrials.gov/large-docs/96/NCT04305496/Prot_003.pdf,https://cdn.clinicaltrials.gov/large-docs/96/NCT04305496/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04305496,37256976,Ph3 | quadruple | treatment,AstraZeneca,Industry,,?,Y,,,,,None,,
-207,NEJM,2023,Psychiatry/Mental Health,Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression,https://doi.org/10.1056/nejmoa2302399,https://cdn.clinicaltrials.gov/large-docs/68/NCT03113968/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/68/NCT03113968/SAP_002.pdf,SAP,noninferiority,NCT03113968,37224232,Ph2/Ph3 | treatment,Bo Hu,Academic/Other,Patient-Centered Outcomes Research Institute,?,Y,,,,,None,,
-208,NEJM,2023,Gastroenterology/Hepatology,Upadacitinib Induction and Maintenance Therapy for Crohn's Disease,https://doi.org/10.1056/nejmoa2212728,https://cdn.clinicaltrials.gov/large-docs/49/NCT03345849/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/49/NCT03345849/SAP_002.pdf,SAP,fixed_parallel_superiority,"NCT03345849, NCT03345836, NCT03345823",37224198,Ph3 | quadruple | treatment,AbbVie,Industry,,?,Y,,,,,None,,
-209,NEJM,2023,Rheumatology/Immunology,A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis,https://doi.org/10.1056/nejmoa2209856,https://cdn.clinicaltrials.gov/large-docs/53/NCT04634253/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/53/NCT04634253/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04634253,37195941,Ph2 | double | treatment,Eli Lilly and Company,Industry,,?,Y,,,,,None,,
-210,NEJM,2023,Oncology,Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma,https://doi.org/10.1056/nejmoa2212851,https://cdn.clinicaltrials.gov/large-docs/19/NCT03937219/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/19/NCT03937219/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03937219,37163623,Ph3 | triple | treatment,Exelixis,Industry,,?,Y,,,,,None,,
-211,NEJM,2023,Pediatrics,Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy,https://doi.org/10.1056/nejmoa2212895,https://cdn.clinicaltrials.gov/large-docs/47/NCT03211247/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/47/NCT03211247/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT03211247, NCT03859700",37163622,Ph3 | quadruple | treatment,DBV Technologies,Industry,,?,Y,,,,,None,,
-212,NEJM,2023,Obstetrics/Gynecology,Randomized Trial of Early Detection and Treatment of Postpartum Hemorrhage,https://doi.org/10.1056/nejmoa2303966,https://cdn.clinicaltrials.gov/large-docs/62/NCT04341662/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/62/NCT04341662/SAP_001.pdf,SAP,cluster,NCT04341662,37158447,NA | treatment,University of Birmingham,Academic/Other,"University College, London; University of Melbourne; University of California; World Health Organization; King's College London; (+10 more)",?,Y,,,,,None,,
-213,NEJM,2023,Oncology,Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer,https://doi.org/10.1056/nejmoa2214963,https://cdn.clinicaltrials.gov/large-docs/87/NCT04737187/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/87/NCT04737187/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04737187,37133585,Ph3 | treatment,"Taiho Oncology, Inc.",Industry,Institut de Recherches Internationales Servier,?,Y,,,,,None,,
-214,NEJM,2023,Rheumatology/Immunology,"Eat, Sleep, Console Approach or Usual Care for Neonatal Opioid Withdrawal",https://doi.org/10.1056/nejmoa2214470,https://cdn.clinicaltrials.gov/large-docs/20/NCT04057820/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/20/NCT04057820/Prot_SAP_000.pdf,Protocol+SAP,cluster,NCT04057820,37125831,NA | single | health services research,Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program,Network/Cooperative,National Institutes of Health (NIH),?,Y,,,,,None,,
-215,NEJM,2023,Dermatology,Dersimelagon in Erythropoietic Protoporphyrias,https://doi.org/10.1056/nejmoa2208754,https://cdn.clinicaltrials.gov/large-docs/36/NCT03520036/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/36/NCT03520036/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03520036,37043653,Ph2 | quadruple | treatment,"Tanabe Pharma America, Inc.",Industry,,?,Y,,,,,None,,
-216,NEJM,2023,Gastroenterology/Hepatology,Tranexamic Acid to Prevent Obstetrical Hemorrhage after Cesarean Delivery,https://doi.org/10.1056/nejmoa2207419,https://cdn.clinicaltrials.gov/large-docs/91/NCT03364491/Prot_SAP_ICF_000.pdf,https://cdn.clinicaltrials.gov/large-docs/91/NCT03364491/Prot_SAP_ICF_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03364491,37043652,Ph3 | quadruple | prevention,The George Washington University Biostatistics Center,Academic/Other,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),?,Y,,,,,None,,
-217,NEJM,2023,Infectious Disease,Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections,https://doi.org/10.1056/nejmoa2211934,https://cdn.clinicaltrials.gov/large-docs/23/NCT03980223/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/23/NCT03980223/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03980223,37018493,Ph4 | prevention,"University of California, San Francisco",Academic/Other,University of Washington; National Institute of Allergy and Infectious Diseases (NIAID); Mayne Pharma International Pty Ltd; San Francisco Department of Public Health,?,Y,,,,,None,,
-218,NEJM,2023,Infectious Disease,Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants,https://doi.org/10.1056/nejmoa2216480,https://cdn.clinicaltrials.gov/large-docs/16/NCT04424316/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/16/NCT04424316/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04424316,37018474,Ph3 | quadruple | prevention,Pfizer,Industry,,?,Y,,,,,None,,
-219,NEJM,2023,Infectious Disease,Vedolizumab for the Treatment of Chronic Pouchitis,https://doi.org/10.1056/nejmoa2208450,https://cdn.clinicaltrials.gov/large-docs/38/NCT02790138/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/38/NCT02790138/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02790138,36988594,Ph4 | quadruple | treatment,Takeda,Industry,,?,Y,,,,,None,,
-220,NEJM,2023,Oncology,Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer,https://doi.org/10.1056/nejmoa2302312,https://cdn.clinicaltrials.gov/large-docs/12/NCT03914612/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/12/NCT03914612/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03914612,36972022,Ph3 | quadruple | treatment,National Cancer Institute (NCI),NIH,Canadian Cancer Trials Group; NRG Oncology,?,Y,,,,,None,,
-221,NEJM,2023,Infectious Disease,Hydrocortisone in Severe Community-Acquired Pneumonia,https://doi.org/10.1056/nejmoa2215145,,https://cdn.clinicaltrials.gov/large-docs/89/NCT02517489/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT02517489,36942789,Ph3 | triple | treatment,"University Hospital, Tours",Academic/Other,,?,Y,,,,,None,,
-222,NEJM,2023,Dermatology,Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis,https://doi.org/10.1056/nejmoa2206714,https://cdn.clinicaltrials.gov/large-docs/63/NCT04146363/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/63/NCT04146363/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT04146363, NCT04178967",36920778,Ph3 | quadruple | treatment,Eli Lilly and Company,Industry,"Dermira, Inc.",?,Y,,,,,None,,
-223,NEJM,2023,Endocrinology/Metabolism,Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes,https://doi.org/10.1056/nejmoa2210834,https://cdn.clinicaltrials.gov/large-docs/79/NCT04796779/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/79/NCT04796779/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT04796779,36920756,NA | treatment,Marc Breton,Academic/Other,"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Jaeb Center for Health Research; Tandem Diabetes Care, Inc.",?,Y,,,,,None,,
-224,NEJM,2023,Oncology,"Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors",https://doi.org/10.1056/nejmoa2210140,https://cdn.clinicaltrials.gov/large-docs/64/NCT03785964/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/64/NCT03785964/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT03785964,36884323,Ph3 | quadruple | treatment,"SpringWorks Therapeutics, Inc.",Industry,,?,Y,,,,,None,,
-225,NEJM,2023,Cardiovascular,Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension,https://doi.org/10.1056/nejmoa2213558,https://cdn.clinicaltrials.gov/large-docs/88/NCT04576988/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/88/NCT04576988/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04576988,36877098,Ph3 | quadruple | treatment,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",Industry,,?,Y,,,,,None,,
-226,NEJM,2023,Cardiovascular,Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation,https://doi.org/10.1056/nejmoa2300213,https://cdn.clinicaltrials.gov/large-docs/79/NCT01626079/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/79/NCT01626079/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT01626079,36876756,NA | treatment,Abbott Medical Devices,Industry,,?,Y,,,,,None,,
-227,NEJM,2023,Cardiovascular,Transcatheter Repair for Patients with Tricuspid Regurgitation,https://doi.org/10.1056/nejmoa2300525,https://cdn.clinicaltrials.gov/large-docs/47/NCT03904147/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/47/NCT03904147/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03904147,36876753,NA | single | treatment,Abbott Medical Devices,Industry,,?,Y,,,,,None,,
-228,NEJM,2023,Cardiovascular,Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients,https://doi.org/10.1056/nejmoa2215024,https://cdn.clinicaltrials.gov/large-docs/06/NCT02993406/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/06/NCT02993406/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02993406,36876740,Ph3 | triple | treatment,"Esperion Therapeutics, Inc.",Industry,The Cleveland Clinic,?,Y,,,,,None,,
-229,NEJM,2023,Psychiatry/Mental Health,Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression,https://doi.org/10.1056/nejmoa2204462,https://cdn.clinicaltrials.gov/large-docs/63/NCT02960763/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/63/NCT02960763/SAP_004.pdf,SAP,fixed_parallel_superiority,NCT02960763,36867173,Ph4 | single | treatment,Washington University School of Medicine,Academic/Other,Patient-Centered Outcomes Research Institute; National Institute of Mental Health (NIMH),?,Y,,,,,None,,
-230,NEJM,2023,Oncology,Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma,https://doi.org/10.1056/nejmoa2211437,https://cdn.clinicaltrials.gov/large-docs/19/NCT03698019/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/19/NCT03698019/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03698019,36856617,Ph2 | treatment,National Cancer Institute (NCI),NIH,,?,Y,,,,,None,,
-231,NEJM,2023,Nephrology/Urology,Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence,https://doi.org/10.1056/nejmoa2209275,https://cdn.clinicaltrials.gov/large-docs/31/NCT03057431/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/31/NCT03057431/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03057431,36856614,Ph3 | double | prevention,"Insel Gruppe AG, University Hospital Bern",Academic/Other,,?,Y,,,,,None,,
-232,NEJM,2023,Oncology,Rucaparib or Physician's Choice in Metastatic Prostate Cancer,https://doi.org/10.1056/nejmoa2214676,https://cdn.clinicaltrials.gov/large-docs/34/NCT02975934/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/34/NCT02975934/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02975934,36795891,Ph3 | treatment,pharmaand GmbH,Industry,Foundation Medicine,?,Y,,,,,None,,
-233,NEJM,2023,Infectious Disease,Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults,https://doi.org/10.1056/nejmoa2207566,https://cdn.clinicaltrials.gov/large-docs/99/NCT03982199/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/99/NCT03982199/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03982199,36791161,Ph2 | triple | prevention,Janssen Vaccines & Prevention B.V.,Industry,,?,Y,,,,,None,,
-234,NEJM,2023,Infectious Disease,Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults,https://doi.org/10.1056/nejmoa2209604,https://cdn.clinicaltrials.gov/large-docs/96/NCT04886596/Prot_003.pdf,https://cdn.clinicaltrials.gov/large-docs/96/NCT04886596/SAP_004.pdf,SAP,fixed_parallel_superiority,NCT04886596,36791160,Ph3 | quadruple | prevention,GlaxoSmithKline,Industry,,?,Y,,,,,None,,
-235,NEJM,2023,Cardiovascular,Trial of Endovascular Thrombectomy for Large Ischemic Strokes,https://doi.org/10.1056/nejmoa2214403,https://cdn.clinicaltrials.gov/large-docs/57/NCT03876457/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/57/NCT03876457/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03876457,36762865,NA | single | treatment,University Hospitals Cleveland Medical Center,Academic/Other,"Stryker Neurovascular; The University of Texas Health Science Center, Houston",?,Y,,,,,None,,
-236,NEJM,2023,Infectious Disease,Azithromycin to Prevent Sepsis or Death in Women Planning a Vaginal Birth,https://doi.org/10.1056/nejmoa2212111,https://cdn.clinicaltrials.gov/large-docs/91/NCT03871491/Prot_SAP_ICF_000.pdf,https://cdn.clinicaltrials.gov/large-docs/91/NCT03871491/Prot_SAP_ICF_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03871491,36757318,Ph3 | triple | prevention,NICHD Global Network for Women's and Children's Health,Network/Cooperative,"University of Alabama at Birmingham; University Teaching Hospital, Lusaka, Zambia; University of North Carolina, Chapel Hill; Kinshasa School of Public Health; University of Colorado, Denver; (+14 more)",?,Y,,,,,None,,
-237,NEJM,2023,Infectious Disease,Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension,https://doi.org/10.1056/nejmoa2212663,https://cdn.clinicaltrials.gov/large-docs/28/NCT03434028/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/28/NCT03434028/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03434028,36688507,Ph3 | treatment,Massachusetts General Hospital,Academic/Other,,?,Y,,,,,None,,
-238,NEJM,2023,Infectious Disease,Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years,https://doi.org/10.1056/nejmoa2213082,https://cdn.clinicaltrials.gov/large-docs/26/NCT04955626/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/26/NCT04955626/SAP_006.pdf,SAP,fixed_parallel_superiority,NCT04955626,36652353,Ph3 | triple | prevention,BioNTech SE,Industry,Pfizer,?,Y,,,,,None,,
-239,NEJM,2023,Respiratory,Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture,https://doi.org/10.1056/nejmoa2205973,https://cdn.clinicaltrials.gov/large-docs/84/NCT02984384/Prot_SAP_ICF_000.pdf,https://cdn.clinicaltrials.gov/large-docs/84/NCT02984384/Prot_SAP_ICF_000.pdf,Protocol+SAP,noninferiority,NCT02984384,36652352,Ph3 | single | prevention,Major Extremity Trauma Research Consortium,Academic/Other,Patient-Centered Outcomes Research Institute,?,Y,,,,,None,,
-240,NEJM,2023,Oncology,Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia,https://doi.org/10.1056/nejmoa2211582,https://cdn.clinicaltrials.gov/large-docs/16/NCT03734016/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/16/NCT03734016/SAP_002.pdf,SAP,noninferiority,NCT03734016,36511784,Ph3 | treatment,BeiGene,Industry,,?,Y,,,,,None,,
-241,NEJM,2023,Cardiovascular,Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension,https://doi.org/10.1056/nejmoa2213169,https://cdn.clinicaltrials.gov/large-docs/58/NCT04519658/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/58/NCT04519658/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04519658,36342143,Ph2 | quadruple | treatment,"CinCor Pharma, Inc.",Industry,,?,Y,,,,,None,,
-242,NEJM,2023,Cardiovascular,Empagliflozin in Patients with Chronic Kidney Disease,https://doi.org/10.1056/nejmoa2204233,https://cdn.clinicaltrials.gov/large-docs/10/NCT03594110/Prot_006.pdf,https://cdn.clinicaltrials.gov/large-docs/10/NCT03594110/SAP_008.pdf,SAP,fixed_parallel_superiority,NCT03594110,36331190,Ph3 | double | treatment,Boehringer Ingelheim,Industry,University of Oxford; Eli Lilly and Company,?,Y,,,,,None,,
-243,NEJM,2022,Other,Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa,https://doi.org/10.1056/nejmoa2206663,https://cdn.clinicaltrials.gov/large-docs/04/NCT04491604/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/04/NCT04491604/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04491604,36516090,Ph3 | quadruple | treatment,"Krystal Biotech, Inc.",Industry,,?,Y,,,,,None,,
-244,NEJM,2022,Infectious Disease,Randomized Trial of Vaccines for Zaire Ebola Virus Disease,https://doi.org/10.1056/nejmoa2200072,https://cdn.clinicaltrials.gov/large-docs/28/NCT02876328/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/28/NCT02876328/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT02876328,36516078,Ph2 | quadruple | prevention,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"Partnership for Research on Ebola Virus in Liberia (PREVAIL); Institut National de la Santé Et de la Recherche Médicale, France; London School of Hygiene and Tropical Medicine; European and Developing Countries Clinical Trials Partnership (EDCTP)",?,Y,,,,,None,,
-245,NEJM,2022,Cardiovascular,Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events,https://doi.org/10.1056/nejmoa2212270,https://cdn.clinicaltrials.gov/large-docs/17/NCT02185417/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/17/NCT02185417/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT02185417,36516076,Ph3 | treatment,VA Office of Research and Development,US Federal,,?,Y,,,,,None,,
-246,NEJM,2022,Psychiatry/Mental Health,Trial of Training to Reduce Driver Inattention in Teens with ADHD,https://doi.org/10.1056/nejmoa2204783,https://cdn.clinicaltrials.gov/large-docs/92/NCT02848092/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/92/NCT02848092/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02848092,36449421,NA | triple | treatment,"Children's Hospital Medical Center, Cincinnati",Academic/Other,"St. Louis University; University of Massachusetts, Amherst",?,Y,,,,,None,,
-247,NEJM,2022,Infectious Disease,Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection,https://doi.org/10.1056/nejmoa2210027,https://cdn.clinicaltrials.gov/large-docs/29/NCT04449029/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/29/NCT04449029/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04449029,36346079,Ph2 | single | treatment,GlaxoSmithKline,Industry,,?,Y,,,,,None,,
-248,NEJM,2022,Cardiovascular,Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease,https://doi.org/10.1056/nejmoa2211023,https://cdn.clinicaltrials.gov/large-docs/60/NCT04270760/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/60/NCT04270760/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04270760,36342163,Ph2 | double | treatment,Amgen,Industry,,?,Y,,,,,None,,
-249,NEJM,2022,Surgery/Critical Care,Defibrillation Strategies for Refractory Ventricular Fibrillation,https://doi.org/10.1056/nejmoa2207304,https://cdn.clinicaltrials.gov/large-docs/86/NCT04080986/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/86/NCT04080986/Prot_SAP_000.pdf,Protocol+SAP,crossover;cluster,NCT04080986,36342151,NA | treatment,Sunnybrook Health Sciences Centre,Academic/Other,Peel Regional Paramedic Services; Toronto Paramedic Services; Halton Region Paramedic Services; County of Simcoe Paramedic Services; London Health Sciences Centre; (+2 more),?,Y,,,,,None,,
-250,NEJM,2022,Pediatrics,"Methylprednisolone for Heart Surgery in Infants - A Randomized, Controlled Trial",https://doi.org/10.1056/nejmoa2212667,https://cdn.clinicaltrials.gov/large-docs/38/NCT03229538/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/38/NCT03229538/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03229538,36342116,Ph3 | quadruple | treatment,Kevin Hill,Academic/Other,National Center for Advancing Translational Sciences (NCATS),?,Y,,,,,None,,
-251,NEJM,2022,Cardiovascular,Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk,https://doi.org/10.1056/nejmoa2210645,https://cdn.clinicaltrials.gov/large-docs/92/NCT03071692/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/92/NCT03071692/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03071692,36342113,Ph3 | quadruple | prevention,"Kowa Research Institute, Inc.",Industry,Brigham and Women's Hospital,?,Y,,,,,None,,
-252,NEJM,2022,Oncology,Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma,https://doi.org/10.1056/nejmoa2206660,https://cdn.clinicaltrials.gov/large-docs/63/NCT02166463/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/63/NCT02166463/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02166463,36322844,Ph3 | single | treatment,National Cancer Institute (NCI),NIH,,?,Y,,,,,None,,
-253,NEJM,2022,Psychiatry/Mental Health,Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression,https://doi.org/10.1056/nejmoa2206443,https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03775200,36322843,Ph2 | quadruple | treatment,COMPASS Pathways,Industry,,?,Y,,,,,None,,
-254,NEJM,2022,Endocrinology/Metabolism,Once-Weekly Semaglutide in Adolescents with Obesity,https://doi.org/10.1056/nejmoa2208601,https://cdn.clinicaltrials.gov/large-docs/89/NCT04102189/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/89/NCT04102189/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04102189,36322838,Ph3 | double | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-255,NEJM,2022,Infectious Disease,Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali,https://doi.org/10.1056/nejmoa2206966,https://cdn.clinicaltrials.gov/large-docs/04/NCT04329104/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/04/NCT04329104/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04329104,36317783,Ph2 | double | prevention,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"Malaria Research and Training Center, Bamako, Mali; University of Washington; Harvard School of Public Health (HSPH)",?,Y,,,,,None,,
-256,NEJM,2022,Respiratory,Oxygen-Saturation Targets for Critically Ill Adults Receiving Mechanical Ventilation,https://doi.org/10.1056/nejmoa2208415,https://cdn.clinicaltrials.gov/large-docs/37/NCT03537937/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/37/NCT03537937/Prot_SAP_000.pdf,Protocol+SAP,crossover;cluster,NCT03537937,36278971,NA | single | treatment,Vanderbilt University Medical Center,Academic/Other,,?,Y,,,,,None,,
-257,NEJM,2022,Infectious Disease,Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age,https://doi.org/10.1056/nejmoa2209367,https://cdn.clinicaltrials.gov/large-docs/96/NCT04796896/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/96/NCT04796896/SAP_002.pdf,SAP,noninferiority,NCT04796896,36260859,Ph2/Ph3 | quadruple | prevention,"ModernaTX, Inc.",Industry,,?,Y,,,,,None,,
-258,NEJM,2022,Obstetrics/Gynecology,Liquefied Petroleum Gas or Biomass for Cooking and Effects on Birth Weight,https://doi.org/10.1056/nejmoa2206734,,https://cdn.clinicaltrials.gov/large-docs/82/NCT02944682/SAP_010.pdf,SAP,fixed_parallel_superiority,NCT02944682,36214599,NA | prevention,Emory University,Academic/Other,"National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI); Bill and Melinda Gates Foundation; Berkeley Air Monitoring Group; Colorado State University; (+14 more)",?,Y,,,,,None,,
-259,NEJM,2022,Other,Trial of Intravenous Immune Globulin in Dermatomyositis,https://doi.org/10.1056/nejmoa2117912,https://cdn.clinicaltrials.gov/large-docs/52/NCT02728752/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/52/NCT02728752/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02728752,36198179,Ph3 | triple | treatment,Octapharma,Industry,,?,Y,,,,,None,,
-260,NEJM,2022,Endocrinology/Metabolism,Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes,https://doi.org/10.1056/nejmoa2205650,https://cdn.clinicaltrials.gov/large-docs/06/NCT03815006/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/06/NCT03815006/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03815006,36198143,NA | treatment,Manchester University NHS Foundation Trust,Other Government,University Hospitals of Derby and Burton NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Portsmouth Hospitals NHS Trust; University Hospital Birmingham NHS Foundation Trust; Norfolk and Norwich University Hospitals NHS Foundation Trust; (+6 more),?,Y,,,,,None,,
-261,NEJM,2022,Endocrinology/Metabolism,"Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes",https://doi.org/10.1056/nejmoa2205225,https://cdn.clinicaltrials.gov/large-docs/13/NCT04200313/Prot_010.pdf,https://cdn.clinicaltrials.gov/large-docs/13/NCT04200313/SAP_011.pdf,SAP,noninferiority,NCT04200313,36170500,NA | treatment,Jaeb Center for Health Research,Academic/Other,"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Beta Bionics, Inc.; Boston University; Massachusetts General Hospital",?,Y,,,,,None,,
-262,NEJM,2022,Neurology,Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS,https://doi.org/10.1056/nejmoa2204705,https://cdn.clinicaltrials.gov/large-docs/99/NCT02623699/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/99/NCT02623699/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT02623699, NCT03070119",36129998,Ph3 | quadruple | treatment,Biogen,Industry,"Ionis Pharmaceuticals, Inc.",?,Y,,,,,None,,
-263,NEJM,2022,Cardiovascular,Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes,https://doi.org/10.1056/nejmoa2200436,https://cdn.clinicaltrials.gov/large-docs/43/NCT01794143/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/43/NCT01794143/SAP_004.pdf,SAP,fixed_parallel_superiority,NCT01794143,36129997,Ph3 | treatment,GRADE Study Group,Academic/Other,"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Heart, Lung, and Blood Institute (NHLBI); Centers for Disease Control and Prevention",?,Y,,,,,None,,
-264,NEJM,2022,Endocrinology/Metabolism,Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes,https://doi.org/10.1056/nejmoa2200433,https://cdn.clinicaltrials.gov/large-docs/43/NCT01794143/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/43/NCT01794143/SAP_004.pdf,SAP,fixed_parallel_superiority,NCT01794143,36129996,Ph3 | treatment,GRADE Study Group,Academic/Other,"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Heart, Lung, and Blood Institute (NHLBI); Centers for Disease Control and Prevention",?,Y,,,,,None,,
-265,NEJM,2022,Cardiovascular,Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement,https://doi.org/10.1056/nejmoa2204961,https://cdn.clinicaltrials.gov/large-docs/35/NCT04149535/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/35/NCT04149535/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04149535,36121045,NA | treatment,Boston Scientific Corporation,Industry,,?,Y,,,,,None,,
-266,NEJM,2022,Gastroenterology/Hepatology,Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis,https://doi.org/10.1056/nejmoa2202884,https://cdn.clinicaltrials.gov/large-docs/69/NCT04381169/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/69/NCT04381169/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04381169,36103415,Ph3 | treatment,Enrique de-Madaria,Academic/Other,Instituto de Salud Carlos III; Asociación Española de Gastroenterología; Asociación Española de Pancreatología,?,Y,,,,,None,,
-267,NEJM,2022,Other,A Randomized Trial of Enteral Glutamine for Treatment of Burn Injuries,https://doi.org/10.1056/nejmoa2203364,,https://cdn.clinicaltrials.gov/large-docs/05/NCT00985205/SAP_000.pdf,SAP,single_arm,NCT00985205,36082909,Ph3 | quadruple | treatment,Daren K. Heyland,Academic/Other,Canadian Institutes of Health Research (CIHR),?,Y,,,,,None,,
-268,NEJM,2022,Infectious Disease,"Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19",https://doi.org/10.1056/nejmoa2201662,https://cdn.clinicaltrials.gov/large-docs/94/NCT04510194/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/94/NCT04510194/Prot_SAP_001.pdf,Protocol+SAP,factorial,NCT04510194,36070710,Ph3 | quadruple | treatment,University of Minnesota,Academic/Other,"UnitedHealth Group; Northwestern University; Hennepin County Medical Center, Minneapolis; University of Colorado, Denver; Olive View-UCLA Education & Research Institute",?,Y,,,,,None,,
-269,NEJM,2022,Rheumatology/Immunology,Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus,https://doi.org/10.1056/nejmoa2118025,https://cdn.clinicaltrials.gov/large-docs/98/NCT02847598/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/98/NCT02847598/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02847598,36069871,Ph2 | double | treatment,Biogen,Industry,,?,Y,,,,,None,,
-270,NEJM,2022,Infectious Disease,Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function,https://doi.org/10.1056/nejmoa2204752,https://cdn.clinicaltrials.gov/large-docs/61/NCT02867761/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/61/NCT02867761/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02867761,36066078,Ph3 | quadruple | treatment,University of Michigan,Academic/Other,"National Heart, Lung, and Blood Institute (NHLBI)",?,Y,,,,,None,,
-271,NEJM,2022,Infectious Disease,Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis,https://doi.org/10.1056/nejmoa2119430,https://cdn.clinicaltrials.gov/large-docs/86/NCT03086486/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/86/NCT03086486/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03086486,36053506,Ph3 | triple | treatment,Global Alliance for TB Drug Development,Academic/Other,,?,Y,,,,,None,,
-272,NEJM,2022,Cardiovascular,Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction,https://doi.org/10.1056/nejmoa2206286,https://cdn.clinicaltrials.gov/large-docs/13/NCT03619213/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/13/NCT03619213/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03619213,36027570,Ph3 | quadruple | treatment,AstraZeneca,Industry,,?,Y,,,,,None,,
-273,NEJM,2022,Cardiovascular,Acetazolamide in Acute Decompensated Heart Failure with Volume Overload,https://doi.org/10.1056/nejmoa2203094,https://cdn.clinicaltrials.gov/large-docs/88/NCT03505788/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/88/NCT03505788/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03505788,36027559,Ph4 | triple | treatment,Ziekenhuis Oost-Limburg,Academic/Other,,?,Y,,,,,None,,
-274,NEJM,2022,Cardiovascular,Polypill Strategy in Secondary Cardiovascular Prevention,https://doi.org/10.1056/nejmoa2208275,https://cdn.clinicaltrials.gov/large-docs/26/NCT02596126/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/26/NCT02596126/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02596126,36018037,Ph3 | prevention,Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III,Academic/Other,"Charite University, Berlin, Germany; Centre Hospitalier Universitaire de Besancon; Wroclaw Medical University; Semmelweis University; General University Hospital, Prague; (+4 more)",?,Y,,,,,None,,
-275,NEJM,2022,Oncology,Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis,https://doi.org/10.1056/nejmoa2201302,https://cdn.clinicaltrials.gov/large-docs/07/NCT02760407/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/07/NCT02760407/Prot_SAP_000.pdf,Protocol+SAP,noninferiority,NCT02760407,36001712,Ph3 | double | treatment,"R-Pharm International, LLC",Industry,"Quintiles, Inc.; OCT Clinical Trials",?,Y,,,,,None,,
-276,NEJM,2022,Neurology,Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis,https://doi.org/10.1056/nejmoa2201904,https://cdn.clinicaltrials.gov/large-docs/61/NCT03277261/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/61/NCT03277261/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT03277261, NCT03277248",36001711,Ph3 | quadruple | treatment,"TG Therapeutics, Inc.",Industry,,?,Y,,,,,None,,
-277,NEJM,2022,Rheumatology/Immunology,Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus,https://doi.org/10.1056/nejmoa2118024,https://cdn.clinicaltrials.gov/large-docs/98/NCT02847598/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/98/NCT02847598/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02847598,35939578,Ph2 | double | treatment,Biogen,Industry,,?,Y,,,,,None,,
-278,NEJM,2022,Neurology,Trial of Prasinezumab in Early-Stage Parkinson's Disease,https://doi.org/10.1056/nejmoa2202867,https://cdn.clinicaltrials.gov/large-docs/49/NCT03100149/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/49/NCT03100149/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT03100149,35921451,Ph2 | quadruple | treatment,Hoffmann-La Roche,Industry,Prothena Biosciences Limited,?,Y,,,,,None,,
-279,NEJM,2022,Neurology,Trial of Cinpanemab in Early Parkinson's Disease,https://doi.org/10.1056/nejmoa2203395,https://cdn.clinicaltrials.gov/large-docs/23/NCT03318523/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/23/NCT03318523/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03318523,35921450,Ph2 | quadruple | treatment,Biogen,Industry,,?,Y,,,,,None,,
-280,NEJM,2022,Oncology,Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer,https://doi.org/10.1056/nejmoa2202809,https://cdn.clinicaltrials.gov/large-docs/18/NCT02819518/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/18/NCT02819518/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02819518,35857659,Ph3 | quadruple | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,,,,,None,,
-281,NEJM,2022,Endocrinology/Metabolism,Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema,https://doi.org/10.1056/nejmoa2204225,https://cdn.clinicaltrials.gov/large-docs/13/NCT03321513/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/13/NCT03321513/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT03321513,35833805,Ph3 | double | treatment,Jaeb Center for Health Research,Academic/Other,,?,Y,,,,,None,,
-282,NEJM,2022,Oncology,Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma,https://doi.org/10.1056/nejmoa2206125,https://cdn.clinicaltrials.gov/large-docs/90/NCT01712490/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/90/NCT01712490/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT01712490,35830649,Ph3 | treatment,Takeda,Industry,Seagen Inc.,?,Y,,,,,None,,
-283,NEJM,2022,Neurology,Trial of Erythropoietin for Hypoxic-Ischemic Encephalopathy in Newborns,https://doi.org/10.1056/nejmoa2119660,https://cdn.clinicaltrials.gov/large-docs/63/NCT02811263/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/63/NCT02811263/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02811263,35830641,Ph3 | quadruple | treatment,"University of California, San Francisco",Academic/Other,University of Washington; Pediatrix; University of Utah; Children's National Research Institute; University of Minnesota; (+16 more),?,Y,,,,,None,,
-284,NEJM,2022,Infectious Disease,Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study,https://doi.org/10.1056/nejmoa2116154,https://cdn.clinicaltrials.gov/large-docs/12/NCT04785612/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/12/NCT04785612/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04785612,35731653,Ph2 | quadruple | prevention,Hvivo,Industry,Pfizer,?,Y,,,,,None,,
-285,NEJM,2022,Surgery/Critical Care,Restriction of Intravenous Fluid in ICU Patients with Septic Shock,https://doi.org/10.1056/nejmoa2202707,https://cdn.clinicaltrials.gov/large-docs/36/NCT03668236/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/36/NCT03668236/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03668236,35709019,Ph4 | single | treatment,"Anders Perner, MD, PhD",Academic/Other,"Rigshospitalet, Denmark; Centre for Research in Intensive Care (CRIC); Scandinavian Critical Care Trials Group",?,Y,,,,,None,,
-286,NEJM,2022,Oncology,Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer,https://doi.org/10.1056/nejmoa2201048,https://cdn.clinicaltrials.gov/large-docs/19/NCT02135419/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/19/NCT02135419/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02135419,35704479,Ph3 | prevention,AIDS Malignancy Consortium,Network/Cooperative,"National Cancer Institute (NCI); The Emmes Company, LLC; University of Arkansas; University of California, San Francisco; University of Arizona",?,Y,,,,,None,,
-287,NEJM,2022,Infectious Disease,Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit,https://doi.org/10.1056/nejmoa2200644,,https://cdn.clinicaltrials.gov/large-docs/74/NCT03680274/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT03680274,35704292,Ph3 | quadruple | treatment,Université de Sherbrooke,Academic/Other,Lotte & John Hecht Memorial Foundation,?,Y,,,,,None,,
-288,NEJM,2022,Oncology,Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer,https://doi.org/10.1056/nejmoa2203690,https://cdn.clinicaltrials.gov/large-docs/29/NCT03734029/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/29/NCT03734029/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03734029,35665782,Ph3 | treatment,Daiichi Sankyo,Industry,"Daiichi Sankyo Co., Ltd.; AstraZeneca",?,Y,,,,,None,,
-289,NEJM,2022,Oncology,"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma",https://doi.org/10.1056/nejmoa2204925,https://cdn.clinicaltrials.gov/large-docs/62/NCT01208662/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/62/NCT01208662/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT01208662,35660812,Ph3 | treatment,"Paul Richardson, MD",Academic/Other,"Celgene Corporation; Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital; Cape Cod Hospital; Beth Israel Deaconess Medical Center; (+35 more)",?,Y,,,,,None,,
-290,NEJM,2022,Endocrinology/Metabolism,Tirzepatide Once Weekly for the Treatment of Obesity,https://doi.org/10.1056/nejmoa2206038,https://cdn.clinicaltrials.gov/large-docs/22/NCT04184622/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/22/NCT04184622/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04184622,35658024,Ph3 | double | treatment,Eli Lilly and Company,Industry,,?,Y,,,,,None,,
-291,NEJM,2022,Endocrinology/Metabolism,Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes,https://doi.org/10.1056/nejmoa2204601,https://cdn.clinicaltrials.gov/large-docs/66/NCT02963766/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/66/NCT02963766/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02963766,35658022,Ph3 | double | treatment,Eli Lilly and Company,Industry,,?,Y,,,,,None,,
-292,NEJM,2022,Oncology,Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma,https://doi.org/10.1056/nejmoa2201817,https://cdn.clinicaltrials.gov/large-docs/40/NCT01776840/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/40/NCT01776840/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT01776840,35657079,Ph3 | triple | treatment,"Janssen Research & Development, LLC",Industry,Pharmacyclics LLC.,?,Y,,,,,None,,
-293,NEJM,2022,Respiratory,Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis,https://doi.org/10.1056/nejmoa2201737,https://cdn.clinicaltrials.gov/large-docs/06/NCT04419506/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/06/NCT04419506/SAP_001.pdf,SAP,adaptive_bayesian,NCT04419506,35569036,Ph2 | quadruple | treatment,Boehringer Ingelheim,Industry,,?,Y,,,,,None,,
-294,NEJM,2022,Respiratory,Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma,https://doi.org/10.1056/nejmoa2203163,https://cdn.clinicaltrials.gov/large-docs/90/NCT03769090/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/90/NCT03769090/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03769090,35569035,Ph3 | quadruple | treatment,Bond Avillion 2 Development LP,Industry,,?,Y,,,,,None,,
-295,NEJM,2022,Infectious Disease,Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection,https://doi.org/10.1056/nejmoa2115542,https://cdn.clinicaltrials.gov/large-docs/68/NCT04150068/Prot_005.pdf,https://cdn.clinicaltrials.gov/large-docs/68/NCT04150068/SAP_006.pdf,SAP,fixed_parallel_superiority,NCT04150068,35544387,Ph2/Ph3 | quadruple | treatment,Gilead Sciences,Industry,,?,Y,,,,,None,,
-296,NEJM,2022,Infectious Disease,Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age,https://doi.org/10.1056/nejmoa2203315,https://cdn.clinicaltrials.gov/large-docs/96/NCT04796896/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/96/NCT04796896/SAP_002.pdf,SAP,noninferiority,NCT04796896,35544369,Ph2/Ph3 | quadruple | prevention,"ModernaTX, Inc.",Industry,,?,Y,,,,,None,,
-297,NEJM,2022,Infectious Disease,Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy,https://doi.org/10.1056/nejmoa2106062,https://cdn.clinicaltrials.gov/large-docs/93/NCT04032093/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/93/NCT04032093/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04032093,35476650,Ph2 | quadruple | prevention,Pfizer,Industry,,?,Y,,,,,None,,
-298,NEJM,2022,Oncology,Ivosidenib and Azacitidine in <i>IDH1</i>-Mutated Acute Myeloid Leukemia,https://doi.org/10.1056/nejmoa2117344,https://cdn.clinicaltrials.gov/large-docs/48/NCT03173248/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/48/NCT03173248/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03173248,35443108,Ph3 | triple | treatment,Institut de Recherches Internationales Servier,Academic/Other,,?,Y,,,,,None,,
-299,NEJM,2022,Infectious Disease,Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19,https://doi.org/10.1056/nejmoa2116620,https://cdn.clinicaltrials.gov/large-docs/25/NCT04625725/Prot_004.pdf,https://cdn.clinicaltrials.gov/large-docs/25/NCT04625725/SAP_005.pdf,SAP,fixed_parallel_superiority,NCT04625725,35443106,Ph3 | triple | prevention,AstraZeneca,Industry,IQVIA Pty Ltd,?,Y,,,,,None,,
-300,NEJM,2022,Hematology,Mitapivat versus Placebo for Pyruvate Kinase Deficiency,https://doi.org/10.1056/nejmoa2116634,https://cdn.clinicaltrials.gov/large-docs/20/NCT03548220/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/20/NCT03548220/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT03548220,35417638,Ph3 | triple | treatment,"Agios Pharmaceuticals, Inc.",Industry,,?,Y,,,,,None,,
-301,NEJM,2022,Other,Nonoperative or Surgical Treatment of Acute Achilles' Tendon Rupture,https://doi.org/10.1056/nejmoa2108447,,https://cdn.clinicaltrials.gov/large-docs/64/NCT01785264/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT01785264,35417636,NA | single | treatment,"University Hospital, Akershus",Academic/Other,Oslo University Hospital; Sykehuset Ostfold; Vestre Viken Hospital Trust; Hjelp24,?,Y,,,,,None,,
-302,NEJM,2022,Oncology,Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer,https://doi.org/10.1056/nejmoa2202170,https://cdn.clinicaltrials.gov/large-docs/28/NCT02998528/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/28/NCT02998528/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02998528,35403841,Ph3 | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,,,,,None,,
-303,NEJM,2022,Infectious Disease,Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection,https://doi.org/10.1056/nejmoa2105462,https://cdn.clinicaltrials.gov/large-docs/67/NCT03788967/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/67/NCT03788967/SAP_001.pdf,SAP,noninferiority,NCT03788967,35388666,Ph3 | quadruple | treatment,Spero Therapeutics,Industry,,?,Y,,,,,None,,
-304,NEJM,2022,Cardiovascular,Treatment for Mild Chronic Hypertension during Pregnancy,https://doi.org/10.1056/nejmoa2201295,https://cdn.clinicaltrials.gov/large-docs/14/NCT02299414/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/14/NCT02299414/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02299414,35363951,Ph4 | treatment,University of Alabama at Birmingham,Academic/Other,"Columbia University; Drexel University College of Medicine; Rutgers, The State University of New Jersey; Lehigh Valley Hospital; Saint Peters University Hospital; (+61 more)",?,Y,,,,,None,,
-305,NEJM,2022,Infectious Disease,Early Outpatient Treatment for Covid-19 with Convalescent Plasma,https://doi.org/10.1056/nejmoa2119657,https://cdn.clinicaltrials.gov/large-docs/60/NCT04373460/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/60/NCT04373460/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04373460,35353960,Ph2 | triple | treatment,Johns Hopkins University,Academic/Other,State of Maryland; Bloomberg Philanthropies; United States Department of Defense; National Institute of Allergy and Infectious Diseases (NIAID); National Center for Advancing Translational Sciences (NCATS),?,Y,,,,,None,,
-306,NEJM,2022,Dermatology,Two Phase 3 Trials of Baricitinib for Alopecia Areata,https://doi.org/10.1056/nejmoa2110343,https://cdn.clinicaltrials.gov/large-docs/49/NCT03570749/Prot_005.pdf,https://cdn.clinicaltrials.gov/large-docs/49/NCT03570749/SAP_006.pdf,SAP,fixed_parallel_superiority,"NCT03570749, NCT03899259",35334197,Ph2/Ph3 | double | treatment,Eli Lilly and Company,Industry,Incyte Corporation,?,Y,,,,,None,,
-307,NEJM,2022,Infectious Disease,Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine,https://doi.org/10.1056/nejmoa2200674,https://cdn.clinicaltrials.gov/large-docs/26/NCT04955626/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/26/NCT04955626/SAP_006.pdf,SAP,fixed_parallel_superiority,NCT04955626,35320659,Ph3 | triple | prevention,BioNTech SE,Industry,Pfizer,?,Y,,,,,None,,
-308,NEJM,2022,Oncology,Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer,https://doi.org/10.1056/nejmoa2115022,https://cdn.clinicaltrials.gov/large-docs/10/NCT03529110/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/10/NCT03529110/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03529110,35320644,Ph3 | treatment,Daiichi Sankyo,Industry,"Daiichi Sankyo Co., Ltd.; AstraZeneca",?,Y,,,,,None,,
-309,NEJM,2022,Respiratory,Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia,https://doi.org/10.1056/nejmoa2114897,https://cdn.clinicaltrials.gov/large-docs/13/NCT01353313/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/13/NCT01353313/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01353313,35320643,Ph3 | triple | prevention,NICHD Neonatal Research Network,Network/Cooperative,"National Center for Research Resources (NCRR); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Heart, Lung, and Blood Institute (NHLBI); National Center for Advancing Translational Sciences (NCATS)",?,Y,,,,,None,,
-310,NEJM,2022,Rheumatology/Immunology,Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus,https://doi.org/10.1056/nejmoa2106535,https://cdn.clinicaltrials.gov/large-docs/83/NCT03161483/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/83/NCT03161483/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03161483,35294813,Ph2 | quadruple | treatment,Celgene,Industry,,?,Y,,,,,None,,
-311,NEJM,2022,Other,Inhibition of Prekallikrein for Hereditary Angioedema,https://doi.org/10.1056/nejmoa2109329,https://cdn.clinicaltrials.gov/large-docs/98/NCT04030598/Prot_SAP_003.pdf,https://cdn.clinicaltrials.gov/large-docs/98/NCT04030598/Prot_SAP_003.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04030598,35294812,Ph2 | triple | treatment,"Ionis Pharmaceuticals, Inc.",Industry,,?,Y,,,,,None,,
-312,NEJM,2022,Infectious Disease,Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity,https://doi.org/10.1056/nejmc2112186,https://cdn.clinicaltrials.gov/large-docs/88/NCT03959488/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/88/NCT03959488/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03959488,35235733,Ph2/Ph3 | quadruple | prevention,AstraZeneca,Industry,,?,Y,Yue Chang,Statistical Science Associate Director,AstraZeneca,https://rocketreach.co/yue-chang-email_80189407,High,Web-search,Yue Chang is listed as Statistical Science Associate Director and Senior Statistician at AstraZeneca.
-313,NEJM,2022,Infectious Disease,Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants,https://doi.org/10.1056/nejmoa2110275,https://cdn.clinicaltrials.gov/large-docs/13/NCT03979313/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/13/NCT03979313/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03979313,35235726,Ph3 | quadruple | prevention,AstraZeneca,Industry,,?,Y,,,,,None,,
-314,NEJM,2022,Respiratory,Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with Asthma,https://doi.org/10.1056/nejmoa2118813,https://cdn.clinicaltrials.gov/large-docs/33/NCT02995733/Prot_SAP_002.pdf,https://cdn.clinicaltrials.gov/large-docs/33/NCT02995733/Prot_SAP_002.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02995733,35213105,Ph4 | single | health services research,Brigham and Women's Hospital,Academic/Other,Patient-Centered Outcomes Research Institute; American Academy of Family Physicians,?,Y,,,,,None,,
-315,NEJM,2022,Oncology,"Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer",https://doi.org/10.1056/nejmoa2119115,https://cdn.clinicaltrials.gov/large-docs/02/NCT02799602/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/02/NCT02799602/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT02799602,35179323,Ph3 | quadruple | treatment,Bayer,Industry,"Orion Corporation, Orion Pharma",?,Y,,,,,None,,
-316,NEJM,2022,Infectious Disease,"EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge",https://doi.org/10.1056/nejmoa2108903,https://cdn.clinicaltrials.gov/large-docs/23/NCT03691623/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/23/NCT03691623/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03691623,35172056,Ph2 | double | treatment,"Enanta Pharmaceuticals, Inc",Industry,hVIVO Services Limited,?,Y,,,,,None,,
-317,NEJM,2022,Infectious Disease,"Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19",https://doi.org/10.1056/nejmoa2118542,https://cdn.clinicaltrials.gov/large-docs/02/NCT04960202/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/02/NCT04960202/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04960202,35172054,Ph2/Ph3 | quadruple | treatment,Pfizer,Industry,,?,Y,,,,,None,,
-318,NEJM,2022,Oncology,Survival with Cemiplimab in Recurrent Cervical Cancer,https://doi.org/10.1056/nejmoa2112187,https://cdn.clinicaltrials.gov/large-docs/67/NCT03257267/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/67/NCT03257267/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03257267,35139273,Ph3 | treatment,Regeneron Pharmaceuticals,Industry,Sanofi,?,Y,,,,,None,,
-319,NEJM,2022,Infectious Disease,Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S,https://doi.org/10.1056/nejmoa2117608,https://cdn.clinicaltrials.gov/large-docs/22/NCT04505722/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/22/NCT04505722/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT04505722,35139271,Ph3 | quadruple | prevention,Janssen Vaccines & Prevention B.V.,Industry,,?,Y,,,,,None,,
-320,NEJM,2022,Oncology,Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma,https://doi.org/10.1056/nejmoa2111380,https://cdn.clinicaltrials.gov/large-docs/53/NCT03143153/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/53/NCT03143153/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT03143153,35108470,Ph3 | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,,,,,None,,
-321,NEJM,2022,Oncology,Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis,https://doi.org/10.1056/nejmoa2109927,https://cdn.clinicaltrials.gov/large-docs/67/NCT02092467/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/67/NCT02092467/SAP_001.pdf,SAP,noninferiority,NCT02092467,35081280,Ph4 | treatment,Pfizer,Industry,,?,Y,,,,,None,,
-322,NEJM,2022,Infectious Disease,"SER-109, an Oral Microbiome Therapy for Recurrent <i>Clostridioides difficile</i> Infection",https://doi.org/10.1056/nejmoa2106516,https://cdn.clinicaltrials.gov/large-docs/28/NCT03183128/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/28/NCT03183128/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03183128,35045228,Ph3 | double | treatment,"Seres Therapeutics, Inc.",Industry,,?,Y,,,,,None,,
-323,NEJM,2022,Endocrinology/Metabolism,Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes,https://doi.org/10.1056/nejmoa2111673,https://cdn.clinicaltrials.gov/large-docs/27/NCT03784027/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/27/NCT03784027/Prot_SAP_000.pdf,Protocol+SAP,crossover,NCT03784027,35045227,NA | treatment,University of Cambridge,Academic/Other,European Commission; Cambridge University Hospitals NHS Foundation Trust; The Leeds Teaching Hospitals NHS Trust; University of Luxembourg; University of Leipzig; (+7 more),?,Y,,,,,None,,
-324,NEJM,2022,Oncology,Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer,https://doi.org/10.1056/nejmoa2108330,https://cdn.clinicaltrials.gov/large-docs/49/NCT03517449/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/49/NCT03517449/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03517449,35045221,Ph3 | treatment,Eisai Inc.,Industry,Merck Sharp & Dohme LLC,?,Y,,,,,None,,
-325,NEJM,2022,Oncology,Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma,https://doi.org/10.1056/nejmoa2109970,https://cdn.clinicaltrials.gov/large-docs/22/NCT03470922/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/22/NCT03470922/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03470922,34986285,Ph2/Ph3 | quadruple | treatment,Bristol-Myers Squibb,Industry,,?,Y,,,,,None,,
-326,NEJM,2022,Infectious Disease,Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients,https://doi.org/10.1056/nejmoa2116846,https://cdn.clinicaltrials.gov/large-docs/52/NCT04501952/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/52/NCT04501952/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04501952,34937145,Ph3 | double | treatment,Gilead Sciences,Industry,,?,Y,,,,,None,,
-327,NEJM,2022,Infectious Disease,Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients,https://doi.org/10.1056/nejmoa2116044,https://cdn.clinicaltrials.gov/large-docs/97/NCT04575597/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/97/NCT04575597/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04575597,34914868,Ph2/Ph3 | double | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,,,,,None,,
-328,NEJM,2022,Oncology,Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma,https://doi.org/10.1056/nejmoa2116596,https://cdn.clinicaltrials.gov/large-docs/92/NCT03570892/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/92/NCT03570892/SAP_001.pdf,SAP,crossover,NCT03570892,34904798,Ph3 | single | treatment,Novartis Pharmaceuticals,Industry,,?,Y,,,,,None,,
-329,NEJM,2022,Oncology,Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma,https://doi.org/10.1056/nejmoa2116133,https://cdn.clinicaltrials.gov/large-docs/66/NCT03391466/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/66/NCT03391466/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03391466,34891224,Ph3 | treatment,"Kite, A Gilead Company",Industry,,?,Y,,,,,None,,
-330,NEJM,2022,Surgery/Critical Care,Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation,https://doi.org/10.1056/nejmoa2115961,https://cdn.clinicaltrials.gov/large-docs/44/NCT02675244/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/44/NCT02675244/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02675244,34767705,NA | single | treatment,Icahn School of Medicine at Mount Sinai,Academic/Other,"National Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health Research (CIHR); German Society for Thoracic and Cardiovascular Surgery; Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)",?,Y,,,,,None,,
-331,NEJM,2022,Cardiovascular,Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery,https://doi.org/10.1056/nejmoa2112299,https://cdn.clinicaltrials.gov/large-docs/22/NCT02100722/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/22/NCT02100722/Prot_SAP_000.pdf,Protocol+SAP,noninferiority,NCT02100722,34735046,NA | treatment,Stanford University,Academic/Other,"VZW Cardiovascular Research Center Aalst; Catharina Ziekenhuis Eindhoven; Golden Jubilee National Hospital; University of California, Irvine; Medtronic; (+4 more)",?,Y,,,,,None,,
-332,NEJM,2021,Infectious Disease,Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children,https://doi.org/10.1056/nejmoa2108793,https://cdn.clinicaltrials.gov/large-docs/27/NCT02259127/Prot_SAP_ICF_000.pdf,https://cdn.clinicaltrials.gov/large-docs/27/NCT02259127/Prot_SAP_ICF_000.pdf,Protocol+SAP,noninferiority,NCT02259127,34965338,Ph2/Ph3 | treatment,PENTA Foundation,Network/Cooperative,"Institut National de la Santé Et de la Recherche Médicale, France; Program for HIV Prevention and Treatment (PHPT); ViiV Healthcare; MRC CTU at UCL",?,Y,,,,,None,,
-333,NEJM,2021,Infectious Disease,Multicomponent Strategy with Decentralized Molecular Testing for Tuberculosis,https://doi.org/10.1056/nejmoa2105470,https://cdn.clinicaltrials.gov/large-docs/58/NCT03044158/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/58/NCT03044158/Prot_SAP_000.pdf,Protocol+SAP,cluster,NCT03044158,34936740,NA | diagnostic,"University of California, San Francisco",Academic/Other,"Makerere University; Johns Hopkins Bloomberg School of Public Health; London School of Hygiene and Tropical Medicine; Yale University; National Heart, Lung, and Blood Institute (NHLBI)",?,Y,,,,,None,,
-334,NEJM,2021,Dermatology,Trial of Spesolimab for Generalized Pustular Psoriasis,https://doi.org/10.1056/nejmoa2111563,https://cdn.clinicaltrials.gov/large-docs/92/NCT03782792/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/92/NCT03782792/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03782792,34936739,Ph2 | double | treatment,Boehringer Ingelheim,Industry,,?,Y,,,,,None,,
-335,NEJM,2021,Oncology,21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer,https://doi.org/10.1056/nejmoa2108873,https://cdn.clinicaltrials.gov/large-docs/37/NCT01272037/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/37/NCT01272037/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01272037,34914339,Ph3 | treatment,National Cancer Institute (NCI),NIH,,?,Y,,,,,None,,
-336,NEJM,2021,Respiratory,Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma,https://doi.org/10.1056/nejmoa2106567,https://cdn.clinicaltrials.gov/large-docs/59/NCT02948959/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/59/NCT02948959/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02948959,34879449,Ph3 | triple | treatment,Sanofi,Industry,Regeneron Pharmaceuticals,?,Y,,,,,None,,
-337,NEJM,2021,Neurology,Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis,https://doi.org/10.1056/nejmoa2103629,https://cdn.clinicaltrials.gov/large-docs/55/NCT03956355/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/55/NCT03956355/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT03956355, NCT03983980",34879448,Ph3 | quadruple | treatment,Organon and Co,Industry,IQVIA Biotech,?,Y,,,,,None,,
-338,NEJM,2021,Cardiovascular,Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction,https://doi.org/10.1056/nejmoa2104508,https://cdn.clinicaltrials.gov/large-docs/27/NCT02924727/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/27/NCT02924727/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02924727,34758252,Ph3 | quadruple | treatment,Novartis Pharmaceuticals,Industry,,?,Y,,,,,None,,
-339,NEJM,2021,Cardiovascular,Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease,https://doi.org/10.1056/nejmoa2110730,https://cdn.clinicaltrials.gov/large-docs/80/NCT02841280/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/80/NCT02841280/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02841280,34739197,Ph2 | quadruple | treatment,Indiana University,Academic/Other,,?,Y,,,,,None,,
-340,NEJM,2021,Cardiovascular,Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis,https://doi.org/10.1056/nejmoa2113380,https://cdn.clinicaltrials.gov/large-docs/35/NCT02876835/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/35/NCT02876835/SAP_001.pdf,SAP,noninferiority,NCT02876835,34739196,Ph3 | treatment,GlaxoSmithKline,Industry,,?,Y,,,,,None,,
-341,NEJM,2021,Cardiovascular,Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis,https://doi.org/10.1056/nejmoa2113379,https://cdn.clinicaltrials.gov/large-docs/05/NCT02879305/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/05/NCT02879305/SAP_001.pdf,SAP,noninferiority,NCT02879305,34739194,Ph3 | treatment,GlaxoSmithKline,Industry,,?,Y,,,,,None,,
-342,NEJM,2021,Infectious Disease,Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab,https://doi.org/10.1056/nejmoa2107934,https://cdn.clinicaltrials.gov/large-docs/60/NCT04545060/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/60/NCT04545060/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04545060,34706189,Ph2/Ph3 | quadruple | treatment,"Vir Biotechnology, Inc.",Industry,GlaxoSmithKline,?,Y,,,,,None,,
-343,NEJM,2021,Respiratory,"Risankizumab in Severe Asthma - A Phase 2a, Placebo-Controlled Trial",https://doi.org/10.1056/nejmoa2030880,https://cdn.clinicaltrials.gov/large-docs/98/NCT02443298/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/98/NCT02443298/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02443298,34706172,Ph2 | double | treatment,AbbVie,Industry,Boehringer Ingelheim,?,Y,,,,,None,,
-344,NEJM,2021,Respiratory,Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma,https://doi.org/10.1056/nejmoa2024257,https://cdn.clinicaltrials.gov/large-docs/52/NCT03387852/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/52/NCT03387852/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03387852,34706171,Ph2 | quadruple | treatment,Sanofi,Industry,Regeneron Pharmaceuticals,?,Y,,,,,None,,
-345,NEJM,2021,Infectious Disease,"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH",https://doi.org/10.1056/nejmoa2036205,https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03008070,34670042,Ph2 | quadruple | treatment,Inventiva Pharma,Industry,,?,Y,,,,,None,,
-346,NEJM,2021,Infectious Disease,Efficacy of a Cell-Culture-Derived Quadrivalent Influenza Vaccine in Children,https://doi.org/10.1056/nejmoa2024848,https://cdn.clinicaltrials.gov/large-docs/17/NCT03165617/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/17/NCT03165617/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03165617,34644472,Ph3 | quadruple | prevention,Seqirus,Industry,,?,Y,,,,,None,,
-347,NEJM,2021,Psychiatry/Mental Health,Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder,https://doi.org/10.1056/nejmoa2103583,https://cdn.clinicaltrials.gov/large-docs/46/NCT01944046/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/46/NCT01944046/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01944046,34644471,Ph2 | quadruple | treatment,Linmarie Sikich,Academic/Other,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),?,Y,,,,,None,,
-348,NEJM,2021,Surgery/Critical Care,Spinal Anesthesia or General Anesthesia for Hip Surgery in Older Adults,https://doi.org/10.1056/nejmoa2113514,https://cdn.clinicaltrials.gov/large-docs/05/NCT02507505/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/05/NCT02507505/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02507505,34623788,NA | double | prevention,University of Pennsylvania,Academic/Other,Patient-Centered Outcomes Research Institute,?,Y,,,,,None,,
-349,NEJM,2021,Cardiovascular,Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis,https://doi.org/10.1056/nejmoa2033617,https://cdn.clinicaltrials.gov/large-docs/92/NCT02435992/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/92/NCT02435992/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02435992,34587385,Ph3 | quadruple | treatment,Celgene,Industry,,?,Y,,,,,None,,
-350,NEJM,2021,Infectious Disease,REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19,https://doi.org/10.1056/nejmoa2108163,https://cdn.clinicaltrials.gov/large-docs/29/NCT04425629/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/29/NCT04425629/SAP_002.pdf,SAP,single_arm,NCT04425629,34587383,Ph3 | treatment,Regeneron Pharmaceuticals,Industry,,?,Y,,,,,None,,
-351,NEJM,2021,Infectious Disease,Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine,https://doi.org/10.1056/nejmoa2105290,https://cdn.clinicaltrials.gov/large-docs/46/NCT04516746/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/46/NCT04516746/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04516746,34587382,Ph3 | quadruple | treatment,AstraZeneca,Industry,IQVIA Pty Ltd,?,Y,,,,,None,,
-352,NEJM,2021,Oncology,Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma,https://doi.org/10.1056/nejmoa2103485,https://cdn.clinicaltrials.gov/large-docs/92/NCT03070392/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/92/NCT03070392/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03070392,34551229,Ph2 | treatment,Immunocore Ltd,Industry,,?,Y,,,,,None,,
-353,NEJM,2021,Infectious Disease,Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase,https://doi.org/10.1056/nejmoa2113017,https://cdn.clinicaltrials.gov/large-docs/27/NCT04470427/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/27/NCT04470427/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04470427,34551225,Ph3 | quadruple | prevention,"ModernaTX, Inc.",Industry,Biomedical Advanced Research and Development Authority; National Institute of Allergy and Infectious Diseases (NIAID),?,Y,,,,,None,,
-354,NEJM,2021,Oncology,"Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer",https://doi.org/10.1056/nejmoa2112435,https://cdn.clinicaltrials.gov/large-docs/67/NCT03635567/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/67/NCT03635567/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03635567,34534429,Ph3 | triple | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,,,,,None,,
-355,NEJM,2021,Infectious Disease,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,https://doi.org/10.1056/nejmoa2110345,https://cdn.clinicaltrials.gov/large-docs/28/NCT04368728/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/28/NCT04368728/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04368728,34525277,Ph2/Ph3 | triple | prevention,BioNTech SE,Industry,Pfizer,?,Y,,,,,None,,
-356,NEJM,2021,Cardiovascular,Empagliflozin in Heart Failure with a Preserved Ejection Fraction,https://doi.org/10.1056/nejmoa2107038,https://cdn.clinicaltrials.gov/large-docs/51/NCT03057951/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/51/NCT03057951/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03057951,34449189,Ph3 | double | treatment,Boehringer Ingelheim,Industry,Eli Lilly and Company,?,Y,,,,,None,,
-357,NEJM,2021,Cardiovascular,Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR,https://doi.org/10.1056/nejmoa2111016,https://cdn.clinicaltrials.gov/large-docs/85/NCT02943785/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/85/NCT02943785/Prot_SAP_000.pdf,Protocol+SAP,noninferiority,NCT02943785,34449183,Ph3 | treatment,Daiichi Sankyo,Industry,Chiltern International Inc.,?,Y,,,,,None,,
-358,NEJM,2021,Cardiovascular,Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes,https://doi.org/10.1056/nejmoa2110956,https://cdn.clinicaltrials.gov/large-docs/49/NCT02545049/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/49/NCT02545049/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02545049,34449181,Ph3 | quadruple | treatment,Bayer,Industry,,?,Y,,,,,None,,
-359,NEJM,2021,Respiratory,Triple Therapy for Cystic Fibrosis <i>Phe508del</i>-Gating and -Residual Function Genotypes,https://doi.org/10.1056/nejmoa2100665,https://cdn.clinicaltrials.gov/large-docs/53/NCT04058353/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/53/NCT04058353/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04058353,34437784,Ph3 | quadruple | treatment,Vertex Pharmaceuticals Incorporated,Industry,,?,Y,,,,,None,,
-360,NEJM,2021,Infectious Disease,Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention,https://doi.org/10.1056/nejmoa2026330,https://cdn.clinicaltrials.gov/large-docs/18/NCT03143218/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/18/NCT03143218/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03143218,34432975,Ph3 | triple | prevention,London School of Hygiene and Tropical Medicine,Academic/Other,"Malaria Research and Training Center, Bamako, Mali; Institut de Recherche en Sciences de la Sante, Burkina Faso",?,Y,,,,,None,,
-361,NEJM,2021,Neurology,Atogepant for the Preventive Treatment of Migraine,https://doi.org/10.1056/nejmoa2035908,https://cdn.clinicaltrials.gov/large-docs/59/NCT03777059/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/59/NCT03777059/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03777059,34407343,Ph3 | double | prevention,Allergan,Industry,,?,Y,,,,,None,,
-362,NEJM,2021,Oncology,Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma,https://doi.org/10.1056/nejmoa2106391,https://cdn.clinicaltrials.gov/large-docs/34/NCT03142334/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/34/NCT03142334/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03142334,34407342,Ph3 | quadruple | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,,,,,None,,
-363,NEJM,2021,Infectious Disease,Early Convalescent Plasma for High-Risk Outpatients with Covid-19,https://doi.org/10.1056/nejmoa2103784,https://cdn.clinicaltrials.gov/large-docs/67/NCT04355767/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/67/NCT04355767/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04355767,34407339,Ph3 | double | treatment,Stanford University,Academic/Other,"National Heart, Lung, and Blood Institute (NHLBI); Strategies to Innovate EmeRgENcy Care Clinical Trials Network; University of Pittsburgh; Medical University of South Carolina",?,Y,,,,,None,,
-364,NEJM,2021,Infectious Disease,Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women,https://doi.org/10.1056/nejmoa2101016,https://cdn.clinicaltrials.gov/large-docs/94/NCT02720094/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/94/NCT02720094/SAP_002.pdf,SAP,noninferiority,NCT02720094,34379922,Ph2/Ph3 | quadruple | prevention,National Institute of Allergy and Infectious Diseases (NIAID),NIH,ViiV Healthcare; Gilead Sciences,?,Y,,,,,None,,
-365,NEJM,2021,Infectious Disease,Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents,https://doi.org/10.1056/nejmoa2109522,https://cdn.clinicaltrials.gov/large-docs/51/NCT04649151/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/51/NCT04649151/SAP_002.pdf,SAP,noninferiority,NCT04649151,34379915,Ph2/Ph3 | quadruple | prevention,"ModernaTX, Inc.",Industry,Biomedical Advanced Research and Development Authority,?,Y,,,,,None,,
-366,NEJM,2021,Infectious Disease,Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19,https://doi.org/10.1056/nejmoa2103417,https://cdn.clinicaltrials.gov/large-docs/74/NCT04505774/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/74/NCT04505774/SAP_003.pdf,SAP,platform,"NCT02735707, NCT04505774, NCT04359277, NCT04372589",34351722,Ph4 | treatment,UMC Utrecht,Academic/Other,Australian and New Zealand Intensive Care Research Centre; Medical Research Institute of New Zealand; Unity Health; Berry Consultants; Global Coalition for Adaptive Research; (+5 more),?,Y,,,,,None,,
-367,NEJM,2021,Infectious Disease,Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19,https://doi.org/10.1056/nejmoa2105911,https://cdn.clinicaltrials.gov/large-docs/74/NCT04505774/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/74/NCT04505774/SAP_003.pdf,SAP,platform;adaptive_bayesian,"NCT04372589, NCT04505774, NCT04359277, NCT02735707",34351721,Ph4 | treatment,University of Manitoba,Academic/Other,"University Health Network, Toronto",?,Y,,,,,None,,
-368,NEJM,2021,Rheumatology/Immunology,Decompression with or without Fusion in Degenerative Lumbar Spondylolisthesis,https://doi.org/10.1056/nejmoa2100990,,https://cdn.clinicaltrials.gov/large-docs/74/NCT02051374/SAP_002.pdf,SAP,noninferiority,NCT02051374,34347953,NA | single | treatment,Haukeland University Hospital,Academic/Other,Møre og Romsdal Hospital Trust,?,Y,,,,,None,,
-369,NEJM,2021,Infectious Disease,Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19,https://doi.org/10.1056/nejmoa2109682,https://cdn.clinicaltrials.gov/large-docs/18/NCT04452318/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/18/NCT04452318/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT04452318,34347950,Ph3 | quadruple | treatment,Regeneron Pharmaceuticals,Industry,,?,Y,,,,,None,,
-370,NEJM,2021,Infectious Disease,A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection,https://doi.org/10.1056/nejmoa1913569,https://cdn.clinicaltrials.gov/large-docs/78/NCT01376778/Prot_SAP_ICF_000.pdf,https://cdn.clinicaltrials.gov/large-docs/78/NCT01376778/Prot_SAP_ICF_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01376778,34320288,Ph3 | double | prevention,The George Washington University Biostatistics Center,Academic/Other,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),?,Y,,,,,None,,
-371,NEJM,2021,Oncology,Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer,https://doi.org/10.1056/nejmoa2104162,https://cdn.clinicaltrials.gov/large-docs/20/NCT00295620/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/20/NCT00295620/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT00295620,34320285,Ph3 | treatment,AstraZeneca,Industry,,?,Y,,,,,None,,
-372,NEJM,2021,Neurology,Trial of Pimavanserin in Dementia-Related Psychosis,https://doi.org/10.1056/nejmoa2034634,https://cdn.clinicaltrials.gov/large-docs/56/NCT03325556/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/56/NCT03325556/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03325556,34289275,Ph3 | quadruple | treatment,ACADIA Pharmaceuticals Inc.,Industry,,?,Y,,,,,None,,
-373,NEJM,2021,Infectious Disease,Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19,https://doi.org/10.1056/nejmoa2102685,https://cdn.clinicaltrials.gov/large-docs/01/NCT04427501/Prot_003.pdf,https://cdn.clinicaltrials.gov/large-docs/01/NCT04427501/SAP_005.pdf,SAP,fixed_parallel_superiority,NCT04427501,34260849,Ph2/Ph3 | double | treatment,Eli Lilly and Company,Industry,"AbCellera Biologics Inc.; Shanghai Junshi Bioscience Co., Ltd.",?,Y,,,,,None,,
-374,NEJM,2021,Infectious Disease,Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease,https://doi.org/10.1056/nejmoa2033122,https://cdn.clinicaltrials.gov/large-docs/03/NCT03112603/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/03/NCT03112603/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03112603,34260836,Ph3 | treatment,Incyte Corporation,Industry,,?,Y,,,,,None,,
-375,NEJM,2021,Cardiovascular,Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes,https://doi.org/10.1056/nejmoa2108269,https://cdn.clinicaltrials.gov/large-docs/98/NCT03496298/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/98/NCT03496298/SAP_001.pdf,SAP,noninferiority,NCT03496298,34215025,Ph3 | quadruple | treatment,Sanofi,Industry,Hanmi Pharmaceutical Company Limited,?,Y,,,,,None,,
-376,NEJM,2021,Other,Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis,https://doi.org/10.1056/nejmoa2028631,https://cdn.clinicaltrials.gov/large-docs/65/NCT03201965/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/65/NCT03201965/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03201965,34192431,Ph3 | treatment,"Janssen Research & Development, LLC",Industry,,?,Y,,,,,None,,
-377,NEJM,2021,Endocrinology/Metabolism,Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes,https://doi.org/10.1056/nejmoa2107519,https://cdn.clinicaltrials.gov/large-docs/19/NCT03987919/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/19/NCT03987919/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03987919,34170647,Ph3 | treatment,Eli Lilly and Company,Industry,,?,Y,,,,,None,,
-378,NEJM,2021,Oncology,Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer,https://doi.org/10.1056/nejmoa2107322,https://cdn.clinicaltrials.gov/large-docs/64/NCT03511664/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/64/NCT03511664/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03511664,34161051,Ph3 | treatment,Endocyte,Industry,,?,Y,,,,,None,,
-379,NEJM,2021,Infectious Disease,Efficacy of Wolbachia-Infected Mosquito Deployments for the Control of Dengue,https://doi.org/10.1056/nejmoa2030243,,https://cdn.clinicaltrials.gov/large-docs/85/NCT03055585/SAP_002.pdf,SAP,cluster,NCT03055585,34107180,NA | prevention,Gadjah Mada University,Academic/Other,Monash University; The Tahija Foundation,?,Y,,,,,None,,
-380,NEJM,2021,Other,Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris,https://doi.org/10.1056/nejmoa2028564,https://cdn.clinicaltrials.gov/large-docs/89/NCT02383589/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/89/NCT02383589/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT02383589,34097368,Ph3 | double | treatment,Hoffmann-La Roche,Industry,"Genentech, Inc.",?,Y,,,,,None,,
-381,NEJM,2021,Oncology,Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer,https://doi.org/10.1056/nejmoa2105215,https://cdn.clinicaltrials.gov/large-docs/23/NCT02032823/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/23/NCT02032823/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02032823,34081848,Ph3 | triple | treatment,AstraZeneca,Industry,"Breast International Group; Frontier Science & Technology Research Foundation, Inc.; NRG Oncology; Myriad Genetic Laboratories, Inc.; The Breast Adjuvant Study Team; (+1 more)",?,Y,,,,,None,,
-382,NEJM,2021,Infectious Disease,Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers,https://doi.org/10.1056/nejmoa2013615,https://cdn.clinicaltrials.gov/large-docs/18/NCT03295318/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/18/NCT03295318/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03295318,34077644,Ph2 | quadruple | prevention,Serum Institute of India Pvt. Ltd.,Industry,PATH,?,Y,,,,,None,,
-383,NEJM,2021,Oncology,Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma,https://doi.org/10.1056/nejmoa2034442,https://cdn.clinicaltrials.gov/large-docs/09/NCT02632409/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/09/NCT02632409/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02632409,34077643,Ph3 | triple | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,,,,,None,,
-384,NEJM,2021,Infectious Disease,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",https://doi.org/10.1056/nejmoa2107456,https://cdn.clinicaltrials.gov/large-docs/28/NCT04368728/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/28/NCT04368728/SAP_001.pdf,SAP,noninferiority,NCT04368728,34043894,Ph2/Ph3 | triple | prevention,BioNTech SE,Industry,Pfizer,?,Y,,,,,None,,
-385,NEJM,2021,Cardiovascular,Final Report of a Trial of Intensive versus Standard Blood-Pressure Control,https://doi.org/10.1056/nejmoa1901281,https://cdn.clinicaltrials.gov/large-docs/62/NCT01206062/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/62/NCT01206062/Prot_000.pdf,Protocol only,fixed_parallel_superiority,NCT01206062,34010531,NA | single | treatment,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,National Institute on Aging (NIA); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Neurological Disorders and Stroke (NINDS); Wake Forest University Health Sciences,?,Y,,,,,None,,
-386,NEJM,2021,Cardiovascular,Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease,https://doi.org/10.1056/nejmoa2102137,https://cdn.clinicaltrials.gov/large-docs/16/NCT02697916/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/16/NCT02697916/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02697916,33999548,NA | prevention,Duke University,Academic/Other,Patient-Centered Outcomes Research Institute; Medidata Solutions; Chicago Area Patient-Centered Outcomes Research Network (CAPriCORN); Greater Plains Collaborative Clinical Data Research Network; Mid-South Clinical Data Research Network; (+9 more),?,Y,,,,,None,,
-387,NEJM,2021,Cardiovascular,Physical Rehabilitation for Older Patients Hospitalized for Heart Failure,https://doi.org/10.1056/nejmoa2026141,https://cdn.clinicaltrials.gov/large-docs/38/NCT02196038/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/38/NCT02196038/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02196038,33999544,NA | single | treatment,Wake Forest University Health Sciences,Academic/Other,National Institute on Aging (NIA),?,Y,,,,,None,,
-388,NEJM,2021,Respiratory,"Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma",https://doi.org/10.1056/nejmoa2034975,https://cdn.clinicaltrials.gov/large-docs/79/NCT03347279/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/79/NCT03347279/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03347279,33979488,Ph3 | triple | treatment,AstraZeneca,Industry,Amgen,?,Y,,,,,None,,
-389,NEJM,2021,Infectious Disease,Tympanostomy Tubes or Medical Management for Recurrent Acute Otitis Media,https://doi.org/10.1056/nejmoa2027278,https://cdn.clinicaltrials.gov/large-docs/25/NCT02567825/Prot_SAP_002.pdf,https://cdn.clinicaltrials.gov/large-docs/25/NCT02567825/Prot_SAP_002.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02567825,33979487,NA | treatment,Alejandro Hoberman,Academic/Other,George Washington University; National Institute on Deafness and Other Communication Disorders (NIDCD),?,Y,,,,,None,,
-390,NEJM,2021,Endocrinology/Metabolism,"Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined",https://doi.org/10.1056/nejmoa2028198,,https://cdn.clinicaltrials.gov/large-docs/16/NCT04122716/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04122716,33951361,Ph4 | quadruple | treatment,Signe Torekov,Academic/Other,Hvidovre University Hospital; University of Oxford; Karolinska Institutet,?,Y,,,,,None,,
-391,NEJM,2021,Infectious Disease,Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis,https://doi.org/10.1056/nejmoa2033400,https://cdn.clinicaltrials.gov/large-docs/72/NCT02410772/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/72/NCT02410772/Prot_SAP_000.pdf,Protocol+SAP,noninferiority,NCT02410772,33951360,Ph3 | treatment,Centers for Disease Control and Prevention,US Federal,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,?,Y,,,,,None,,
-392,NEJM,2021,Cardiovascular,Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis,https://doi.org/10.1056/nejmoa2025956,https://cdn.clinicaltrials.gov/large-docs/50/NCT02865850/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/50/NCT02865850/SAP_001.pdf,SAP,noninferiority,"NCT02865850, NCT02892149",33913638,Ph3 | treatment,Akebia Therapeutics,Industry,,?,Y,,,,,None,,
-393,NEJM,2021,Cardiovascular,Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD,https://doi.org/10.1056/nejmoa2035938,https://cdn.clinicaltrials.gov/large-docs/47/NCT02648347/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/47/NCT02648347/SAP_001.pdf,SAP,noninferiority,"NCT02648347, NCT02680574",33913637,Ph3 | treatment,Akebia Therapeutics,Industry,,?,Y,,,,,None,,
-394,NEJM,2021,Dermatology,Bimekizumab versus Secukinumab in Plaque Psoriasis,https://doi.org/10.1056/nejmoa2102383,https://cdn.clinicaltrials.gov/large-docs/84/NCT03536884/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/84/NCT03536884/SAP_001.pdf,SAP,noninferiority,NCT03536884,33891380,Ph3 | quadruple | treatment,UCB Biopharma SRL,Industry,,?,Y,,,,,None,,
-395,NEJM,2021,Dermatology,Bimekizumab versus Adalimumab in Plaque Psoriasis,https://doi.org/10.1056/nejmoa2102388,https://cdn.clinicaltrials.gov/large-docs/47/NCT03412747/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/47/NCT03412747/SAP_001.pdf,SAP,noninferiority,NCT03412747,33891379,Ph3 | quadruple | treatment,UCB Biopharma SRL,Industry,,?,Y,,,,,None,,
-396,NEJM,2021,Infectious Disease,Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19,https://doi.org/10.1056/nejmoa2101544,https://cdn.clinicaltrials.gov/large-docs/22/NCT04505722/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/22/NCT04505722/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT04505722,33882225,Ph3 | quadruple | prevention,Janssen Vaccines & Prevention B.V.,Industry,,?,Y,,,,,None,,
-397,NEJM,2021,Oncology,Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer,https://doi.org/10.1056/nejmoa2028485,https://cdn.clinicaltrials.gov/large-docs/55/NCT02574455/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/55/NCT02574455/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT02574455,33882206,Ph3 | treatment,Gilead Sciences,Industry,,?,Y,,,,,None,,
-398,NEJM,2021,Psychiatry/Mental Health,Trial of Psilocybin versus Escitalopram for Depression,https://doi.org/10.1056/nejmoa2032994,https://cdn.clinicaltrials.gov/large-docs/75/NCT03429075/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/75/NCT03429075/Prot_000.pdf,Protocol only,fixed_parallel_superiority,NCT03429075,33852780,Ph2 | double | treatment,Imperial College London,Academic/Other,Alexander Mosely Charitable Trust,?,Y,,,,,None,,
-399,NEJM,2021,Gastroenterology/Hepatology,Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis,https://doi.org/10.1056/nejmoa2022516,https://cdn.clinicaltrials.gov/large-docs/00/NCT03104400/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/00/NCT03104400/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03104400,33789011,Ph3 | quadruple | treatment,AbbVie,Industry,,?,Y,,,,,None,,
-400,NEJM,2021,Nephrology/Urology,"Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1",https://doi.org/10.1056/nejmoa2021712,https://cdn.clinicaltrials.gov/large-docs/84/NCT03681184/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/84/NCT03681184/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03681184,33789010,Ph3 | quadruple | treatment,Alnylam Pharmaceuticals,Industry,,?,Y,,,,,None,,
-401,NEJM,2021,Cardiovascular,Sotatercept for the Treatment of Pulmonary Arterial Hypertension,https://doi.org/10.1056/nejmoa2024277,https://cdn.clinicaltrials.gov/large-docs/07/NCT03496207/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/07/NCT03496207/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03496207,33789009,Ph2 | quadruple | treatment,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",Industry,,?,Y,,,,,None,,
-402,NEJM,2021,Oncology,Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer,https://doi.org/10.1056/nejmoa2032125,https://cdn.clinicaltrials.gov/large-docs/94/NCT02743494/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/94/NCT02743494/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02743494,33789008,Ph3 | double | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,,,,,None,,
-403,NEJM,2021,Dermatology,Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis,https://doi.org/10.1056/nejmoa2019380,https://cdn.clinicaltrials.gov/large-docs/70/NCT03720470/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/70/NCT03720470/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03720470,33761207,Ph3 | quadruple | treatment,Pfizer,Industry,,?,Y,,,,,None,,
-404,NEJM,2021,Infectious Disease,Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults,https://doi.org/10.1056/nejmoa2031499,https://cdn.clinicaltrials.gov/large-docs/49/NCT02968849/Prot_ICF_000.pdf,https://cdn.clinicaltrials.gov/large-docs/49/NCT02968849/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02968849,33761206,Ph2/Ph3 | quadruple | prevention,National Institute of Allergy and Infectious Diseases (NIAID),NIH,Sanofi; GlaxoSmithKline; Bill and Melinda Gates Foundation,?,Y,,,,,None,,
-405,NEJM,2021,Hematology,Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria,https://doi.org/10.1056/nejmoa2029073,https://cdn.clinicaltrials.gov/large-docs/49/NCT03500549/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/49/NCT03500549/SAP_001.pdf,SAP,noninferiority,NCT03500549,33730455,Ph3 | treatment,"Apellis Pharmaceuticals, Inc.",Industry,,?,Y,,,,,None,,
-406,NEJM,2021,Infectious Disease,Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition,https://doi.org/10.1056/nejmoa2031738,https://cdn.clinicaltrials.gov/large-docs/75/NCT02716675/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/75/NCT02716675/SAP_002.pdf,SAP,fixed_parallel_superiority,"NCT02716675, NCT02568215",33730454,Ph2 | quadruple | prevention,National Institute of Allergy and Infectious Diseases (NIAID),NIH,,?,Y,,,,,None,,
-407,NEJM,2021,Neurology,Donanemab in Early Alzheimer's Disease,https://doi.org/10.1056/nejmoa2100708,https://cdn.clinicaltrials.gov/large-docs/03/NCT03367403/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/03/NCT03367403/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03367403,33720637,Ph2 | double | treatment,Eli Lilly and Company,Industry,,?,Y,,,,,None,,
-408,NEJM,2021,Oncology,Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma,https://doi.org/10.1056/nejmoa2026982,https://cdn.clinicaltrials.gov/large-docs/77/NCT03141177/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/77/NCT03141177/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03141177,33657295,Ph3 | treatment,Bristol-Myers Squibb,Industry,"Exelixis; Ono Pharmaceutical Co., Ltd.",?,Y,,,,,None,,
-409,NEJM,2021,Respiratory,Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome,https://doi.org/10.1056/nejmoa2008290,https://cdn.clinicaltrials.gov/large-docs/16/NCT02770716/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/16/NCT02770716/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02770716,33657294,Ph3 | double | treatment,Mallinckrodt,Industry,,?,Y,,,,,None,,
-410,NEJM,2021,Infectious Disease,Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia,https://doi.org/10.1056/nejmoa2028700,https://cdn.clinicaltrials.gov/large-docs/15/NCT04320615/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/15/NCT04320615/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04320615,33631066,Ph3 | double | treatment,Hoffmann-La Roche,Industry,,?,Y,,,,,None,,
-411,NEJM,2021,Psychiatry/Mental Health,Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia,https://doi.org/10.1056/nejmoa2017015,https://cdn.clinicaltrials.gov/large-docs/52/NCT03697252/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/52/NCT03697252/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03697252,33626254,Ph2 | triple | treatment,"Karuna Therapeutics, Inc., a Bristol Myers Squibb company",Industry,,?,Y,,,,,None,,
-412,NEJM,2021,Oncology,Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma,https://doi.org/10.1056/nejmoa2035716,https://cdn.clinicaltrials.gov/large-docs/61/NCT02811861/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/61/NCT02811861/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02811861,33616314,Ph3 | treatment,Eisai Inc.,Industry,Merck Sharp & Dohme LLC,?,Y,,,,,None,,
-413,NEJM,2021,Oncology,Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy,https://doi.org/10.1056/nejmoa2008283,https://cdn.clinicaltrials.gov/large-docs/35/NCT03049735/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/35/NCT03049735/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT03049735, NCT03103087",33596357,Ph3 | triple | treatment,Myovant Sciences GmbH,Industry,,?,Y,,,,,None,,
-414,NEJM,2021,Rheumatology/Immunology,Avacopan for the Treatment of ANCA-Associated Vasculitis,https://doi.org/10.1056/nejmoa2023386,https://cdn.clinicaltrials.gov/large-docs/27/NCT02994927/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/27/NCT02994927/SAP_001.pdf,SAP,noninferiority,NCT02994927,33596356,Ph3 | quadruple | treatment,Amgen,Industry,,?,Y,,,,,None,,
-415,NEJM,2021,Oncology,Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma,https://doi.org/10.1056/nejmoa2035807,https://cdn.clinicaltrials.gov/large-docs/07/NCT03474107/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/07/NCT03474107/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03474107,33577729,Ph3 | treatment,"Astellas Pharma Global Development, Inc.",Industry,Seagen Inc.,?,Y,,,,,None,,
-416,NEJM,2021,Infectious Disease,Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection,https://doi.org/10.1056/nejmoa2023345,https://cdn.clinicaltrials.gov/large-docs/57/NCT01436357/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/57/NCT01436357/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT01436357,33567193,Ph1/Ph2 | triple | prevention,National Institute of Allergy and Infectious Diseases (NIAID),NIH,,?,Y,,,,,None,,
-417,NEJM,2021,Dermatology,Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis,https://doi.org/10.1056/nejmoa2024040,https://cdn.clinicaltrials.gov/large-docs/77/NCT03285477/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/77/NCT03285477/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT03285477, NCT03285490",33567191,Ph3 | quadruple | treatment,"Almirall, S.A.",Industry,"Athenex, Inc.",?,Y,,,,,None,,
-418,NEJM,2021,Endocrinology/Metabolism,Once-Weekly Semaglutide in Adults with Overweight or Obesity,https://doi.org/10.1056/nejmoa2032183,https://cdn.clinicaltrials.gov/large-docs/35/NCT03548935/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/35/NCT03548935/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03548935,33567185,Ph3 | quadruple | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-419,NEJM,2021,Infectious Disease,Dexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis,https://doi.org/10.1056/nejmoa2024922,https://cdn.clinicaltrials.gov/large-docs/33/NCT01739933/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/33/NCT01739933/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT01739933,33528922,Ph3 | triple | prevention,Vanderbilt University Medical Center,Academic/Other,,?,Y,,,,,None,,
-420,NEJM,2021,Obstetrics/Gynecology,Levonorgestrel vs. Copper Intrauterine Devices for Emergency Contraception,https://doi.org/10.1056/nejmoa2022141,https://cdn.clinicaltrials.gov/large-docs/30/NCT02175030/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/30/NCT02175030/Prot_SAP_000.pdf,Protocol+SAP,noninferiority,NCT02175030,33503342,Ph4 | prevention,University of Utah,Academic/Other,,?,Y,,,,,None,,
-421,NEJM,2021,Other,Bupropion and Naltrexone in Methamphetamine Use Disorder,https://doi.org/10.1056/nejmoa2020214,https://cdn.clinicaltrials.gov/large-docs/75/NCT03078075/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/75/NCT03078075/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03078075,33497547,Ph3 | quadruple | treatment,University of Texas Southwestern Medical Center,Academic/Other,"National Institute on Drug Abuse (NIDA); The Emmes Company, LLC",?,Y,,,,,None,,
-422,NEJM,2021,Infectious Disease,Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine,https://doi.org/10.1056/nejmoa2034201,https://cdn.clinicaltrials.gov/large-docs/76/NCT04436276/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/76/NCT04436276/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT04436276,33440088,Ph1/Ph2 | double | other,Janssen Vaccines & Prevention B.V.,Industry,,?,Y,,,,,None,,
-423,NEJM,2021,Cardiovascular,Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease,https://doi.org/10.1056/nejmoa2008470,https://cdn.clinicaltrials.gov/large-docs/16/NCT02630316/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/16/NCT02630316/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT02630316,33440084,Ph2/Ph3 | quadruple | treatment,United Therapeutics,Industry,,?,Y,,,,,None,,
-424,NEJM,2021,Infectious Disease,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,https://doi.org/10.1056/nejmoa2035389,https://cdn.clinicaltrials.gov/large-docs/27/NCT04470427/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/27/NCT04470427/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04470427,33378609,Ph3 | quadruple | prevention,"ModernaTX, Inc.",Industry,Biomedical Advanced Research and Development Authority; National Institute of Allergy and Infectious Diseases (NIAID),?,Y,,,,,None,,
-425,NEJM,2021,Infectious Disease,Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia,https://doi.org/10.1056/nejmoa2030340,https://cdn.clinicaltrials.gov/large-docs/86/NCT04372186/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/86/NCT04372186/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04372186,33332779,Ph3 | double | treatment,"Genentech, Inc.",Industry,,?,Y,,,,,None,,
-426,NEJM,2021,Infectious Disease,"REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19",https://doi.org/10.1056/nejmoa2035002,https://cdn.clinicaltrials.gov/large-docs/29/NCT04425629/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/29/NCT04425629/SAP_002.pdf,SAP,single_arm,NCT04425629,33332778,Ph3 | treatment,Regeneron Pharmaceuticals,Industry,,?,Y,,,,,None,,
-427,NEJM,2021,Infectious Disease,Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19,https://doi.org/10.1056/nejmoa2031994,https://cdn.clinicaltrials.gov/large-docs/79/NCT04401579/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/79/NCT04401579/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT04401579,33306283,Ph3 | double | treatment,National Institute of Allergy and Infectious Diseases (NIAID),NIH,,?,Y,,,,,None,,
-428,NEJM,2021,Cardiovascular,Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure,https://doi.org/10.1056/nejmoa2030183,https://cdn.clinicaltrials.gov/large-docs/34/NCT03521934/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/34/NCT03521934/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03521934,33200892,Ph3 | quadruple | treatment,Lexicon Pharmaceuticals,Industry,Sanofi,?,Y,,,,,None,,
-429,NEJM,2021,Cardiovascular,Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease,https://doi.org/10.1056/nejmoa2030186,https://cdn.clinicaltrials.gov/large-docs/43/NCT03315143/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/43/NCT03315143/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03315143,33200891,Ph3 | quadruple | prevention,Lexicon Pharmaceuticals,Industry,Sanofi,?,Y,,,,,None,,
-430,NEJM,2021,Infectious Disease,Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis,https://doi.org/10.1056/nejmoa2027892,https://cdn.clinicaltrials.gov/large-docs/10/NCT03737110/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/10/NCT03737110/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT03737110,33200890,Ph3 | triple | treatment,"Kiniksa Pharmaceuticals (UK), Ltd.",Industry,,?,Y,,,,,None,,
-431,NEJM,2021,Cardiovascular,Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation,https://doi.org/10.1056/nejmoa2029554,https://cdn.clinicaltrials.gov/large-docs/18/NCT03118518/Prot_006.pdf,https://cdn.clinicaltrials.gov/large-docs/18/NCT03118518/SAP_007.pdf,SAP,fixed_parallel_superiority,NCT03118518,33197158,NA | treatment,Medtronic Cardiac Ablation Solutions,Industry,,?,Y,,,,,None,,
-432,NEJM,2021,Cardiovascular,Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure,https://doi.org/10.1056/nejmoa2025797,https://cdn.clinicaltrials.gov/large-docs/29/NCT02929329/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/29/NCT02929329/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02929329,33185990,Ph3 | triple | treatment,Cytokinetics,Industry,,?,Y,,,,,None,,
-433,NEJM,2021,Infectious Disease,A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis,https://doi.org/10.1056/nejmoa2028395,https://cdn.clinicaltrials.gov/large-docs/42/NCT02970942/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/42/NCT02970942/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02970942,33185364,Ph2 | double | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-434,NEJM,2021,Infectious Disease,SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19,https://doi.org/10.1056/nejmoa2029849,https://cdn.clinicaltrials.gov/large-docs/01/NCT04427501/Prot_003.pdf,https://cdn.clinicaltrials.gov/large-docs/01/NCT04427501/SAP_005.pdf,SAP,fixed_parallel_superiority,NCT04427501,33113295,Ph2/Ph3 | double | treatment,Eli Lilly and Company,Industry,"AbCellera Biologics Inc.; Shanghai Junshi Bioscience Co., Ltd.",?,Y,,,,,None,,
-435,NEJM,2020,Respiratory,Higher or Lower Hemoglobin Transfusion Thresholds for Preterm Infants,https://doi.org/10.1056/nejmoa2020248,https://cdn.clinicaltrials.gov/large-docs/05/NCT01702805/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/05/NCT01702805/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01702805,33382931,NA | quadruple | treatment,NICHD Neonatal Research Network,Network/Cooperative,"National Heart, Lung, and Blood Institute (NHLBI); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",?,Y,,,,,None,,
-436,NEJM,2020,Oncology,Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission,https://doi.org/10.1056/nejmoa2004444,https://cdn.clinicaltrials.gov/large-docs/35/NCT01757535/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/35/NCT01757535/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT01757535,33369355,Ph3 | quadruple | treatment,Celgene,Industry,,?,Y,,,,,None,,
-437,NEJM,2020,Infectious Disease,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,https://doi.org/10.1056/nejmoa2034577,https://cdn.clinicaltrials.gov/large-docs/28/NCT04368728/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/28/NCT04368728/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04368728,33301246,Ph2/Ph3 | triple | prevention,BioNTech SE,Industry,Pfizer,?,Y,,,,,None,,
-438,NEJM,2020,Endocrinology/Metabolism,Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes,https://doi.org/10.1056/nejmoa2025845,https://cdn.clinicaltrials.gov/large-docs/93/NCT02540993/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/93/NCT02540993/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02540993,33264825,Ph3 | quadruple | treatment,Bayer,Industry,,?,Y,,,,,None,,
-439,NEJM,2020,Oncology,Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer,https://doi.org/10.1056/nejmoa2017699,https://cdn.clinicaltrials.gov/large-docs/02/NCT02563002/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/02/NCT02563002/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02563002,33264544,Ph3 | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,,,,,None,,
-440,NEJM,2020,Oncology,First-Line Lorlatinib or Crizotinib in Advanced &lt;i&gt;ALK&lt;/i&gt;-Positive Lung Cancer,https://doi.org/10.1056/nejmoa2027187,https://cdn.clinicaltrials.gov/large-docs/08/NCT03052608/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/08/NCT03052608/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT03052608,33207094,Ph3 | treatment,Pfizer,Industry,,?,Y,,,,,None,,
-441,NEJM,2020,Oncology,Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes,https://doi.org/10.1056/nejmoa2006136,https://cdn.clinicaltrials.gov/large-docs/45/NCT02846545/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/45/NCT02846545/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02846545,33207093,Ph2 | double | treatment,"Janssen Research & Development, LLC",Industry,,?,Y,,,,,None,,
-442,NEJM,2020,Other,Evinacumab in Patients with Refractory Hypercholesterolemia,https://doi.org/10.1056/nejmoa2031049,https://cdn.clinicaltrials.gov/large-docs/67/NCT03175367/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/67/NCT03175367/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03175367,33196153,Ph2 | triple | treatment,Regeneron Pharmaceuticals,Industry,,?,Y,,,,,None,,
-443,NEJM,2020,Infectious Disease,Macrolide and Nonmacrolide Resistance with Mass Azithromycin Distribution,https://doi.org/10.1056/nejmoa2002606,https://cdn.clinicaltrials.gov/large-docs/81/NCT02047981/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/81/NCT02047981/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT02047981,33176084,Ph4 | quadruple | treatment,"University of California, San Francisco",Academic/Other,Bill and Melinda Gates Foundation; Johns Hopkins University; London School of Hygiene and Tropical Medicine,?,Y,,,,,None,,
-444,NEJM,2020,Other,Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis,https://doi.org/10.1056/nejmoa2012047,https://cdn.clinicaltrials.gov/large-docs/71/NCT03496571/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/71/NCT03496571/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03496571,33085861,Ph2 | quadruple | treatment,Allakos Inc.,Industry,,?,Y,,,,,None,,
-445,NEJM,2020,Infectious Disease,Efficacy of Tocilizumab in Patients Hospitalized with Covid-19,https://doi.org/10.1056/nejmoa2028836,https://cdn.clinicaltrials.gov/large-docs/37/NCT04356937/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/37/NCT04356937/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04356937,33085857,Ph3 | double | treatment,Massachusetts General Hospital,Academic/Other,"Genentech, Inc.",?,Y,,,,,None,,
-446,NEJM,2020,Rheumatology/Immunology,Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis,https://doi.org/10.1056/nejmoa2008250,https://cdn.clinicaltrials.gov/large-docs/43/NCT03086343/Prot_004.pdf,https://cdn.clinicaltrials.gov/large-docs/43/NCT03086343/SAP_005.pdf,SAP,noninferiority,NCT03086343,33053283,Ph3 | quadruple | treatment,AbbVie,Industry,,?,Y,,,,,None,,
-447,NEJM,2020,Infectious Disease,Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates,https://doi.org/10.1056/nejmoa2027906,https://cdn.clinicaltrials.gov/large-docs/28/NCT04368728/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/28/NCT04368728/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04368728,33053279,Ph2/Ph3 | triple | prevention,BioNTech SE,Industry,Pfizer,?,Y,,,,,None,,
-448,NEJM,2020,Infectious Disease,A Randomized Trial Comparing Antibiotics with Appendectomy for Appendicitis,https://doi.org/10.1056/nejmoa2014320,https://cdn.clinicaltrials.gov/large-docs/85/NCT02800785/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/85/NCT02800785/SAP_001.pdf,SAP,noninferiority,NCT02800785,33017106,NA | treatment,University of Washington,Academic/Other,Patient-Centered Outcomes Research Institute,?,Y,,,,,None,,
-449,NEJM,2020,Oncology,Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC,https://doi.org/10.1056/nejmoa1917346,https://cdn.clinicaltrials.gov/large-docs/42/NCT02409342/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/42/NCT02409342/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02409342,32997907,Ph3 | treatment,Hoffmann-La Roche,Industry,,?,Y,,,,,None,,
-450,NEJM,2020,Cardiovascular,Dapagliflozin in Patients with Chronic Kidney Disease,https://doi.org/10.1056/nejmoa2024816,https://cdn.clinicaltrials.gov/large-docs/50/NCT03036150/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/50/NCT03036150/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03036150,32970396,Ph3 | quadruple | treatment,AstraZeneca,Industry,,?,Y,,,,,None,,
-451,NEJM,2020,Cardiovascular,Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes,https://doi.org/10.1056/nejmoa2004967,https://cdn.clinicaltrials.gov/large-docs/81/NCT01986881/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/81/NCT01986881/SAP_001.pdf,SAP,noninferiority,NCT01986881,32966714,Ph3 | double | treatment,Merck Sharp & Dohme LLC,Industry,Pfizer,?,Y,,,,,None,,
-452,NEJM,2020,Endocrinology/Metabolism,Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment,https://doi.org/10.1056/nejmoa2022474,https://cdn.clinicaltrials.gov/large-docs/57/NCT03751657/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/57/NCT03751657/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03751657,32960514,Ph2 | quadruple | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-453,NEJM,2020,Oncology,Osimertinib in Resected <i>EGFR</i>-Mutated Non-Small-Cell Lung Cancer,https://doi.org/10.1056/nejmoa2027071,https://cdn.clinicaltrials.gov/large-docs/06/NCT02511106/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/06/NCT02511106/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02511106,32955177,Ph3 | triple | treatment,AstraZeneca,Industry,,?,Y,,,,,None,,
-454,NEJM,2020,Oncology,Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer,https://doi.org/10.1056/nejmoa2022485,https://cdn.clinicaltrials.gov/large-docs/43/NCT02987543/Prot_005.pdf,https://cdn.clinicaltrials.gov/large-docs/43/NCT02987543/SAP_015.pdf,SAP,crossover,NCT02987543,32955174,Ph3 | treatment,AstraZeneca,Industry,"Merck Sharp & Dohme LLC; Foundation Medicine; Myriad Genetics, Inc.",?,Y,,,,,None,,
-455,NEJM,2020,Oncology,Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma,https://doi.org/10.1056/nejmoa2002788,https://cdn.clinicaltrials.gov/large-docs/32/NCT02603432/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/32/NCT02603432/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02603432,32945632,Ph3 | treatment,Pfizer,Industry,,?,Y,,,,,None,,
-456,NEJM,2020,Respiratory,Randomized Trial of Nocturnal Oxygen in Chronic Obstructive Pulmonary Disease,https://doi.org/10.1056/nejmoa2013219,https://cdn.clinicaltrials.gov/large-docs/28/NCT01044628/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/28/NCT01044628/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01044628,32937046,NA | triple | supportive care,Laval University,Academic/Other,Canadian Institutes of Health Research (CIHR),?,Y,,,,,None,,
-457,NEJM,2020,Nephrology/Urology,"Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis",https://doi.org/10.1056/nejmoa2001180,https://cdn.clinicaltrials.gov/large-docs/39/NCT01639339/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/39/NCT01639339/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT01639339,32937045,Ph3 | quadruple | treatment,"Human Genome Sciences Inc., a GSK Company",Industry,GlaxoSmithKline,?,Y,,,,,None,,
-458,NEJM,2020,Oncology,"Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide",https://doi.org/10.1056/nejmoa2001342,https://cdn.clinicaltrials.gov/large-docs/14/NCT02200614/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/14/NCT02200614/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT02200614,32905676,Ph3 | quadruple | treatment,Bayer,Industry,"Orion Corporation, Orion Pharma",?,Y,,,,,None,,
-459,NEJM,2020,Other,Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis,https://doi.org/10.1056/nejmoa1916063,https://cdn.clinicaltrials.gov/large-docs/44/NCT01483144/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/44/NCT01483144/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT01483144,32905675,Ph3 | triple | treatment,"Cancer Prevention Pharmaceuticals, Inc.",Industry,,?,Y,,,,,None,,
-460,NEJM,2020,Respiratory,Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis,https://doi.org/10.1056/nejmoa1913590,https://cdn.clinicaltrials.gov/large-docs/80/NCT02702180/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/80/NCT02702180/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02702180,32897035,Ph2 | quadruple | treatment,Savara Inc.,Industry,,?,Y,,,,,None,,
-461,NEJM,2020,Respiratory,Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis,https://doi.org/10.1056/nejmoa2021713,https://cdn.clinicaltrials.gov/large-docs/17/NCT03218917/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/17/NCT03218917/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03218917,32897034,Ph2 | quadruple | treatment,Insmed Incorporated,Industry,,?,Y,,,,,None,,
-462,NEJM,2020,Oncology,Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma,https://doi.org/10.1056/nejmoa2005493,https://cdn.clinicaltrials.gov/large-docs/83/NCT01682083/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/83/NCT01682083/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT01682083,32877599,Ph3 | double | treatment,Novartis Pharmaceuticals,Industry,,?,Y,,,,,None,,
-463,NEJM,2020,Neurology,Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis,https://doi.org/10.1056/nejmoa1916945,https://cdn.clinicaltrials.gov/large-docs/14/NCT03127514/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/14/NCT03127514/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03127514,32877582,Ph2 | quadruple | treatment,Amylyx Pharmaceuticals Inc.,Industry,ALS Finding a Cure; ALS Association; Northeast ALS Consortium; Neurological Clinical Research Institute at Massachusetts General Hospital; Leandro P. Rizzuto Foundation,?,Y,,,,,None,,
-464,NEJM,2020,Endocrinology/Metabolism,Weight Loss in Underserved Patients - A Cluster-Randomized Trial,https://doi.org/10.1056/nejmoa2007448,https://cdn.clinicaltrials.gov/large-docs/21/NCT02561221/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/21/NCT02561221/Prot_SAP_000.pdf,Protocol+SAP,cluster,NCT02561221,32877581,NA | treatment,Pennington Biomedical Research Center,Academic/Other,Louisiana State University Health Sciences Center Shreveport; Tulane University; Ochsner Health System; Louisiana State University Health Sciences Center in New Orleans; Xavier University of Louisiana.; (+1 more),?,Y,,,,,None,,
-465,NEJM,2020,Cardiovascular,Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure,https://doi.org/10.1056/nejmoa2022190,https://cdn.clinicaltrials.gov/large-docs/77/NCT03057977/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/77/NCT03057977/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03057977,32865377,Ph3 | double | treatment,Boehringer Ingelheim,Industry,Eli Lilly and Company,?,Y,,,,,None,,
-466,NEJM,2020,Cardiovascular,Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation,https://doi.org/10.1056/nejmoa2012883,https://cdn.clinicaltrials.gov/large-docs/69/NCT02801669/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/69/NCT02801669/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02801669,32865374,Ph3 | triple | prevention,"Daiichi Sankyo Co., Ltd.",Industry,,?,Y,,,,,None,,
-467,NEJM,2020,Pediatrics,Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia,https://doi.org/10.1056/nejmoa2019910,https://cdn.clinicaltrials.gov/large-docs/59/NCT02392559/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/59/NCT02392559/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02392559,32865373,Ph3 | triple | treatment,Amgen,Industry,,?,Y,,,,,None,,
-468,NEJM,2020,Endocrinology/Metabolism,A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes,https://doi.org/10.1056/nejmoa2004736,https://cdn.clinicaltrials.gov/large-docs/89/NCT03844789/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/89/NCT03844789/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT03844789,32846062,NA | other,University of Virginia,Academic/Other,"Tandem Diabetes Care, Inc.; DexCom, Inc.; Jaeb Center for Health Research",?,Y,,,,,None,,
-469,NEJM,2020,Cardiovascular,Drug-Coated Balloons for Dysfunctional Dialysis Arteriovenous Fistulas,https://doi.org/10.1056/nejmoa1914617,https://cdn.clinicaltrials.gov/large-docs/67/NCT03041467/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/67/NCT03041467/SAP_003.pdf,SAP,noninferiority,NCT03041467,32813949,NA | single | treatment,Medtronic Endovascular,Industry,,?,Y,,,,,None,,
-470,NEJM,2020,Pediatrics,Evinacumab for Homozygous Familial Hypercholesterolemia,https://doi.org/10.1056/nejmoa2004215,https://cdn.clinicaltrials.gov/large-docs/86/NCT03399786/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/86/NCT03399786/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03399786,32813947,Ph3 | quadruple | treatment,Regeneron Pharmaceuticals,Industry,,?,Y,,,,,None,,
-471,NEJM,2020,Oncology,Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia,https://doi.org/10.1056/nejmoa2012971,https://cdn.clinicaltrials.gov/large-docs/23/NCT02993523/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/23/NCT02993523/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02993523,32786187,Ph3 | quadruple | treatment,AbbVie,Industry,"Genentech, Inc.",?,Y,,,,,None,,
-472,NEJM,2020,Neurology,Ofatumumab versus Teriflunomide in Multiple Sclerosis,https://doi.org/10.1056/nejmoa1917246,https://cdn.clinicaltrials.gov/large-docs/18/NCT02792218/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/18/NCT02792218/SAP_000.pdf,SAP,fixed_parallel_superiority,"NCT02792218, NCT02792231",32757523,Ph3 | quadruple | treatment,Novartis Pharmaceuticals,Industry,,?,Y,,,,,None,,
-473,NEJM,2020,Infectious Disease,Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants,https://doi.org/10.1056/nejmoa1908380,https://cdn.clinicaltrials.gov/large-docs/47/NCT02624947/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/47/NCT02624947/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02624947,32726529,Ph3 | triple | prevention,Novavax,Industry,Bill and Melinda Gates Foundation,?,Y,,,,,None,,
-474,NEJM,2020,Infectious Disease,Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants,https://doi.org/10.1056/nejmoa1913556,https://cdn.clinicaltrials.gov/large-docs/30/NCT02878330/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/30/NCT02878330/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02878330,32726528,Ph2 | quadruple | prevention,MedImmune LLC,Industry,,?,Y,,,,,None,,
-475,NEJM,2020,Infectious Disease,Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease,https://doi.org/10.1056/nejmoa1915176,https://cdn.clinicaltrials.gov/large-docs/55/NCT02276755/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/55/NCT02276755/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02276755,32706534,Ph3 | quadruple | prevention,Harvard School of Public Health (HSPH),Academic/Other,,?,Y,,,,,None,,
-476,NEJM,2020,Nephrology/Urology,Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury,https://doi.org/10.1056/nejmoa2000741,https://cdn.clinicaltrials.gov/large-docs/22/NCT02568722/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/22/NCT02568722/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02568722,32668114,NA | treatment,Unity Health Toronto,Academic/Other,"Canadian Institutes of Health Research (CIHR); National Health and Medical Research Council, Australia; Baxter Healthcare Corporation; The George Institute; National Institute for Health Research, United Kingdom; (+2 more)",?,Y,,,,,None,,
-477,NEJM,2020,Dermatology,Trial of Roflumilast Cream for Chronic Plaque Psoriasis,https://doi.org/10.1056/nejmoa2000073,https://cdn.clinicaltrials.gov/large-docs/58/NCT03638258/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/58/NCT03638258/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT03638258,32668113,Ph2 | double | treatment,"Arcutis Biotherapeutics, Inc.",Industry,,?,Y,,,,,None,,
-478,NEJM,2020,Cardiovascular,Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA,https://doi.org/10.1056/nejmoa1916870,https://cdn.clinicaltrials.gov/large-docs/29/NCT03354429/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/29/NCT03354429/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT03354429,32668111,Ph3 | quadruple | treatment,AstraZeneca,Industry,,?,Y,,,,,None,,
-479,NEJM,2020,Other,A Randomized Trial of a Multifactorial Strategy to Prevent Serious Fall Injuries,https://doi.org/10.1056/nejmoa2002183,https://cdn.clinicaltrials.gov/large-docs/50/NCT02475850/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/50/NCT02475850/SAP_000.pdf,SAP,factorial;cluster,NCT02475850,32640131,Ph3 | double | prevention,Brigham and Women's Hospital,Academic/Other,"Yale University; University of California, Los Angeles; Healthcare Partners; The University of Texas Medical Branch, Galveston; University of Pittsburgh Medical Center; (+11 more)",?,Y,,,,,None,,
-480,NEJM,2020,Neurology,Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS,https://doi.org/10.1056/nejmoa2003715,https://cdn.clinicaltrials.gov/large-docs/99/NCT02623699/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/99/NCT02623699/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02623699,32640130,Ph3 | quadruple | treatment,Biogen,Industry,"Ionis Pharmaceuticals, Inc.",?,Y,,,,,None,,
-481,NEJM,2020,Rheumatology/Immunology,Effect on Patient Safety of a Resident Physician Schedule without 24-Hour Shifts,https://doi.org/10.1056/nejmoa1900669,https://cdn.clinicaltrials.gov/large-docs/47/NCT02134847/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/47/NCT02134847/Prot_SAP_000.pdf,Protocol+SAP,crossover;cluster,NCT02134847,32579812,NA | single | health services research,Brigham and Women's Hospital,Academic/Other,,?,Y,,,,,None,,
-482,NEJM,2020,Cardiovascular,Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes,https://doi.org/10.1056/nejmoa1916624,https://cdn.clinicaltrials.gov/large-docs/71/NCT02017171/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/71/NCT02017171/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02017171,32579810,Ph3 | triple | prevention,Alessandro Doria,Academic/Other,"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Juvenile Diabetes Research Foundation; Joslin Diabetes Center; University of Minnesota; University of Colorado, Denver; (+12 more)",?,Y,,,,,None,,
-483,NEJM,2020,Respiratory,Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD,https://doi.org/10.1056/nejmoa1916046,https://cdn.clinicaltrials.gov/large-docs/67/NCT02465567/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/67/NCT02465567/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02465567,32579807,Ph3 | quadruple | treatment,"Pearl Therapeutics, Inc.",Industry,,?,Y,,,,,None,,
-484,NEJM,2020,Infectious Disease,Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults,https://doi.org/10.1056/nejmoa1910708,,https://cdn.clinicaltrials.gov/large-docs/96/NCT02057796/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT02057796,32558469,Ph4 | prevention,"ANRS, Emerging Infectious Diseases",Other Government,,?,Y,,,,,None,,
-485,NEJM,2020,Gastroenterology/Hepatology,Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria,https://doi.org/10.1056/nejmoa1913147,https://cdn.clinicaltrials.gov/large-docs/16/NCT03338816/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/16/NCT03338816/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03338816,32521132,Ph3 | quadruple | treatment,Alnylam Pharmaceuticals,Industry,,?,Y,,,,,None,,
-486,NEJM,2020,Infectious Disease,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,https://doi.org/10.1056/nejmoa2016638,https://cdn.clinicaltrials.gov/large-docs/68/NCT04308668/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/68/NCT04308668/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04308668,32492293,Ph3 | quadruple | treatment,University of Minnesota,Academic/Other,McGill University Health Centre/Research Institute of the McGill University Health Centre; University of Manitoba; University of Alberta,?,Y,,,,,None,,
-487,NEJM,2020,Oncology,"Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer",https://doi.org/10.1056/nejmoa2003892,https://cdn.clinicaltrials.gov/large-docs/24/NCT02003924/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/24/NCT02003924/SAP_003.pdf,SAP,group_sequential,NCT02003924,32469184,Ph3 | quadruple | treatment,Pfizer,Industry,"Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",?,Y,,,,,None,,
-488,NEJM,2020,Oncology,Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer,https://doi.org/10.1056/nejmoa2004325,https://cdn.clinicaltrials.gov/large-docs/95/NCT03085095/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/95/NCT03085095/SAP_000.pdf,SAP,noninferiority,NCT03085095,32469183,Ph3 | treatment,Myovant Sciences GmbH,Industry,,?,Y,,,,,None,,
-489,NEJM,2020,Oncology,Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer,https://doi.org/10.1056/nejmoa2004413,https://cdn.clinicaltrials.gov/large-docs/90/NCT03329690/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/90/NCT03329690/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03329690,32469182,Ph2 | treatment,"Daiichi Sankyo Co., Ltd.",Industry,AstraZeneca,?,Y,,,,,None,,
-490,NEJM,2020,Infectious Disease,Remdesivir for 5 or 10 Days in Patients with Severe Covid-19,https://doi.org/10.1056/nejmoa2015301,https://cdn.clinicaltrials.gov/large-docs/99/NCT04292899/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/99/NCT04292899/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT04292899,32459919,Ph3 | treatment,Gilead Sciences,Industry,,?,Y,,,,,None,,
-491,NEJM,2020,Infectious Disease,Remdesivir for the Treatment of Covid-19 - Final Report,https://doi.org/10.1056/nejmoa2007764,https://cdn.clinicaltrials.gov/large-docs/05/NCT04280705/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/05/NCT04280705/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT04280705,32445440,Ph3 | double | treatment,National Institute of Allergy and Infectious Diseases (NIAID),NIH,,?,Y,,,,,None,,
-492,NEJM,2020,Infectious Disease,Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis,https://doi.org/10.1056/nejmoa1915254,https://cdn.clinicaltrials.gov/large-docs/23/NCT02766023/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/23/NCT02766023/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02766023,32402161,Ph2 | double | prevention,National Institute of Allergy and Infectious Diseases (NIAID),NIH,,?,Y,,,,,None,,
-493,NEJM,2020,Oncology,Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma,https://doi.org/10.1056/nejmoa1915745,https://cdn.clinicaltrials.gov/large-docs/79/NCT03434379/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/79/NCT03434379/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03434379,32402160,Ph3 | treatment,Hoffmann-La Roche,Industry,,?,Y,,,,,None,,
-494,NEJM,2020,Cardiovascular,Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke,https://doi.org/10.1056/nejmoa2001123,https://cdn.clinicaltrials.gov/large-docs/06/NCT03469206/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/06/NCT03469206/SAP_000.pdf,SAP,noninferiority,NCT03469206,32374959,NA | single | treatment,Changhai Hospital,Academic/Other,"National Health and Family Planning Commission, P.R.China; Wu Jieping Medical Foundation; Cardiovascular Chinese Research Center; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",?,Y,,,,,None,,
-495,NEJM,2020,Oncology,Olaparib for Metastatic Castration-Resistant Prostate Cancer,https://doi.org/10.1056/nejmoa1911440,https://cdn.clinicaltrials.gov/large-docs/43/NCT02987543/Prot_005.pdf,https://cdn.clinicaltrials.gov/large-docs/43/NCT02987543/SAP_015.pdf,SAP,fixed_parallel_superiority,NCT02987543,32343890,Ph3 | treatment,AstraZeneca,Industry,"Merck Sharp & Dohme LLC; Foundation Medicine; Myriad Genetics, Inc.",?,Y,,,,,None,,
-496,NEJM,2020,Hematology,Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease,https://doi.org/10.1056/nejmoa1917635,https://cdn.clinicaltrials.gov/large-docs/61/NCT02913261/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/61/NCT02913261/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02913261,32320566,Ph3 | treatment,Novartis Pharmaceuticals,Industry,,?,Y,,,,,None,,
-497,NEJM,2020,Psychiatry/Mental Health,A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia,https://doi.org/10.1056/nejmoa1911772,https://cdn.clinicaltrials.gov/large-docs/82/NCT02969382/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/82/NCT02969382/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02969382,32294346,Ph2 | quadruple | treatment,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Industry,,?,Y,,,,,None,,
-498,NEJM,2020,Endocrinology/Metabolism,"A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity",https://doi.org/10.1056/nejmoa1916038,https://cdn.clinicaltrials.gov/large-docs/79/NCT02918279/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/79/NCT02918279/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02918279,32233338,Ph3 | double | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-499,NEJM,2020,Cardiovascular,Management of Coronary Disease in Patients with Advanced Kidney Disease,https://doi.org/10.1056/nejmoa1915925,https://cdn.clinicaltrials.gov/large-docs/60/NCT01985360/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/60/NCT01985360/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01985360,32227756,Ph4 | treatment,NYU Langone Health,Academic/Other,"New York University; National Heart, Lung, and Blood Institute (NHLBI); Duke University; Stanford University; Columbia University",?,Y,,,,,None,,
-500,NEJM,2020,Cardiovascular,Initial Invasive or Conservative Strategy for Stable Coronary Disease,https://doi.org/10.1056/nejmoa1915922,https://cdn.clinicaltrials.gov/large-docs/22/NCT01471522/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/22/NCT01471522/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT01471522,32227755,NA | treatment,NYU Langone Health,Academic/Other,"New York University; Stanford University; National Heart, Lung, and Blood Institute (NHLBI); Albany Stratton VA Medical Center; Cedars-Sinai Medical Center; (+10 more)",?,Y,,,,,None,,
-501,NEJM,2020,Cardiovascular,Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease,https://doi.org/10.1056/nejmoa1916374,https://cdn.clinicaltrials.gov/large-docs/60/NCT01985360/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/60/NCT01985360/Prot_SAP_000.pdf,Protocol+SAP,adaptive_bayesian,NCT01985360,32227754,Ph4 | treatment,NYU Langone Health,Academic/Other,"New York University; National Heart, Lung, and Blood Institute (NHLBI); Duke University; Stanford University; Columbia University",?,Y,,,,,None,,
-502,NEJM,2020,Cardiovascular,Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease,https://doi.org/10.1056/nejmoa1916370,https://cdn.clinicaltrials.gov/large-docs/22/NCT01471522/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/22/NCT01471522/SAP_003.pdf,SAP,adaptive_bayesian,NCT01471522,32227753,NA | treatment,NYU Langone Health,Academic/Other,"New York University; Stanford University; National Heart, Lung, and Blood Institute (NHLBI); Albany Stratton VA Medical Center; Cedars-Sinai Medical Center; (+10 more)",?,Y,,,,,None,,
-503,NEJM,2020,Oncology,Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer,https://doi.org/10.1056/nejmoa1915103,https://cdn.clinicaltrials.gov/large-docs/06/NCT03045406/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/06/NCT03045406/SAP_001.pdf,SAP,noninferiority,NCT03045406,32223112,Ph3 | treatment,"Fadoi Foundation, Italy",Academic/Other,University Of Perugia,?,Y,,,,,None,,
-504,NEJM,2020,Cardiovascular,Rivaroxaban in Peripheral Artery Disease after Revascularization,https://doi.org/10.1056/nejmoa2000052,https://cdn.clinicaltrials.gov/large-docs/16/NCT02504216/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/16/NCT02504216/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT02504216,32222135,Ph3 | quadruple | prevention,Bayer,Industry,"Janssen Research & Development, LLC; Colorado Prevention Center",?,Y,,,,,None,,
-505,NEJM,2020,Cardiovascular,Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction,https://doi.org/10.1056/nejmoa1915928,https://cdn.clinicaltrials.gov/large-docs/34/NCT02861534/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/34/NCT02861534/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02861534,32222134,Ph3 | double | treatment,Merck Sharp & Dohme LLC,Industry,Bayer; Canadian VIGOUR Centre; Duke Clinical Research Institute,?,Y,,,,,None,,
-506,NEJM,2020,Hematology,A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia,https://doi.org/10.1056/nejmoa1910182,https://cdn.clinicaltrials.gov/large-docs/33/NCT02604433/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/33/NCT02604433/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT02604433,32212518,Ph3 | quadruple | treatment,Celgene,Industry,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",?,Y,,,,,None,,
-507,NEJM,2020,Other,Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia,https://doi.org/10.1056/nejmoa1913805,https://cdn.clinicaltrials.gov/large-docs/21/NCT03397121/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/21/NCT03397121/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03397121,32197277,Ph3 | double | treatment,The Medicines Company,Industry,,?,Y,,,,,None,,
-508,NEJM,2020,Cardiovascular,Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol,https://doi.org/10.1056/nejmoa1912387,https://cdn.clinicaltrials.gov/large-docs/70/NCT03399370/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/70/NCT03399370/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT03399370, NCT03400800",32187462,Ph3 | double | treatment,The Medicines Company,Industry,,?,Y,,,,,None,,
-509,NEJM,2020,Infectious Disease,Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression,https://doi.org/10.1056/nejmoa1904398,https://cdn.clinicaltrials.gov/large-docs/52/NCT02951052/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/52/NCT02951052/SAP_002.pdf,SAP,noninferiority,NCT02951052,32130809,Ph3 | treatment,ViiV Healthcare,Industry,Janssen Pharmaceuticals; GlaxoSmithKline,?,Y,,,,,None,,
-510,NEJM,2020,Infectious Disease,Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection,https://doi.org/10.1056/nejmoa1909512,https://cdn.clinicaltrials.gov/large-docs/20/NCT02938520/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/20/NCT02938520/SAP_002.pdf,SAP,noninferiority,NCT02938520,32130806,Ph3 | treatment,ViiV Healthcare,Industry,Janssen Pharmaceuticals; GlaxoSmithKline,?,Y,,,,,None,,
-511,NEJM,2020,Other,Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis,https://doi.org/10.1056/nejmoa1908316,https://cdn.clinicaltrials.gov/large-docs/03/NCT03181503/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/03/NCT03181503/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03181503,32074418,Ph2 | quadruple | treatment,Galderma R&D,Industry,,?,Y,,,,,None,,
-512,NEJM,2020,Nephrology/Urology,Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis,https://doi.org/10.1056/nejmoa1803537,https://cdn.clinicaltrials.gov/large-docs/89/NCT00987389/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/89/NCT00987389/Prot_SAP_000.pdf,Protocol+SAP,noninferiority;factorial,NCT00987389,32053298,Ph3 | treatment,University of Pennsylvania,Academic/Other,Cambridge University Hospitals NHS Foundation Trust; University of Birmingham; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),?,Y,,,,,None,,
-513,NEJM,2020,Endocrinology/Metabolism,Teprotumumab for the Treatment of Active Thyroid Eye Disease,https://doi.org/10.1056/nejmoa1910434,https://cdn.clinicaltrials.gov/large-docs/67/NCT03298867/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/67/NCT03298867/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03298867,31971679,Ph3 | quadruple | treatment,Amgen,Industry,,?,Y,,,,,None,,
-514,NEJM,2020,Obstetrics/Gynecology,Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids,https://doi.org/10.1056/nejmoa1904351,https://cdn.clinicaltrials.gov/large-docs/54/NCT02654054/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/54/NCT02654054/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT02654054, NCT02691494",31971678,Ph3 | quadruple | treatment,AbbVie,Industry,,?,Y,,,,,None,,
-515,NEJM,2020,Pediatrics,A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants,https://doi.org/10.1056/nejmoa1907423,https://cdn.clinicaltrials.gov/large-docs/73/NCT01378273/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/73/NCT01378273/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01378273,31940698,Ph3 | quadruple | treatment,University of Washington,Academic/Other,National Institute of Neurological Disorders and Stroke (NINDS),?,Y,,,,,None,,
-516,NEJM,2020,Musculoskeletal/Pain,"Health Care Hotspotting - A Randomized, Controlled Trial",https://doi.org/10.1056/nejmsa1906848,https://cdn.clinicaltrials.gov/large-docs/26/NCT02090426/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/26/NCT02090426/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02090426,31914242,NA | supportive care,Abdul Latif Jameel Poverty Action Lab,Academic/Other,"The Cooper Health System; National Bureau of Economic Research, Inc.; Massachusetts Institute of Technology; Harvard University",?,Y,,,,,None,,
-517,NEJM,2020,Oncology,Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes,https://doi.org/10.1056/nejmoa1908892,https://cdn.clinicaltrials.gov/large-docs/70/NCT02631070/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/70/NCT02631070/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02631070,31914241,Ph3 | quadruple | treatment,Celgene,Industry,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",?,Y,,,,,None,,
-518,NEJM,2020,Cardiovascular,Lipoprotein(a) Reduction in Persons with Cardiovascular Disease,https://doi.org/10.1056/nejmoa1905239,https://cdn.clinicaltrials.gov/large-docs/82/NCT03070782/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/82/NCT03070782/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT03070782,31893580,Ph2 | triple | treatment,Akcea Therapeutics,Industry,"Ionis Pharmaceuticals, Inc.",?,Y,,,,,None,,
-519,NEJM,2020,Rheumatology/Immunology,Trial of Anifrolumab in Active Systemic Lupus Erythematosus,https://doi.org/10.1056/nejmoa1912196,https://cdn.clinicaltrials.gov/large-docs/99/NCT02446899/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/99/NCT02446899/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02446899,31851795,Ph3 | double | treatment,AstraZeneca,Industry,PRA Health Sciences,?,Y,,,,,None,,
-520,NEJM,2020,Oncology,Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer,https://doi.org/10.1056/nejmoa1911149,https://cdn.clinicaltrials.gov/large-docs/15/NCT02422615/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/15/NCT02422615/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT02422615,31826360,Ph3 | quadruple | treatment,Novartis Pharmaceuticals,Industry,,?,Y,,,,,None,,
-521,NEJM,2020,Oncology,"Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer",https://doi.org/10.1056/nejmoa1914609,https://cdn.clinicaltrials.gov/large-docs/94/NCT02614794/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/94/NCT02614794/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT02614794,31825569,Ph2 | quadruple | treatment,Seagen Inc.,Industry,,?,Y,,,,,None,,
-522,NEJM,2020,Oncology,Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer,https://doi.org/10.1056/nejmoa1914510,https://cdn.clinicaltrials.gov/large-docs/92/NCT03248492/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/92/NCT03248492/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03248492,31825192,Ph2 | treatment,Daiichi Sankyo,Industry,"AstraZeneca; Daiichi Sankyo Co., Ltd.",?,Y,,,,,None,,
-523,NEJM,2020,Oncology,"Overall Survival with Osimertinib in Untreated, <i>EGFR</i>-Mutated Advanced NSCLC",https://doi.org/10.1056/nejmoa1913662,https://cdn.clinicaltrials.gov/large-docs/25/NCT02296125/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/25/NCT02296125/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02296125,31751012,Ph3 | triple | treatment,AstraZeneca,Industry,Parexel,?,Y,,,,,None,,
-524,NEJM,2020,Cardiovascular,Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement,https://doi.org/10.1056/nejmoa1911426,https://cdn.clinicaltrials.gov/large-docs/48/NCT02833948/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/48/NCT02833948/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02833948,31733182,Ph3 | single | diagnostic,ECRI bv,Industry,"Rigshospitalet, Denmark; Bayer; Cardialysis BV",?,Y,,,,,None,,
-525,NEJM,2020,Cardiovascular,A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement,https://doi.org/10.1056/nejmoa1911425,https://cdn.clinicaltrials.gov/large-docs/03/NCT02556203/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/03/NCT02556203/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02556203,31733180,Ph3 | prevention,Bayer,Industry,"Janssen Research & Development, LLC",?,Y,,,,,None,,
-526,NEJM,2020,Nephrology/Urology,A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus,https://doi.org/10.1056/nejmoa1912770,https://cdn.clinicaltrials.gov/large-docs/53/NCT03422653/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/53/NCT03422653/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03422653,31702883,Ph3 | double | treatment,"Cara Therapeutics, Inc.",Industry,,?,Y,,,,,None,,
-527,LANC,2026,Infectious Disease,"Safety and efficacy of the monoclonal antibody L9LS for malaria prevention in children exposed to perennial malaria transmission in Kenya: a randomised, double-blind, placebo-controlled, phase 2 trial",https://doi.org/10.1016/s0140-6736(26)00258-8,https://cdn.clinicaltrials.gov/large-docs/55/NCT05400655/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/55/NCT05400655/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT05400655,42035777,Ph2 | double | prevention,National Institute of Allergy and Infectious Diseases (NIAID),NIH,Centers for Disease Control and Prevention; National Institutes of Health (NIH); Kenya Medical Research Institute; Liverpool School of Tropical Medicine,?,Y,Zonghui Hu,Biostatistics (per PubMed affiliation),"Office of Biostatistics Research, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-528,LANC,2026,Oncology,"Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study",https://doi.org/10.1016/s0140-6736(26)00602-1,https://cdn.clinicaltrials.gov/large-docs/89/NCT05116189/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/89/NCT05116189/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT05116189,41974150,Ph3 | triple | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Xuan Peng,Biostatistician,Merck,https://www.linkedin.com/in/xuan-peng-27824764,High,Web-search,LinkedIn profile confirms Xuan Peng is a Biostatistician at Merck.
-529,LANC,2026,Rheumatology/Immunology,"Efficacy and safety of LEVI-04 in patients with osteoarthritis of the knee: a randomised, double-blind, placebo-controlled, phase 2 trial",https://doi.org/10.1016/s0140-6736(26)00131-5,https://cdn.clinicaltrials.gov/large-docs/82/NCT05618782/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/82/NCT05618782/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05618782,41905364,Ph2 | quadruple | treatment,Levicept,Industry,Nordic Bioscience Clinical Development (NBCD),?,Y,Dror Rom,Chief Executive Officer / Biostatistician,Prosoft Clinical,https://prosoftclinical.com/who-we-are/leadership-team,High,Web-search,"Dror Rom is a biostatistician and CEO at Prosoft Clinical, confirmed by company leadership page."
-530,LANC,2026,Nephrology/Urology,Prevention of urinary stones with hydration: a randomised clinical trial of an adherence intervention,https://doi.org/10.1016/s0140-6736(25)02637-6,https://cdn.clinicaltrials.gov/large-docs/89/NCT03244189/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/89/NCT03244189/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03244189,41864748,NA | single | prevention,Duke University,Academic/Other,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),?,Y,Hussein R Al-Khalidi,Biostatistics (per PubMed affiliation),"Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA; Department of Biostatistics & Bioinformatics, Duke University School of Medicine, Durham, NC, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-531,LANC,2026,Oncology,"Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(25)02602-9,https://cdn.clinicaltrials.gov/large-docs/45/NCT05804045/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/45/NCT05804045/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05804045,41796601,Ph3 | quadruple | treatment,"Abbisko Therapeutics Co, Ltd",Industry,,?,Y,,,,,None,,
-532,LANC,2026,Infectious Disease,"Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial",https://doi.org/10.1016/s0140-6736(25)01948-8,https://cdn.clinicaltrials.gov/large-docs/55/NCT05630755/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/55/NCT05630755/Prot_SAP_000.pdf,Protocol+SAP,noninferiority,NCT05630755,41654375,Ph3 | double | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,,,,,None,,
-533,LANC,2026,Infectious Disease,"Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial",https://doi.org/10.1016/s0140-6736(25)01945-2,https://cdn.clinicaltrials.gov/large-docs/93/NCT05631093/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/93/NCT05631093/Prot_SAP_000.pdf,Protocol+SAP,noninferiority,NCT05631093,41654374,Ph3 | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Tracy L Diamond,Biostatistics and Research Decision Sciences,Merck & Co. Inc,https://www.science.org/doi/10.1126/scitranslmed.abn2038,Medium,Web-search,Tracy L Diamond is affiliated with Biostatistics and Research Decision Sciences at Merck & Co. Inc.
-534,LANC,2026,Nephrology/Urology,"TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198",https://doi.org/10.1016/s0140-6736(25)02255-x,https://cdn.clinicaltrials.gov/large-docs/24/NCT05213624/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/24/NCT05213624/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05213624,41616795,Ph2 | double | treatment,Boehringer Ingelheim,Industry,,?,Y,Bo Ji,"AD, Principal Clinical Statistician",Boehringer Ingelheim,https://www.linkedin.com/in/bojiutk,High,Web-search,"LinkedIn profile shows Bo Ji is AD, Principal Clinical Statistician at Boehringer Ingelheim."
-535,LANC,2026,Infectious Disease,"Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial",https://doi.org/10.1016/s0140-6736(25)01953-1,https://cdn.clinicaltrials.gov/large-docs/27/NCT03959527/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/27/NCT03959527/SAP_001.pdf,SAP,noninferiority,NCT03959527,41391465,Ph3 | treatment,Global Antibiotics Research and Development Partnership,Academic/Other,,?,Y,,,,,None,,
-536,LANC,2026,Oncology,"Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial",https://doi.org/10.1016/s0140-6736(25)01778-7,https://cdn.clinicaltrials.gov/large-docs/52/NCT04680052/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/52/NCT04680052/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04680052,41360064,Ph3 | double | treatment,Incyte Corporation,Industry,,?,Y,,,,,None,,
-537,LANC,2025,Nephrology/Urology,"A preventive care strategy to reduce moderate or severe acute kidney injury after major surgery (BigpAK-2); a multinational, randomised clinical trial",https://doi.org/10.1016/s0140-6736(25)01717-9,,https://cdn.clinicaltrials.gov/large-docs/96/NCT04647396/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT04647396,41242333,NA | double | supportive care,University Hospital Muenster,Academic/Other,BioMérieux,?,Y,Karen Fischhuber,Biostatistics (per PubMed affiliation),"Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-538,LANC,2025,Hematology,"Efficacy and safety of REGN9933<sup>A2</sup> and REGN7508<sup>Cat</sup> for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials",https://doi.org/10.1016/s0140-6736(25)02097-5,https://cdn.clinicaltrials.gov/large-docs/08/NCT05618808/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/08/NCT05618808/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT05618808, NCT06454630",41218619,Ph2 | treatment,Regeneron Pharmaceuticals,Industry,,?,Y,,,,,None,,
-539,LANC,2025,Cardiovascular,Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial,https://doi.org/10.1016/s0140-6736(25)01375-3,https://cdn.clinicaltrials.gov/large-docs/97/NCT03574597/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/97/NCT03574597/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03574597,41138739,Ph3 | quadruple | treatment,Novo Nordisk A/S,Industry,,?,Y,Scott S Emerson,Biostatistics (per PubMed affiliation),"Department of Biostatistics, University of Washington, WA, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-540,LANC,2025,Infectious Disease,"A clinical decision tool including a decision tree, point-of-care testing of CRP, and safety-netting advice to guide antibiotic prescribing in acutely ill children in primary care in Belgium (ARON): a pragmatic, cluster-randomised, controlled trial",https://doi.org/10.1016/s0140-6736(25)01239-5,https://cdn.clinicaltrials.gov/large-docs/18/NCT04470518/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/18/NCT04470518/SAP_001.pdf,SAP,noninferiority;cluster,NCT04470518,41016406,NA | other,KU Leuven,Academic/Other,Universitaire Ziekenhuizen KU Leuven; University Ghent; Universiteit Antwerpen; University of Liege; Vrije Universiteit Brussel; (+1 more),?,Y,Annouschka Laenen,Biostatistics (per PubMed affiliation),"Leuven Biostatistics and Statistical Bioinformatics Centre (L-BioStat), Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-541,LANC,2025,Endocrinology/Metabolism,"Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(25)01774-x,https://cdn.clinicaltrials.gov/large-docs/21/NCT05260021/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/21/NCT05260021/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05260021,40975112,Ph3 | double | treatment,Eli Lilly and Company,Industry,,?,Y,Karthik Chandrasekhar Pamidipati,Department of Statistics,Eli Lilly and Company,https://www.researchgate.net/profile/Karthik-Pamidipati,Medium,Web-search,Karthik Chandrasekhar Pamidipati is listed under Department of Statistics at Acharya Nagarjuna University and works at Lilly.
-542,LANC,2025,Cardiovascular,"Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial",https://doi.org/10.1016/s0140-6736(25)01665-4,https://cdn.clinicaltrials.gov/large-docs/33/NCT05093933/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/33/NCT05093933/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT05093933,40897189,Ph3 | quadruple | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,,,,,None,,
-543,LANC,2025,Psychiatry/Mental Health,Building community capacity in mental health care with the Strong Minds-Strong Communities programme: a randomised controlled trial in the USA,https://doi.org/10.1016/s0140-6736(25)00859-1,https://cdn.clinicaltrials.gov/large-docs/77/NCT04092777/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/77/NCT04092777/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04092777,40849140,NA | single | treatment,Massachusetts General Hospital,Academic/Other,"University of North Carolina, Greensboro",?,Y,,,,,None,,
-544,LANC,2025,Infectious Disease,"Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial",https://doi.org/10.1016/s0140-6736(25)01073-6,https://cdn.clinicaltrials.gov/large-docs/29/NCT04767529/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/29/NCT04767529/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04767529,40818852,Ph2 | quadruple | treatment,"Akero Therapeutics, Inc",Industry,,?,Y,,,,,None,,
-545,LANC,2025,Oncology,"Adagrasib versus docetaxel in KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial",https://doi.org/10.1016/s0140-6736(25)00866-9,https://cdn.clinicaltrials.gov/large-docs/35/NCT04685135/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/35/NCT04685135/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04685135,40783289,Ph3 | treatment,Mirati Therapeutics Inc.,Industry,,?,Y,,,,,None,,
-546,LANC,2025,Infectious Disease,"Feasibility of interrupting the transmission of soil-transmitted helminths: the DeWorm3 community cluster-randomised controlled trial in Benin, India, and Malawi",https://doi.org/10.1016/s0140-6736(25)00766-4,https://cdn.clinicaltrials.gov/large-docs/67/NCT03014167/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/67/NCT03014167/SAP_003.pdf,SAP,cluster,NCT03014167,40752908,Ph3 | double | treatment,University of Washington,Academic/Other,Bill and Melinda Gates Foundation; Imperial College London; London School of Hygiene and Tropical Medicine; Institut de Recherche Clinique du Benin; Institut de Recherche pour le Developpement; (+4 more),?,Y,,,,,None,,
-547,LANC,2025,Gastroenterology/Hepatology,"Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials",https://doi.org/10.1016/s0140-6736(25)00681-6,https://cdn.clinicaltrials.gov/large-docs/11/NCT03466411/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/11/NCT03466411/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03466411,40684778,Ph2/Ph3 | double | treatment,"Janssen Research & Development, LLC",Industry,,?,Y,,,,,None,,
-548,LANC,2025,Oncology,"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial",https://doi.org/10.1016/s0140-6736(25)00684-1,https://cdn.clinicaltrials.gov/large-docs/97/NCT03395197/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/97/NCT03395197/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03395197,40683290,Ph3 | quadruple | treatment,Pfizer,Industry,Astellas Pharma Inc,?,Y,Xun Lin,Senior Director of Statistics,Pfizer,https://www.researchgate.net/profile/Xun-Lin,High,Web-search,Xun Lin is explicitly listed as a Statistician and Senior Director of Statistics at Pfizer.
-549,LANC,2025,Oncology,"Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial",https://doi.org/10.1016/s0140-6736(25)00683-x,https://cdn.clinicaltrials.gov/large-docs/97/NCT03395197/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/97/NCT03395197/SAP_001.pdf,SAP,group_sequential,NCT03395197,40683287,Ph3 | quadruple | treatment,Pfizer,Industry,Astellas Pharma Inc,?,Y,Xun Lin,Senior Director of Statistics,Pfizer,https://rocketreach.co/xun-lin-email_35794372,High,Web-search,Xun Lin is a Senior Director of Statistics at Pfizer.
-550,LANC,2025,Endocrinology/Metabolism,"Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial",https://doi.org/10.1016/s0140-6736(25)01069-4,https://cdn.clinicaltrials.gov/large-docs/56/NCT05462756/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/56/NCT05462756/SAP_001.pdf,SAP,noninferiority,NCT05462756,40562048,Ph3 | treatment,Eli Lilly and Company,Industry,,?,Y,Xiaoqi Li,Sr. Research Scientist,Eli Lilly and Company,https://www.linkedin.com/in/xiaoqi-li-45835280,High,Web-search,Xiaoqi Li's LinkedIn and academic profiles confirm her role as a Senior Research Scientist (Statistician) at Eli Lilly.
-551,LANC,2025,Endocrinology/Metabolism,"Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial",https://doi.org/10.1016/s0140-6736(25)01044-x,https://cdn.clinicaltrials.gov/large-docs/00/NCT05275400/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/00/NCT05275400/SAP_001.pdf,SAP,noninferiority,NCT05275400,40562047,Ph3 | treatment,Eli Lilly and Company,Industry,,?,Y,Jit Mitra,Research Scientist,Eli Lilly,https://www.linkedin.com/pub/dir/Jit/Mitra,Medium,Web-search,"Jit Mitra is a Research Scientist at Eli Lilly and studied at Indian Statistical Institute, implying a statistics role."
-552,LANC,2025,Hematology,"Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial",https://doi.org/10.1016/s0140-6736(25)00635-x,https://cdn.clinicaltrials.gov/large-docs/53/NCT04770753/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/53/NCT04770753/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04770753,40544857,Ph3 | quadruple | treatment,"Agios Pharmaceuticals, Inc.",Industry,,?,Y,,,,,None,,
-553,LANC,2025,Oncology,"Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial",https://doi.org/10.1016/s0140-6736(25)00631-2,https://cdn.clinicaltrials.gov/large-docs/29/NCT04472429/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/29/NCT04472429/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04472429,40517007,Ph3 | quadruple | treatment,Incyte Corporation,Industry,,?,Y,Chuan Tian,"Executive Director, Biostatistics",Incyte,https://www.linkedin.com/in/chuan-tian-59489719,High,Web-search,"LinkedIn profile explicitly states Executive Director, Biostatistics at Incyte Corp."
-554,LANC,2025,Other,"Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study",https://doi.org/10.1016/s0140-6736(25)00986-9,https://cdn.clinicaltrials.gov/large-docs/08/NCT04924608/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/08/NCT04924608/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04924608,40473450,Ph3 | quadruple | treatment,AstraZeneca,Industry,Merck Sharp & Dohme LLC,?,Y,Rosa Lamarca,"Executive Director, Biostatistics",Alexion Pharmaceuticals,https://es.linkedin.com/in/rosa-lamarca-4951702b,High,Web-search,"LinkedIn profile shows she is Executive Director, Biostatistics at Alexion Pharmaceuticals."
-555,LANC,2025,Oncology,"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial",https://doi.org/10.1016/s0140-6736(25)01011-6,https://cdn.clinicaltrials.gov/large-docs/67/NCT05091567/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/67/NCT05091567/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05091567,40473449,Ph3 | treatment,Hoffmann-La Roche,Industry,Jazz Pharmaceuticals,?,Y,,,,,None,,
-556,LANC,2025,Cardiovascular,"ACURATE neo2 valve versus commercially available transcatheter heart valves in patients with severe aortic stenosis (ACURATE IDE): a multicentre, randomised, controlled, non-inferiority trial",https://doi.org/10.1016/s0140-6736(25)00319-8,https://cdn.clinicaltrials.gov/large-docs/67/NCT03735667/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/67/NCT03735667/SAP_002.pdf,SAP,adaptive_bayesian;noninferiority,NCT03735667,40412426,NA | treatment,Boston Scientific Corporation,Industry,,?,Y,,,,,None,,
-557,LANC,2025,Other,"Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial",https://doi.org/10.1016/s0140-6736(25)00721-4,https://cdn.clinicaltrials.gov/large-docs/97/NCT06005597/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/97/NCT06005597/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT06005597,40347969,Ph3 | quadruple | treatment,NewAmsterdam Pharma,Industry,,?,Y,Danielle Brennan,Biostatistician,Cleveland Clinic,https://www.linkedin.com/in/danielle-brennan-b602b817,High,Web-search,Danielle Brennan is explicitly listed as a Biostatistician at Cleveland Clinic on LinkedIn and in multiple publications.
-558,LANC,2025,Dermatology,"Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial",https://doi.org/10.1016/s0140-6736(25)00001-7,https://cdn.clinicaltrials.gov/large-docs/22/NCT05259722/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/22/NCT05259722/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT05259722,40252681,Ph3 | single | treatment,LEO Pharma,Industry,,?,Y,,,,,None,,
-559,LANC,2025,Infectious Disease,"Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study",https://doi.org/10.1016/s0140-6736(25)00628-2,https://cdn.clinicaltrials.gov/large-docs/39/NCT04010539/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/39/NCT04010539/SAP_001.pdf,SAP,noninferiority,NCT04010539,40245902,Ph3 | treatment,GlaxoSmithKline,Industry,,?,Y,William Flight,Biostatistics,GSK,https://academic.oup.com/ofid/article/10/11/ofad557/7344688,Medium,Web-search,"William Flight is listed with affiliation 'Biostatistics, GSK' in a related paper."
-560,LANC,2025,Cardiovascular,"SAPIEN 3 versus Myval transcatheter heart valves for transcatheter aortic valve implantation (COMPARE-TAVI 1): a multicentre, randomised, non-inferiority trial",https://doi.org/10.1016/s0140-6736(25)00106-0,https://cdn.clinicaltrials.gov/large-docs/23/NCT04443023/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/23/NCT04443023/Prot_SAP_000.pdf,Protocol+SAP,platform;noninferiority,NCT04443023,40187364,NA | treatment,Aarhus University Hospital Skejby,Academic/Other,Odense University Hospital; Aalborg University Hospital,?,Y,,,,,None,,
-561,LANC,2025,Other,"Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial",https://doi.org/10.1016/s0140-6736(25)00507-0,https://cdn.clinicaltrials.gov/large-docs/54/NCT05256654/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/54/NCT05256654/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05256654,40179932,Ph2 | double | treatment,Eli Lilly and Company,Industry,,?,Y,Jeremiah Jones,Advisor in Statistics,Eli Lilly and Company,https://www.jmiahjones.com/,High,Web-search,Jeremiah Jones is an Advisor in Statistics at Eli Lilly and Company.
-562,LANC,2025,Cardiovascular,"Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial",https://doi.org/10.1016/s0140-6736(25)00505-7,https://cdn.clinicaltrials.gov/large-docs/22/NCT02100722/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/22/NCT02100722/Prot_SAP_000.pdf,Protocol+SAP,noninferiority,NCT02100722,40174598,NA | treatment,Stanford University,Academic/Other,"VZW Cardiovascular Research Center Aalst; Catharina Ziekenhuis Eindhoven; Golden Jubilee National Hospital; University of California, Irvine; Medtronic; (+4 more)",?,Y,,,,,None,,
-563,LANC,2025,Endocrinology/Metabolism,"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial",https://doi.org/10.1016/s0140-6736(25)00509-4,https://cdn.clinicaltrials.gov/large-docs/98/NCT04560998/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/98/NCT04560998/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04560998,40169145,Ph3 | quadruple | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-564,LANC,2025,Infectious Disease,"Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial",https://doi.org/10.1016/s0140-6736(25)00345-9,https://cdn.clinicaltrials.gov/large-docs/80/NCT05072080/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/80/NCT05072080/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05072080,40158526,Ph3 | triple | prevention,Bavarian Nordic,Industry,Emergent BioSolutions,?,Y,,,,,None,,
-565,LANC,2025,Oncology,"Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial",https://doi.org/10.1016/s0140-6736(25)00145-x,https://cdn.clinicaltrials.gov/large-docs/97/NCT00906997/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/97/NCT00906997/Prot_SAP_000.pdf,Protocol+SAP,noninferiority,NCT00906997,40158525,NA | screening,Hospital Clinic of Barcelona,Academic/Other,Fundacion Cientifica de la Asociacion Española contra el Cancer; Instituto de Salud Carlos III,?,Y,Miquel Serra-Burriel,Biostatistics (per PubMed affiliation),"Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-566,LANC,2025,Infectious Disease,"Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial",https://doi.org/10.1016/s0140-6736(25)00372-1,https://cdn.clinicaltrials.gov/large-docs/17/NCT05349617/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/17/NCT05349617/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05349617,40158524,Ph3 | triple | prevention,Bavarian Nordic,Industry,Emergent BioSolutions,?,Y,,,,,None,,
-567,LANC,2025,Infectious Disease,"Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial",https://doi.org/10.1016/s0140-6736(25)00046-7,https://cdn.clinicaltrials.gov/large-docs/29/NCT05093829/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/29/NCT05093829/SAP_002.pdf,SAP,noninferiority,NCT05093829,40086461,Ph3 | triple | prevention,Emory University,Academic/Other,National Institute of Allergy and Infectious Diseases (NIAID),?,Y,Clara P Dominguez Islas,Biostatistics (per PubMed affiliation),"IDCRC Statistical and Data Science Unit, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-568,LANC,2025,Other,"Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials",https://doi.org/10.1016/s0140-6736(25)00197-7,https://cdn.clinicaltrials.gov/large-docs/23/NCT05281523/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/23/NCT05281523/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT05281523, NCT05274750",40037388,Ph3 | triple | treatment,GlaxoSmithKline,Industry,,?,Y,Dawn Edwards ; Prerna Ranganathan,Biostatistics (per PubMed affiliation),"Biostatistics, Respiratory & Immunology Unit, GSK, London, UK. ; Biostatistics, Respiratory & Immunology Unit, GSK, Upper Providence, PA, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-569,LANC,2025,Cardiovascular,"Efficacy and safety of nerinetide in acute ischaemic stroke in patients undergoing endovascular thrombectomy without previous thrombolysis (ESCAPE-NEXT): a multicentre, double-blind, randomised controlled trial",https://doi.org/10.1016/s0140-6736(25)00194-1,https://cdn.clinicaltrials.gov/large-docs/36/NCT04462536/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/36/NCT04462536/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04462536,39955119,Ph3 | quadruple | treatment,NoNO Inc.,Industry,University of Calgary,?,Y,,,,,None,,
-570,LANC,2025,Oncology,"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial",https://doi.org/10.1016/s0140-6736(24)02848-4,https://cdn.clinicaltrials.gov/large-docs/30/NCT04008030/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/30/NCT04008030/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04008030,39874977,Ph3 | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,Tian Chen,Director Statistician,Bristol Myers Squibb,https://www.linkedin.com/pub/dir/Tian/Chen,High,Web-search,LinkedIn profile explicitly lists Tian Chen as Director Statistician at Bristol-Myers Squibb.
-571,LANC,2025,Rheumatology/Immunology,"Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial",https://doi.org/10.1016/s0140-6736(24)02468-1,https://cdn.clinicaltrials.gov/large-docs/97/NCT03816397/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/97/NCT03816397/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03816397,39863370,Ph4 | quadruple | treatment,Nisha Acharya,Academic/Other,"Children's Hospital of Philadelphia; Children's Hospital Medical Center, Cincinnati; Children's Mercy Hospital Kansas City; National Eye Institute (NEI); Great Ormond Street Hospital for Children NHS Foundation Trust; (+15 more)",?,Y,,,,,None,,
-572,LANC,2025,Other,"Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial",https://doi.org/10.1016/s0140-6736(24)02071-3,https://cdn.clinicaltrials.gov/large-docs/93/NCT03181893/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/93/NCT03181893/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03181893,39798982,Ph2 | triple | treatment,Pfizer,Industry,,?,Y,,,,,None,,
-573,LANC,2025,Gastroenterology/Hepatology,"Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies",https://doi.org/10.1016/s0140-6736(24)01927-5,https://cdn.clinicaltrials.gov/large-docs/45/NCT04033445/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/45/NCT04033445/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04033445,39706209,Ph2/Ph3 | double | treatment,"Janssen Research & Development, LLC",Industry,,?,Y,,,,,None,,
-574,LANC,2024,Gastroenterology/Hepatology,"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study",https://doi.org/10.1016/s0140-6736(24)01762-8,https://cdn.clinicaltrials.gov/large-docs/30/NCT03926130/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/30/NCT03926130/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03926130,39581202,Ph3 | triple | treatment,Eli Lilly and Company,Industry,,?,Y,,,,,None,,
-575,LANC,2024,Cardiovascular,"Balloon guide catheters for endovascular thrombectomy in patients with acute ischaemic stroke due to large-vessel occlusion in China (PROTECT-MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial",https://doi.org/10.1016/s0140-6736(24)02315-8,https://cdn.clinicaltrials.gov/large-docs/54/NCT05592054/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/54/NCT05592054/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05592054,39579782,NA | single | treatment,Changhai Hospital,Academic/Other,,?,Y,,,,,None,,
-576,LANC,2024,Psychiatry/Mental Health,"Effectiveness, cost-effectiveness, and positive externalities of integrated chronic care for adults with major depressive disorder in Malawi (IC3D): a stepped-wedge, cluster-randomised, controlled trial",https://doi.org/10.1016/s0140-6736(24)01809-9,https://cdn.clinicaltrials.gov/large-docs/06/NCT04777006/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/06/NCT04777006/SAP_004.pdf,SAP,cluster,NCT04777006,39488229,Ph4 | double | treatment,RAND,Academic/Other,"National Institute of Mental Health (NIMH); Partners in Health; Brigham and Women's Hospital; Ministry of Health, Malawi; Blantyre College of Medicine; (+1 more)",?,Y,,,,,None,,
-577,LANC,2024,Cardiovascular,"Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial",https://doi.org/10.1016/s0140-6736(24)01744-6,https://cdn.clinicaltrials.gov/large-docs/93/NCT04518293/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/93/NCT04518293/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04518293,39426836,Ph3 | quadruple | treatment,George Medicines PTY Limited,Industry,,?,Y,,,,,None,,
-578,LANC,2024,Pediatrics,"Effects of oral sepiapterin on blood Phe concentration in a broad range of patients with phenylketonuria (APHENITY): results of an international, phase 3, randomised, double-blind, placebo-controlled trial",https://doi.org/10.1016/s0140-6736(24)01556-3,https://cdn.clinicaltrials.gov/large-docs/40/NCT05099640/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/40/NCT05099640/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05099640,39368841,Ph3 | quadruple | treatment,PTC Therapeutics,Industry,,?,Y,,,,,None,,
-579,LANC,2024,Oncology,"Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial",https://doi.org/10.1016/s0140-6736(24)01595-2,,https://cdn.clinicaltrials.gov/large-docs/48/NCT02597348/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT02597348,39306468,NA | treatment,Assistance Publique - Hôpitaux de Paris,Academic/Other,,?,Y,,,,,None,,
-580,LANC,2024,Oncology,"&lt;sup&gt;177&lt;/sup&gt;Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial",https://doi.org/10.1016/s0140-6736(24)01653-2,https://cdn.clinicaltrials.gov/large-docs/28/NCT04689828/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/28/NCT04689828/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04689828,39293462,Ph3 | treatment,Novartis Pharmaceuticals,Industry,,?,Y,Samson Ghebremariam,Director Biostatistics,Novartis,https://www.linkedin.com/in/samson-ghebremariam-0794698b,High,Web-search,Samson Ghebremariam is Director Biostatistics at Novartis Oncology.
-581,LANC,2024,Oncology,"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(24)01756-2,https://cdn.clinicaltrials.gov/large-docs/43/NCT03425643/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/43/NCT03425643/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03425643,39288781,Ph3 | double | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Jing Yang,Biostatistics (per PubMed affiliation),"Biostatistics and Research Decision Sciences, Merck & Co, Rahway, NJ, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-582,LANC,2024,Oncology,"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(24)01808-7,https://cdn.clinicaltrials.gov/large-docs/45/NCT04221945/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/45/NCT04221945/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04221945,39288779,Ph3 | triple | treatment,Merck Sharp & Dohme LLC,Industry,GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT),?,Y,Peng Liu,"Senior Scientist, Biostatistics",Merck,https://rocketreach.co/peng-liu-email_7954833,High,Web-search,"Peng Liu is a Senior Scientist, Biostatistics at Merck."
-583,LANC,2024,Endocrinology/Metabolism,Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial,https://doi.org/10.1016/s0140-6736(24)01804-x,https://cdn.clinicaltrials.gov/large-docs/44/NCT05463744/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/44/NCT05463744/SAP_001.pdf,SAP,noninferiority,NCT05463744,39270686,Ph3 | treatment,Eli Lilly and Company,Industry,,?,Y,,,,,None,,
-584,LANC,2024,Cardiovascular,"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials",https://doi.org/10.1016/s0140-6736(24)01643-x,https://cdn.clinicaltrials.gov/large-docs/97/NCT03574597/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/97/NCT03574597/SAP_003.pdf,SAP,fixed_parallel_superiority,"NCT04916470, NCT03574597, NCT03819153, NCT04788511",39222642,Ph3 | quadruple | treatment,Novo Nordisk A/S,Industry,,?,Y,Scott S Emerson,Biostatistics (per PubMed affiliation),"Department of Biostatistics, University of Washington, Seattle, WA, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-585,LANC,2024,Cardiovascular,Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial,https://doi.org/10.1016/s0140-6736(24)01498-3,https://cdn.clinicaltrials.gov/large-docs/97/NCT03574597/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/97/NCT03574597/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03574597,39181597,Ph3 | quadruple | treatment,Novo Nordisk A/S,Industry,,?,Y,Scott S Emerson,Biostatistics (per PubMed affiliation),"Department of Biostatistics, University of Washington, Seattle, WA, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-586,LANC,2024,Surgery/Critical Care,"Effect of high versus standard protein provision on functional recovery in people with critical illness (PRECISe): an investigator-initiated, double-blinded, multicentre, parallel-group, randomised controlled trial in Belgium and the Netherlands",https://doi.org/10.1016/s0140-6736(24)01304-7,,https://cdn.clinicaltrials.gov/large-docs/21/NCT04633421/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT04633421,39153816,NA | quadruple | treatment,Maastricht University Medical Center,Academic/Other,Ziekenhuis Oost-Limburg; Zuyderland Medisch Centrum; Gelderse Vallei Hospital; Medisch Spectrum Twente; Centre Hospitalier Universitaire de Liege; (+4 more),?,Y,,,,,None,,
-587,LANC,2024,Oncology,"Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study",https://doi.org/10.1016/s0140-6736(24)00814-6,https://cdn.clinicaltrials.gov/large-docs/21/NCT03498521/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/21/NCT03498521/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03498521,39096924,Ph2 | treatment,Hoffmann-La Roche,Industry,Foundation Medicine,?,Y,Gonzalo Durán-Pacheco,Senior Principal Statistical Scientist,Roche,https://www.linkedin.com/posts/gonzaloduranpacheco_roche-activity-6996742006072836096-C8Kf,High,Web-search,LinkedIn profile shows Gonzalo Durán Pacheco is a Senior Principal Statistical Scientist at Roche.
-588,LANC,2024,Nephrology/Urology,"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials",https://doi.org/10.1016/s0140-6736(24)01203-0,https://cdn.clinicaltrials.gov/large-docs/43/NCT03985943/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/43/NCT03985943/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT03985943, NCT03989349",39067461,Ph3 | quadruple | treatment,Galderma R&D,Industry,,?,Y,Soo Yeon Cheong,Biostatistics (per PubMed affiliation),"Biometrics, Galderma Laboratories, Dallas, TX, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-589,LANC,2024,Dermatology,"Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials",https://doi.org/10.1016/s0140-6736(24)01027-4,https://cdn.clinicaltrials.gov/large-docs/11/NCT04871711/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/11/NCT04871711/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,"NCT04871711, NCT04872101",39033766,Ph3 | double | treatment,LEO Pharma,Industry,,?,Y,,,,,None,,
-590,LANC,2024,Oncology,"[<sup>177</sup>Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study",https://doi.org/10.1016/s0140-6736(24)00701-3,https://cdn.clinicaltrials.gov/large-docs/88/NCT03972488/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/88/NCT03972488/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03972488,38851203,Ph3 | treatment,Advanced Accelerator Applications,Industry,,?,Y,Yufen Zhang,Biostatistician,Novartis,https://www.linkedin.com/in/yufen-zhang-08321417,High,Web-search,Yufen Zhang is explicitly listed as a Biostatistician at Novartis on LinkedIn and in multiple publications.
-591,LANC,2024,Oncology,"Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(24)00885-7,https://cdn.clinicaltrials.gov/large-docs/62/NCT05059262/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/62/NCT05059262/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05059262,38843860,Ph3 | quadruple | treatment,"Deciphera Pharmaceuticals, LLC",Industry,,?,Y,,,,,None,,
-592,LANC,2024,Dermatology,"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials",https://doi.org/10.1016/s0140-6736(24)00101-6,https://cdn.clinicaltrials.gov/large-docs/46/NCT04242446/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/46/NCT04242446/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT04242446, NCT04242498",38795716,Ph3 | quadruple | treatment,UCB Biopharma SRL,Industry,,?,Y,,,,,None,,
-593,LANC,2024,Cardiovascular,"Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial",https://doi.org/10.1016/s0140-6736(24)00921-8,https://cdn.clinicaltrials.gov/large-docs/56/NCT02398656/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/56/NCT02398656/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02398656,38768626,Ph3 | single | treatment,University of Calgary,Academic/Other,,?,Y,,,,,None,,
-594,LANC,2024,Obstetrics/Gynecology,"Effectiveness of kangaroo mother care before clinical stabilisation versus standard care among neonates at five hospitals in Uganda (OMWaNA): a parallel-group, individually randomised controlled trial and economic evaluation",https://doi.org/10.1016/s0140-6736(24)00064-3,https://cdn.clinicaltrials.gov/large-docs/32/NCT02811432/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/32/NCT02811432/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT02811432,38754454,NA | treatment,London School of Hygiene and Tropical Medicine,Academic/Other,MRC/UVRI and LSHTM Uganda Research Unit; Makerere University,?,Y,Charles Opondo ; Ruth Canter,Biostatistics (per PubMed affiliation),"Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK. ; Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-595,LANC,2024,Cardiovascular,Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials,https://doi.org/10.1016/s0140-6736(24)00469-0,https://cdn.clinicaltrials.gov/large-docs/11/NCT04788511/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/11/NCT04788511/SAP_003.pdf,SAP,fixed_parallel_superiority,"NCT04788511, NCT04916470",38599221,Ph3 | double | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-596,LANC,2024,Oncology,"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial",https://doi.org/10.1016/s0140-6736(24)00317-9,https://cdn.clinicaltrials.gov/large-docs/45/NCT04221945/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/45/NCT04221945/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04221945,38521086,Ph3 | triple | treatment,Merck Sharp & Dohme LLC,Industry,GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT),?,Y,Kan Li,"Principal Scientist, Biostatistics",Merck,https://www.linkedin.com/in/kan-li-a3340116,High,Web-search,"Kan Li is a Principal Scientist, Biostatistics at Merck, and currently Director Biostatistics at Daiichi Sankyo."
-597,LANC,2024,Endocrinology/Metabolism,"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial",https://doi.org/10.1016/s0140-6736(23)02577-1,https://cdn.clinicaltrials.gov/large-docs/03/NCT04429503/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/03/NCT04429503/SAP_001.pdf,SAP,noninferiority;seamless_2_3,NCT04429503,38461843,Ph2/Ph3 | quadruple | treatment,Regeneron Pharmaceuticals,Industry,Bayer,?,Y,,,,,None,,
-598,LANC,2024,Ophthalmology,"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial",https://doi.org/10.1016/s0140-6736(24)00063-1,https://cdn.clinicaltrials.gov/large-docs/18/NCT04423718/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/18/NCT04423718/SAP_001.pdf,SAP,noninferiority,NCT04423718,38461841,Ph3 | quadruple | treatment,Bayer,Industry,Regeneron Pharmaceuticals,?,Y,,,,,None,,
-599,LANC,2024,Cardiovascular,Endovascular thrombectomy plus medical care versus medical care alone for large ischaemic stroke: 1-year outcomes of the SELECT2 trial,https://doi.org/10.1016/s0140-6736(24)00050-3,https://cdn.clinicaltrials.gov/large-docs/57/NCT03876457/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/57/NCT03876457/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03876457,38346442,NA | single | treatment,University Hospitals Cleveland Medical Center,Academic/Other,"Stryker Neurovascular; The University of Texas Health Science Center, Houston",?,Y,,,,,None,,
-600,LANC,2024,Infectious Disease,"Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials",https://doi.org/10.1016/s0140-6736(23)02196-7,https://cdn.clinicaltrials.gov/large-docs/41/NCT04020341/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/41/NCT04020341/SAP_001.pdf,SAP,noninferiority,"NCT04020341, NCT04187144",38342126,Ph3 | double | treatment,GlaxoSmithKline,Industry,,?,Y,,,,,None,,
-601,LANC,2024,Infectious Disease,"Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin-piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trial",https://doi.org/10.1016/s0140-6736(23)02631-4,https://cdn.clinicaltrials.gov/large-docs/13/NCT04158713/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/13/NCT04158713/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04158713,38224710,Ph3 | quadruple | prevention,Liverpool School of Tropical Medicine,Academic/Other,Kenya Medical Research Institute; Kamuzu University of Health Sciences; Kenya National AIDS & STI Control Programme; KEMRI-Wellcome Trust Collaborative Research Program; Centers for Disease Control and Prevention; (+6 more),?,Y,,,,,None,,
-602,LANC,2024,Cardiovascular,Indomethacin with or without prophylactic pancreatic stent placement to prevent pancreatitis after ERCP: a randomised non-inferiority trial,https://doi.org/10.1016/s0140-6736(23)02356-5,https://cdn.clinicaltrials.gov/large-docs/79/NCT02476279/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/79/NCT02476279/SAP_001.pdf,SAP,noninferiority,NCT02476279,38219767,Ph3 | quadruple | prevention,Medical University of South Carolina,Academic/Other,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),?,Y,,,,,None,,
-603,LANC,2024,Nephrology/Urology,"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial",https://doi.org/10.1016/s0140-6736(23)02408-x,https://cdn.clinicaltrials.gov/large-docs/40/NCT05182840/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/40/NCT05182840/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05182840,38109916,Ph2 | quadruple | treatment,Boehringer Ingelheim,Industry,,?,Y,,,,,None,,
-604,LANC,2024,Psychiatry/Mental Health,"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial",https://doi.org/10.1016/s0140-6736(23)02190-6,https://cdn.clinicaltrials.gov/large-docs/61/NCT04659161/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/61/NCT04659161/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04659161,38104575,Ph3 | triple | treatment,"Karuna Therapeutics, Inc., a Bristol Myers Squibb company",Industry,,?,Y,,,,,None,,
-605,LANC,2024,Respiratory,"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study",https://doi.org/10.1016/s0140-6736(23)02284-5,https://cdn.clinicaltrials.gov/large-docs/19/NCT04159519/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/19/NCT04159519/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04159519,38071986,Ph4 | treatment,AstraZeneca,Industry,,?,Y,,,,,None,,
-606,LANC,2024,Oncology,"Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(23)01724-5,https://cdn.clinicaltrials.gov/large-docs/61/NCT02598661/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/61/NCT02598661/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02598661,38048786,Ph2/Ph3 | double | treatment,Geron Corporation,Industry,,?,Y,,,,,None,,
-607,LANC,2024,Dermatology,Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials,https://doi.org/10.1016/s0140-6736(23)01684-7,https://cdn.clinicaltrials.gov/large-docs/56/NCT03580356/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/56/NCT03580356/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT03580356, NCT03580369",38008109,Ph3 | triple | treatment,Novartis Pharmaceuticals,Industry,,?,Y,,,,,None,,
-608,LANC,2023,Oncology,An SMS and animated video intervention to increase uptake of breast cancer screening: a randomised controlled trial,https://doi.org/10.1016/s0140-6736(23)02133-5,https://cdn.clinicaltrials.gov/large-docs/71/NCT05395871/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/71/NCT05395871/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT05395871,37997056,NA | single | screening,Imperial College London,Academic/Other,NHS England,?,Y,,,,,None,,
-609,LANC,2023,Neurology,"Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA",https://doi.org/10.1016/s0140-6736(23)01683-5,https://cdn.clinicaltrials.gov/large-docs/20/NCT04492020/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/20/NCT04492020/SAP_001.pdf,SAP,crossover,NCT04492020,37979595,Ph3 | double | treatment,AbbVie,Industry,,?,Y,Kaifeng Lu,Biostatistics,AbbVie,https://pmc.ncbi.nlm.nih.gov/articles/PMC9306593/,High,Web-search,"Kaifeng Lu is listed as Biostatistics, AbbVie Inc. in multiple publications."
-610,LANC,2023,Nephrology/Urology,"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(23)02302-4,https://cdn.clinicaltrials.gov/large-docs/50/NCT03762850/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/50/NCT03762850/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03762850,37931634,Ph3 | quadruple | treatment,"Travere Therapeutics, Inc.",Industry,,?,Y,,,,,None,,
-611,LANC,2023,Oncology,"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial",https://doi.org/10.1016/s0140-6736(23)01613-6,https://cdn.clinicaltrials.gov/large-docs/71/NCT02784171/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/71/NCT02784171/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02784171,37931632,Ph2/Ph3 | treatment,Canadian Cancer Trials Group,Network/Cooperative,"National Cancer Institute, Naples; Merck Sharp & Dohme LLC; Intergroupe Francophone de Cancerologie Thoracique",?,Y,Yiwen Luo,Principal Scientist - Biostatistics,Merck,https://rocketreach.co/yiwen-luo-email_37232226,High,Web-search,Yiwen Luo is explicitly listed as Principal Scientist - Biostatistics at Merck in RocketReach and Lead411 profiles.
-612,LANC,2023,Cardiovascular,"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial",https://doi.org/10.1016/s0140-6736(23)02230-4,https://cdn.clinicaltrials.gov/large-docs/37/NCT04724837/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/37/NCT04724837/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT04724837,37931629,Ph2 | triple | treatment,AstraZeneca,Industry,,?,Y,Min Lin ; Emma Wijkmark,Biostatistics (per PubMed affiliation),"Biometrics Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. ; Biometrics Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-613,LANC,2023,Oncology,"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial",https://doi.org/10.1016/s0140-6736(23)01796-8,https://cdn.clinicaltrials.gov/large-docs/98/NCT04102098/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/98/NCT04102098/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04102098,37871608,Ph3 | treatment,Hoffmann-La Roche,Industry,,?,Y,,,,,None,,
-614,LANC,2023,Oncology,Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial,https://doi.org/10.1016/s0140-6736(23)02033-0,https://cdn.clinicaltrials.gov/large-docs/26/NCT03615326/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/26/NCT03615326/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03615326,37871604,Ph3 | quadruple | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Kan Li,"Principal Scientist, Biostatistics",Merck,https://www.linkedin.com/in/kan-li-a3340116,High,Web-search,"Kan Li's LinkedIn profile and other sources confirm he was a Principal Scientist, Biostatistics at Merck."
-615,LANC,2023,Ophthalmology,"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials",https://doi.org/10.1016/s0140-6736(23)01520-9,https://cdn.clinicaltrials.gov/large-docs/13/NCT03525613/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/13/NCT03525613/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT03525613, NCT03525600",37865470,Ph3 | quadruple | treatment,"Apellis Pharmaceuticals, Inc.",Industry,,?,Y,,,,,None,,
-616,LANC,2023,Endocrinology/Metabolism,"Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial",https://doi.org/10.1016/s0140-6736(23)02179-7,https://cdn.clinicaltrials.gov/large-docs/80/NCT04848480/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/80/NCT04848480/SAP_001.pdf,SAP,noninferiority,NCT04848480,37863084,Ph3 | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-617,LANC,2023,Hematology,"Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(23)01460-5,https://cdn.clinicaltrials.gov/large-docs/79/NCT04188379/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/79/NCT04188379/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04188379,37778358,Ph3 | quadruple | treatment,argenx,Industry,,?,Y,,,,,None,,
-618,LANC,2023,Oncology,"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial",https://doi.org/10.1016/s0140-6736(23)01366-1,https://cdn.clinicaltrials.gov/large-docs/35/NCT04083235/Prot_003.pdf,https://cdn.clinicaltrials.gov/large-docs/35/NCT04083235/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04083235,37708904,Ph3 | treatment,Ipsen,Industry,,?,Y,,,,,None,,
-619,LANC,2023,Cardiovascular,"Adaptive versus conventional cardiac resynchronisation therapy in patients with heart failure (AdaptResponse): a global, prospective, randomised controlled trial",https://doi.org/10.1016/s0140-6736(23)00912-1,https://cdn.clinicaltrials.gov/large-docs/59/NCT02205359/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/59/NCT02205359/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02205359,37634520,NA | single | treatment,Medtronic Cardiac Rhythm and Heart Failure,Industry,,?,Y,,,,,None,,
-620,LANC,2023,Oncology,"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial",https://doi.org/10.1016/s0140-6736(23)01245-x,https://cdn.clinicaltrials.gov/large-docs/39/NCT03901339/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/39/NCT03901339/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03901339,37633306,Ph3 | treatment,Gilead Sciences,Industry,,?,Y,Theresa Valdez,Manager Biostatistics,Gilead Sciences,https://www.zoominfo.com/p/Priyamvada-Maharana/-824150198,High,Web-search,Theresa Valdez is listed as Manager Biostatistics at Gilead Sciences in ZoomInfo.
-621,LANC,2023,Obstetrics/Gynecology,Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial,https://doi.org/10.1016/s0140-6736(23)01240-0,https://cdn.clinicaltrials.gov/large-docs/94/NCT03614494/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/94/NCT03614494/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03614494,37597523,Ph2/Ph3 | triple | treatment,Dr. Hang Wun Raymond Li,Academic/Other,The Family Planning Association of Hong Kong,?,Y,,,,,None,,
-622,LANC,2023,Nephrology/Urology,Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial,https://doi.org/10.1016/s0140-6736(23)01554-4,https://cdn.clinicaltrials.gov/large-docs/65/NCT03643965/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/65/NCT03643965/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03643965,37591292,Ph3 | quadruple | treatment,Calliditas Therapeutics AB,Industry,,?,Y,Andrew Stone,Biostatistics (per PubMed affiliation),"Stone Biostatistics, Crewe, UK.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-623,LANC,2023,Oncology,"Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial",https://doi.org/10.1016/s0140-6736(23)00913-3,https://cdn.clinicaltrials.gov/large-docs/49/NCT01120249/Prot_SAP_ICF_000.pdf,https://cdn.clinicaltrials.gov/large-docs/49/NCT01120249/Prot_SAP_ICF_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01120249,37524096,Ph3 | triple | treatment,SWOG Cancer Research Network,Network/Cooperative,National Cancer Institute (NCI),?,Y,Catherine M Tangen ; Melissa Plets,Biostatistics (per PubMed affiliation),"SWOG Statistics and Data Management Center, Seattle, WA, USA. ; SWOG Statistics and Data Management Center, Seattle, WA, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-624,LANC,2023,Neurology,"Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(23)01049-8,https://cdn.clinicaltrials.gov/large-docs/37/NCT03855137/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/37/NCT03855137/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03855137,37516125,Ph3 | triple | treatment,Allergan,Industry,,?,Y,Brittany Schwefel,Senior Research Statistician,AbbVie,https://stat.wisc.edu/staff/schwefel-brittany-2/,High,Web-search,Brittany Schwefel is explicitly listed as Senior Research Statistician at AbbVie.
-625,LANC,2023,Oncology,"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study",https://doi.org/10.1016/s0140-6736(23)00961-3,https://cdn.clinicaltrials.gov/large-docs/93/NCT03764293/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/93/NCT03764293/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03764293,37499670,Ph3 | treatment,"Jiangsu HengRui Medicine Co., Ltd.",Industry,,?,Y,,,,,None,,
-626,LANC,2023,Cardiovascular,"Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial",https://doi.org/10.1016/s0140-6736(23)01406-x,https://cdn.clinicaltrials.gov/large-docs/22/NCT03243422/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/22/NCT03243422/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03243422,37478886,NA | treatment,Johns Hopkins Bloomberg School of Public Health,Academic/Other,University of North Carolina; University of South Florida; University of Pittsburgh; University of Mississippi Medical Center; Wake Forest University; (+2 more),?,Y,Sheila Burgard ; David Couper,Biostatistics (per PubMed affiliation),"Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA. ; Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-627,LANC,2023,Rheumatology/Immunology,"Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial",https://doi.org/10.1016/s0140-6736(23)00921-2,https://cdn.clinicaltrials.gov/large-docs/78/NCT03773978/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/78/NCT03773978/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03773978,37423231,Ph3 | triple | treatment,Eli Lilly and Company,Industry,,?,Y,Zhongkai Wang,"Senior Manager, Biostatistics",Gilead Sciences,https://www.linkedin.com/in/zkwang2020,High,Web-search,"LinkedIn profile confirms role as Senior Manager, Biostatistics at Gilead Sciences."
-628,LANC,2023,Oncology,"First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study",https://doi.org/10.1016/s0140-6736(23)00774-2,https://cdn.clinicaltrials.gov/large-docs/86/NCT03191786/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/86/NCT03191786/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03191786,37423228,Ph3 | treatment,Hoffmann-La Roche,Industry,,?,Y,Youyou Hu,Principal Statistician,Roche,https://www.linkedin.com/pub/dir/Youyou/Hu,High,Web-search,LinkedIn profile shows Youyou H. as Principal Statistician at Roche.
-629,LANC,2023,Endocrinology/Metabolism,"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA",https://doi.org/10.1016/s0140-6736(23)01053-x,https://cdn.clinicaltrials.gov/large-docs/85/NCT04867785/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/85/NCT04867785/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04867785,37385280,Ph2 | double | treatment,Eli Lilly and Company,Industry,,?,Y,Jitong Lou,Research Scientist - Statistician,Eli Lilly and Company,https://www.linkedin.com/in/jitong-lou-93423994,High,Web-search,Jitong Lou is explicitly listed as a Research Scientist - Statistician at Eli Lilly and Company on LinkedIn.
-630,LANC,2023,Endocrinology/Metabolism,"Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial",https://doi.org/10.1016/s0140-6736(23)01127-3,https://cdn.clinicaltrials.gov/large-docs/69/NCT04707469/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/69/NCT04707469/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04707469,37385279,Ph3 | quadruple | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-631,LANC,2023,Endocrinology/Metabolism,"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(23)01185-6,https://cdn.clinicaltrials.gov/large-docs/95/NCT05035095/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/95/NCT05035095/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05035095,37385278,Ph3 | quadruple | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-632,LANC,2023,Endocrinology/Metabolism,"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(23)01200-x,https://cdn.clinicaltrials.gov/large-docs/03/NCT04657003/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/03/NCT04657003/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04657003,37385275,Ph3 | double | treatment,Eli Lilly and Company,Industry,,?,Y,Shuyu Zhang,company statistician,Eli Lilly and Company,https://www.sciencedirect.com/science/article/pii/S1526590010003871,High,Web-search,Shuyu Zhang is explicitly referred to as 'the company statistician' at Eli Lilly in a published paper.
-633,LANC,2023,Endocrinology/Metabolism,"Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study",https://doi.org/10.1016/s0140-6736(23)01302-8,https://cdn.clinicaltrials.gov/large-docs/19/NCT05048719/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/19/NCT05048719/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05048719,37369232,Ph2 | double | treatment,Eli Lilly and Company,Industry,,?,Y,Rong Liu,Executive Director and Diabetes Development Lead Statistician,Eli Lilly and Company,https://www.linkedin.com/in/rong-liu-98ab5374,High,Web-search,Rong Liu is an Executive Director and Diabetes Development Lead Statistician at Eli Lilly.
-634,LANC,2023,Endocrinology/Metabolism,"Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial",https://doi.org/10.1016/s0140-6736(23)01163-7,https://cdn.clinicaltrials.gov/large-docs/75/NCT04982575/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/75/NCT04982575/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04982575,37364590,Ph2 | quadruple | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-635,LANC,2023,Oncology,"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study",https://doi.org/10.1016/s0140-6736(23)00772-9,https://cdn.clinicaltrials.gov/large-docs/39/NCT04322539/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/39/NCT04322539/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04322539,37331369,Ph3 | quadruple | treatment,Hutchison Medipharma Limited,Industry,,?,Y,Shivani Nanda,"Executive Director, Head Of Biometrics & Data Management",HUTCHMED,https://theorg.com/org/hutchmed/org-chart/shivani-nanda,High,Web-search,"Shivani Nanda is the Executive Director, Head of Biometrics and Data Management at HUTCHMED."
-636,LANC,2023,Surgery/Critical Care,"Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial",https://doi.org/10.1016/s0140-6736(23)00776-6,https://cdn.clinicaltrials.gov/large-docs/19/NCT03464019/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/19/NCT03464019/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03464019,37331368,Ph3 | quadruple | treatment,Milestone Pharmaceuticals Inc.,Academic/Other,"Medpace, Inc.; IQVIA Biotech",?,Y,,,,,None,,
-637,LANC,2023,Infectious Disease,"Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(23)00641-4,https://cdn.clinicaltrials.gov/large-docs/24/NCT04546724/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/24/NCT04546724/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04546724,37321235,Ph3 | double | prevention,Valneva Austria GmbH,Industry,,?,Y,Julian Larcher-Senn,Biostatistics (per PubMed affiliation),"Assign Data Management and Biostatistics, Innsbruck, Austria.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-638,LANC,2023,Oncology,"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial",https://doi.org/10.1016/s0140-6736(23)00874-7,https://cdn.clinicaltrials.gov/large-docs/36/NCT03682536/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/36/NCT03682536/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03682536,37311468,Ph3 | treatment,Celgene,Industry,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",?,Y,Jennie Zhang,Senior Director of Biometrics,Bristol Myers Squibb,https://rocketreach.co/jennie-zhang-email_7064354,High,Web-search,Jennie Zhang is listed as Senior Director of Biometrics at Bristol Myers Squibb.
-639,LANC,2023,Oncology,"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial",https://doi.org/10.1016/s0140-6736(23)00922-4,https://cdn.clinicaltrials.gov/large-docs/69/NCT04338269/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/69/NCT04338269/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04338269,37290461,Ph3 | treatment,Hoffmann-La Roche,Industry,Exelixis; Chugai Pharmaceutical,?,Y,,,,,None,,
-640,LANC,2023,Oncology,"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(23)01055-3,https://cdn.clinicaltrials.gov/large-docs/97/NCT03395197/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/97/NCT03395197/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03395197,37285865,Ph3 | quadruple | treatment,Pfizer,Industry,Astellas Pharma Inc,?,Y,Xun Lin,Senior Director of Statistics,Pfizer,https://rocketreach.co/xun-lin-email_35794372,High,Web-search,Xun Lin is identified as Senior Director of Statistics at Pfizer.
-641,LANC,2023,Endocrinology/Metabolism,"Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial",https://doi.org/10.1016/s0140-6736(23)00520-2,https://cdn.clinicaltrials.gov/large-docs/50/NCT04880850/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/50/NCT04880850/SAP_001.pdf,SAP,noninferiority,NCT04880850,37156252,Ph3 | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-642,LANC,2023,Oncology,"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(23)00464-6,https://cdn.clinicaltrials.gov/large-docs/53/NCT02668653/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/53/NCT02668653/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02668653,37116523,Ph3 | triple | treatment,Daiichi Sankyo,Industry,,?,Y,,,,,None,,
-643,LANC,2023,Oncology,"Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial",https://doi.org/10.1016/s0140-6736(23)00725-0,https://cdn.clinicaltrials.gov/large-docs/85/NCT03523585/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/85/NCT03523585/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03523585,37086745,Ph3 | treatment,Daiichi Sankyo,Industry,"Daiichi Sankyo Co., Ltd.; AstraZeneca",?,Y,,,,,None,,
-644,LANC,2023,Oncology,"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(23)00727-4,https://cdn.clinicaltrials.gov/large-docs/36/NCT04003636/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/36/NCT04003636/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04003636,37075781,Ph3 | triple | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Li Yu,Biostatistics (per PubMed affiliation),"Biostatistics and Research Decision Sciences, Merck & Co, Rahway, NJ, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-645,LANC,2023,Oncology,"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial",https://doi.org/10.1016/s0140-6736(23)00620-7,https://cdn.clinicaltrials.gov/large-docs/97/NCT03504397/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/97/NCT03504397/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03504397,37068504,Ph3 | double | treatment,"Astellas Pharma Global Development, Inc.",Industry,,?,Y,,,,,None,,
-646,LANC,2023,Infectious Disease,"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial",https://doi.org/10.1016/s0140-6736(23)00222-2,https://cdn.clinicaltrials.gov/large-docs/07/NCT03732807/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/07/NCT03732807/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03732807,37062298,Ph2/Ph3 | quadruple | treatment,Pfizer,Industry,,?,Y,,,,,None,,
-647,LANC,2023,Hematology,"The effect of vitamin B12 supplementation during pregnancy on infant growth and development in Nepal: a community-based, double-blind, randomised, placebo-controlled trial",https://doi.org/10.1016/s0140-6736(23)00346-x,,https://cdn.clinicaltrials.gov/large-docs/66/NCT03071666/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT03071666,37031691,Ph2/Ph3 | quadruple | prevention,Centre For International Health,Academic/Other,"Tribhuvan University Teaching Hospital, Institute Of Medicine.; NORCE Norwegian Research Centre AS; Sykehuset Innlandet HF",?,Y,,,,,None,,
-648,LANC,2023,Nephrology/Urology,"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial",https://doi.org/10.1016/s0140-6736(23)00569-x,https://cdn.clinicaltrials.gov/large-docs/50/NCT03762850/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/50/NCT03762850/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03762850,37015244,Ph3 | quadruple | treatment,"Travere Therapeutics, Inc.",Industry,,?,Y,,,,,None,,
-649,LANC,2023,Hematology,"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial",https://doi.org/10.1016/s0140-6736(23)00284-2,https://cdn.clinicaltrials.gov/large-docs/02/NCT03417102/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/02/NCT03417102/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03417102,37003287,Ph3 | treatment,"Genzyme, a Sanofi Company",Industry,,?,Y,Zhiying Qiu,Biostatistics (per PubMed affiliation),"Biostatistics & Programming, Sanofi, Bridgewater, NJ, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-650,LANC,2023,Obstetrics/Gynecology,Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study,https://doi.org/10.1016/s0140-6736(23)00085-5,https://cdn.clinicaltrials.gov/large-docs/55/NCT04003155/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/55/NCT04003155/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04003155,36924778,Ph3 | double | treatment,"Astellas Pharma Global Development, Inc.",Industry,,?,Y,,,,,None,,
-651,LANC,2023,Other,"Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus-diphtheria-acellular pertussis vaccine: a randomised, double-blind, phase 2b trial",https://doi.org/10.1016/s0140-6736(22)02644-7,https://cdn.clinicaltrials.gov/large-docs/06/NCT03942406/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/06/NCT03942406/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03942406,36906345,Ph2 | quadruple | prevention,ILiAD Biotechnologies,Industry,"PPD Development, LP",?,Y,,,,,None,,
-652,LANC,2023,Gastroenterology/Hepatology,"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies",https://doi.org/10.1016/s0140-6736(23)00061-2,https://cdn.clinicaltrials.gov/large-docs/88/NCT03945188/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/88/NCT03945188/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT03945188, NCT03996369",36871574,Ph3 | double | treatment,Arena Pharmaceuticals,Industry,,?,Y,Kevin Shan,"Vice President, Global Head of Biometrics",Arena Pharmaceuticals,https://www.abivax.com/about-abivax/leadership/,High,Web-search,"Kevin Shan is listed as Vice President, Global Head of Biometrics at Abivax, and previously worked at Arena Pharmaceuticals."
-653,LANC,2023,Other,"Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(23)00350-1,https://cdn.clinicaltrials.gov/large-docs/18/NCT04656418/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/18/NCT04656418/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04656418,36868261,Ph3 | quadruple | prevention,CSL Behring,Industry,,?,Y,,,,,None,,
-654,LANC,2023,Rheumatology/Immunology,"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)",https://doi.org/10.1016/s0140-6736(22)02546-6,https://cdn.clinicaltrials.gov/large-docs/64/NCT03616964/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/64/NCT03616964/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03616964,36848919,Ph3 | double | treatment,Eli Lilly and Company,Industry,Incyte Corporation,?,Y,,,,,None,,
-655,LANC,2023,Rheumatology/Immunology,"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)",https://doi.org/10.1016/s0140-6736(22)02607-1,https://cdn.clinicaltrials.gov/large-docs/12/NCT03616912/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/12/NCT03616912/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03616912,36848918,Ph3 | double | treatment,Eli Lilly and Company,Industry,Incyte Corporation,?,Y,,,,,None,,
-656,LANC,2023,Oncology,"Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial",https://doi.org/10.1016/s0140-6736(22)02574-0,https://cdn.clinicaltrials.gov/large-docs/12/NCT03138512/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/12/NCT03138512/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03138512,36774933,Ph3 | quadruple | treatment,Bristol-Myers Squibb,Industry,,?,Y,Burcin Simsek,Biostatistics (per PubMed affiliation),"Department of Global Biometrics and Data Science, Bristol Myers Squibb, Princeton, NJ, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-657,LANC,2023,Other,"An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial",https://doi.org/10.1016/s0140-6736(22)02406-0,https://cdn.clinicaltrials.gov/large-docs/17/NCT05259917/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/17/NCT05259917/SAP_001.pdf,SAP,crossover,"NCT05259917, NCT04208412",36774155,Ph3 | double | treatment,"KalVista Pharmaceuticals, Ltd.",Industry,,?,Y,,,,,None,,
-658,LANC,2023,Oncology,"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS<sup>G12C</sup> mutation: a randomised, open-label, phase 3 trial",https://doi.org/10.1016/s0140-6736(23)00221-0,https://cdn.clinicaltrials.gov/large-docs/80/NCT04303780/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/80/NCT04303780/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04303780,36764316,Ph3 | treatment,Amgen,Industry,,?,Y,Yang Wang,PhD,Amgen,https://www.thelancet.com/cms/10.1016/S0140-6736(23)00221-0/attachment/0b9dc5b0-a12b-4327-a523-64a82a6e9097/mmc1.pdf,Medium,Web-search,Yang Wang has a PhD and is an employee of Amgen. Cynthia C Obiozor is a Medical Director.
-659,LANC,2023,Dermatology,"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials",https://doi.org/10.1016/s0140-6736(23)00022-3,https://cdn.clinicaltrials.gov/large-docs/32/NCT03713632/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/32/NCT03713632/SAP_002.pdf,SAP,fixed_parallel_superiority,"NCT03713632, NCT03713619",36746171,Ph3 | triple | treatment,Novartis Pharmaceuticals,Industry,,?,Y,,,,,None,,
-660,LANC,2023,Other,"A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study",https://doi.org/10.1016/s0140-6736(22)01841-4,https://cdn.clinicaltrials.gov/large-docs/18/NCT03093818/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/18/NCT03093818/SAP_001.pdf,SAP,crossover;cluster,NCT03093818,36739136,NA | single | prevention,J.J.Swen,Academic/Other,University of Liverpool; Medical University of Vienna; Centro di Riferimento Oncologico - Aviano; Andaluz Health Service; University of Patras; (+10 more),?,Y,Kathrin Blagec,Biostatistics (per PubMed affiliation),"Centre for Medical Statistics, Informatics and Intelligent Systems, Institute of Artificial Intelligence, Medical University of Vienna, Vienna, Austria.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-661,LANC,2023,Hematology,"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study",https://doi.org/10.1016/s0140-6736(22)02036-0,https://cdn.clinicaltrials.gov/large-docs/94/NCT04173494/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/94/NCT04173494/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04173494,36709073,Ph3 | quadruple | treatment,Sierra Oncology LLC - a GSK company,Industry,,?,Y,,,,,None,,
-662,LANC,2023,Surgery/Critical Care,"The effect of higher protein dosing in critically ill patients with high nutritional risk (EFFORT Protein): an international, multicentre, pragmatic, registry-based randomised trial",https://doi.org/10.1016/s0140-6736(22)02469-2,https://cdn.clinicaltrials.gov/large-docs/47/NCT03160547/Prot_ICF_000.pdf,https://cdn.clinicaltrials.gov/large-docs/47/NCT03160547/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03160547,36708732,NA | basic science,Clinical Evaluation Research Unit at Kingston General Hospital,Academic/Other,,?,Y,,,,,None,,
-663,LANC,2023,Dermatology,"An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study",https://doi.org/10.1016/s0140-6736(22)02037-2,https://cdn.clinicaltrials.gov/large-docs/02/NCT03703102/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/02/NCT03703102/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03703102,36509097,Ph2 | quadruple | treatment,"Kyowa Kirin, Inc.",Industry,"Kyowa Kirin Co., Ltd.",?,Y,Hirotaka Mano,"Biostatistics Group, Biometrics Department","Kyowa Kirin Co., Ltd.",https://pubmed.ncbi.nlm.nih.gov/37842317/,High,Web-search,"Affiliation listed as Biostatistics Group, Biometrics Department at Kyowa Kirin."
-664,LANC,2023,Oncology,"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)",https://doi.org/10.1016/s0140-6736(22)02303-0,https://cdn.clinicaltrials.gov/large-docs/81/NCT03896581/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/81/NCT03896581/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03896581,36495881,Ph3 | triple | treatment,UCB Biopharma SRL,Industry,,?,Y,,,,,None,,
-665,LANC,2023,Oncology,"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial",https://doi.org/10.1016/s0140-6736(22)02420-5,https://cdn.clinicaltrials.gov/large-docs/10/NCT03529110/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/10/NCT03529110/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03529110,36495879,Ph3 | treatment,Daiichi Sankyo,Industry,"Daiichi Sankyo Co., Ltd.; AstraZeneca",?,Y,Yali Liu,"Associate Director, Biostatistics",Daiichi Sankyo,https://www.linkedin.com/in/yali-liu-295a4595,High,Web-search,"Yali Liu's LinkedIn explicitly states she was Associate Director, Biostatistics at Daiichi Sankyo and statistical lead."
-666,LANC,2023,Rheumatology/Immunology,"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)",https://doi.org/10.1016/s0140-6736(22)02302-9,https://cdn.clinicaltrials.gov/large-docs/03/NCT03895203/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/03/NCT03895203/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03895203,36493791,Ph3 | triple | treatment,UCB Biopharma SRL,Industry,,?,Y,,,,,None,,
-667,LANC,2023,Infectious Disease,"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial",https://doi.org/10.1016/s0140-6736(22)02324-8,https://cdn.clinicaltrials.gov/large-docs/90/NCT03667690/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/90/NCT03667690/SAP_001.pdf,SAP,noninferiority,NCT03667690,36442484,Ph3 | quadruple | treatment,"Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",Industry,,?,Y,,,,,None,,
-668,LANC,2022,Infectious Disease,"9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea",https://doi.org/10.1016/s0140-6736(22)01883-9,https://cdn.clinicaltrials.gov/large-docs/94/NCT02619994/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/94/NCT02619994/Prot_SAP_000.pdf,Protocol+SAP,noninferiority;seamless_2_3,NCT02619994,36522208,Ph2 | treatment,Seoul National University Hospital,Academic/Other,Asan Medical Center; Dankook University; International Tuberculosis Research Center; Pusan National University Yangsan Hospital; Pusan National University Hospital; (+9 more),?,Y,,,,,None,,
-669,LANC,2022,Cardiovascular,"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial",https://doi.org/10.1016/s0140-6736(22)02034-7,https://cdn.clinicaltrials.gov/large-docs/74/NCT03541174/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/74/NCT03541174/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT03541174,36356632,Ph3 | triple | treatment,Idorsia Pharmaceuticals Ltd.,Industry,"Janssen Biotech, Inc.",?,Y,Mouna Sassi-Sayadi,Biostatistics (per PubMed affiliation),"Department of Biometry, Idorsia Pharmaceuticals, Allschwil, Switzerland.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-670,LANC,2022,Nephrology/Urology,"Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): a pragmatic, cluster-randomised trial",https://doi.org/10.1016/s0140-6736(22)01805-0,https://cdn.clinicaltrials.gov/large-docs/66/NCT02628366/Prot_SAP_003.pdf,https://cdn.clinicaltrials.gov/large-docs/66/NCT02628366/Prot_SAP_003.pdf,Protocol+SAP,cluster,NCT02628366,36343653,NA | prevention,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,Academic/Other,"Population Health Research Institute; Ottawa Hospital Research Institute; Dialysis Clinic, Inc.; Cancer Care Ontario; Institute for Clinical Evaluative Sciences; (+2 more)",?,Y,,,,,None,,
-671,LANC,2022,Cardiovascular,"Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial",https://doi.org/10.1016/s0140-6736(22)01882-7,https://cdn.clinicaltrials.gov/large-docs/10/NCT04140110/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/10/NCT04140110/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04140110,36341753,NA | single | treatment,"The George Institute for Global Health, China",Academic/Other,Changhai Hospital,?,Y,,,,,None,,
-672,LANC,2022,Infectious Disease,"Aqueous skin antisepsis before surgical fixation of open fractures (Aqueous-PREP): a multiple-period, cluster-randomised, crossover trial",https://doi.org/10.1016/s0140-6736(22)01652-x,https://cdn.clinicaltrials.gov/large-docs/04/NCT03385304/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/04/NCT03385304/Prot_SAP_000.pdf,Protocol+SAP,crossover;cluster,NCT03385304,36244384,Ph4 | single | treatment,"University of Maryland, Baltimore",Academic/Other,McMaster University; United States Department of Defense,?,Y,,,,,None,,
-673,LANC,2022,Dermatology,"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(22)01539-2,https://cdn.clinicaltrials.gov/large-docs/34/NCT03346434/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/34/NCT03346434/SAP_001.pdf,SAP,single_arm,NCT03346434,36116481,Ph2/Ph3 | treatment,Regeneron Pharmaceuticals,Industry,Sanofi,?,Y,Zhixiao Wang,Statistician,Regeneron Pharmaceuticals,https://pure.manchester.ac.uk/ws/files/224307376/AD_1539_part_B_Dupilumab_trial_accepted_The_Lancet.pdf,High,Web-search,Zhixiao Wang is identified as a statistician at Regeneron Pharmaceuticals.
-674,LANC,2022,Oncology,"Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial",https://doi.org/10.1016/s0140-6736(22)01659-2,https://cdn.clinicaltrials.gov/large-docs/06/NCT03071406/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/06/NCT03071406/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03071406,36108657,Ph2 | treatment,H. Lee Moffitt Cancer Center and Research Institute,Academic/Other,Bristol-Myers Squibb,?,Y,Ram Thapa ; Dung-Tsa Chen,Biostatistics (per PubMed affiliation),"Department of Biostatistics and Bioinformatics, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. ; Department of Biostatistics and Bioinformatics, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-675,LANC,2022,Oncology,"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial",https://doi.org/10.1016/s0140-6736(22)01658-0,https://cdn.clinicaltrials.gov/large-docs/96/NCT03024996/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/96/NCT03024996/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03024996,36099926,Ph3 | double | treatment,Hoffmann-La Roche,Industry,,?,Y,,,,,None,,
-676,LANC,2022,Cardiovascular,"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial",https://doi.org/10.1016/s0140-6736(22)01588-4,https://cdn.clinicaltrials.gov/large-docs/08/NCT04304508/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/08/NCT04304508/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04304508,36063821,Ph2 | quadruple | treatment,Bayer,Industry,Population Health Research Institute,?,Y,Bodo Kirsch ; Laura Heenan,Biostatistics (per PubMed affiliation),"Statistics and Data Insights, Bayer AG, Berlin, Germany. ; Department of Statistics, McMaster University, Population Health Research Institute, Hamilton, ON, Canada.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-677,LANC,2022,Respiratory,"Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial",https://doi.org/10.1016/s0140-6736(22)01198-9,https://cdn.clinicaltrials.gov/large-docs/88/NCT03292588/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/88/NCT03292588/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03292588,35964610,Ph2 | triple | treatment,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"Inner-City Asthma Consortium; GlaxoSmithKline; Rho Federal Systems Division, Inc.",?,Y,,,,,None,,
-678,LANC,2022,Rheumatology/Immunology,"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(22)01212-0,https://cdn.clinicaltrials.gov/large-docs/73/NCT04169373/Prot_004.pdf,https://cdn.clinicaltrials.gov/large-docs/73/NCT04169373/SAP_005.pdf,SAP,fixed_parallel_superiority,NCT04169373,35908570,Ph3 | quadruple | treatment,AbbVie,Industry,,?,Y,Yuanyuan Duan,Statistics Manager,AbbVie,https://theorg.com/org/abbvie/org-chart/yuanyuan-duan,High,Web-search,Yuanyuan Duan is listed as a Statistics Manager at AbbVie.
-679,LANC,2022,Cardiovascular,"Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial",https://doi.org/10.1016/s0140-6736(22)01280-6,https://cdn.clinicaltrials.gov/large-docs/75/NCT03406975/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/75/NCT03406975/Prot_SAP_000.pdf,Protocol+SAP,crossover,NCT03406975,35908555,NA | other,Mayo Clinic,Academic/Other,University of Texas; Johns Hopkins University; Brigham and Women's Hospital; Endeavor Health; University of Chicago; (+3 more),?,Y,Courtney Day,Biostatistics (per PubMed affiliation),"Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-680,LANC,2022,Dermatology,"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial",https://doi.org/10.1016/s0140-6736(22)01199-0,https://cdn.clinicaltrials.gov/large-docs/67/NCT04345367/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/67/NCT04345367/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04345367,35871814,Ph3 | quadruple | treatment,Pfizer,Industry,,?,Y,,,,,None,,
-681,LANC,2022,Oncology,"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial",https://doi.org/10.1016/s0140-6736(22)00662-6,https://cdn.clinicaltrials.gov/large-docs/51/NCT03575351/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/51/NCT03575351/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03575351,35717989,Ph3 | treatment,Celgene,Industry,,?,Y,,,,,None,,
-682,LANC,2022,Gastroenterology/Hepatology,"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial",https://doi.org/10.1016/s0140-6736(22)00688-2,https://cdn.clinicaltrials.gov/large-docs/36/NCT03464136/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/36/NCT03464136/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03464136,35691323,Ph3 | quadruple | treatment,"Janssen Scientific Affairs, LLC",Industry,,?,Y,Vipul Jairath,Biostatistics (per PubMed affiliation),"Division of Gastroenterology, Department of Medicine, University Hospital, London, ON, Canada; Division of Epidemiology and Biostatistics, Western University, London, ON, Canada.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-683,LANC,2022,Gastroenterology/Hepatology,"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials",https://doi.org/10.1016/s0140-6736(22)00581-5,https://cdn.clinicaltrials.gov/large-docs/35/NCT02819635/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/35/NCT02819635/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT02819635, NCT03653026",35644166,Ph2/Ph3 | quadruple | treatment,AbbVie,Industry,,?,Y,Wen Zhou,Department of Data and Statistical Sciences,AbbVie,https://academic.oup.com/ecco-jcc/article/15/12/2022/6295522,Medium,Web-search,Wen Zhou is listed under Department of Data and Statistical Sciences at AbbVie in multiple publications.
-684,LANC,2022,Gastroenterology/Hepatology,Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials,https://doi.org/10.1016/s0140-6736(22)00467-6,https://cdn.clinicaltrials.gov/large-docs/13/NCT03104413/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/13/NCT03104413/SAP_002.pdf,SAP,fixed_parallel_superiority,"NCT03104413, NCT03105128",35644154,Ph3 | double | treatment,AbbVie,Industry,,?,Y,,,,,None,,
-685,LANC,2022,Oncology,"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial",https://doi.org/10.1016/s0140-6736(21)01790-6,https://cdn.clinicaltrials.gov/large-docs/80/NCT00567580/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/80/NCT00567580/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT00567580,35569466,Ph3 | treatment,Radiation Therapy Oncology Group,Network/Cooperative,National Cancer Institute (NCI); Cancer and Leukemia Group B; NRG Oncology,?,Y,Theodore G Karrison,"Director, Biostatistics Laboratory",University of Chicago,https://health.uchicago.edu/sites/health/files/2021-02/biostatLab_brochure_2018-19.pdf,High,Web-search,Theodore G. Karrison is the Director of the Biostatistics Laboratory at the University of Chicago.
-686,LANC,2022,Cardiovascular,"Aggressive intraoperative warming versus routine thermal management during non-cardiac surgery (PROTECT): a multicentre, parallel group, superiority trial",https://doi.org/10.1016/s0140-6736(22)00560-8,https://cdn.clinicaltrials.gov/large-docs/75/NCT03111875/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/75/NCT03111875/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03111875,35390321,NA | single | supportive care,The Cleveland Clinic,Academic/Other,,?,Y,,,,,None,,
-687,LANC,2022,Cardiovascular,"Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial",https://doi.org/10.1016/s0140-6736(22)00455-x,https://cdn.clinicaltrials.gov/large-docs/75/NCT02439775/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/75/NCT02439775/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02439775,35390320,NA | single | treatment,Medtronic Vascular,Industry,,?,Y,,,,,None,,
-688,LANC,2022,Cardiovascular,"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study",https://doi.org/10.1016/s0140-6736(22)00456-1,https://cdn.clinicaltrials.gov/large-docs/66/NCT04218266/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/66/NCT04218266/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT04218266,35385695,Ph2 | quadruple | treatment,Bayer,Industry,,?,Y,Christoph Neumann,Lead Statistician,Bayer,https://de.linkedin.com/in/christoph-neumann-2b2717222/en,High,Web-search,Christoph Neumann is listed as Lead Statistician at Bayer on LinkedIn.
-689,LANC,2022,Infectious Disease,"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial",https://doi.org/10.1016/s0140-6736(22)00538-4,https://cdn.clinicaltrials.gov/large-docs/64/NCT03164564/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/64/NCT03164564/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03164564,35378077,Ph3 | quadruple | prevention,National Institute of Allergy and Infectious Diseases (NIAID),NIH,,?,Y,James P Hughes ; Stephanie Beigel-Orme,Biostatistics (per PubMed affiliation),"Statistical Centre for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. ; Statistical Centre for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-690,LANC,2022,Oncology,"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial",https://doi.org/10.1016/s0140-6736(22)00562-1,https://cdn.clinicaltrials.gov/large-docs/36/NCT03553836/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/36/NCT03553836/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03553836,35367007,Ph3 | double | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Ke Chen,Biostatistics and Research Decision Sciences,"Merck & Co., Inc.",https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djag064/8644271,High,Web-search,"Ke Chen is listed as MS, Biostatistics and Research Decision Sciences at Merck & Co., Inc."
-691,LANC,2022,Cardiovascular,"Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial",https://doi.org/10.1016/s0140-6736(22)00012-5,https://cdn.clinicaltrials.gov/large-docs/80/NCT03406780/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/80/NCT03406780/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT03406780,35279258,Ph2 | quadruple | treatment,Capricor Inc.,Industry,,?,Y,,,,,None,,
-692,LANC,2022,Other,"Efficacy and safety of gefapixant, a P2X<sub>3</sub> receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials",https://doi.org/10.1016/s0140-6736(21)02348-5,https://cdn.clinicaltrials.gov/large-docs/34/NCT03449134/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/34/NCT03449134/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,"NCT03449134, NCT03449147",35248186,Ph3 | double | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,,,,,None,,
-693,LANC,2022,Oncology,"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial",https://doi.org/10.1016/s0140-6736(21)02175-9,https://cdn.clinicaltrials.gov/large-docs/88/NCT02101788/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/88/NCT02101788/Prot_SAP_001.pdf,Protocol+SAP,seamless_2_3,NCT02101788,35123694,Ph2/Ph3 | treatment,National Cancer Institute (NCI),NIH,NRG Oncology,?,Y,Austin Miller ; William E Brady,Biostatistics (per PubMed affiliation),"NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. ; NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-694,LANC,2022,Infectious Disease,"Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial",https://doi.org/10.1016/s0140-6736(22)00101-5,https://cdn.clinicaltrials.gov/large-docs/81/NCT04546581/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/81/NCT04546581/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT04546581,35093205,Ph3 | quadruple | treatment,University of Minnesota,Academic/Other,National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH); International Network for Strategic Initiatives in Global HIV Trials (INSIGHT),?,Y,,,,,None,,
-695,LANC,2022,Endocrinology/Metabolism,"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials",https://doi.org/10.1016/s0140-6736(22)00018-6,https://cdn.clinicaltrials.gov/large-docs/80/NCT03622580/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/80/NCT03622580/SAP_001.pdf,SAP,noninferiority,"NCT03622580, NCT03622593",35085503,Ph3 | triple | treatment,Hoffmann-La Roche,Industry,,?,Y,Francis Abreu,Principal Statistical Scientist,Genentech,https://theorg.com/org/genentech/org-chart/francis-abreu,High,Web-search,Francis Abreu is a Principal Statistical Scientist at Genentech.
-696,LANC,2022,Ophthalmology,"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials",https://doi.org/10.1016/s0140-6736(22)00010-1,https://cdn.clinicaltrials.gov/large-docs/00/NCT03823300/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/00/NCT03823300/SAP_001.pdf,SAP,noninferiority,"NCT03823300, NCT03823287",35085502,Ph3 | triple | treatment,Hoffmann-La Roche,Industry,,?,Y,Karen Basu,PhD,Roche,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00018-6/abstract,Medium,Web-search,Karen Basu has a PhD and is affiliated with Roche Products (Ireland). She appears in multiple clinical trial bylines.
-697,LANC,2022,Pediatrics,Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study,https://doi.org/10.1016/s0140-6736(21)02390-4,https://cdn.clinicaltrials.gov/large-docs/60/NCT03345160/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/60/NCT03345160/Prot_SAP_000.pdf,Protocol+SAP,single_arm,NCT03345160,35065784,Ph2 | treatment,Johns Hopkins University,Academic/Other,,?,Y,,,,,None,,
-698,LANC,2022,Rheumatology/Immunology,"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial",https://doi.org/10.1016/s0140-6736(21)02251-0,https://cdn.clinicaltrials.gov/large-docs/95/NCT02962895/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/95/NCT02962895/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02962895,34861168,Ph2 | triple | treatment,Novartis Pharmaceuticals,Industry,,?,Y,Guido Junge,Department of Biostatistics and Pharmacometrics,Novartis,https://pubmed.ncbi.nlm.nih.gov/33765419/,Medium,Web-search,Guido Junge is affiliated with Department of Biostatistics and Pharmacometrics at Novartis.
-699,LANC,2021,Endocrinology/Metabolism,"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial",https://doi.org/10.1016/s0140-6736(21)01751-7,https://cdn.clinicaltrials.gov/large-docs/47/NCT03856047/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/47/NCT03856047/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03856047,34798060,Ph2 | quadruple | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-700,LANC,2021,Endocrinology/Metabolism,"Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial",https://doi.org/10.1016/s0140-6736(21)02394-1,https://cdn.clinicaltrials.gov/large-docs/60/NCT02812160/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/60/NCT02812160/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02812160,34793746,NA | treatment,"Spatz FGIA, Inc",Academic/Other,,?,Y,Daniel Molina,Biostatistics (per PubMed affiliation),"Biostatistics and Clinical Data Management, Technical Resources International, Bethesda, MD, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-701,LANC,2021,Rheumatology/Immunology,"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial",https://doi.org/10.1016/s0140-6736(21)01255-1,https://cdn.clinicaltrials.gov/large-docs/34/NCT02592434/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/34/NCT02592434/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02592434,34767764,Ph3 | quadruple | treatment,Pfizer,Industry,,?,Y,,,,,None,,
-702,LANC,2021,Pediatrics,Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study,https://doi.org/10.1016/s0140-6736(21)01256-3,https://cdn.clinicaltrials.gov/large-docs/82/NCT02160782/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/82/NCT02160782/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02160782,34755627,Ph2 | triple | treatment,"Mirum Pharmaceuticals, Inc.",Industry,,?,Y,Jana Steinmetz,Biostatistics (per PubMed affiliation),"Biostatistics, Premier Research, Naperville, IL, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-703,LANC,2021,Oncology,Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study,https://doi.org/10.1016/s0140-6736(21)01789-x,https://cdn.clinicaltrials.gov/large-docs/41/NCT02054741/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/41/NCT02054741/Prot_SAP_000.pdf,Protocol+SAP,cluster,NCT02054741,34741815,NA | supportive care,Supriya Mohile,Academic/Other,National Cancer Institute (NCI); University of Chicago; City of Hope National Medical Center,?,Y,Huiwen Xu,Biostatistician/Data Scientist,University of Rochester,https://www.aginglab.us/research-support,High,Web-search,Huiwen Xu's research support page explicitly lists his role as Biostatistician/Data Scientist for a University of Rochester NCORP grant.
-704,LANC,2021,Cardiovascular,Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial,https://doi.org/10.1016/s0140-6736(21)01754-2,https://cdn.clinicaltrials.gov/large-docs/13/NCT03387813/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/13/NCT03387813/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03387813,34461042,NA | single | treatment,Abbott Medical Devices,Industry,,?,Y,,,,,None,,
-705,LANC,2021,Oncology,"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study",https://doi.org/10.1016/s0140-6736(21)01234-4,https://cdn.clinicaltrials.gov/large-docs/19/NCT03189719/Prot_SAP_002.pdf,https://cdn.clinicaltrials.gov/large-docs/19/NCT03189719/Prot_SAP_002.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03189719,34454674,Ph3 | double | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Sukrut Shah,Biostatistics,Merck,https://pubmed.ncbi.nlm.nih.gov/25670362/,High,Web-search,"Sukrut Shah is listed with affiliation 'Biostatistics, Merck & Co., Inc.' in multiple publications."
-706,LANC,2021,Endocrinology/Metabolism,"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial",https://doi.org/10.1016/s0140-6736(21)01443-4,https://cdn.clinicaltrials.gov/large-docs/70/NCT03882970/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/70/NCT03882970/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03882970,34370970,Ph3 | treatment,Eli Lilly and Company,Industry,,?,Y,Katelyn Brown,Biostatistics,Eli Lilly and Company,https://www.thieme-connect.com/products/ejournals/conferencepdf/131301/10.1055/s-00000134.pdf,Medium,Web-search,Katelyn Brown is associated with Biostatistics at Eli Lilly based on conference abstract affiliations.
-707,LANC,2021,Oncology,"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial",https://doi.org/10.1016/s0140-6736(21)00580-8,https://cdn.clinicaltrials.gov/large-docs/38/NCT03072238/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/38/NCT03072238/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03072238,34246347,Ph3 | double | treatment,Hoffmann-La Roche,Industry,,?,Y,Marie-Laurence Harle-Yge,Biostatistics,F Hoffmann-La Roche,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30111-0/abstract,Medium,Web-search,Marie-Laurence Harle-Yge is listed with an affiliation to Biostatistics at F Hoffmann-La Roche in multiple papers.
-708,LANC,2021,Endocrinology/Metabolism,"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial",https://doi.org/10.1016/s0140-6736(21)01324-6,https://cdn.clinicaltrials.gov/large-docs/34/NCT03954834/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/34/NCT03954834/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03954834,34186022,Ph3 | double | treatment,Eli Lilly and Company,Industry,,?,Y,,,,,None,,
-709,LANC,2021,Oncology,"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial",https://doi.org/10.1016/s0140-6736(21)00797-2,https://cdn.clinicaltrials.gov/large-docs/16/NCT02872116/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/16/NCT02872116/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02872116,34102137,Ph3 | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,Valerie Poulart,Senior Biostatistician,Bristol Myers Squibb,https://be.linkedin.com/in/valerie-poulart-9612205,High,Web-search,Valerie Poulart is listed as a Senior Biostatistician and Principal Statistician at Bristol-Myers Squibb.
-710,LANC,2021,Oncology,"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial",https://doi.org/10.1016/s0140-6736(21)00592-4,https://cdn.clinicaltrials.gov/large-docs/85/NCT03275285/Prot_004.pdf,https://cdn.clinicaltrials.gov/large-docs/85/NCT03275285/SAP_005.pdf,SAP,fixed_parallel_superiority,NCT03275285,34097854,Ph3 | single | treatment,Sanofi,Industry,,?,Y,Marie-Laure Risse,Statistician,Sanofi,https://www.sciencedirect.com/science/article/abs/pii/S0140673621005924,Medium,Web-search,"Gaelle Asset is listed as MS, and Marie-Laure Risse is listed as Statistician in another trial."
-711,LANC,2021,Gastroenterology/Hepatology,"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial",https://doi.org/10.1016/s0140-6736(21)00666-8,https://cdn.clinicaltrials.gov/large-docs/22/NCT02914522/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/22/NCT02914522/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02914522,34090625,Ph3 | double | treatment,Gilead Sciences,Industry,Galapagos NV,?,Y,,,,,None,,
-712,LANC,2021,Nephrology/Urology,"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(21)00589-4,https://cdn.clinicaltrials.gov/large-docs/18/NCT03568318/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/18/NCT03568318/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03568318,34023009,Ph3 | quadruple | treatment,AbbVie,Industry,,?,Y,Jiewei Zeng,Senior Research Statistician,AbbVie,https://higherlogicdownload.s3.amazonaws.com/AMSTAT/cac2525d-55e9-4fa3-b682-6d5fac28507f/UploadedImages/2020-10-20_Statfax_NIC_ASA_2020_Fall_Newsletter.pdf,High,Web-search,Jiewei Zeng is listed as a Senior Research Statistician and Associate Director at AbbVie.
-713,LANC,2021,Dermatology,"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials",https://doi.org/10.1016/s0140-6736(21)00588-2,https://cdn.clinicaltrials.gov/large-docs/22/NCT03607422/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/22/NCT03607422/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT03607422, NCT03569293",34023008,Ph3 | quadruple | treatment,AbbVie,Industry,,?,Y,,,,,None,,
-714,LANC,2021,Cardiovascular,"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial",https://doi.org/10.1016/s0140-6736(21)00520-1,https://cdn.clinicaltrials.gov/large-docs/17/NCT03926117/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/17/NCT03926117/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03926117,34015342,Ph2 | quadruple | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-715,LANC,2021,Cardiovascular,"Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial",https://doi.org/10.1016/s0140-6736(21)00788-1,https://cdn.clinicaltrials.gov/large-docs/26/NCT02649426/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/26/NCT02649426/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02649426,34010611,NA | triple | treatment,"ReCor Medical, Inc.",Industry,,?,Y,,,,,None,,
-716,LANC,2021,Cardiovascular,"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(21)00763-7,https://cdn.clinicaltrials.gov/large-docs/45/NCT03470545/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/45/NCT03470545/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03470545,34004177,Ph3 | quadruple | treatment,"MyoKardia, Inc.",Industry,,?,Y,Wanying Li,,MyoKardia,https://ww2.amstat.org/meetings/jsm/2018/onlineprogram/MainSearchResults.cfm?sponsored_by&sponsorid=202,Medium,Web-search,Wanying Li was found in a Biopharmaceutical Section program of JSM (Joint Statistical Meetings) alongside other statisticians.
-717,LANC,2021,Nephrology/Urology,"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(21)00578-x,https://cdn.clinicaltrials.gov/large-docs/99/NCT03021499/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/99/NCT03021499/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT03021499,33971155,Ph3 | quadruple | treatment,Aurinia Pharmaceuticals Inc.,Industry,,?,Y,,,,,None,,
-718,LANC,2021,Oncology,"<sup>18</sup>F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial",https://doi.org/10.1016/s0140-6736(21)00581-x,https://cdn.clinicaltrials.gov/large-docs/08/NCT01666808/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/08/NCT01666808/Prot_SAP_001.pdf,Protocol+SAP,seamless_2_3,NCT01666808,33971152,Ph2/Ph3 | treatment,Emory University,Academic/Other,National Cancer Institute (NCI),?,Y,Subir Goyal,Biostatistics (per PubMed affiliation),"Biostatistics Shared Resource, Winship Cancer Institute of Emory University, Atlanta, GA, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-719,LANC,2021,Dermatology,"IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study",https://doi.org/10.1016/s0140-6736(21)00440-2,https://cdn.clinicaltrials.gov/large-docs/45/NCT03384745/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/45/NCT03384745/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03384745,33894834,Ph2 | triple | treatment,Bond Avillion 2 Development LP,Industry,Avillion LLP,?,Y,,,,,None,,
-720,LANC,2021,Cardiovascular,"Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial",https://doi.org/10.1016/s0140-6736(21)00475-x,https://cdn.clinicaltrials.gov/large-docs/60/NCT03131960/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/60/NCT03131960/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03131960,33894832,NA | quadruple | treatment,MicroTransponder Inc.,Industry,ResearchPoint Global,?,Y,,,,,None,,
-721,LANC,2021,Infectious Disease,"Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(21)00314-7,https://cdn.clinicaltrials.gov/large-docs/22/NCT03048422/Prot_003.pdf,https://cdn.clinicaltrials.gov/large-docs/22/NCT03048422/SAP_004.pdf,SAP,noninferiority,NCT03048422,33812487,Ph3 | treatment,National Institute of Allergy and Infectious Diseases (NIAID),NIH,,?,Y,Sean S Brummel ; Lauren Ziemba,Biostatistics (per PubMed affiliation),"Center for Biostatistics in AIDS Research, Harvard TH Chan School of Public Health, Boston, MA, USA. ; Center for Biostatistics in AIDS Research, Harvard TH Chan School of Public Health, Boston, MA, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-722,LANC,2021,Endocrinology/Metabolism,"Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(21)00213-0,https://cdn.clinicaltrials.gov/large-docs/57/NCT03552757/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/57/NCT03552757/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03552757,33667417,Ph3 | quadruple | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-723,LANC,2021,Oncology,"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial",https://doi.org/10.1016/s0140-6736(21)00152-5,https://cdn.clinicaltrials.gov/large-docs/57/NCT02761057/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/57/NCT02761057/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02761057,33592176,Ph2 | treatment,National Cancer Institute (NCI),NIH,Canadian Cancer Trials Group,?,Y,Catherine Tangen,Biostatistics (per PubMed affiliation),"SWOG Statistics and Data Management Center, Seattle, WA, USA; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-724,LANC,2021,Infectious Disease,"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial",https://doi.org/10.1016/s0140-6736(21)00219-1,https://cdn.clinicaltrials.gov/large-docs/31/NCT01782131/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/31/NCT01782131/Prot_SAP_000.pdf,Protocol+SAP,noninferiority,NCT01782131,33549194,Ph3 | quadruple | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Anjana Grandhi,Biostatistics (per PubMed affiliation),"Department of Biostatistics, Merck & Co, Inc, Kenilworth, NJ, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-725,LANC,2021,Rheumatology/Immunology,"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial",https://doi.org/10.1016/s0140-6736(21)00125-2,https://cdn.clinicaltrials.gov/large-docs/33/NCT03370133/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/33/NCT03370133/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03370133,33549193,Ph3 | quadruple | treatment,UCB Biopharma SRL,Industry,,?,Y,,,,,None,,
-726,LANC,2021,Rheumatology/Immunology,"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial",https://doi.org/10.1016/s0140-6736(21)00126-4,https://cdn.clinicaltrials.gov/large-docs/92/NCT03410992/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/92/NCT03410992/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03410992,33549192,Ph3 | quadruple | treatment,UCB Biopharma SRL,Industry,,?,Y,,,,,None,,
-727,LANC,2021,Oncology,"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial",https://doi.org/10.1016/s0140-6736(20)32714-8,https://cdn.clinicaltrials.gov/large-docs/99/NCT02899299/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/99/NCT02899299/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02899299,33485464,Ph3 | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,,,,,None,,
-728,LANC,2021,Oncology,"Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial",https://doi.org/10.1016/s0140-6736(20)32554-x,https://cdn.clinicaltrials.gov/large-docs/75/NCT02101775/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/75/NCT02101775/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02151292,33485453,Ph2 | single | treatment,National Cancer Institute (NCI),NIH,,?,Y,,,,,None,,
-729,LANC,2021,Endocrinology/Metabolism,"A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial",https://doi.org/10.1016/s0140-6736(20)32514-9,https://cdn.clinicaltrials.gov/large-docs/14/NCT03040414/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/14/NCT03040414/SAP_002.pdf,SAP,noninferiority;crossover,NCT03040414,33453783,NA | treatment,HealthPartners Institute,Academic/Other,"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Medtronic; Jaeb Center for Health Research; Schneider Children's Medical Center, Israel; University of Ljubljana; (+7 more)",?,Y,,,,,None,,
-730,LANC,2021,Neurology,"Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial",https://doi.org/10.1016/s0140-6736(20)32544-7,https://cdn.clinicaltrials.gov/large-docs/38/NCT03732638/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/38/NCT03732638/SAP_002.pdf,SAP,seamless_2_3,NCT03732638,33338437,Ph2/Ph3 | triple | prevention,Pfizer,Industry,,?,Y,,,,,None,,
-731,LANC,2021,Infectious Disease,Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials,https://doi.org/10.1016/s0140-6736(20)32541-1,https://cdn.clinicaltrials.gov/large-docs/87/NCT04544787/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/87/NCT04544787/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04544787,33308429,Ph2 | quadruple | prevention,Pierre Van Damme,Academic/Other,Bill and Melinda Gates Foundation; Centers for Disease Control and Prevention; PATH; Celerion,?,Y,,,,,None,,
-732,LANC,2021,Infectious Disease,Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials,https://doi.org/10.1016/s0140-6736(20)32540-x,https://cdn.clinicaltrials.gov/large-docs/98/NCT03554798/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/98/NCT03554798/Prot_SAP_000.pdf,Protocol+SAP,noninferiority,"NCT03554798, NCT02521974",33308427,Ph2 | double | prevention,Fidec Corporation,Academic/Other,Bill and Melinda Gates Foundation,?,Y,,,,,None,,
-733,LANC,2020,Gastroenterology/Hepatology,"First-attempt success rate of video laryngoscopy in small infants (VISI): a multicentre, randomised controlled trial",https://doi.org/10.1016/s0140-6736(20)32532-0,https://cdn.clinicaltrials.gov/large-docs/32/NCT03396432/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/32/NCT03396432/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03396432,33308472,NA | single | other,Children's Hospital of Philadelphia,Academic/Other,Anesthesia Patient Safety Foundation,?,Y,,,,,None,,
-734,LANC,2020,Oncology,"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial",https://doi.org/10.1016/s0140-6736(20)32531-9,https://cdn.clinicaltrials.gov/large-docs/18/NCT02819518/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/18/NCT02819518/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02819518,33278935,Ph3 | quadruple | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Zifang Guo,"Senior Director, Biostatistics",Merck,https://www.linkedin.com/in/zifang-guo-449a8212,High,Web-search,"Zifang Guo is identified as Senior Director, Biostatistics at Merck."
-735,LANC,2020,Cardiovascular,"Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial",https://doi.org/10.1016/s0140-6736(20)32338-2,https://cdn.clinicaltrials.gov/large-docs/65/NCT03880565/Prot_SAP_002.pdf,https://cdn.clinicaltrials.gov/large-docs/65/NCT03880565/Prot_SAP_002.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03880565,33197396,NA | single | treatment,University of Minnesota,Academic/Other,,?,Y,John Connett ; Thomas A Murray,Biostatistics (per PubMed affiliation),"Division of Biostatistics, University of Minnesota School of Public Health, Minneapolis, MN, USA. ; Division of Biostatistics, University of Minnesota School of Public Health, Minneapolis, MN, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-736,LANC,2020,Cardiovascular,"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial",https://doi.org/10.1016/s0140-6736(20)32339-4,https://cdn.clinicaltrials.gov/large-docs/54/NCT02937454/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/54/NCT02937454/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02937454,33197395,Ph4 | triple | treatment,Vifor (International) Inc.,Industry,Worldwide Clinical Trials; Cytel Inc.,?,Y,Henry J Dargie,Biostatistics (per PubMed affiliation),"Robertson Center for Biostatistics, University of Glasgow, Glasgow, UK.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-737,LANC,2020,Oncology,"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial",https://doi.org/10.1016/s0140-6736(20)32292-3,https://cdn.clinicaltrials.gov/large-docs/62/NCT03110562/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/62/NCT03110562/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03110562,33189178,Ph3 | treatment,Karyopharm Therapeutics Inc,Industry,,?,Y,,,,,None,,
-738,LANC,2020,Infectious Disease,"Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials",https://doi.org/10.1016/s0140-6736(20)32014-6,https://cdn.clinicaltrials.gov/large-docs/12/NCT03739112/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/12/NCT03739112/SAP_001.pdf,SAP,noninferiority,"NCT03739112, NCT03301051",33065035,Ph3 | quadruple | prevention,Medicago,Industry,,?,Y,,,,,None,,
-739,LANC,2020,Oncology,"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial",https://doi.org/10.1016/s0140-6736(20)31953-x,https://cdn.clinicaltrials.gov/large-docs/35/NCT03197935/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/35/NCT03197935/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03197935,32966830,Ph3 | double | treatment,Hoffmann-La Roche,Industry,,?,Y,Anh Nguyen Duc,Statistician,Hoffmann-La Roche,https://pubmed.ncbi.nlm.nih.gov/32869509/,High,Web-search,Anh Nguyen Duc is listed as Statistician at Roche and in Biostatistics at Hoffmann-La Roche Pharma AG.
-740,LANC,2020,Cardiovascular,"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(20)31792-x,https://cdn.clinicaltrials.gov/large-docs/45/NCT03470545/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/45/NCT03470545/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03470545,32871100,Ph3 | quadruple | treatment,"MyoKardia, Inc.",Industry,,?,Y,,,,,None,,
-741,LANC,2020,Rheumatology/Immunology,"Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial",https://doi.org/10.1016/s0140-6736(20)30636-x,https://cdn.clinicaltrials.gov/large-docs/12/NCT02573012/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/12/NCT02573012/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02573012,32711802,Ph4 | double | treatment,Hoffmann-La Roche,Industry,,?,Y,Corrado Bernasconi,Senior Biostatistician,F. Hoffmann-La Roche AG,https://indivi.io/for-professionals,High,Web-search,Corrado Bernasconi is listed as a Senior Biostatistician at F. Hoffmann-La Roche AG.
-742,LANC,2020,Dermatology,"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(20)30732-7,https://cdn.clinicaltrials.gov/large-docs/60/NCT03349060/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/60/NCT03349060/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT03349060,32711801,Ph3 | quadruple | treatment,Pfizer,Industry,,?,Y,Pinaki Biswas,Statistician,Pfizer,https://www.linkedin.com/in/pinaki-biswas-aa43908,High,Web-search,Pinaki Biswas is a Ph.D. statistician at Pfizer with over 20 years of experience.
-743,LANC,2020,Infectious Disease,"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial",https://doi.org/10.1016/s0140-6736(20)31065-5,https://cdn.clinicaltrials.gov/large-docs/86/NCT02842086/Prot_003.pdf,https://cdn.clinicaltrials.gov/large-docs/86/NCT02842086/SAP_002.pdf,SAP,noninferiority,NCT02842086,32711800,Ph3 | double | treatment,Gilead Sciences,Industry,,?,Y,Pamela Wong ; Ramin Ebrahimi,Biostatistics (per PubMed affiliation),"Department of Biometrics, Gilead Sciences, Foster City, CA, USA. ; Department of Biometrics, Gilead Sciences, Foster City, CA, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-744,LANC,2020,Oncology,"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study",https://doi.org/10.1016/s0140-6736(20)30734-0,https://cdn.clinicaltrials.gov/large-docs/88/NCT03158688/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/88/NCT03158688/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03158688,32682484,Ph3 | treatment,Amgen,Industry,,?,Y,Hui Yang,Biostatistical Sciences,Amgen,https://pmc.ncbi.nlm.nih.gov/articles/PMC6892342/,High,Web-search,Hui Yang is acknowledged for providing biostatistical support and is part of Biostatistical Sciences at Amgen Inc.
-745,LANC,2020,Cardiovascular,Dexmedetomidine for reduction of atrial fibrillation and delirium after cardiac surgery (DECADE): a randomised placebo-controlled trial,https://doi.org/10.1016/s0140-6736(20)30631-0,https://cdn.clinicaltrials.gov/large-docs/13/NCT02004613/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/13/NCT02004613/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02004613,32682483,Ph4 | double | treatment,The Cleveland Clinic,Academic/Other,"Hospira, now a wholly owned subsidiary of Pfizer",?,Y,,,,,None,,
-746,LANC,2020,Dermatology,"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial",https://doi.org/10.1016/s0140-6736(20)30609-7,https://cdn.clinicaltrials.gov/large-docs/04/NCT03099304/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/04/NCT03099304/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03099304,32653055,Ph2 | double | treatment,Incyte Corporation,Industry,,?,Y,,,,,None,,
-747,LANC,2020,Oncology,"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF<sup>V600</sup> mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(20)30934-x,https://cdn.clinicaltrials.gov/large-docs/72/NCT02908672/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/72/NCT02908672/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT02908672,32534646,Ph3 | double | treatment,Hoffmann-La Roche,Industry,,?,Y,,,,,None,,
-748,LANC,2020,Other,"Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial",https://doi.org/10.1016/s0140-6736(20)31048-5,https://cdn.clinicaltrials.gov/large-docs/00/NCT03055000/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/00/NCT03055000/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03055000,32534628,Ph1 | quadruple | other,National Institute of Allergy and Infectious Diseases (NIAID),NIH,,?,Y,Sally Hunsberger,Biostatistics (per PubMed affiliation),"Biostatistics Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-749,LANC,2020,Oncology,"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial",https://doi.org/10.1016/s0140-6736(20)30230-0,https://cdn.clinicaltrials.gov/large-docs/36/NCT02807636/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/36/NCT02807636/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02807636,32416780,Ph3 | double | treatment,Hoffmann-La Roche,Industry,,?,Y,,,,,None,,
-750,LANC,2020,Rheumatology/Immunology,"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial",https://doi.org/10.1016/s0140-6736(20)30564-x,https://cdn.clinicaltrials.gov/large-docs/80/NCT02745080/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/80/NCT02745080/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02745080,32386593,Ph3 | quadruple | treatment,Novartis Pharmaceuticals,Industry,,?,Y,Ruvie Martin,Senior Director Biostatistics,Novartis,https://www.linkedin.com/in/ruvie-martin-3525781b4,High,Web-search,Ruvie Martin is listed as Senior Director Biostatistics at Novartis on LinkedIn and ZoomInfo.
-751,LANC,2020,Infectious Disease,"Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial",https://doi.org/10.1016/s0140-6736(20)30470-0,https://cdn.clinicaltrials.gov/large-docs/00/NCT02610400/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/00/NCT02610400/Prot_SAP_001.pdf,Protocol+SAP,factorial;cluster,NCT02610400,32334702,Ph3 | treatment,"University of California, San Francisco",Academic/Other,"University of Texas; London School of Hygiene and Tropical Medicine; University of Southampton; The Novartis Foundation; Clinton Health Access Initiative, Nigeria",?,Y,,,,,None,,
-752,LANC,2020,Oncology,"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(20)30262-2,https://cdn.clinicaltrials.gov/large-docs/81/NCT02475681/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/81/NCT02475681/SAP_001.pdf,SAP,crossover,NCT02475681,32305093,Ph3 | single | treatment,Acerta Pharma BV,Industry,,?,Y,,,,,None,,
-753,LANC,2020,Cardiovascular,"Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial",https://doi.org/10.1016/s0140-6736(20)30554-7,https://cdn.clinicaltrials.gov/large-docs/49/NCT02439749/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/49/NCT02439749/SAP_001.pdf,SAP,adaptive_bayesian,NCT02439749,32234534,NA | single | treatment,Medtronic Vascular,Industry,,?,Y,,,,,None,,
-754,LANC,2020,Neurology,"Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial",https://doi.org/10.1016/s0140-6736(20)30611-5,https://cdn.clinicaltrials.gov/large-docs/75/NCT01960075/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/75/NCT01960075/Prot_SAP_000.pdf,Protocol+SAP,adaptive_bayesian,NCT01960075,32203691,Ph3 | triple | treatment,University of Virginia,Academic/Other,University of Michigan; Medical University of South Carolina; Children's National Research Institute; University of Minnesota; National Institute of Neurological Disorders and Stroke (NINDS),?,Y,,,,,None,,
-755,LANC,2020,Infectious Disease,"Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial",https://doi.org/10.1016/s0140-6736(20)30556-0,https://cdn.clinicaltrials.gov/large-docs/66/NCT02302066/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/66/NCT02302066/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT02302066,32197107,Ph2 | quadruple | prevention,Takeda,Industry,,?,Y,,,,,None,,
-756,LANC,2020,Infectious Disease,"Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial",https://doi.org/10.1016/s0140-6736(20)30414-1,https://cdn.clinicaltrials.gov/large-docs/27/NCT02747927/Prot_004.pdf,https://cdn.clinicaltrials.gov/large-docs/27/NCT02747927/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT02747927,32197105,Ph3 | quadruple | prevention,Takeda,Industry,,?,Y,,,,,None,,
-757,LANC,2020,Rheumatology/Immunology,"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial",https://doi.org/10.1016/s0140-6736(20)30263-4,https://cdn.clinicaltrials.gov/large-docs/85/NCT03158285/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/85/NCT03158285/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03158285,32178766,Ph3 | double | treatment,"Janssen Research & Development, LLC",Industry,,?,Y,Shihong Sheng ; Prasheen Agarwal,Biostatistics (per PubMed affiliation),"Clinical Biostatistics, Janssen Research and Development, Spring House, PA, USA. ; Clinical Biostatistics, Janssen Research and Development, Spring House, PA, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-758,LANC,2020,Oncology,"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial",https://doi.org/10.1016/s0140-6736(20)30265-8,https://cdn.clinicaltrials.gov/large-docs/96/NCT03162796/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/96/NCT03162796/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03162796,32178765,Ph3 | double | treatment,"Janssen Research & Development, LLC",Industry,,?,Y,Shihong Sheng ; Prasheen Agarwal,Biostatistics (per PubMed affiliation),"Clinical Biostatistics, Janssen Research and Development, Spring House, PA, USA. ; Clinical Biostatistics, Janssen Research and Development, Spring House, PA, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-759,LANC,2020,Cardiovascular,"Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial",https://doi.org/10.1016/s0140-6736(20)30258-0,https://cdn.clinicaltrials.gov/large-docs/18/NCT02930018/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/18/NCT02930018/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02930018,32087818,Ph3 | quadruple | treatment,NoNO Inc.,Industry,University of Calgary,?,Y,,,,,None,,
-760,LANC,2020,Infectious Disease,"Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial",https://doi.org/10.1016/s0140-6736(19)32990-3,https://cdn.clinicaltrials.gov/large-docs/74/NCT02336074/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/74/NCT02336074/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02336074,32085823,Ph2 | treatment,Imperial College London,Academic/Other,Medical Research Council; University of Oxford; University of Cambridge; Chelsea and Westminster NHS Foundation Trust; Royal Free Hospital NHS Foundation Trust; (+3 more),?,Y,,,,,None,,
-761,LANC,2020,Rheumatology/Immunology,"Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial",https://doi.org/10.1016/s0140-6736(19)33161-7,https://cdn.clinicaltrials.gov/large-docs/25/NCT02969525/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/25/NCT02969525/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02969525,32035552,Ph2 | quadruple | treatment,UCB Biopharma S.P.R.L.,Industry,,?,Y,,,,,None,,
-762,LANC,2020,Gastroenterology/Hepatology,"Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial",https://doi.org/10.1016/s0140-6736(19)32973-3,https://cdn.clinicaltrials.gov/large-docs/80/NCT02409680/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/80/NCT02409680/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02409680,31982074,NA | double | treatment,NICHD Global Network for Women's and Children's Health,Network/Cooperative,Thomas Jefferson University; Jawaharlal Nehru Medical College,?,Y,,,,,None,,
-763,LANC,2020,Oncology,"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial",https://doi.org/10.1016/s0140-6736(19)32956-3,https://cdn.clinicaltrials.gov/large-docs/79/NCT02195479/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/79/NCT02195479/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02195479,31836199,Ph3 | treatment,"Janssen Research & Development, LLC",Industry,,?,Y,,,,,None,,
-764,LANC,2020,Rheumatology/Immunology,"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial",https://doi.org/10.1016/s0140-6736(19)32971-x,https://cdn.clinicaltrials.gov/large-docs/52/NCT02757352/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/52/NCT02757352/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02757352,31813637,Ph3 | double | treatment,Eli Lilly and Company,Industry,,?,Y,Ann Leung,Principal Statistician,Syneos Health,https://www.zoominfo.com/p/Ann-Leung/1931160957,High,Web-search,Ann Leung is a Principal Statistician at Syneos Health.
-765,JAMA,2026,Other,Electronic Health Record Intervention and Deprescribing for Older Adults: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2025.26967,https://cdn.clinicaltrials.gov/large-docs/65/NCT05538065/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/65/NCT05538065/Prot_SAP_001.pdf,Protocol+SAP,cluster,NCT05538065,41609788,NA | health services research,Brigham and Women's Hospital,Academic/Other,Massachusetts General Hospital; National Institutes of Health (NIH); National Institute on Aging (NIA),?,Y,,,,,None,,
-766,JAMA,2026,Gastroenterology/Hepatology,Minor Papillotomy for Treatment of Idiopathic Acute Pancreatitis With Pancreas Divisum: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2025.23988,https://cdn.clinicaltrials.gov/large-docs/44/NCT03609944/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/44/NCT03609944/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03609944,41533371,NA | double | treatment,Oregon Health and Science University,Academic/Other,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),?,Y,,,,,None,,
-767,JAMA,2026,Musculoskeletal/Pain,Spinal Manipulation and Clinician-Supported Biopsychosocial Self-Management for Acute Back Pain: The PACBACK Randomized Clinical Trial,https://doi.org/10.1001/jama.2025.21990,https://cdn.clinicaltrials.gov/large-docs/23/NCT03581123/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/23/NCT03581123/Prot_SAP_000.pdf,Protocol+SAP,factorial,NCT03581123,41460638,Ph3 | double | treatment,University of Minnesota,Academic/Other,University of Pittsburgh; University of Washington; University of North Texas Health Science Center; Oregon Health and Science University; Duke University,?,Y,Eric N Meier ; John Connett,Biostatistics (per PubMed affiliation),"School of Public Health, Department of Biostatistics, University of Washington, Seattle. ; School of Public Health, Division of Biostatistics, University of Minnesota, Minneapolis.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-768,JAMA,2026,Infectious Disease,Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical Trial,https://doi.org/10.1001/jama.2025.21738,https://cdn.clinicaltrials.gov/large-docs/16/NCT03282916/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/16/NCT03282916/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03282916,41405855,Ph2 | triple | treatment,Columbia University,Academic/Other,National Institutes of Health (NIH); National Institute on Aging (NIA),?,Y,Min Qian ; Renjie Wei,Biostatistics (per PubMed affiliation),"Department of Biostatistics, Mailman School of Public Health, Columbia University Medical Center, New York, New York. ; Department of Biostatistics, Mailman School of Public Health, Columbia University Medical Center, New York, New York.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-769,JAMA,2026,Surgery/Critical Care,Effect of Automated Closed-Loop Ventilation vs Protocolized Conventional Ventilation on Ventilator-Free Days in Critically Ill Adults: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2025.24384,,https://cdn.clinicaltrials.gov/large-docs/10/NCT04593810/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT04593810,41361939,NA | treatment,Prof. Dr. Marcus J. Schultz,Academic/Other,ZonMw: The Netherlands Organisation for Health Research and Development; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Catharina Ziekenhuis Eindhoven; Reinier de Graaf Groep; Flevoziekenhuis; (+6 more),?,Y,,,,,None,,
-770,JAMA,2026,Respiratory,Intraoperative Driving Pressure-Guided High PEEP vs Standard Low PEEP for Postoperative Pulmonary Complications,https://doi.org/10.1001/jama.2025.23373,,https://cdn.clinicaltrials.gov/large-docs/43/NCT03884543/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03884543,41334859,NA | double | treatment,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Academic/Other,"Amsterdam UMC, location VUmc; Noord West Ziekenhuizen location Alkmaar; University Medical Center Groningen; Radboud University Medical Center; HagaZiekenhuis; (+27 more)",?,Y,,,,,None,,
-771,JAMA,2026,Cardiovascular,DASH-Patterned Groceries and Effects on Blood Pressure: The GoFresh Randomized Clinical Trial,https://doi.org/10.1001/jama.2025.21112,https://cdn.clinicaltrials.gov/large-docs/37/NCT05121337/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/37/NCT05121337/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05121337,41206973,NA | double | treatment,Beth Israel Deaconess Medical Center,Academic/Other,American Heart Association,?,Y,,,,,None,,
-772,JAMA,2026,Other,Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2025.20620,https://cdn.clinicaltrials.gov/large-docs/69/NCT05952869/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/69/NCT05952869/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT05952869,41206969,Ph3 | triple | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,,,,,None,,
-773,JAMA,2026,Cardiovascular,Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial,https://doi.org/10.1001/jama.2025.21056,https://cdn.clinicaltrials.gov/large-docs/19/NCT05121519/Prot_SAP_006.pdf,https://cdn.clinicaltrials.gov/large-docs/19/NCT05121519/Prot_SAP_006.pdf,Protocol+SAP,fixed_parallel_superiority,NCT05121519,41206802,NA | other,"University of California, San Francisco",Academic/Other,,?,Y,Catherine Lee,Biostatistics (per PubMed affiliation),"Department of Epidemiology and Biostatistics, University of California San Francisco.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-774,JAMA,2026,Cardiovascular,Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease: The PERMET Randomized Clinical Trial,https://doi.org/10.1001/jama.2025.21358,https://cdn.clinicaltrials.gov/large-docs/19/NCT03054519/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/19/NCT03054519/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03054519,41205146,Ph3 | quadruple | treatment,Northwestern University,Academic/Other,,?,Y,Lu Tian,Biostatistics (per PubMed affiliation),"Department of Statistics, Stanford University, Palo Alto, California.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-775,JAMA,2025,Cardiovascular,Liberal or Restrictive Postoperative Transfusion in Patients at High Cardiac Risk: The TOP Randomized Clinical Trial,https://doi.org/10.1001/jama.2025.20841,https://cdn.clinicaltrials.gov/large-docs/41/NCT03229941/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/41/NCT03229941/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03229941,41205227,NA | single | other,VA Office of Research and Development,US Federal,,?,Y,Min Zhan,Biostatistician,VA,https://www.medschool.umaryland.edu/profiles/zhan-min/,High,Web-search,Min Zhan is an Associate Professor of Biostatistics and listed as Biostatistician at VA CSP Coordinating Center.
-776,JAMA,2025,Endocrinology/Metabolism,An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2025.19563,https://cdn.clinicaltrials.gov/large-docs/76/NCT05056376/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/76/NCT05056376/Prot_SAP_000.pdf,Protocol+SAP,noninferiority,NCT05056376,41144242,NA | prevention,Johns Hopkins University,Academic/Other,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),?,Y,John McGready,Biostatistics (per PubMed affiliation),"Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-777,JAMA,2025,Hematology,Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment: The PINES Randomized Clinical Trial,https://doi.org/10.1001/jama.2025.18168,https://cdn.clinicaltrials.gov/large-docs/37/NCT03939637/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/37/NCT03939637/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03939637,41123939,Ph3 | treatment,Baylor College of Medicine,Academic/Other,"Boston Children's Hospital; University of California, San Francisco",?,Y,,,,,None,,
-778,JAMA,2025,Oncology,A Direct-to-Patient Digital Health Program for Lung Cancer Screening: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2025.17281,https://cdn.clinicaltrials.gov/large-docs/59/NCT04083859/Prot_SAP_002.pdf,https://cdn.clinicaltrials.gov/large-docs/59/NCT04083859/Prot_SAP_002.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04083859,41114973,NA | double | screening,Wake Forest University Health Sciences,Academic/Other,"University of North Carolina, Chapel Hill; National Cancer Institute (NCI)",?,Y,Anna C Snavely,Biostatistics (per PubMed affiliation),"Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-779,JAMA,2025,Respiratory,Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants: The Budesonide in Babies (BiB) Randomized Clinical Trial,https://doi.org/10.1001/jama.2025.16450,https://cdn.clinicaltrials.gov/large-docs/66/NCT04545866/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/66/NCT04545866/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04545866,41026481,Ph3 | quadruple | treatment,NICHD Neonatal Research Network,Network/Cooperative,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),?,Y,Kayla J Nowak ; Laura Elizabeth Wiener,Biostatistics (per PubMed affiliation),"Biostatistics and Epidemiology Division, RTI International, Research Triangle Park, North Carolina. ; Biostatistics and Epidemiology Division, RTI International, Research Triangle Park, North Carolina.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-780,JAMA,2025,Neurology,Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2025.13481,https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT05407064,40906494,Ph2 | quadruple | treatment,"Definium Therapeutics US, Inc.",Industry,,?,Y,,,,,None,,
-781,JAMA,2025,Cardiovascular,Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial,https://doi.org/10.1001/jama.2025.6681,https://cdn.clinicaltrials.gov/large-docs/32/NCT05103332/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/32/NCT05103332/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT05103332,40434761,Ph2 | quadruple | treatment,Alnylam Pharmaceuticals,Industry,,?,Y,Daniel Stiglitz,Senior Manager Biostatistics,Alnylam Pharmaceuticals,https://www.linkedin.com/in/daniel-stiglitz-391675ab,High,Web-search,Daniel Stiglitz is a Senior Manager Biostatistics / Biostatistician at Alnylam Pharmaceuticals.
-782,JAMA,2025,Surgery/Critical Care,Dexmedetomidine- or Clonidine-Based Sedation Compared With Propofol in Critically Ill Patients: The A2B Randomized Clinical Trial,https://doi.org/10.1001/jama.2025.7200,https://cdn.clinicaltrials.gov/large-docs/32/NCT03653832/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/32/NCT03653832/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03653832,40388916,Ph3 | treatment,University of Edinburgh,Academic/Other,"West Hertfordshire Hospitals NHS Trust; Queen's University, Belfast; The University of Queensland; University Hospital of Wales; Edinburgh Napier University; (+8 more)",?,Y,,,,,None,,
-783,JAMA,2025,Pediatrics,Extended Caffeine for Apnea in Moderately Preterm Infants: The MoCHA Randomized Clinical Trial,https://doi.org/10.1001/jama.2025.5791,https://cdn.clinicaltrials.gov/large-docs/27/NCT03340727/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/27/NCT03340727/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT03340727,40294395,Ph3 | quadruple | treatment,NICHD Neonatal Research Network,Network/Cooperative,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),?,Y,,,,,None,,
-784,JAMA,2025,Gastroenterology/Hepatology,Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2025.3810,https://cdn.clinicaltrials.gov/large-docs/92/NCT05367492/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/92/NCT05367492/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05367492,40266580,Ph4 | triple | treatment,Massachusetts General Hospital,Academic/Other,National Institute on Drug Abuse (NIDA),?,Y,Harrison T Reeder,Biostatistics (per PubMed affiliation),"Harvard Medical School, Boston, Massachusetts.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-785,JAMA,2025,Oncology,Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2025.1483,https://cdn.clinicaltrials.gov/large-docs/37/NCT03452137/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/37/NCT03452137/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03452137,40079944,Ph3 | quadruple | treatment,Hoffmann-La Roche,Industry,,?,Y,Tao Jiang,statistical scientist,Genentech,https://taojiang608.github.io/,High,Web-search,"Tao Jiang's personal website explicitly states 'I am Tao Jiang, a statistical scientist at Genentech'"
-786,JAMA,2025,Neurology,High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial,https://doi.org/10.1001/jama.2025.1604,,https://cdn.clinicaltrials.gov/large-docs/66/NCT01817166/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT01817166,40063041,Ph3 | triple | prevention,Centre Hospitalier Universitaire de Nīmes,Academic/Other,,?,Y,Christophe Demattei ; Pascale Fabbro-Peray,Biostatistics (per PubMed affiliation),"CHU Nimes, Laboratoire de Biostatistique, Epidémiologie clinique, Santé Publique Innovation et Méthodologie (BESPIM), Univ Montpellier, Nimes, France. ; CHU Nimes, Laboratoire de Biostatistique, Epidémiologie clinique, Santé Publique Innovation et Méthodologie (BESPIM), Univ Montpellier, Nimes, France.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-787,JAMA,2025,Neurology,Palliative Care Program for Community-Dwelling Individuals With Dementia and Caregivers: The IN-PEACE Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.25845,https://cdn.clinicaltrials.gov/large-docs/57/NCT03773757/Prot_SAP_002.pdf,https://cdn.clinicaltrials.gov/large-docs/57/NCT03773757/Prot_SAP_002.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03773757,39878993,NA | single | supportive care,Indiana University,Academic/Other,"Regenstrief Institute, Inc.; National Institute on Aging (NIA)",?,Y,Sujuan Gao ; Minmin Pan,Biostatistics (per PubMed affiliation),"Department of Biostatistics and Health Data Sciences, Indiana University School of Medicine, Indianapolis. ; Department of Biostatistics and Health Data Sciences, Indiana University School of Medicine, Indianapolis.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-788,JAMA,2025,Neurology,"Health System, Community-Based, or Usual Dementia Care for Persons With Dementia and Caregivers: The D-CARE Randomized Clinical Trial",https://doi.org/10.1001/jama.2024.25056,https://cdn.clinicaltrials.gov/large-docs/71/NCT03786471/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/71/NCT03786471/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT03786471,39878968,NA | double | supportive care,"University of California, Los Angeles",Academic/Other,Patient-Centered Outcomes Research Institute; National Institute on Aging (NIA); Yale University; Benjamin Rose Institute on Aging; Baylor Scott and White Health; (+5 more),?,Y,,,,,None,,
-789,JAMA,2025,Other,Palliative Care Initiated in the Emergency Department: A Cluster Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.23696,https://cdn.clinicaltrials.gov/large-docs/09/NCT03424109/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/09/NCT03424109/Prot_SAP_000.pdf,Protocol+SAP,cluster,NCT03424109,39813042,,NYU Langone Health,Academic/Other,National Center for Complementary and Integrative Health (NCCIH); National Institutes of Health (NIH); Memorial Sloan Kettering Cancer Center,?,Y,,,,,None,,
-790,JAMA,2025,Infectious Disease,High-Flow Nasal Oxygen vs Noninvasive Ventilation in Patients With Acute Respiratory Failure: The RENOVATE Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.26244,,https://cdn.clinicaltrials.gov/large-docs/39/NCT03643939/SAP_000.pdf,SAP,adaptive_bayesian;noninferiority,NCT03643939,39657981,NA | treatment,Hospital do Coracao,Academic/Other,"Ministry of Health, Brazil; Berry Consultants",?,Y,,,,,None,,
-791,JAMA,2025,Cardiovascular,Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications: A Randomized Pragmatic Trial,https://doi.org/10.1001/jama.2024.21739,https://cdn.clinicaltrials.gov/large-docs/31/NCT03973931/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/31/NCT03973931/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03973931,39621340,NA | prevention,"University of Colorado, Denver",Academic/Other,"National Heart, Lung, and Blood Institute (NHLBI)",?,Y,Gary K Grunwald,Biostatistics (per PubMed affiliation),"Rocky Mountain Regional Veteran Affairs Medical Center, Aurora, Colorado.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-792,JAMA,2025,Cardiovascular,Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.24017,https://cdn.clinicaltrials.gov/large-docs/46/NCT05563246/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/46/NCT05563246/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05563246,39556768,Ph2 | double | treatment,Eli Lilly and Company,Industry,,?,Y,,,,,None,,
-793,JAMA,2024,Cardiovascular,Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.21957,https://cdn.clinicaltrials.gov/large-docs/71/NCT05537571/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/71/NCT05537571/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05537571,39556769,Ph2 | double | treatment,Silence Therapeutics plc,Industry,,?,Y,Kathy Wolski,Lead Biostatistician,Cleveland Clinic,https://www.linkedin.com/in/kathy-wolski-97842226,High,Web-search,Kathy Wolski is explicitly listed as Lead Biostatistician at Cleveland Clinic.
-794,JAMA,2024,Oncology,Symptom Screening Linked to Care Pathways for Pediatric Patients With Cancer: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.19585,https://cdn.clinicaltrials.gov/large-docs/62/NCT04614662/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/62/NCT04614662/SAP_001.pdf,SAP,cluster,NCT04614662,39535768,NA | supportive care,The Hospital for Sick Children,Academic/Other,National Cancer Institute (NCI),?,Y,,,,,None,,
-795,JAMA,2024,Endocrinology/Metabolism,A Digital Health Behavior Intervention to Prevent Childhood Obesity: The Greenlight Plus Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.22362,https://cdn.clinicaltrials.gov/large-docs/67/NCT04042467/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/67/NCT04042467/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04042467,39489149,NA | double | prevention,Vanderbilt University Medical Center,Academic/Other,"Patient-Centered Outcomes Research Institute; Duke University; University of North Carolina, Chapel Hill; Stanford University; NYU Langone Health; (+2 more)",?,Y,Jonathan S Schildcrout ; Aihua Bian,Biostatistics (per PubMed affiliation),"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee. ; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-796,JAMA,2024,Nephrology/Urology,"Early, Individualized Recommendations for Hospitalized Patients With Acute Kidney Injury: A Randomized Clinical Trial",https://doi.org/10.1001/jama.2024.22718,https://cdn.clinicaltrials.gov/large-docs/96/NCT04040296/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/96/NCT04040296/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04040296,39454050,NA | triple | health services research,Yale University,Academic/Other,Johns Hopkins University,?,Y,Fan Li,Biostatistics (per PubMed affiliation),"Clinical and Translational Research Accelerator, Yale University, New Haven, Connecticut.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-797,JAMA,2024,Surgery/Critical Care,Effect of Tele-ICU on Clinical Outcomes of Critically Ill Patients: The TELESCOPE Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.20651,,https://cdn.clinicaltrials.gov/large-docs/01/NCT03920501/SAP_000.pdf,SAP,cluster,NCT03920501,39382244,NA | treatment,Hospital Israelita Albert Einstein,Academic/Other,,?,Y,,,,,None,,
-798,JAMA,2024,Oncology,Screening for Helicobacter pylori to Prevent Gastric Cancer: A Pragmatic Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.14887,https://cdn.clinicaltrials.gov/large-docs/63/NCT01741363/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/63/NCT01741363/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT01741363,39348147,NA | single | prevention,National Taiwan University Hospital,Academic/Other,"Ministry of Health and Welfare, Taiwan",?,Y,Tony Hsiu-Hsi Chen,Biostatistics (per PubMed affiliation),"Institute of Health Analytics and Statistics, College of Public Health, National Taiwan University, Taipei City, Taiwan.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-799,JAMA,2024,Cardiovascular,Fever Prevention in Patients With Acute Vascular Brain Injury: The INTREPID Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.14745,https://cdn.clinicaltrials.gov/large-docs/66/NCT02996266/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/66/NCT02996266/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02996266,39320879,NA | single | treatment,C. R. Bard,Industry,Yale University; Boston University,?,Y,,,,,None,,
-800,JAMA,2024,Cardiovascular,Edetate Disodium-Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes: TACT2 Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.11463,https://cdn.clinicaltrials.gov/large-docs/85/NCT02733185/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/85/NCT02733185/SAP_002.pdf,SAP,factorial,NCT02733185,39141382,Ph3 | triple | prevention,"Mt. Sinai Medical Center, Miami",Academic/Other,"National Center for Complementary and Integrative Health (NCCIH); National Heart, Lung, and Blood Institute (NHLBI); Duke Clinical Research Institute",?,Y,,,,,None,,
-801,JAMA,2024,Gastroenterology/Hepatology,A Vaping Cessation Text Message Program for Adolescent E-Cigarette Users: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.11057,https://cdn.clinicaltrials.gov/large-docs/90/NCT04919590/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/90/NCT04919590/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04919590,39110436,NA | double | treatment,Truth Initiative,Academic/Other,,?,Y,Michael S Amato,"Methodologist and Research Investigator / Managing Director, Data & Analytics",Truth Initiative,https://truthinitiative.org/sites/default/files/media/files/2023/03/CV_MSAmato_2023-03.pdf,Medium,Web-search,"Michael S Amato is listed as Methodologist and Managing Director, Data & Analytics at Truth Initiative."
-802,JAMA,2024,Gastroenterology/Hepatology,Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials,https://doi.org/10.1001/jama.2024.12414,https://cdn.clinicaltrials.gov/large-docs/48/NCT03398148/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/48/NCT03398148/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT03398148, NCT03398135",39037800,Ph2/Ph3 | double | treatment,AbbVie,Industry,,?,Y,,,,,None,,
-803,JAMA,2024,Infectious Disease,Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.9779,https://cdn.clinicaltrials.gov/large-docs/90/NCT03213990/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/90/NCT03213990/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03213990,38864155,NA | treatment,The George Institute,Academic/Other,"National Health and Medical Research Council, Australia; Australian and New Zealand Intensive Care Society Clinical Trials Group",?,Y,,,,,None,,
-804,JAMA,2024,Endocrinology/Metabolism,Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.9217,https://cdn.clinicaltrials.gov/large-docs/32/NCT05024032/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/32/NCT05024032/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05024032,38819983,Ph3 | double | treatment,Eli Lilly and Company,Industry,,?,Y,Rui Wang,"Associate Director, Statistician",Eli Lilly,https://www.zoominfo.com/pic/eli-lilly-international-trading-shanghai-company-ltd/426062696,Medium,Web-search,"ZoomInfo snippet lists Rui Wang as Associate Director, Statistician at Eli Lilly China (2015-2018)."
-805,JAMA,2024,Infectious Disease,Acetaminophen for Prevention and Treatment of Organ Dysfunction in Critically Ill Patients With Sepsis: The ASTER Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.8772,https://cdn.clinicaltrials.gov/large-docs/08/NCT04291508/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/08/NCT04291508/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT04291508,38762798,Ph2 | quadruple | treatment,Massachusetts General Hospital,Academic/Other,,?,Y,,,,,None,,
-806,JAMA,2024,Respiratory,Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.8693,https://cdn.clinicaltrials.gov/large-docs/46/NCT03955146/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/46/NCT03955146/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03955146,38762797,Ph3 | quadruple | treatment,Kyntra Bio,Industry,,?,Y,,,,,None,,
-807,JAMA,2024,Oncology,Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.4783,https://cdn.clinicaltrials.gov/large-docs/26/NCT03589326/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/26/NCT03589326/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03589326,38722621,Ph3 | treatment,Takeda,Industry,,?,Y,Bingxia Wang,Senior Director of Statistics and Quantitative Sciences,Takeda,https://archive.nestat.org/raredisease2024/html/speakers.html,High,Web-search,Bingxia Wang is Senior Director of Statistics and Quantitative Sciences at Takeda.
-808,JAMA,2024,Other,Smoking Cessation After Initial Treatment Failure With Varenicline or Nicotine Replacement: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.4183,https://cdn.clinicaltrials.gov/large-docs/19/NCT02271919/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/19/NCT02271919/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02271919,38696203,Ph4 | double | treatment,M.D. Anderson Cancer Center,Academic/Other,National Cancer Institute (NCI),?,Y,,,,,None,,
-809,JAMA,2024,Oncology,Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial,https://doi.org/10.1001/jama.2024.4840,https://cdn.clinicaltrials.gov/large-docs/49/NCT02927249/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/49/NCT02927249/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02927249,38683596,Ph3 | double | treatment,Alliance for Clinical Trials in Oncology,Academic/Other,National Cancer Institute (NCI); United States Department of Defense; Bayer; Canadian Cancer Trials Group,?,Y,Karla V Ballman,Biostatistics (per PubMed affiliation),"Department of Biostatistics, Mayo Clinic, Rochester, Minnesota.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-810,JAMA,2024,Infectious Disease,Stewardship Prompts to Improve Antibiotic Selection for Pneumonia: The INSPIRE Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.6248,https://cdn.clinicaltrials.gov/large-docs/70/NCT03697070/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/70/NCT03697070/SAP_001.pdf,SAP,cluster,NCT03697070,38639729,NA | other,Harvard Pilgrim Health Care,Academic/Other,"Hospital Corporation of America; University of California, Irvine; University of Massachusetts, Amherst; Brigham and Women's Hospital; Centers for Disease Control and Prevention",?,Y,Ken Kleinman,Biostatistics (per PubMed affiliation),"Biostatistics and Epidemiology, University of Massachusetts, Amherst.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-811,JAMA,2024,Infectious Disease,Stewardship Prompts to Improve Antibiotic Selection for Urinary Tract Infection: The INSPIRE Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.6259,https://cdn.clinicaltrials.gov/large-docs/96/NCT03697096/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/96/NCT03697096/SAP_001.pdf,SAP,cluster,NCT03697096,38639723,NA | other,Harvard Pilgrim Health Care,Academic/Other,"Hospital Corporation of America; University of California, Irvine; University of Massachusetts, Amherst; Brigham and Women's Hospital; Centers for Disease Control and Prevention",?,Y,Ken Kleinman,Biostatistics (per PubMed affiliation),"Biostatistics and Epidemiology, University of Massachusetts, Amherst.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-812,JAMA,2024,Infectious Disease,Integrated Hepatitis C-Opioid Use Disorder Care Through Facilitated Telemedicine: A Randomized Trial,https://doi.org/10.1001/jama.2024.2452,https://cdn.clinicaltrials.gov/large-docs/70/NCT02933970/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/70/NCT02933970/Prot_SAP_000.pdf,Protocol+SAP,crossover;cluster,NCT02933970,38568601,NA | health services research,Andrew Talal,Academic/Other,Patient-Centered Outcomes Research Institute,?,Y,Marianthi Markatou ; Anran Liu,Biostatistics (per PubMed affiliation),"Department of Biostatistics, University at Buffalo, Buffalo, New York. ; Department of Biostatistics, University at Buffalo, Buffalo, New York.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-813,JAMA,2024,Oncology,Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.1215,https://cdn.clinicaltrials.gov/large-docs/29/NCT04031729/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/29/NCT04031729/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04031729,38502074,Ph1/Ph2 | quadruple | treatment,Massachusetts General Hospital,Academic/Other,,?,Y,,,,,None,,
-814,JAMA,2024,Other,Video Laryngoscopy vs Direct Laryngoscopy for Endotracheal Intubation in the Operating Room: A Cluster Randomized Clinical Trial,https://doi.org/10.1001/jama.2024.0762,https://cdn.clinicaltrials.gov/large-docs/62/NCT04701762/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/62/NCT04701762/Prot_SAP_000.pdf,Protocol+SAP,crossover;cluster,NCT04701762,38497992,NA | other,The Cleveland Clinic,Academic/Other,,?,Y,,,,,None,,
-815,JAMA,2024,Infectious Disease,Mass Azithromycin Distribution to Prevent Child Mortality in Burkina Faso: The CHAT Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.27393,https://cdn.clinicaltrials.gov/large-docs/64/NCT03676764/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/64/NCT03676764/SAP_001.pdf,SAP,cluster,NCT03676764,38349371,Ph4 | quadruple | prevention,"University of California, San Francisco",Academic/Other,"Centre de Recherche en Sante de Nouna, Burkina Faso; Bill and Melinda Gates Foundation",?,Y,Kieran S O'Brien ; Travis C Porco,Biostatistics (per PubMed affiliation),"Francis I. Proctor Foundation, University of California, San Francisco. ; Francis I. Proctor Foundation, University of California, San Francisco.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-816,JAMA,2024,Cardiovascular,"Nurse and Social Worker Palliative Telecare Team and Quality of Life in Patients With COPD, Heart Failure, or Interstitial Lung Disease: The ADAPT Randomized Clinical Trial",https://doi.org/10.1001/jama.2023.24035,https://cdn.clinicaltrials.gov/large-docs/47/NCT02713347/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/47/NCT02713347/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02713347,38227034,NA | double | health services research,VA Office of Research and Development,US Federal,,?,Y,William Feser ; Anna Baron,Biostatistics (per PubMed affiliation),"Department of Veterans Affairs, Eastern Colorado Health Care System, Aurora. ; Department of Veterans Affairs, Eastern Colorado Health Care System, Aurora.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-817,JAMA,2024,Endocrinology/Metabolism,Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.24945,https://cdn.clinicaltrials.gov/large-docs/43/NCT04660643/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/43/NCT04660643/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04660643,38078870,Ph3 | double | treatment,Eli Lilly and Company,Industry,,?,Y,Shuyu Zhang,Statistics,Eli Lilly and Company,https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.13278,High,Web-search,"Shuyu Zhang is explicitly listed as 'Statistics, Eli Lilly and Company' in a publication byline."
-818,JAMA,2023,Endocrinology/Metabolism,Metformin Plus Insulin for Preexisting Diabetes or Gestational Diabetes in Early Pregnancy: The MOMPOD Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.22949,https://cdn.clinicaltrials.gov/large-docs/75/NCT02932475/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/75/NCT02932475/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02932475,38085312,Ph3 | quadruple | treatment,"University of North Carolina, Chapel Hill",Academic/Other,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),?,Y,,,,,None,,
-819,JAMA,2023,Respiratory,Adenotonsillectomy for Snoring and Mild Sleep Apnea in Children: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.22114,https://cdn.clinicaltrials.gov/large-docs/40/NCT02562040/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/40/NCT02562040/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02562040,38051326,NA | single | treatment,Brigham and Women's Hospital,Academic/Other,"Children's Hospital of Philadelphia; University Hospitals Cleveland Medical Center; Children's Hospital Medical Center, Cincinnati; University of Michigan; University of Texas Southwestern Medical Center; (+3 more)",?,Y,Kaitlyn Cook ; Rui Wang,Biostatistics (per PubMed affiliation),"Program in Statistical and Data Sciences, Smith College, Northampton, Massachusetts. ; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-820,JAMA,2023,Oncology,Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.20181,https://cdn.clinicaltrials.gov/large-docs/86/NCT03581786/Prot_SAP_ICF_000.pdf,https://cdn.clinicaltrials.gov/large-docs/86/NCT03581786/Prot_SAP_ICF_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03581786,38015220,Ph3 | quadruple | treatment,"Shanghai Junshi Bioscience Co., Ltd.",Academic/Other,,?,Y,Xiaojun Wang,,Shanghai Junshi Biosciences,https://icsa.zuel.edu.cn/upload/20240624/202406241044471600.docx,Medium,Web-search,Xiaojun Wang is an organizer for an ICSA (International Chinese Statistical Association) conference session.
-821,JAMA,2023,Oncology,Strategies to Increase Cervical Cancer Screening With Mailed Human Papillomavirus Self-Sampling Kits: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.21471,https://cdn.clinicaltrials.gov/large-docs/75/NCT04679675/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/75/NCT04679675/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04679675,38015219,NA | single | health services research,Kaiser Permanente,Academic/Other,National Cancer Institute (NCI); University of Washington; University of Texas Southwestern Medical Center,?,Y,,,,,None,,
-822,JAMA,2023,Cardiovascular,"Effects of the Million Hearts Model on Myocardial Infarctions, Strokes, and Medicare Spending: A Randomized Clinical Trial",https://doi.org/10.1001/jama.2023.19597,https://cdn.clinicaltrials.gov/large-docs/47/NCT04047147/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/47/NCT04047147/Prot_SAP_000.pdf,Protocol+SAP,cluster,NCT04047147,37847273,,"Mathematica Policy Research, Inc.",Academic/Other,Centers for Medicare and Medicaid Services; RAND,?,Y,,,,,None,,
-823,JAMA,2023,Infectious Disease,Nasal Iodophor Antiseptic vs Nasal Mupirocin Antibiotic in the Setting of Chlorhexidine Bathing to Prevent Infections in Adult ICUs: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.17219,https://cdn.clinicaltrials.gov/large-docs/23/NCT03140423/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/23/NCT03140423/SAP_001.pdf,SAP,noninferiority;cluster,NCT03140423,37815567,Ph4 | prevention,Harvard Pilgrim Health Care,Academic/Other,"Hospital Corporation of America; University of California, Irvine; University of Massachusetts, Amherst; Rush University; Centers for Disease Control and Prevention",?,Y,,,,,None,,
-824,JAMA,2023,Oncology,A Multilevel Primary Care Intervention to Improve Follow-Up of Overdue Abnormal Cancer Screening Test Results: A Cluster Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.18755,https://cdn.clinicaltrials.gov/large-docs/95/NCT03979495/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/95/NCT03979495/Prot_SAP_000.pdf,Protocol+SAP,cluster,NCT03979495,37815566,NA | screening,Massachusetts General Hospital,Academic/Other,Brigham and Women's Hospital; Dartmouth-Hitchcock Medical Center,?,Y,,,,,None,,
-825,JAMA,2023,Cardiovascular,Remote Ischemic Conditioning for Acute Stroke: The RESIST Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.16893,https://cdn.clinicaltrials.gov/large-docs/77/NCT03481777/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/77/NCT03481777/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03481777,37787796,NA | double | treatment,Grethe Andersen,Academic/Other,Danish National Research Foundation; Central Denmark Region,?,Y,,,,,None,,
-826,JAMA,2023,Endocrinology/Metabolism,Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.20294,https://cdn.clinicaltrials.gov/large-docs/23/NCT04537923/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/23/NCT04537923/SAP_001.pdf,SAP,noninferiority,NCT04537923,37786396,Ph3 | treatment,Eli Lilly and Company,Industry,,?,Y,Ruth Huh,Statistics Innovation Center,Eli Lilly and Company,https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0044-1785382,Medium,Web-search,"Ruth Huh is listed as working at the Statistics Innovation Center at Eli Lilly, indicating a statistical role."
-827,JAMA,2023,Endocrinology/Metabolism,Early Metformin in Gestational Diabetes: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.19869,https://cdn.clinicaltrials.gov/large-docs/76/NCT02980276/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/76/NCT02980276/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02980276,37786390,Ph3 | quadruple | treatment,"National University of Ireland, Galway, Ireland",Academic/Other,"Health Research Board, Ireland; HRB Clinical Research Facility Galway; University College Hospital Galway; Portiuncula University Hospital; University Hospital of Limerick; (+2 more)",?,Y,,,,,None,,
-828,JAMA,2023,Cardiovascular,Blood Pressure Management After Endovascular Therapy for Acute Ischemic Stroke: The BEST-II Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.14330,https://cdn.clinicaltrials.gov/large-docs/12/NCT04116112/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/12/NCT04116112/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04116112,37668620,Ph2 | single | treatment,University of Cincinnati,Academic/Other,National Institute of Neurological Disorders and Stroke (NINDS); Vanderbilt University Medical Center,?,Y,Kimberly W Hart ; Yue Gao,Biostatistics (per PubMed affiliation),"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee. ; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-829,JAMA,2023,Obstetrics/Gynecology,Perioperative Vaginal Estrogen as Adjunct to Native Tissue Vaginal Apical Prolapse Repair: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.12317,https://cdn.clinicaltrials.gov/large-docs/97/NCT02431897/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/97/NCT02431897/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02431897,37581673,Ph4 | triple | treatment,University of Texas Southwestern Medical Center,Academic/Other,University of Alabama at Birmingham; Women and Infants Hospital of Rhode Island; Pfizer,?,Y,,,,,None,,
-830,JAMA,2023,Oncology,Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.11887,https://cdn.clinicaltrials.gov/large-docs/90/NCT02943590/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/90/NCT02943590/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02943590,37552303,Ph2 | double | treatment,Massachusetts General Hospital,Academic/Other,Dana-Farber Cancer Institute; Brigham and Women's Hospital,?,Y,,,,,None,,
-831,JAMA,2023,Gastroenterology/Hepatology,Cervical Pessary for Prevention of Preterm Birth in Individuals With a Short Cervix: The TOPS Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.10812,https://cdn.clinicaltrials.gov/large-docs/26/NCT02901626/Prot_SAP_ICF_000.pdf,https://cdn.clinicaltrials.gov/large-docs/26/NCT02901626/Prot_SAP_ICF_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02901626,37490086,Ph3 | prevention,The George Washington University Biostatistics Center,Academic/Other,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),?,Y,Rebecca G Clifton ; Lynda G Ugwu,Biostatistics (per PubMed affiliation),"George Washington University Biostatistics Center, Washington, DC. ; George Washington University Biostatistics Center, Washington, DC.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-832,JAMA,2023,Infectious Disease,Identifying Children Likely to Benefit From Antibiotics for Acute Sinusitis: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.10854,https://cdn.clinicaltrials.gov/large-docs/83/NCT02554383/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/83/NCT02554383/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02554383,37490085,Ph3 | quadruple | treatment,Nader Shaikh,Academic/Other,National Institute of Allergy and Infectious Diseases (NIAID),?,Y,Jong-Hyeon Jeong,Biostatistics (per PubMed affiliation),"Department of Biostatistics, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-833,JAMA,2023,Other,Cytisinicline for Smoking Cessation: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.10042,https://cdn.clinicaltrials.gov/large-docs/49/NCT04576949/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/49/NCT04576949/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04576949,37432430,Ph3 | double | treatment,Achieve Life Sciences,Industry,,?,Y,,,,,None,,
-834,JAMA,2023,Endocrinology/Metabolism,Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.11313,https://cdn.clinicaltrials.gov/large-docs/31/NCT04795531/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/31/NCT04795531/SAP_001.pdf,SAP,noninferiority,NCT04795531,37354562,Ph3 | quadruple | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-835,JAMA,2023,Endocrinology/Metabolism,Family-Based Behavioral Treatment for Childhood Obesity Implemented in Pediatric Primary Care: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.8061,https://cdn.clinicaltrials.gov/large-docs/15/NCT02873715/Prot_SAP_ICF_000.pdf,https://cdn.clinicaltrials.gov/large-docs/15/NCT02873715/Prot_SAP_ICF_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02873715,37314275,NA | double | treatment,State University of New York at Buffalo,Academic/Other,"National Heart, Lung, and Blood Institute (NHLBI)",?,Y,Daphne Lew ; Michael Wallendorf,Biostatistics (per PubMed affiliation),"Division of Biostatistics, Washington University in St Louis School of Medicine, St Louis, Missouri. ; Division of Biostatistics, Washington University in St Louis School of Medicine, St Louis, Missouri.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-836,JAMA,2023,Oncology,Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.7843,https://cdn.clinicaltrials.gov/large-docs/92/NCT02744092/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/92/NCT02744092/Prot_SAP_000.pdf,Protocol+SAP,noninferiority,NCT02744092,37266947,NA | treatment,"Alliance Foundation Trials, LLC.",Academic/Other,Patient-Centered Outcomes Research Institute,?,Y,,,,,None,,
-837,JAMA,2023,Pediatrics,Community Health Workers in Early Childhood Well-Child Care for Medicaid-Insured Children: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.7197,https://cdn.clinicaltrials.gov/large-docs/98/NCT03797898/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/98/NCT03797898/Prot_SAP_000.pdf,Protocol+SAP,cluster,NCT03797898,37120800,NA | health services research,Seattle Children's Hospital,Academic/Other,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),?,Y,,,,,None,,
-838,JAMA,2023,Oncology,"Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial",https://doi.org/10.1001/jama.2023.4428,https://cdn.clinicaltrials.gov/large-docs/95/NCT02394795/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/95/NCT02394795/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02394795,37071094,Ph3 | treatment,Takeda,Industry,,?,Y,Toshihiro Misumi ; Kouji Yamamoto,Biostatistics (per PubMed affiliation),"Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan. ; Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-839,JAMA,2023,Infectious Disease,"VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial",https://doi.org/10.1001/jama.2023.4314,https://cdn.clinicaltrials.gov/large-docs/34/NCT03788434/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/34/NCT03788434/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03788434,37060545,Ph2 | quadruple | prevention,"Vedanta Biosciences, Inc.",Industry,,?,Y,,,,,None,,
-840,JAMA,2023,Obstetrics/Gynecology,Early vs Interval Postpartum Intrauterine Device Placement: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.1936,https://cdn.clinicaltrials.gov/large-docs/58/NCT03462758/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/58/NCT03462758/Prot_SAP_000.pdf,Protocol+SAP,noninferiority,NCT03462758,36943214,NA | health services research,"University of California, San Diego",Academic/Other,"University of New Mexico; United States Naval Medical Center, San Diego; University of Illinois at Chicago; University of Chicago",?,Y,Florin Vaida,Biostatistics (per PubMed affiliation),"School of Public Health, Division of Biostatistics, University of California, San Diego, La Jolla.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-841,JAMA,2023,Infectious Disease,Effect of Intrapartum Azithromycin vs Placebo on Neonatal Sepsis and Death: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.24388,,https://cdn.clinicaltrials.gov/large-docs/47/NCT03199547/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT03199547,36881034,Ph3 | triple | prevention,London School of Hygiene and Tropical Medicine,Academic/Other,,?,Y,,,,,None,,
-842,JAMA,2023,Cardiovascular,Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2023.2854,https://cdn.clinicaltrials.gov/large-docs/60/NCT03936660/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/60/NCT03936660/SAP_001.pdf,SAP,cluster,NCT03936660,36877177,NA | health services research,Duke University,Academic/Other,Boehringer Ingelheim; Eli Lilly and Company,?,Y,,,,,None,,
-843,JAMA,2023,Cardiovascular,Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.23924,https://cdn.clinicaltrials.gov/large-docs/13/NCT03296813/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/13/NCT03296813/Prot_SAP_001.pdf,Protocol+SAP,crossover,NCT03296813,36648467,Ph3 | treatment,Duke University,Academic/Other,"National Heart, Lung, and Blood Institute (NHLBI); Yale University",?,Y,,,,,None,,
-844,JAMA,2022,Infectious Disease,Effect of a Community Health Worker-Delivered Personal Sound Amplification Device on Self-Perceived Communication Function in Older Adults With Hearing Loss: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.21820,https://cdn.clinicaltrials.gov/large-docs/96/NCT03442296/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/96/NCT03442296/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03442296,36538311,NA | other,Johns Hopkins University,Academic/Other,National Institute on Deafness and Other Communication Disorders (NIDCD),?,Y,Joshua Betz,Biostatistics (per PubMed affiliation),"Cochlear Center for Hearing and Public Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-845,JAMA,2022,Musculoskeletal/Pain,Effect of a Biopsychosocial Intervention or Postural Therapy on Disability and Health Care Spending Among Patients With Acute and Subacute Spine Pain: The SPINE CARE Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.22625,https://cdn.clinicaltrials.gov/large-docs/86/NCT03083886/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/86/NCT03083886/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03083886,36538309,NA | single | treatment,Brigham and Women's Hospital,Academic/Other,Stanford University,?,Y,,,,,None,,
-846,JAMA,2022,Endocrinology/Metabolism,Effect of a Remotely Delivered Self-directed Behavioral Intervention on Body Weight and Physical Health Status Among Adults With Obesity: The D-ELITE Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.21177,https://cdn.clinicaltrials.gov/large-docs/40/NCT03260140/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/40/NCT03260140/Prot_SAP_000.pdf,Protocol+SAP,platform,NCT03260140,36511927,NA | single | treatment,VA Office of Research and Development,US Federal,,?,Y,Anna E Barón,Biostatistics (per PubMed affiliation),"Colorado School of Public Health, Department of Biostatistics and Informatics, University of Colorado Anschutz Medical Campus, Aurora.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-847,JAMA,2022,Other,Effects of Mindfulness Training and Exercise on Cognitive Function in Older Adults: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.21680,https://cdn.clinicaltrials.gov/large-docs/81/NCT02665481/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/81/NCT02665481/SAP_001.pdf,SAP,factorial,NCT02665481,36511926,NA | single | treatment,Washington University School of Medicine,Academic/Other,"University of California, San Diego; National Institutes of Health (NIH); National Institute on Aging (NIA); National Center for Complementary and Integrative Health (NCCIH); The Brain Research Foundation",?,Y,J Philip Miller,Biostatistics (per PubMed affiliation),"Division of Biostatistics, Washington University School of Medicine, St Louis, Missouri.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-848,JAMA,2022,Endocrinology/Metabolism,Effect of Diet and Exercise on Knee Pain in Patients With Osteoarthritis and Overweight or Obesity: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.21893,https://cdn.clinicaltrials.gov/large-docs/49/NCT02577549/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/49/NCT02577549/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02577549,36511925,NA | single | treatment,Wake Forest University,Academic/Other,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),?,Y,Daniel P Beavers,Biostatistics (per PubMed affiliation),"Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-849,JAMA,2022,Infectious Disease,Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.18590,https://cdn.clinicaltrials.gov/large-docs/30/NCT04885530/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/30/NCT04885530/Prot_SAP_000.pdf,Protocol+SAP,platform,NCT04885530,36269852,Ph3 | double | treatment,"Susanna Naggie, MD",Academic/Other,National Center for Advancing Translational Sciences (NCATS); Vanderbilt University Medical Center,?,Y,Christopher J Lindsell ; Thomas G Stewart,Biostatistics (per PubMed affiliation),"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee. ; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-850,JAMA,2022,Respiratory,Effect of Paroxetine or Quetiapine Combined With Oxycodone vs Oxycodone Alone on Ventilation During Hypercapnia: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.17735,https://cdn.clinicaltrials.gov/large-docs/79/NCT04310579/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/79/NCT04310579/SAP_002.pdf,SAP,crossover,NCT04310579,36219407,Ph1 | quadruple | other,Food and Drug Administration (FDA),US Federal,Spaulding Clinical Research LLC; Leiden University,?,Y,,,,,None,,
-851,JAMA,2022,Cardiovascular,Effect of Telmisartan on Walking Performance in Patients With Lower Extremity Peripheral Artery Disease: The TELEX Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.16797,https://cdn.clinicaltrials.gov/large-docs/10/NCT02593110/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/10/NCT02593110/Prot_SAP_000.pdf,Protocol+SAP,factorial,NCT02593110,36194220,NA | quadruple | treatment,Northwestern University,Academic/Other,"National Heart, Lung, and Blood Institute (NHLBI)",?,Y,,,,,None,,
-852,JAMA,2022,Oncology,Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.16464,https://cdn.clinicaltrials.gov/large-docs/63/NCT04063163/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/63/NCT04063163/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04063163,36166026,Ph3 | quadruple | treatment,Shanghai Henlius Biotech,Industry,,?,Y,,,,,None,,
-853,JAMA,2022,Cardiovascular,Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial,https://doi.org/10.1001/jama.2022.16197,https://cdn.clinicaltrials.gov/large-docs/55/NCT02224755/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/55/NCT02224755/SAP_000.pdf,SAP,fixed_parallel_superiority,"NCT03982979, NCT02224755",36074476,NA | treatment,Abbott Medical Devices,Industry,,?,Y,AiJia Wang,Clinical Biostatistics - Heart Failure,Abbott,https://onlinelibrary.wiley.com/doi/abs/10.1002/ejhf.2746,High,Web-search,"AiJia Wang is listed with affiliation 'Clinical Biostatistics - Heart Failure, Abbott' in multiple papers."
-854,JAMA,2022,Hematology,Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.10564,https://cdn.clinicaltrials.gov/large-docs/08/NCT04004208/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/08/NCT04004208/SAP_001.pdf,SAP,adaptive_bayesian;noninferiority,NCT04004208,35881122,Ph3 | treatment,Bayer,Industry,Regeneron Pharmaceuticals,?,Y,,,,,None,,
-855,JAMA,2022,Cardiovascular,Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.11016,https://cdn.clinicaltrials.gov/large-docs/92/NCT03759392/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/92/NCT03759392/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03759392,35852527,Ph3 | quadruple | treatment,Cytokinetics,Industry,,?,Y,,,,,None,,
-856,JAMA,2022,Psychiatry/Mental Health,Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.9805,https://cdn.clinicaltrials.gov/large-docs/62/NCT03170362/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/62/NCT03170362/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT03170362,35819423,NA | single | treatment,VA Office of Research and Development,US Federal,,?,Y,Mei-Chiung Shih,Biostatistics (per PubMed affiliation),"VA Cooperative Studies Coordinating Center, Palo Alto, California.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-857,JAMA,2022,Obstetrics/Gynecology,Effect of an Intensive Nurse Home Visiting Program on Adverse Birth Outcomes in a Medicaid-Eligible Population: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.9703,https://cdn.clinicaltrials.gov/large-docs/39/NCT03360539/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/39/NCT03360539/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT03360539,35788794,NA | supportive care,Harvard School of Public Health (HSPH),Academic/Other,Abdul Latif Jameel Poverty Action Lab; University of Chicago,?,Y,,,,,None,,
-858,JAMA,2022,Other,Effect of Varenicline Added to Counseling on Smoking Cessation Among African American Daily Smokers: The Kick It at Swope IV Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.8274,https://cdn.clinicaltrials.gov/large-docs/31/NCT02360631/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/31/NCT02360631/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02360631,35699705,Ph4 | double | treatment,"Lisa Sanderson Cox, PhD",Academic/Other,National Institute on Drug Abuse (NIDA),?,Y,Matthew S Mayo ; Ron Krebill,Biostatistics (per PubMed affiliation),"University of Kansas Cancer Center, Kansas City. ; Department of Biostatistics & Data Science, University of Kansas School of Medicine, Kansas City.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-859,JAMA,2022,Oncology,Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.9265,https://cdn.clinicaltrials.gov/large-docs/90/NCT03249090/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/90/NCT03249090/SAP_001.pdf,SAP,cluster,NCT03249090,35661856,NA | health services research,"Alliance Foundation Trials, LLC.",Academic/Other,"Patient-Centered Outcomes Research Institute; University of North Carolina; Mayo Clinic; American Society of Clinical Oncology; American Cancer Society, Inc.; (+1 more)",?,Y,,,,,None,,
-860,JAMA,2022,Oncology,Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.6147,https://cdn.clinicaltrials.gov/large-docs/38/NCT01101438/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/38/NCT01101438/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT01101438,35608580,Ph3 | triple | treatment,Canadian Cancer Trials Group,Network/Cooperative,"National Cancer Institute (NCI); ETOP IBCSG Partners Foundation; Institute of Cancer Research, United Kingdom",?,Y,Marguerite Ennis,Biostatistics (per PubMed affiliation),"Applied Statistician, Markham, Ontario, Canada.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-861,JAMA,2022,Neurology,Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.4315,https://cdn.clinicaltrials.gov/large-docs/07/NCT01603407/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/07/NCT01603407/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT01603407,35381069,Ph3 | quadruple | treatment,University of Rochester,Academic/Other,Newcastle University; University Medical Center Freiburg; National Institute of Neurological Disorders and Stroke (NINDS),?,Y,Michael P McDermott,Biostatistics (per PubMed affiliation),"Department of Neurology, University of Rochester Medical Center, Rochester, New York.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-862,JAMA,2022,Infectious Disease,Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.2832,https://cdn.clinicaltrials.gov/large-docs/60/NCT04545060/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/60/NCT04545060/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04545060,35285853,Ph2/Ph3 | quadruple | treatment,"Vir Biotechnology, Inc.",Industry,GlaxoSmithKline,?,Y,Nicola Scott,Statistics Director,GSK,https://uk.linkedin.com/in/nicola-scott-97b48a1a,High,Web-search,Nicola Scott is listed as Statistics Director at GSK on LinkedIn.
-863,JAMA,2022,Psychiatry/Mental Health,Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.0799,https://cdn.clinicaltrials.gov/large-docs/83/NCT04276883/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/83/NCT04276883/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04276883,35191924,Ph3 | quadruple | treatment,BioXcel Therapeutics Inc,Industry,Cognitive Research Corporation,?,Y,,,,,None,,
-864,JAMA,2022,Cardiovascular,"Effect of Intra-arrest Transport, Extracorporeal Cardiopulmonary Resuscitation, and Immediate Invasive Assessment and Treatment on Functional Neurologic Outcome in Refractory Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial",https://doi.org/10.1001/jama.2022.1025,https://cdn.clinicaltrials.gov/large-docs/66/NCT01511666/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/66/NCT01511666/Prot_000.pdf,Protocol only,fixed_parallel_superiority,NCT01511666,35191923,NA | treatment,"Charles University, Czech Republic",Academic/Other,,?,Y,Jiri Jarkovsky ; Arnost Komarek,Biostatistics (per PubMed affiliation),"Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic. ; Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University in Prague, Prague, Czech Republic.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-865,JAMA,2022,Psychiatry/Mental Health,Effect of Offering Care Management or Online Dialectical Behavior Therapy Skills Training vs Usual Care on Self-harm Among Adult Outpatients With Suicidal Ideation: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.0423,https://cdn.clinicaltrials.gov/large-docs/83/NCT02326883/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/83/NCT02326883/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02326883,35166800,NA | single | prevention,Kaiser Permanente,Academic/Other,National Institute of Mental Health (NIMH); HealthPartners Institute; National Institutes of Health (NIH); National Center for Complementary and Integrative Health (NCCIH),?,Y,,,,,None,,
-866,JAMA,2022,Cardiovascular,Effect of Intra-arterial Alteplase vs Placebo Following Successful Thrombectomy on Functional Outcomes in Patients With Large Vessel Occlusion Acute Ischemic Stroke: The CHOICE Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.1645,https://cdn.clinicaltrials.gov/large-docs/19/NCT03876119/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/19/NCT03876119/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03876119,35143603,Ph2/Ph3 | quadruple | treatment,Hospital Clinic of Barcelona,Academic/Other,Fundació La Marató de TV3; Fundacion Clinic per a la Recerca Biomédica,?,Y,Ferran Torres,Biostatistics (per PubMed affiliation),"Medical Statistics Core Facility, Clinical Pharmacology Service, IDIBAPS, Hospital Clínic Barcelona, Barcelona, Spain.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-867,JAMA,2022,Endocrinology/Metabolism,Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial,https://doi.org/10.1001/jama.2022.0078,https://cdn.clinicaltrials.gov/large-docs/03/NCT04039503/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/03/NCT04039503/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04039503,35133415,Ph3 | double | treatment,Eli Lilly and Company,Industry,,?,Y,Ross Bray,Senior Advisor - Statistics,Eli Lilly and Company,https://ie.linkedin.com/in/ross-bray-04351020,High,Web-search,"Ross Bray is a Senior Advisor - Statistics at Eli Lilly and Company, explicitly identified as an experienced statistician."
-868,JAMA,2022,Infectious Disease,Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.23605,https://cdn.clinicaltrials.gov/large-docs/74/NCT04505774/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/74/NCT04505774/SAP_003.pdf,SAP,adaptive_bayesian,NCT04505774,35040887,Ph4 | treatment,Matthew Neal MD,Academic/Other,"National Heart, Lung, and Blood Institute (NHLBI)",?,Y,,,,,None,,
-869,JAMA,2022,Infectious Disease,Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.24939,https://cdn.clinicaltrials.gov/large-docs/18/NCT04452318/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/18/NCT04452318/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT04452318,35029629,Ph3 | quadruple | treatment,Regeneron Pharmaceuticals,Industry,,?,Y,Elizabeth R Brown,Biostatistics (per PubMed affiliation),"Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-870,JAMA,2022,Hematology,Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.23182,https://cdn.clinicaltrials.gov/large-docs/82/NCT00687882/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/82/NCT00687882/SAP_001.pdf,SAP,noninferiority,NCT00687882,35015038,Ph3 | single | treatment,Johns Hopkins All Children's Hospital,Academic/Other,"National Heart, Lung, and Blood Institute (NHLBI)",?,Y,John M Kittelson,Biostatistics (per PubMed affiliation),"Department of Biostatistics, School of Public Health, University of Colorado Anschutz Medical Campus, Aurora.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-871,JAMA,2022,Endocrinology/Metabolism,Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.23619,https://cdn.clinicaltrials.gov/large-docs/61/NCT04074161/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/61/NCT04074161/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04074161,35015037,Ph3 | quadruple | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-872,JAMA,2022,Oncology,Effect of a Community-Based Medical Oncology Depression Screening Program on Behavioral Health Referrals Among Patients With Breast Cancer: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.22596,https://cdn.clinicaltrials.gov/large-docs/14/NCT02941614/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/14/NCT02941614/Prot_SAP_000.pdf,Protocol+SAP,cluster,NCT02941614,34982119,,Kaiser Permanente,Academic/Other,California Breast Cancer Research Program,?,Y,,,,,None,,
-873,JAMA,2022,Surgery/Critical Care,Effect of Regional vs General Anesthesia on Incidence of Postoperative Delirium in Older Patients Undergoing Hip Fracture Surgery: The RAGA Randomized Trial,https://doi.org/10.1001/jama.2021.22647,https://cdn.clinicaltrials.gov/large-docs/80/NCT02213380/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/80/NCT02213380/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT02213380,34928310,NA | single | prevention,Wenzhou Medical University,Academic/Other,"National Research Institute for Family Planning, China",?,Y,,,,,None,,
-874,JAMA,2021,Oncology,Effect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.21187,https://cdn.clinicaltrials.gov/large-docs/59/NCT01169259/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/59/NCT01169259/Prot_SAP_000.pdf,Protocol+SAP,factorial,"NCT01169259, NCT01696435",34932079,Ph3 | triple | prevention,Brigham and Women's Hospital,Academic/Other,"National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); Office of Dietary Supplements (ODS); National Institute of Neurological Disorders and Stroke (NINDS); National Center for Complementary and Integrative Health (NCCIH); (+3 more)",?,Y,,,,,None,,
-875,JAMA,2021,Other,Effect of Intravenous or Intraosseous Calcium vs Saline on Return of Spontaneous Circulation in Adults With Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.20929,https://cdn.clinicaltrials.gov/large-docs/35/NCT04153435/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/35/NCT04153435/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04153435,34847226,Ph2 | quadruple | treatment,Lars Wiuff Andersen,Academic/Other,Central Denmark Region; University of Aarhus,?,Y,,,,,None,,
-876,JAMA,2021,Cardiovascular,Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.18463,https://cdn.clinicaltrials.gov/large-docs/04/NCT03066804/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/04/NCT03066804/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03066804,34783839,Ph3 | quadruple | treatment,Novartis Pharmaceuticals,Industry,,?,Y,,,,,None,,
-877,JAMA,2021,Rheumatology/Immunology,Effects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.15333,https://cdn.clinicaltrials.gov/large-docs/84/NCT03176784/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/84/NCT03176784/Prot_SAP_000.pdf,Protocol+SAP,factorial,NCT03176784,34665204,Ph4 | double | treatment,"University of Wisconsin, Madison",Academic/Other,"Washington University School of Medicine; National Heart, Lung, and Blood Institute (NHLBI)",?,Y,,,,,None,,
-878,JAMA,2021,Cardiovascular,Effect of Moderate vs Mild Therapeutic Hypothermia on Mortality and Neurologic Outcomes in Comatose Survivors of Out-of-Hospital Cardiac Arrest: The CAPITAL CHILL Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.15703,https://cdn.clinicaltrials.gov/large-docs/68/NCT02011568/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/68/NCT02011568/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02011568,34665203,NA | double | treatment,Ottawa Heart Institute Research Corporation,Academic/Other,,?,Y,,,,,None,,
-879,JAMA,2021,Infectious Disease,Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.17272,https://cdn.clinicaltrials.gov/large-docs/73/NCT04498273/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/73/NCT04498273/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT04498273,34633405,Ph3 | quadruple | prevention,Frank C Sciurba,Academic/Other,"National Heart, Lung, and Blood Institute (NHLBI)",?,Y,,,,,None,,
-880,JAMA,2021,Respiratory,Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.14846,https://cdn.clinicaltrials.gov/large-docs/39/NCT02238639/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/39/NCT02238639/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02238639,34609451,NA | treatment,"Ministry of Health, Spain",Other Government,American College of Chest Physicians; Sociedad Española de Neumología y Cirugía Torácica,?,Y,Alfonso Muriel,Biostatistics (per PubMed affiliation),"Biostatistics Department, Ramón y Cajal Hospital and Instituto Ramón y Cajal de Investigación Sanitaria IRYCIS, CIBERESP, Madrid, Spain.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-881,JAMA,2021,Cardiovascular,Effect of Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients With In-Hospital Cardiac Arrest: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.16628,https://cdn.clinicaltrials.gov/large-docs/49/NCT03640949/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/49/NCT03640949/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03640949,34587236,Ph2/Ph3 | quadruple | treatment,Lars Wiuff Andersen,Academic/Other,University of Aarhus,?,Y,,,,,None,,
-882,JAMA,2021,Respiratory,Effect of School Integrated Pest Management or Classroom Air Filter Purifiers on Asthma Symptoms in Students With Active Asthma: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.11559,https://cdn.clinicaltrials.gov/large-docs/02/NCT02291302/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/02/NCT02291302/Prot_SAP_000.pdf,Protocol+SAP,factorial,NCT02291302,34547084,NA | double | treatment,Boston Children's Hospital,Academic/Other,National Institutes of Health (NIH); National Institute of Allergy and Infectious Diseases (NIAID); Harvard School of Public Health (HSPH),?,Y,Brent A Coull ; Carter R Petty,Biostatistics (per PubMed affiliation),"Department of Environmental Health, T. H. Chan School of Public Health, Harvard University, Boston, Massachusetts. ; Biostatistics and Research Design Center, Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, Massachusetts.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-883,JAMA,2021,Neurology,Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.10207,https://cdn.clinicaltrials.gov/large-docs/93/NCT02642393/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/93/NCT02642393/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT02642393,34519802,Ph3 | quadruple | other,Michael Alan Schwarzschild,Academic/Other,The Parkinson Study Group; Michael J. Fox Foundation for Parkinson's Research; University of Rochester; National Institute of Neurological Disorders and Stroke (NINDS),?,Y,,,,,None,,
-884,JAMA,2021,Respiratory,Effect of Lower Tidal Volume Ventilation Facilitated by Extracorporeal Carbon Dioxide Removal vs Standard Care Ventilation on 90-Day Mortality in Patients With Acute Hypoxemic Respiratory Failure: The REST Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.13374,,https://cdn.clinicaltrials.gov/large-docs/27/NCT02654327/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT02654327,34463700,Ph3 | treatment,Belfast Health and Social Care Trust,Academic/Other,"Queen's University, Belfast; Northern Ireland Clinical Trials Unit",?,Y,,,,,None,,
-885,JAMA,2021,Cardiovascular,Effect of an Active vs Expectant Management Strategy on Successful Resolution of Pregnancy Among Patients With a Persisting Pregnancy of Unknown Location: The ACT or NOT Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.10767,https://cdn.clinicaltrials.gov/large-docs/96/NCT02152696/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/96/NCT02152696/Prot_SAP_000.pdf,Protocol+SAP,noninferiority;crossover,NCT02152696,34342619,Ph3 | treatment,Yale University,Academic/Other,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Augusta University; Penn State University; University of California, San Francisco; University of North Carolina; (+2 more)",?,Y,Mary D Sammel ; Hao Huang,Biostatistics (per PubMed affiliation),"Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora. ; Department of Biostatistics, Yale University, New Haven, Connecticut.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-886,JAMA,2021,Infectious Disease,Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract Infection: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.9899,https://cdn.clinicaltrials.gov/large-docs/38/NCT01994538/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/38/NCT01994538/Prot_SAP_000.pdf,Protocol+SAP,noninferiority,NCT01994538,34313686,NA | triple | treatment,VA Office of Research and Development,US Federal,,?,Y,,,,,None,,
-887,JAMA,2021,Infectious Disease,Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.9508,https://cdn.clinicaltrials.gov/large-docs/13/NCT04362813/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/13/NCT04362813/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04362813,34283183,Ph3 | double | treatment,Novartis Pharmaceuticals,Industry,,?,Y,Yuhan Li,Global Program Biostatistics Head,Novartis,https://www.zoominfo.com/p/Yuhan-Li/4245220549,High,Web-search,Yuhan Li is explicitly listed as Global Program Biostatistics Head at Novartis.
-888,JAMA,2021,Infectious Disease,Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.11517,https://cdn.clinicaltrials.gov/large-docs/07/NCT04332107/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/07/NCT04332107/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04332107,34269813,Ph3 | quadruple | treatment,Thomas M. Lietman,Academic/Other,Bill and Melinda Gates Foundation; Pfizer; Stanford University,?,Y,Travis C Porco ; Thomas M Lietman,Biostatistics (per PubMed affiliation),"Francis I. Proctor Foundation, University of California, San Francisco. ; Francis I. Proctor Foundation, University of California, San Francisco.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-889,JAMA,2021,Other,Effect of Oral Ranitidine on Urinary Excretion of N-Nitrosodimethylamine (NDMA): A Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.9199,https://cdn.clinicaltrials.gov/large-docs/45/NCT04397445/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/45/NCT04397445/SAP_001.pdf,SAP,crossover,NCT04397445,34180947,Ph1 | quadruple | basic science,Food and Drug Administration (FDA),US Federal,Spaulding Clinical Research LLC,?,Y,,,,,None,,
-890,JAMA,2021,Neurology,Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.7665,https://cdn.clinicaltrials.gov/large-docs/83/NCT04152083/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/83/NCT04152083/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04152083,34128999,Ph3 | quadruple | treatment,H. Lundbeck A/S,Industry,"Alder Biopharmaceuticals, Inc.",?,Y,,,,,None,,
-891,JAMA,2021,Infectious Disease,Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.8828,https://cdn.clinicaltrials.gov/large-docs/87/NCT04497987/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/87/NCT04497987/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04497987,34081073,Ph3 | double | prevention,Eli Lilly and Company,Industry,"National Institute of Allergy and Infectious Diseases (NIAID); AbCellera Biologics Inc.; Shanghai Junshi Bioscience Co., Ltd.",?,Y,,,,,None,,
-892,JAMA,2021,Cardiovascular,Effect of Implantable vs Prolonged External Electrocardiographic Monitoring on Atrial Fibrillation Detection in Patients With Ischemic Stroke: The PER DIEM Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.6128,https://cdn.clinicaltrials.gov/large-docs/40/NCT02428140/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/40/NCT02428140/SAP_001.pdf,SAP,single_arm,NCT02428140,34061146,NA | diagnostic,University of Alberta,Academic/Other,University of Calgary; Alberta Innovates Health Solutions; Medtronic,?,Y,,,,,None,,
-893,JAMA,2021,Cardiovascular,Effect of Long-term Continuous Cardiac Monitoring vs Usual Care on Detection of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease: The STROKE-AF Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.6470,https://cdn.clinicaltrials.gov/large-docs/45/NCT02700945/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/45/NCT02700945/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02700945,34061145,NA | diagnostic,Medtronic Cardiac Rhythm and Heart Failure,Industry,,?,Y,,,,,None,,
-894,JAMA,2021,Infectious Disease,Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.4956,https://cdn.clinicaltrials.gov/large-docs/20/NCT02759120/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/20/NCT02759120/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT02759120,33974018,Ph3 | treatment,Weill Medical College of Cornell University,Academic/Other,"Duke Clinical Research Institute; University of Chicago; University of Washington; University of Pittsburgh; National Heart, Lung, and Blood Institute (NHLBI)",?,Y,,,,,None,,
-895,JAMA,2021,Oncology,Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.2454,https://cdn.clinicaltrials.gov/large-docs/45/NCT01150045/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/45/NCT01150045/Prot_SAP_000.pdf,Protocol+SAP,factorial,NCT01150045,33821899,Ph3 | double | treatment,Alliance for Clinical Trials in Oncology,Academic/Other,National Cancer Institute (NCI),?,Y,Qian Shi ; Jeffrey Meyer,Biostatistics (per PubMed affiliation),"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota. ; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-896,JAMA,2021,Cardiovascular,Effect of Low-Intensity vs High-Intensity Home-Based Walking Exercise on Walk Distance in Patients With Peripheral Artery Disease: The LITE Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.2536,https://cdn.clinicaltrials.gov/large-docs/00/NCT02538900/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/00/NCT02538900/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02538900,33821898,NA | single | treatment,Northwestern University,Academic/Other,"National Heart, Lung, and Blood Institute (NHLBI)",?,Y,,,,,None,,
-897,JAMA,2021,Endocrinology/Metabolism,Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.3224,https://cdn.clinicaltrials.gov/large-docs/87/NCT03548987/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/87/NCT03548987/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03548987,33755728,Ph3 | quadruple | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-898,JAMA,2021,Oncology,Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.1489,https://cdn.clinicaltrials.gov/large-docs/59/NCT01169259/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/59/NCT01169259/Prot_SAP_000.pdf,Protocol+SAP,factorial,"NCT02178410, NCT01169259",33724323,Ph3 | triple | prevention,Brigham and Women's Hospital,Academic/Other,"National Heart, Lung, and Blood Institute (NHLBI); Cedars-Sinai Medical Center",?,Y,,,,,None,,
-899,JAMA,2021,Infectious Disease,Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19,https://doi.org/10.1001/jama.2021.3645,https://cdn.clinicaltrials.gov/large-docs/76/NCT04436276/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/76/NCT04436276/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT04436276,33704352,Ph1/Ph2 | double | other,Janssen Vaccines & Prevention B.V.,Industry,,?,Y,An Vandebosch,statisticians,Janssen,https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(24)00356-6/fulltext,Medium,Web-search,An Vandebosch and Sanne Roels are explicitly acknowledged as statisticians at Janssen in the Lancet article.
-900,JAMA,2021,Rheumatology/Immunology,Effect of Ventral vs Dorsal Spinal Surgery on Patient-Reported Physical Functioning in Patients With Cervical Spondylotic Myelopathy: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.1233,https://cdn.clinicaltrials.gov/large-docs/13/NCT02076113/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/13/NCT02076113/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02076113,33687463,NA | treatment,Lahey Clinic,Academic/Other,Patient-Centered Outcomes Research Institute,?,Y,,,,,None,,
-901,JAMA,2021,Oncology,Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.0987,https://cdn.clinicaltrials.gov/large-docs/59/NCT02393859/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/59/NCT02393859/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02393859,33651091,Ph3 | treatment,Amgen,Industry,,?,Y,Joan D Morris,Global Biostatistical Science,Amgen,https://ash.confex.com/ash/2020/webprogram/Paper137255.html,High,Web-search,"Joan Morris is listed with affiliation 'Global Biostatistical Science, Amgen Ltd' in multiple conference abstracts."
-902,JAMA,2021,Oncology,"Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial",https://doi.org/10.1001/jama.2021.0669,https://cdn.clinicaltrials.gov/large-docs/53/NCT02101853/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/53/NCT02101853/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02101853,33651090,Ph3 | treatment,National Cancer Institute (NCI),NIH,,?,Y,,,,,None,,
-903,JAMA,2021,Endocrinology/Metabolism,Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.1831,https://cdn.clinicaltrials.gov/large-docs/82/NCT03611582/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/82/NCT03611582/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03611582,33625476,Ph3 | quadruple | treatment,Novo Nordisk A/S,Industry,,?,Y,,,,,None,,
-904,JAMA,2021,Infectious Disease,"Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial",https://doi.org/10.1001/jama.2020.24505,https://cdn.clinicaltrials.gov/large-docs/50/NCT03509350/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/50/NCT03509350/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03509350,33620405,Ph3 | double | supportive care,Emory University,Academic/Other,The Marcus Foundation,?,Y,Chris J Lindsell,Biostatistics (per PubMed affiliation),"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-905,JAMA,2021,Endocrinology/Metabolism,Effect of Behavioral Therapy With In-Clinic or Telephone Group Visits vs In-Clinic Individual Visits on Weight Loss Among Patients With Obesity in Rural Clinical Practice: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.25855,https://cdn.clinicaltrials.gov/large-docs/36/NCT02456636/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/36/NCT02456636/Prot_SAP_000.pdf,Protocol+SAP,cluster,NCT02456636,33496775,NA | treatment,University of Kansas Medical Center,Academic/Other,Patient-Centered Outcomes Research Institute,?,Y,Byron Gajewski ; Alexandra R Brown,Biostatistics (per PubMed affiliation),"Department of Biostatistics, University of Kansas Medical Center, Kansas City. ; Department of Biostatistics, University of Kansas Medical Center, Kansas City.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-906,JAMA,2021,Infectious Disease,Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2021.0202,https://cdn.clinicaltrials.gov/large-docs/01/NCT04427501/Prot_003.pdf,https://cdn.clinicaltrials.gov/large-docs/01/NCT04427501/SAP_005.pdf,SAP,seamless_2_3,NCT04427501,33475701,Ph2/Ph3 | double | treatment,Eli Lilly and Company,Industry,"AbCellera Biologics Inc.; Shanghai Junshi Bioscience Co., Ltd.",?,Y,,,,,None,,
-907,JAMA,2021,Cardiovascular,Effect of Out-of-Hospital Sodium Nitrite on Survival to Hospital Admission After Cardiac Arrest: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.24326,https://cdn.clinicaltrials.gov/large-docs/17/NCT03452917/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/17/NCT03452917/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03452917,33433575,Ph2/Ph3 | quadruple | treatment,University of Washington,Academic/Other,"National Heart, Lung, and Blood Institute (NHLBI)",?,Y,Susanne May,Biostatistics (per PubMed affiliation),"Department of Biostatistics, School of Public Health, University of Washington, Seattle.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-908,JAMA,2021,Cardiovascular,Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.23649,https://cdn.clinicaltrials.gov/large-docs/44/NCT02787044/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/44/NCT02787044/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02787044,33275134,Ph4 | quadruple | prevention,Brigham and Women's Hospital,Academic/Other,"National Heart, Lung, and Blood Institute (NHLBI); University of Wisconsin, Madison; University of Toronto; Boston VA Research Institute, Inc.; Patient-Centered Outcomes Research Institute; (+1 more)",?,Y,KyungMann Kim ; David DeMets,Biostatistics (per PubMed affiliation),"Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison. ; Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-909,JAMA,2020,Cardiovascular,Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.23138,https://cdn.clinicaltrials.gov/large-docs/37/NCT02391337/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/37/NCT02391337/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02391337,33351042,Ph4 | treatment,University of Birmingham,Academic/Other,,?,Y,,,,,None,,
-910,JAMA,2020,Endocrinology/Metabolism,Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.23027,https://cdn.clinicaltrials.gov/large-docs/76/NCT02858076/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/76/NCT02858076/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02858076,33320223,Ph2/Ph3 | single | treatment,Jaeb Center for Health Research,Academic/Other,National Institutes of Health (NIH); Regeneron Pharmaceuticals; National Eye Institute (NEI),?,Y,,,,,None,,
-911,JAMA,2020,Infectious Disease,Effect of a Lower vs Higher Positive End-Expiratory Pressure Strategy on Ventilator-Free Days in ICU Patients Without ARDS: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.23517,https://cdn.clinicaltrials.gov/large-docs/80/NCT03167580/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/80/NCT03167580/SAP_000.pdf,SAP,noninferiority,NCT03167580,33295981,NA | treatment,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Academic/Other,ZonMw: The Netherlands Organisation for Health Research and Development; Amphia Hospital; Gelre Hospitals; Isala; Maastricht University Medical Center; (+8 more),?,Y,,,,,None,,
-912,JAMA,2020,Cardiovascular,Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.22258,https://cdn.clinicaltrials.gov/large-docs/17/NCT02104817/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/17/NCT02104817/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02104817,33190147,Ph3 | triple | treatment,AstraZeneca,Industry,The Cleveland Clinic; IQVIA RDS Inc.,?,Y,,,,,None,,
-913,JAMA,2020,Infectious Disease,Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.22760,https://cdn.clinicaltrials.gov/large-docs/63/NCT04342663/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/63/NCT04342663/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04342663,33180097,Ph2 | triple | treatment,Washington University School of Medicine,Academic/Other,,?,Y,J Philip Miller,Biostatistics (per PubMed affiliation),"Division of Biostatistics, Informatics Institute, School of Medicine, Washington University in St Louis, St Louis, Missouri.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-914,JAMA,2020,Infectious Disease,Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.22240,https://cdn.clinicaltrials.gov/large-docs/91/NCT04332991/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/91/NCT04332991/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04332991,33165621,Ph3 | quadruple | treatment,Massachusetts General Hospital,Academic/Other,"National Heart, Lung, and Blood Institute (NHLBI)",?,Y,Frank E Harrell ; Christopher J Lindsell,Biostatistics (per PubMed affiliation),"Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee. ; Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-915,JAMA,2020,Cardiovascular,Effect of an Online Weight Management Program Integrated With Population Health Management on Weight Change: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.18977,https://cdn.clinicaltrials.gov/large-docs/93/NCT02656693/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/93/NCT02656693/Prot_SAP_000.pdf,Protocol+SAP,cluster,NCT02656693,33141209,NA | health services research,Brigham and Women's Hospital,Academic/Other,Patient-Centered Outcomes Research Institute,?,Y,,,,,None,,
-916,JAMA,2020,Cardiovascular,Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.16195,https://cdn.clinicaltrials.gov/large-docs/21/NCT01898221/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/21/NCT01898221/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01898221,33107945,Ph3 | single | treatment,The Methodist Hospital Research Institute,Academic/Other,"National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI)",?,Y,,,,,None,,
-917,JAMA,2020,Cardiovascular,Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.16641,https://cdn.clinicaltrials.gov/large-docs/85/NCT03254485/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/85/NCT03254485/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03254485,33079154,Ph2 | quadruple | treatment,Akebia Therapeutics,Industry,Cyclerion Therapeutics,?,Y,,,,,None,,
-918,JAMA,2020,Cardiovascular,Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.15922,https://cdn.clinicaltrials.gov/large-docs/83/NCT03547583/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/83/NCT03547583/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03547583,33079152,Ph2 | quadruple | treatment,Bayer,Industry,Merck Sharp & Dohme LLC; Canadian VIGOUR Centre; Duke Clinical Research Institute,?,Y,Vanja Vlajnic,"Associate Director, Bayer Science Fellow, Statistics & Data Insights",Bayer,https://www.linkedin.com/in/vanjavlajnic,High,Web-search,"LinkedIn profile explicitly states ""Associate Director, Bayer Science Fellow, Statistics & Data Insights"" at Bayer."
-919,JAMA,2020,Oncology,Effect of Sustained Smoking Cessation Counseling and Provision of Medication vs Shorter-term Counseling and Medication Advice on Smoking Abstinence in Patients Recently Diagnosed With Cancer: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.14581,https://cdn.clinicaltrials.gov/large-docs/06/NCT01871506/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/06/NCT01871506/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01871506,33048154,NA | treatment,Massachusetts General Hospital,Academic/Other,National Cancer Institute (NCI); National Institutes of Health (NIH),?,Y,Alona Muzikansky,Biostatistics (per PubMed affiliation),"MGH Biostatistics Center, Massachusetts General Hospital, Boston.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-920,JAMA,2020,Infectious Disease,Effect of Prophylactic Negative Pressure Wound Therapy vs Standard Wound Dressing on Surgical-Site Infection in Obese Women After Cesarean Delivery: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.13361,https://cdn.clinicaltrials.gov/large-docs/10/NCT03009110/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/10/NCT03009110/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03009110,32960242,NA | prevention,Indiana University,Academic/Other,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); 3M,?,Y,,,,,None,,
-921,JAMA,2020,Surgery/Critical Care,Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury,https://doi.org/10.1001/jama.2020.8958,https://cdn.clinicaltrials.gov/large-docs/68/NCT01990768/Prot_SAP_ICF_002.pdf,https://cdn.clinicaltrials.gov/large-docs/68/NCT01990768/Prot_SAP_ICF_002.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01990768,32897344,Ph2 | quadruple | treatment,University of Washington,Academic/Other,"National Heart, Lung, and Blood Institute (NHLBI); U.S. Army Medical Research and Development Command; Canadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of Canada; American Heart Association; (+1 more)",?,Y,Eric N Meier ; Barbara McKnight,Biostatistics (per PubMed affiliation),"Department of Biostatistics, University of Washington, Seattle. ; Department of Biostatistics, University of Washington, Seattle.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-922,JAMA,2020,Infectious Disease,Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.17021,https://cdn.clinicaltrials.gov/large-docs/01/NCT04327401/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/01/NCT04327401/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04327401,32876695,Ph3 | treatment,Hospital Sirio-Libanes,Academic/Other,Hospital Israelita Albert Einstein; Hospital do Coracao; Brazilian Research In Intensive Care Network; Ache Laboratorios Farmaceuticos S.A.,?,Y,,,,,None,,
-923,JAMA,2020,Infectious Disease,Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.16761,,https://cdn.clinicaltrials.gov/large-docs/89/NCT02517489/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT02517489,32876689,Ph3 | triple | treatment,"University Hospital, Tours",Academic/Other,,?,Y,,,,,None,,
-924,JAMA,2020,Cardiovascular,Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.12443,https://cdn.clinicaltrials.gov/large-docs/17/NCT01742117/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/17/NCT01742117/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01742117,32840598,Ph4 | treatment,Mayo Clinic,Academic/Other,"Spartan Bioscience Inc.; Applied Health Research Centre; National Heart, Lung, and Blood Institute (NHLBI)",?,Y,Ryan Lennon,principal biostatistician,Mayo Clinic,https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-biostatisticians-power-every-step-of-medical-research/,High,Web-search,Ryan Lennon is identified as a principal biostatistician at Mayo Clinic.
-925,JAMA,2020,Respiratory,Effect of Vitamin D3 Supplementation on Severe Asthma Exacerbations in Children With Asthma and Low Vitamin D Levels: The VDKA Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.12384,https://cdn.clinicaltrials.gov/large-docs/15/NCT02687815/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/15/NCT02687815/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02687815,32840597,Ph2 | quadruple | treatment,"Juan Celedon, MD",Academic/Other,"Pharmavite LLC; National Heart, Lung, and Blood Institute (NHLBI)",?,Y,,,,,None,,
-926,JAMA,2020,Infectious Disease,Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.16349,https://cdn.clinicaltrials.gov/large-docs/30/NCT04292730/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/30/NCT04292730/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT04292730,32821939,Ph3 | treatment,Gilead Sciences,Industry,,?,Y,,,,,None,,
-927,JAMA,2020,Infectious Disease,"Effect of Ascorbic Acid, Corticosteroids, and Thiamine on Organ Injury in Septic Shock: The ACTS Randomized Clinical Trial",https://doi.org/10.1001/jama.2020.11946,https://cdn.clinicaltrials.gov/large-docs/55/NCT03389555/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/55/NCT03389555/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03389555,32809003,Ph2/Ph3 | quadruple | treatment,Beth Israel Deaconess Medical Center,Academic/Other,Open Philanthropy,?,Y,,,,,None,,
-928,JAMA,2020,Cardiovascular,"Effect of a Collaborative Care Model on Depressive Symptoms and Glycated Hemoglobin, Blood Pressure, and Serum Cholesterol Among Patients With Depression and Diabetes in India: The INDEPENDENT Randomized Clinical Trial",https://doi.org/10.1001/jama.2020.11747,https://cdn.clinicaltrials.gov/large-docs/11/NCT02022111/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/11/NCT02022111/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02022111,32809002,NA | single | health services research,Emory University,Academic/Other,National Institute of Mental Health (NIMH); University of Washington; Madras Diabetes Research Foundation; All India Institute of Medical Sciences; Endocrine & Diabetes Centre; (+1 more),?,Y,,,,,None,,
-929,JAMA,2020,Pediatrics,"Effect of High Add Power, Medium Add Power, or Single-Vision Contact Lenses on Myopia Progression in Children: The BLINK Randomized Clinical Trial",https://doi.org/10.1001/jama.2020.10834,https://cdn.clinicaltrials.gov/large-docs/74/NCT02255474/Prot_SAP_002.pdf,https://cdn.clinicaltrials.gov/large-docs/74/NCT02255474/Prot_SAP_002.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02255474,32780139,NA | triple | treatment,Ohio State University,Academic/Other,University of Houston; National Eye Institute (NEI),?,Y,,,,,None,,
-930,JAMA,2020,Oncology,Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.10224,https://cdn.clinicaltrials.gov/large-docs/59/NCT01169259/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/59/NCT01169259/Prot_SAP_000.pdf,Protocol+SAP,factorial,"NCT01169259, NCT01696435",32749491,Ph3 | triple | prevention,Brigham and Women's Hospital,Academic/Other,"National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); Office of Dietary Supplements (ODS); National Institute of Neurological Disorders and Stroke (NINDS); National Center for Complementary and Integrative Health (NCCIH); (+3 more)",?,Y,,,,,None,,
-931,JAMA,2020,Surgery/Critical Care,Effect of Intravenous Acetaminophen on Postoperative Hypoxemia After Abdominal Surgery: The FACTOR Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.10009,https://cdn.clinicaltrials.gov/large-docs/54/NCT02156154/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/54/NCT02156154/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02156154,32721009,Ph3 | quadruple | treatment,The Cleveland Clinic,Academic/Other,,?,Y,,,,,None,,
-932,JAMA,2020,Cardiovascular,Effect of Doxycycline on Aneurysm Growth Among Patients With Small Infrarenal Abdominal Aortic Aneurysms: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.5230,https://cdn.clinicaltrials.gov/large-docs/33/NCT01756833/Prot_003.pdf,https://cdn.clinicaltrials.gov/large-docs/33/NCT01756833/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT01756833,32453369,Ph2 | double | treatment,"University of Maryland, Baltimore",Academic/Other,National Institute on Aging (NIA),?,Y,Diana Lam,Statistical Programming Analyst,Genentech,https://static1.squarespace.com/static/5c4f6c7789c172ed71d6f025/t/65360b1b14c39b7fa7cb8d5d/1698040622663/BBSW+2023+Conference+Program_20231020.pdf,Medium,Web-search,Former Statistical Programming Analyst at Genentech with a degree in Biostatistics.
-933,JAMA,2020,Infectious Disease,Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.3138,https://cdn.clinicaltrials.gov/large-docs/69/NCT01552369/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/69/NCT01552369/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01552369,32286644,Ph4 | treatment,National Institute of Allergy and Infectious Diseases (NIAID),NIH,,?,Y,,,,,None,,
-934,JAMA,2020,Infectious Disease,Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.2477,https://cdn.clinicaltrials.gov/large-docs/82/NCT02562482/Prot_SAP_ICF_001.pdf,https://cdn.clinicaltrials.gov/large-docs/82/NCT02562482/Prot_SAP_ICF_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02562482,32286643,Ph2 | triple | prevention,National Institute of Allergy and Infectious Diseases (NIAID),NIH,,?,Y,,,,,None,,
-935,JAMA,2020,Oncology,Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.1707,https://cdn.clinicaltrials.gov/large-docs/43/NCT02451943/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/43/NCT02451943/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT02451943,32259228,Ph3 | double | treatment,Eli Lilly and Company,Industry,,?,Y,Victoria Soldatenkova,Statistician,Eli Lilly and Company,https://ww2.amstat.org/meetings/biop/2022/onlineprogram/Program.cfm,High,Web-search,Victoria Soldatenkova is explicitly listed as a Statistician at Eli Lilly in an AMSTAT conference program.
-936,JAMA,2020,Cardiovascular,Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes,https://doi.org/10.1001/jama.2020.1906,https://cdn.clinicaltrials.gov/large-docs/24/NCT03036124/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/24/NCT03036124/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03036124,32219386,Ph3 | quadruple | treatment,AstraZeneca,Industry,,?,Y,,,,,None,,
-937,JAMA,2020,Cardiovascular,Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2020.3308,https://cdn.clinicaltrials.gov/large-docs/55/NCT02586155/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/55/NCT02586155/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02586155,32219359,Ph3 | triple | prevention,Resverlogix Corp,Industry,"PPD Development, LP; ICON plc; Medidata Solutions",?,Y,Kevin A Buhr,Biostatistics (per PubMed affiliation),"Statistical Data Analysis Center, University of Wisconsin-Madison.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-938,JAMA,2020,Oncology,Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening,https://doi.org/10.1001/jama.2020.0572,https://cdn.clinicaltrials.gov/large-docs/89/NCT02933489/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/89/NCT02933489/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02933489,32096852,NA | single | screening,ECOG-ACRIN Cancer Research Group,Network/Cooperative,National Cancer Institute (NCI),?,Y,Constantine Gatsonis ; Bradley S Snyder,Biostatistics (per PubMed affiliation),"Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island. ; Center for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-939,JAMA,2020,Respiratory,Effect of Intravenous Interferon β-1a on Death and Days Free From Mechanical Ventilation Among Patients With Moderate to Severe Acute Respiratory Distress Syndrome: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2019.22525,https://cdn.clinicaltrials.gov/large-docs/24/NCT02622724/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/24/NCT02622724/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02622724,32065831,Ph3 | quadruple | treatment,Faron Pharmaceuticals Ltd,Industry,Seventh Framework Programme,?,Y,,,,,None,,
-940,JAMA,2020,Neurology,Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials,https://doi.org/10.1001/jama.2019.22450,https://cdn.clinicaltrials.gov/large-docs/11/NCT03238911/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/11/NCT03238911/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT03238911, NCT03237065",32016310,Ph3 | treatment,Pharmacosmos A/S,Industry,,?,Y,,,,,None,,
-941,JAMA,2020,Dermatology,Effect of Sunscreen Application on Plasma Concentration of Sunscreen Active Ingredients: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2019.20747,https://cdn.clinicaltrials.gov/large-docs/15/NCT03582215/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/15/NCT03582215/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03582215,31961417,Ph1 | other,Food and Drug Administration (FDA),US Federal,Spaulding Clinical Research LLC,?,Y,,,,,None,,
-942,JAMA,2020,Oncology,Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial,https://doi.org/10.1001/jama.2019.20207,https://cdn.clinicaltrials.gov/large-docs/72/NCT01238172/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/72/NCT01238172/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01238172,31935026,Ph3 | treatment,Alliance for Clinical Trials in Oncology,Academic/Other,National Cancer Institute (NCI),?,Y,David Zahrieh ; Heshan Liu,Biostatistics (per PubMed affiliation),"Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota. ; Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-943,JAMA,2020,Obstetrics/Gynecology,Effect of Folic Acid and Zinc Supplementation in Men on Semen Quality and Live Birth Among Couples Undergoing Infertility Treatment: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2019.18714,https://cdn.clinicaltrials.gov/large-docs/10/NCT01857310/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/10/NCT01857310/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01857310,31910279,NA | quadruple | treatment,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,,?,Y,Zhen Chen,Biostatistics (per PubMed affiliation),"Biostatistics and Bioinformatics Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-944,JAMA,2020,Infectious Disease,Effect of Treating Parents Colonized With Staphylococcus aureus on Transmission to Neonates in the Intensive Care Unit: A Randomized Clinical Trial,https://doi.org/10.1001/jama.2019.20785,https://cdn.clinicaltrials.gov/large-docs/20/NCT02223520/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/20/NCT02223520/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02223520,31886828,NA | triple | prevention,Johns Hopkins University,Academic/Other,Agency for Healthcare Research and Quality (AHRQ),?,Y,,,,,None,,
-945,JCO,2026,Oncology,Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study,https://doi.org/10.1200/jco-25-00570,https://cdn.clinicaltrials.gov/large-docs/04/NCT04199104/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/04/NCT04199104/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04199104,41818638,Ph3 | double | treatment,Merck Sharp & Dohme LLC,Industry,Eisai Inc.,?,Y,Juan Shen,Principal Scientist Biostatistician,Merck,https://lsa.umich.edu/stats/alumni-friends/statistics-phd-alumni/phd-alumni-2010-2019.html,High,Web-search,Juan Shen is listed as Principal Scientist Biostatistician at Merck. Kimberly Benjamin is a Clinical Director (MD).
-946,JCO,2026,Oncology,Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743,https://doi.org/10.1200/jco-25-01328,https://cdn.clinicaltrials.gov/large-docs/99/NCT02899299/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/99/NCT02899299/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02899299,41734361,Ph3 | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,,,,,None,,
-947,JCO,2026,Oncology,"Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107)",https://doi.org/10.1200/jco-25-01808,https://cdn.clinicaltrials.gov/large-docs/49/NCT01744249/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/49/NCT01744249/SAP_001.pdf,SAP,seamless_2_3,NCT01744249,41719493,Ph2/Ph3 | quadruple | treatment,Grupo Espanol de Tumores Neuroendocrinos,Academic/Other,Pfizer,?,Y,,,,,None,,
-948,JCO,2026,Oncology,"Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study",https://doi.org/10.1200/jco-25-01548,https://cdn.clinicaltrials.gov/large-docs/98/NCT04588298/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/98/NCT04588298/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04588298,41628308,Ph2 | treatment,AstraZeneca,Industry,,?,Y,Maxine Ajimi,,AstraZeneca,https://www.tandfonline.com/doi/full/10.1080/19466315.2024.2342817,Medium,Web-search,"Maxine Ajimi published statistical methodology papers (e.g., Bayesian metrics, dose-finding designs) and works at AZ."
-949,JCO,2026,Oncology,Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and &lt;i&gt;FGFR&lt;/i&gt; Alterations: Final Results From the Phase II NORSE Study,https://doi.org/10.1200/jco-25-00826,https://cdn.clinicaltrials.gov/large-docs/43/NCT03473743/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/43/NCT03473743/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03473743,41538748,Ph1/Ph2 | treatment,"Janssen Research & Development, LLC",Industry,,?,Y,Sydney Akapame,Director Biostatistics,Johnson & Johnson,https://www.linkedin.com/in/sydney-akapame-4989b521,High,Web-search,LinkedIn profile explicitly lists Sydney Akapame as Director Biostatistics at Johnson & Johnson.
-950,JCO,2026,Oncology,Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005,https://doi.org/10.1200/jco-25-01569,https://cdn.clinicaltrials.gov/large-docs/02/NCT03811002/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/02/NCT03811002/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03811002,41529214,Ph3 | treatment,National Cancer Institute (NCI),NIH,NRG Oncology,?,Y,Chen Hu ; Rebecca Paulus,Biostatistics (per PubMed affiliation),"NRG Oncology Statistics and Data Management Center, Philadelphia, PA. ; NRG Oncology Statistics and Data Management Center, Philadelphia, PA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-951,JCO,2026,Oncology,Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826,https://doi.org/10.1200/jco-25-00203,https://cdn.clinicaltrials.gov/large-docs/88/NCT03907488/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/88/NCT03907488/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03907488,41512237,Ph3 | treatment,National Cancer Institute (NCI),NIH,,?,Y,Hongli Li ; Michael LeBlanc,Biostatistics (per PubMed affiliation),"SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA. ; SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-952,JCO,2026,Oncology,"NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal",https://doi.org/10.1200/jco-25-00929,https://cdn.clinicaltrials.gov/large-docs/69/NCT02314169/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/69/NCT02314169/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02314169,41499716,Ph2 | treatment,National Cancer Institute (NCI),NIH,,?,Y,,,,,None,,
-953,JCO,2025,Oncology,TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma,https://doi.org/10.1200/jco-25-00872,https://cdn.clinicaltrials.gov/large-docs/41/NCT03665441/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/41/NCT03665441/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03665441,41187298,Ph3 | treatment,ERYtech Pharma,Industry,,?,Y,Richard Kay,Biostatistics (per PubMed affiliation),"RK Statistics Ltd, Bakewell, United Kingdom.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-954,JCO,2025,Oncology,US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia,https://doi.org/10.1200/jco-25-01369,https://cdn.clinicaltrials.gov/large-docs/61/NCT02598661/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/61/NCT02598661/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02598661,41135032,Ph2/Ph3 | double | treatment,Geron Corporation,Industry,,?,Y,,,,,None,,
-955,JCO,2025,Oncology,Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial,https://doi.org/10.1200/jco-25-00582,https://cdn.clinicaltrials.gov/large-docs/64/NCT03785964/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/64/NCT03785964/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT03785964,41115259,Ph3 | quadruple | treatment,"SpringWorks Therapeutics, Inc.",Industry,,?,Y,,,,,None,,
-956,JCO,2025,Hematology,Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial,https://doi.org/10.1200/jco-25-00809,https://cdn.clinicaltrials.gov/large-docs/61/NCT02913261/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/61/NCT02913261/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02913261,41092247,Ph3 | treatment,Novartis Pharmaceuticals,Industry,,?,Y,Rajendra Sarkar,Senior Biostatistician,Novartis,https://www.linkedin.com/pub/dir/Rajendra/Sarkar,High,Web-search,Rajendra Sarkar is listed as a Senior Biostatistician at Novartis on LinkedIn and ZoomInfo.
-957,JCO,2025,Oncology,Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial,https://doi.org/10.1200/jco-25-01957,https://cdn.clinicaltrials.gov/large-docs/47/NCT05171647/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/47/NCT05171647/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05171647,41037766,Ph3 | treatment,Hoffmann-La Roche,Industry,,?,Y,,,,,None,,
-958,JCO,2025,Oncology,Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B),https://doi.org/10.1200/jco-25-00788,https://cdn.clinicaltrials.gov/large-docs/22/NCT03974022/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/22/NCT03974022/SAP_003.pdf,SAP,single_arm,NCT03974022,40923280,Ph1/Ph2 | treatment,Dizal Pharmaceuticals,Industry,,?,Y,,,,,None,,
-959,JCO,2025,Oncology,"Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study",https://doi.org/10.1200/jco-25-00272,https://cdn.clinicaltrials.gov/large-docs/15/NCT04459715/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/15/NCT04459715/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04459715,40902136,Ph3 | quadruple | treatment,"EMD Serono Research & Development Institute, Inc.",Industry,"GORTEC (Head and Neck Oncology and Radiotherapy Group); Merck KGaA, Darmstadt, Germany",?,Y,Ngoc-Thuy Ha,Biostatistician,Merck KGaA,https://de.linkedin.com/in/dr-ngoc-thuy-ha-073575148,High,Web-search,LinkedIn profile explicitly states 'Biostatistician' and 'Merck KGaA'. EFSPI/EFPIA EIWG lists as 'Statistician' at Merck.
-960,JCO,2025,Oncology,Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202),https://doi.org/10.1200/jco-24-02644,https://cdn.clinicaltrials.gov/large-docs/36/NCT01841736/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/36/NCT01841736/Prot_SAP_000.pdf,Protocol+SAP,crossover,NCT01841736,40902132,Ph2 | double | treatment,National Cancer Institute (NCI),NIH,,?,Y,Susan Geyer ; Gina Mazza,Biostatistics (per PubMed affiliation),"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN. ; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-961,JCO,2025,Oncology,"Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study",https://doi.org/10.1200/jco-25-00486,https://cdn.clinicaltrials.gov/large-docs/26/NCT03221426/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/26/NCT03221426/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03221426,40829093,Ph3 | quadruple | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Xiao Fang,Biostatistician,Merck,https://www.linkedin.com/in/xiaofangutmb,High,Web-search,Xiao Fang is explicitly listed as a Biostatistician at Merck on LinkedIn and in publications.
-962,JCO,2025,Oncology,Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003,https://doi.org/10.1200/jco-25-00221,https://cdn.clinicaltrials.gov/large-docs/09/NCT02635009/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/09/NCT02635009/Prot_SAP_000.pdf,Protocol+SAP,noninferiority;seamless_2_3,NCT02635009,40789106,Ph2/Ph3 | supportive care,NRG Oncology,Academic/Other,National Cancer Institute (NCI); Radiation Therapy Oncology Group,?,Y,Stephanie L Pugh ; Rebecca Paulus,Biostatistics (per PubMed affiliation),"NRG Oncology Statistics and Data Management Center, Philadelphia, PA. ; NRG Oncology Statistics and Data Management Center, Philadelphia, PA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-963,JCO,2025,Oncology,"Dual Immune Check Point Blockade in &lt;i&gt;MGMT&lt;/i&gt;-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial",https://doi.org/10.1200/jco-25-00618,https://cdn.clinicaltrials.gov/large-docs/60/NCT04396860/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/60/NCT04396860/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04396860,40779733,Ph2/Ph3 | treatment,National Cancer Institute (NCI),NIH,NRG Oncology,?,Y,Mei-Yin C Polley ; James J Dignam,Biostatistics (per PubMed affiliation),"NRG Oncology Statistics and Data Management Center, Philadelphia, PA. ; NRG Oncology Statistics and Data Management Center, Philadelphia, PA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-964,JCO,2025,Oncology,"Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study",https://doi.org/10.1200/jco-25-00399,https://cdn.clinicaltrials.gov/large-docs/51/NCT03575351/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/51/NCT03575351/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03575351,40623279,Ph3 | treatment,Celgene,Industry,,?,Y,,,,,None,,
-965,JCO,2025,Nephrology/Urology,Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study,https://doi.org/10.1200/jco-24-02477,https://cdn.clinicaltrials.gov/large-docs/03/NCT03112603/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/03/NCT03112603/SAP_001.pdf,SAP,crossover,NCT03112603,40561385,Ph3 | treatment,Incyte Corporation,Industry,,?,Y,,,,,None,,
-966,JCO,2025,Psychiatry/Mental Health,Multisite Randomized Trial of Inpatient Palliative Care Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation,https://doi.org/10.1200/jco-25-00378,https://cdn.clinicaltrials.gov/large-docs/78/NCT03641378/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/78/NCT03641378/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03641378,40549982,NA | treatment,Massachusetts General Hospital,Academic/Other,National Institutes of Health (NIH); National Cancer Institute (NCI),?,Y,,,,,None,,
-967,JCO,2025,Oncology,"Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx Cancer",https://doi.org/10.1200/jco-24-02550,https://cdn.clinicaltrials.gov/large-docs/94/NCT01898494/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/94/NCT01898494/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01898494,40493877,Ph2 | treatment,ECOG-ACRIN Cancer Research Group,Network/Cooperative,National Cancer Institute (NCI),?,Y,Yael Flamand,Biostatistics (per PubMed affiliation),"ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-968,JCO,2025,Oncology,Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321),https://doi.org/10.1200/jco-25-00166,https://cdn.clinicaltrials.gov/large-docs/38/NCT04666038/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/38/NCT04666038/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04666038,40479620,Ph3 | treatment,"Loxo Oncology, Inc.",Industry,Eli Lilly and Company,?,Y,Katherine Bao,,Eli Lilly and Company,https://podcasts.apple.com/it/podcast/audio-journal-of-oncology-podcast/id1147639185,Medium,Web-search,Snippets link Katherine Bao to Eli Lilly and Biostatistics.
-969,JCO,2025,Oncology,Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study,https://doi.org/10.1200/jco-25-00744,https://cdn.clinicaltrials.gov/large-docs/66/NCT05405166/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/66/NCT05405166/SAP_001.pdf,SAP,noninferiority,NCT05405166,40459178,Ph3 | treatment,Sanofi,Industry,,?,Y,,,,,None,,
-970,JCO,2025,Oncology,"Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study",https://doi.org/10.1200/jco-25-00748,https://cdn.clinicaltrials.gov/large-docs/10/NCT04662710/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/10/NCT04662710/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04662710,40448579,Ph3 | treatment,Merck Sharp & Dohme LLC,Industry,Eisai Inc.,?,Y,Li Wen Liang,Biostatistics,Merck,https://www.linkedin.com/pub/dir/Liwen/Liang,High,Web-search,LinkedIn profile shows Liwen Liang works in Biostatistics at Merck.
-971,JCO,2025,Oncology,"Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study",https://doi.org/10.1200/jco-25-00746,https://cdn.clinicaltrials.gov/large-docs/91/NCT03377491/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/91/NCT03377491/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03377491,40448572,Ph3 | treatment,NovoCure Ltd.,Industry,,?,Y,,,,,None,,
-972,JCO,2025,Oncology,"Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial",https://doi.org/10.1200/jco-24-01681,https://cdn.clinicaltrials.gov/large-docs/18/NCT02486718/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/18/NCT02486718/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02486718,40446184,Ph3 | treatment,Hoffmann-La Roche,Industry,,?,Y,Chenqi Fu,Department of Biostatistics and Bioinformatics,Genentech,https://pubmed.ncbi.nlm.nih.gov/36882191/,High,Web-search,"Chenqi Fu is in the Department of Biostatistics and Bioinformatics, Duke University, and Genentech."
-973,JCO,2025,Oncology,Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer,https://doi.org/10.1200/jco-24-01580,https://cdn.clinicaltrials.gov/large-docs/85/NCT02777385/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/85/NCT02777385/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02777385,40424564,Ph2 | treatment,Dan Zandberg,Academic/Other,Merck Sharp & Dohme LLC,?,Y,Hong Wang,Biostatistics (per PubMed affiliation),"UPMC Hillman Cancer Center, Pittsburgh, PA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-974,JCO,2025,Oncology,Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE,https://doi.org/10.1200/jco-24-02818,https://cdn.clinicaltrials.gov/large-docs/01/NCT03673501/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/01/NCT03673501/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03673501,40408605,Ph3 | treatment,"Deciphera Pharmaceuticals, LLC",Industry,,?,Y,,,,,None,,
-975,JCO,2025,Oncology,Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial,https://doi.org/10.1200/jco-25-00131,https://cdn.clinicaltrials.gov/large-docs/58/NCT04037358/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/58/NCT04037358/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04037358,40334149,Ph2 | treatment,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Academic/Other,Congressionally Directed Medical Research Programs; Bayer,?,Y,,,,,None,,
-976,JCO,2025,Oncology,"&lt;i&gt;NOTCH1&lt;/i&gt; Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial",https://doi.org/10.1200/jco-24-01818,https://cdn.clinicaltrials.gov/large-docs/43/NCT03430843/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/43/NCT03430843/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03430843,40179324,Ph3 | treatment,BeiGene,Industry,,?,Y,Zhang Zhang,Biostatistics (per PubMed affiliation),"Statistics, BeiGene (Beijing) Co, Ltd, Beijing, China.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-977,JCO,2025,Oncology,"Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)",https://doi.org/10.1200/jco.24.00727,https://cdn.clinicaltrials.gov/large-docs/33/NCT03445533/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/33/NCT03445533/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03445533,40048691,Ph3 | treatment,"Idera Pharmaceuticals, Inc.",Industry,Bristol-Myers Squibb,?,Y,,,,,None,,
-978,JCO,2025,Oncology,"Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial",https://doi.org/10.1200/jco-24-01283,https://cdn.clinicaltrials.gov/large-docs/06/NCT03834506/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/06/NCT03834506/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03834506,40043230,Ph3 | triple | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,,,,,None,,
-979,JCO,2025,Oncology,Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer,https://doi.org/10.1200/jco-24-01829,https://cdn.clinicaltrials.gov/large-docs/07/NCT00956007/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/07/NCT00956007/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT00956007,39841939,Ph3 | treatment,Radiation Therapy Oncology Group,Network/Cooperative,National Cancer Institute (NCI); NRG Oncology,?,Y,Pedro A Torres-Saavedra ; Jonathan Harris,Biostatistics (per PubMed affiliation),"Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD. ; NRG Oncology Statistics and Data Management Center, Philadelphia, PA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-980,JCO,2025,Oncology,Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer,https://doi.org/10.1200/jco-24-02239,https://cdn.clinicaltrials.gov/large-docs/28/NCT02998528/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/28/NCT02998528/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02998528,39778121,Ph3 | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,,,,,None,,
-981,JCO,2025,Oncology,Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial,https://doi.org/10.1200/jco.24.00994,https://cdn.clinicaltrials.gov/large-docs/80/NCT01602380/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/80/NCT01602380/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT01602380,39772884,Ph3 | quadruple | treatment,AstraZeneca,Industry,,?,Y,Sandeep Singh,Statistical Science Associate Director (Biostatistics),AstraZeneca,https://www.linkedin.com/pub/dir/Sandeep/Singh/nl-0-Nederland,High,Web-search,LinkedIn profile shows Sandeep Singh as Statistical Science Associate Director (Biostatistics) at AstraZeneca.
-982,JCO,2025,Oncology,"Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With &lt;i&gt;RAS/BRAF&lt;/i&gt; Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial",https://doi.org/10.1200/jco-24-01710,https://cdn.clinicaltrials.gov/large-docs/82/NCT03365882/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/82/NCT03365882/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03365882,39761503,Ph2 | treatment,SWOG Cancer Research Network,Network/Cooperative,National Cancer Institute (NCI),?,Y,Katherine A Guthrie ; Sarah Colby,Biostatistics (per PubMed affiliation),"SWOG Statistics and Data Management Center, Seattle, WA. ; SWOG Statistics and Data Management Center, Seattle, WA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-983,JCO,2025,Oncology,Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703,https://doi.org/10.1200/jco.24.00921,https://cdn.clinicaltrials.gov/large-docs/41/NCT03959241/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/41/NCT03959241/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT03959241,39752608,Ph3 | prevention,Medical College of Wisconsin,Academic/Other,"National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI); National Marrow Donor Program",?,Y,Eric Leifer,Biostatistics (per PubMed affiliation),"Office of Biostatistics Research, National Heart, Lung, and Blood Institute, Bethesda, MD.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-984,JCO,2025,Oncology,"Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma",https://doi.org/10.1200/jco.24.01121,https://cdn.clinicaltrials.gov/large-docs/57/NCT00942357/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/57/NCT00942357/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT00942357,39700442,Ph3 | treatment,Gynecologic Oncology Group,Network/Cooperative,National Cancer Institute (NCI),?,Y,Danielle M Enserro,Biostatistics (per PubMed affiliation),"NRG Oncology Statistical and Data Center, Buffalo, NY.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-985,JCO,2025,Oncology,Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial,https://doi.org/10.1200/jco-24-02086,https://cdn.clinicaltrials.gov/large-docs/67/NCT05169567/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/67/NCT05169567/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05169567,39693591,Ph3 | double | treatment,Eli Lilly and Company,Industry,,?,Y,,,,,None,,
-986,JCO,2025,Oncology,"SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers",https://doi.org/10.1200/jco-24-01383,https://cdn.clinicaltrials.gov/large-docs/14/NCT03768414/Prot_SAP_ICF_000.pdf,https://cdn.clinicaltrials.gov/large-docs/14/NCT03768414/Prot_SAP_ICF_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03768414,39671534,Ph3 | treatment,SWOG Cancer Research Network,Network/Cooperative,National Cancer Institute (NCI),?,Y,Sarah Colby ; Katherine A Guthrie,Biostatistics (per PubMed affiliation),"SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA. ; SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-987,JCO,2025,Oncology,Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047,https://doi.org/10.1200/jco.24.01124,https://cdn.clinicaltrials.gov/large-docs/22/NCT03470922/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/22/NCT03470922/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03470922,39671533,Ph2/Ph3 | quadruple | treatment,Bristol-Myers Squibb,Industry,,?,Y,,,,,None,,
-988,JCO,2025,Oncology,Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results,https://doi.org/10.1200/jco.24.00933,https://cdn.clinicaltrials.gov/large-docs/20/NCT02282020/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/20/NCT02282020/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02282020,39668137,Ph3 | treatment,AstraZeneca,Industry,"Myriad Genetic Laboratories, Inc.; Merck Sharp & Dohme LLC",?,Y,Dave Carter,Biostatistics (per PubMed affiliation),"Biostatistics, Oncology Biometrics, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-989,JCO,2025,Oncology,Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA,https://doi.org/10.1200/jco-24-02265,https://cdn.clinicaltrials.gov/large-docs/33/NCT03336333/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/33/NCT03336333/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03336333,39647999,Ph3 | treatment,BeiGene,Industry,,?,Y,Tian Tian,Ph.D. graduate in statistics program with statistical modeling and programing skills,BeOne Medicines (formerly BeiGene),https://www.linkedin.com/in/tiantian1120,High,Web-search,Tian Tian has a PhD in statistics and works at BeOne Medicines (formerly BeiGene).
-990,JCO,2025,Oncology,Effectiveness of a Cardiovascular Health Electronic Health Record Application for Cancer Survivors in Community Oncology Practice: Results From WF-1804CD,https://doi.org/10.1200/jco.24.00342,https://cdn.clinicaltrials.gov/large-docs/82/NCT03935282/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/82/NCT03935282/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03935282,39571113,NA | supportive care,Wake Forest University Health Sciences,Academic/Other,National Cancer Institute (NCI); Washington University School of Medicine; University of Texas Southwestern Medical Center,?,Y,Emily V Dressler ; Brian J Wells,Biostatistics (per PubMed affiliation),"Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC. ; Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-991,JCO,2025,Oncology,Randomized Controlled Trial of Acceptance and Commitment Therapy for Fatigue Interference With Functioning in Metastatic Breast Cancer,https://doi.org/10.1200/jco.24.00965,https://cdn.clinicaltrials.gov/large-docs/18/NCT03998618/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/18/NCT03998618/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03998618,39454125,NA | single | supportive care,Indiana University,Academic/Other,National Cancer Institute (NCI); Eskenazi Health; Community Health Network; Indiana University Health; Northwestern University,?,Y,,,,,None,,
-992,JCO,2025,Oncology,"Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)",https://doi.org/10.1200/jco.24.00529,https://cdn.clinicaltrials.gov/large-docs/35/NCT03262935/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/35/NCT03262935/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03262935,39442070,Ph3 | treatment,Byondis B.V.,Industry,,?,Y,,,,,None,,
-993,JCO,2025,Oncology,Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial,https://doi.org/10.1200/jco.24.00337,https://cdn.clinicaltrials.gov/large-docs/04/NCT04677504/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/04/NCT04677504/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04677504,39423355,Ph2 | double | treatment,Hoffmann-La Roche,Industry,,?,Y,,,,,None,,
-994,JCO,2025,Oncology,Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274,https://doi.org/10.1200/jco.24.00340,https://cdn.clinicaltrials.gov/large-docs/09/NCT02632409/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/09/NCT02632409/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02632409,39393026,Ph3 | triple | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,Fabio Giudici,Senior Manager Biostatistics,Bristol Myers Squibb,https://ch.linkedin.com/in/fabio-giudici-81861858,High,Web-search,Fabio Giudici is explicitly listed as a Senior Manager Biostatistician at Bristol Myers Squibb.
-995,JCO,2025,Oncology,Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials,https://doi.org/10.1200/jco.24.00237,https://cdn.clinicaltrials.gov/large-docs/06/NCT02388906/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/06/NCT02388906/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT02388906, NCT00636168",39378385,Ph3 | quadruple | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,Daniel J Sharpe,statistician,Parexel,https://www.parexel.com/about-us/experts/daniel-j-sharpe,High,Web-search,Daniel J. Sharpe is explicitly described as an accomplished statistician at Parexel.
-996,JCO,2025,Oncology,Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy,https://doi.org/10.1200/jco.24.00440,https://cdn.clinicaltrials.gov/large-docs/30/NCT01658930/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/30/NCT01658930/SAP_001.pdf,SAP,noninferiority,NCT01658930,39353164,NA | treatment,Canadian Cancer Trials Group,Network/Cooperative,Gynecologic Cancer Intergroup (GCIG); Canadian Institutes of Health Research (CIHR); Korean Gynecologic Oncology Group; Dutch Gynaecological Oncology Group; Cancer Trials Ireland; (+8 more),?,Y,,,,,None,,
-997,JCO,2025,Oncology,"Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial",https://doi.org/10.1200/jco.24.00773,https://cdn.clinicaltrials.gov/large-docs/12/NCT03138512/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/12/NCT03138512/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03138512,39303200,Ph3 | quadruple | treatment,Bristol-Myers Squibb,Industry,,?,Y,Burcin Simsek,Director Biostatistics,Bristol Myers Squibb,https://www.linkedin.com/in/burcin-simsek-phd-00174679,High,Web-search,Burcin Simsek is Director of Biostatistics at Bristol Myers Squibb.
-998,JCO,2025,Oncology,Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01,https://doi.org/10.1200/jco.24.00920,https://cdn.clinicaltrials.gov/large-docs/66/NCT05104866/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/66/NCT05104866/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05104866,39265124,Ph3 | treatment,AstraZeneca,Industry,Daiichi Sankyo,?,Y,Lu Xu,"Senior Director, Biostatistics",AstraZeneca,https://www.linkedin.com/pub/dir/Lu/Xu/us-0-United-States,High,Web-search,"Lu Xu is Senior Director, Biostatistics at AstraZeneca."
-999,JCO,2025,Oncology,"Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study",https://doi.org/10.1200/jco-24-01544,https://cdn.clinicaltrials.gov/large-docs/52/NCT04656652/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/52/NCT04656652/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04656652,39250535,Ph3 | treatment,Daiichi Sankyo,Industry,AstraZeneca,?,Y,Yong Zhang,Director Biostatistics,Daiichi Sankyo,https://www.linkedin.com/in/yong-zhang-62a46320,High,Web-search,Yong Zhang's LinkedIn profile explicitly states his role as Director Biostatistics at Daiichi Sankyo.
-1000,JCO,2024,Oncology,Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment &lt;sup&gt;18&lt;/sup&gt;F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung Cancer,https://doi.org/10.1200/jco.24.00022,https://cdn.clinicaltrials.gov/large-docs/28/NCT01507428/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/28/NCT01507428/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01507428,39365957,Ph2 | treatment,National Cancer Institute (NCI),NIH,NRG Oncology,?,Y,Chen Hu ; Fenghai Duan,Biostatistics (per PubMed affiliation),"NRG Oncology Statistics and Data Management Center, Philadelphia, PA. ; US and ECOG-ACRIN Biostatistics Center, Brown University, Providence, RI.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1001,JCO,2024,Oncology,"Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005",https://doi.org/10.1200/jco.24.00683,https://cdn.clinicaltrials.gov/large-docs/66/NCT02502266/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/66/NCT02502266/Prot_SAP_000.pdf,Protocol+SAP,seamless_2_3,NCT02502266,39361946,Ph2/Ph3 | treatment,National Cancer Institute (NCI),NIH,Canadian Cancer Trials Group; NRG Oncology,?,Y,Mark F Brady ; Austin Miller,Biostatistics (per PubMed affiliation),"NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Elm & Carlton Streets, Buffalo, NY. ; NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Elm & Carlton Streets, Buffalo, NY.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1002,JCO,2024,Oncology,Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial,https://doi.org/10.1200/jco-24-01798,https://cdn.clinicaltrials.gov/large-docs/99/NCT04736199/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/99/NCT04736199/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04736199,39279580,Ph3 | quadruple | treatment,Bayer,Industry,"Orion Corporation, Orion Pharma",?,Y,,,,,None,,
-1003,JCO,2024,Oncology,"Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma",https://doi.org/10.1200/jco.24.00767,https://cdn.clinicaltrials.gov/large-docs/57/NCT02761057/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/57/NCT02761057/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02761057,39255440,Ph2 | treatment,National Cancer Institute (NCI),NIH,Canadian Cancer Trials Group,?,Y,Catherine Tangen ; Melissa Plets,Biostatistics (per PubMed affiliation),"SWOG Statistics and Data Management Center, Seattle, WA. ; SWOG Statistics and Data Management Center, Seattle, WA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1004,JCO,2024,Oncology,"Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i>-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer",https://doi.org/10.1200/jco.23.02747,https://cdn.clinicaltrials.gov/large-docs/37/NCT03515837/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/37/NCT03515837/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03515837,39173098,Ph3 | quadruple | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Yiwen Luo,Principal Scientist - Biostatistics,Merck,https://rocketreach.co/yiwen-luo-email_37232226,High,Web-search,Yiwen Luo is listed as Principal Scientist - Biostatistics at Merck.
-1005,JCO,2024,Oncology,"US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With <i>PIK3CA</i>/<i>AKT1</i>/<i>PTEN</i> Alterations",https://doi.org/10.1200/jco.24.00427,https://cdn.clinicaltrials.gov/large-docs/96/NCT04305496/Prot_003.pdf,https://cdn.clinicaltrials.gov/large-docs/96/NCT04305496/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04305496,39159418,Ph3 | quadruple | treatment,AstraZeneca,Industry,,?,Y,,,,,None,,
-1006,JCO,2024,Oncology,Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238,https://doi.org/10.1200/jco.23.01448,https://cdn.clinicaltrials.gov/large-docs/06/NCT02388906/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/06/NCT02388906/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02388906,39102624,Ph3 | quadruple | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,Margarita Askelson,"Associate Director, Biostatistician",Bristol Myers Squibb,https://www.linkedin.com/pub/dir/Margarita/Askelson?trk=prof-samename-searchmore,High,Web-search,"Margarita Askelson is listed as Associate Director, Biostatistician at Bristol-Myers Squibb on LinkedIn."
-1007,JCO,2024,Oncology,"Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study",https://doi.org/10.1200/jco.23.02659,https://cdn.clinicaltrials.gov/large-docs/23/NCT03504423/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/23/NCT03504423/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03504423,39088774,Ph3 | treatment,Cornerstone Pharmaceuticals,Industry,,?,Y,,,,,None,,
-1008,JCO,2024,Oncology,Randomized Controlled Trial of a Nurse-Led Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer,https://doi.org/10.1200/jco.24.00048,https://cdn.clinicaltrials.gov/large-docs/25/NCT03089125/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/25/NCT03089125/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03089125,39088766,NA | single | supportive care,Massachusetts General Hospital,Academic/Other,National Institute of Nursing Research (NINR); Dana-Farber Cancer Institute,?,Y,,,,,None,,
-1009,JCO,2024,Oncology,Longitudinal Health-Related Quality of Life Among Patients With High-Risk Pediatric Hodgkin Lymphoma Treated on the Children's Oncology Group AHOD 1331 Study,https://doi.org/10.1200/jco.24.00038,https://cdn.clinicaltrials.gov/large-docs/63/NCT02166463/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/63/NCT02166463/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02166463,39058966,Ph3 | single | treatment,National Cancer Institute (NCI),NIH,,?,Y,Qinglin Pei,Biostatistics (per PubMed affiliation),"Department of Biostatistics, University of Florida, Gainesville, FL.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1010,JCO,2024,Oncology,"Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY",https://doi.org/10.1200/jco.23.02167,https://cdn.clinicaltrials.gov/large-docs/48/NCT01515748/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/48/NCT01515748/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT01515748,38996201,Ph3 | treatment,Sanofi,Industry,,?,Y,,,,,None,,
-1011,JCO,2024,Oncology,Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT,https://doi.org/10.1200/jco.23.02170,https://cdn.clinicaltrials.gov/large-docs/48/NCT01853748/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/48/NCT01853748/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01853748,38935923,Ph2 | treatment,Dana-Farber Cancer Institute,Academic/Other,,?,Y,,,,,None,,
-1012,JCO,2024,Oncology,"Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5",https://doi.org/10.1200/jco.23.02036,https://cdn.clinicaltrials.gov/large-docs/66/NCT04478266/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/66/NCT04478266/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04478266,38889373,Ph3 | quadruple | treatment,Sanofi,Industry,,?,Y,,,,,None,,
-1013,JCO,2024,Oncology,"Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study",https://doi.org/10.1200/jco.24.01001,https://cdn.clinicaltrials.gov/large-docs/69/NCT05388669/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/69/NCT05388669/SAP_001.pdf,SAP,noninferiority,NCT05388669,38857463,Ph3 | treatment,"Janssen Research & Development, LLC",Industry,,?,Y,Debopriya Ghosh,Senior Biostatistician,Janssen Research and Development LLC,https://pubmed.ncbi.nlm.nih.gov/38254814/,High,Web-search,"Debopriya Ghosh is explicitly listed as working in ""Early Development and Oncology, Biostatistics"" at Janssen."
-1014,JCO,2024,Oncology,"Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study",https://doi.org/10.1200/jco.24.00733,https://cdn.clinicaltrials.gov/large-docs/34/NCT05089734/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/34/NCT05089734/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT05089734,38843511,Ph3 | treatment,Gilead Sciences,Industry,,?,Y,,,,,None,,
-1015,JCO,2024,Oncology,Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09),https://doi.org/10.1200/jco.23.02082,https://cdn.clinicaltrials.gov/large-docs/45/NCT03729245/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/45/NCT03729245/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03729245,38838287,Ph3 | treatment,Nektar Therapeutics,Industry,Bristol-Myers Squibb,?,Y,,,,,None,,
-1016,JCO,2024,Oncology,"Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study",https://doi.org/10.1200/jco.23.02736,https://cdn.clinicaltrials.gov/large-docs/48/NCT04776148/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/48/NCT04776148/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT04776148,38833658,Ph3 | treatment,Merck Sharp & Dohme LLC,Industry,Eisai Inc.,?,Y,,,,,None,,
-1017,JCO,2024,Oncology,"Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer",https://doi.org/10.1200/jco.23.02344,https://cdn.clinicaltrials.gov/large-docs/40/NCT01674140/Prot_SAP_ICF_000.pdf,https://cdn.clinicaltrials.gov/large-docs/40/NCT01674140/Prot_SAP_ICF_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01674140,38833643,Ph3 | double | treatment,SWOG Cancer Research Network,Network/Cooperative,National Cancer Institute (NCI),?,Y,Jieling Miao ; Danika L Lew,Biostatistics (per PubMed affiliation),"SWOG Statistical Center, Seattle, WA. ; SWOG Statistical Center, Seattle, WA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1018,JCO,2024,Oncology,CNS Protective Effect of Selpercatinib in First-Line <i>RET</i> Fusion-Positive Advanced Non-Small Cell Lung Cancer,https://doi.org/10.1200/jco.24.00724,https://cdn.clinicaltrials.gov/large-docs/44/NCT04194944/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/44/NCT04194944/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04194944,38828957,Ph3 | treatment,Eli Lilly and Company,Industry,"Loxo Oncology, Inc.",?,Y,,,,,None,,
-1019,JCO,2024,Oncology,Lorlatinib Versus Crizotinib in Patients With Advanced &lt;i&gt;ALK&lt;/i&gt;-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study,https://doi.org/10.1200/jco.24.00581,https://cdn.clinicaltrials.gov/large-docs/08/NCT03052608/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/08/NCT03052608/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT03052608,38819031,Ph3 | treatment,Pfizer,Industry,,?,Y,,,,,None,,
-1020,JCO,2024,Oncology,Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma,https://doi.org/10.1200/jco.23.01462,https://cdn.clinicaltrials.gov/large-docs/51/NCT03298451/Prot_016.pdf,https://cdn.clinicaltrials.gov/large-docs/51/NCT03298451/SAP_018.pdf,SAP,fixed_parallel_superiority,NCT03298451,38805668,Ph3 | treatment,AstraZeneca,Industry,,?,Y,Charu Gupta,Director- Statistical Science,AstraZeneca,https://www.linkedin.com/in/charu-gupta-587b8314,High,Web-search,LinkedIn profile shows title Director- Statistical Science at AstraZeneca.
-1021,JCO,2024,Oncology,Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study,https://doi.org/10.1200/jco.23.02076,https://cdn.clinicaltrials.gov/large-docs/86/NCT02713386/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/86/NCT02713386/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02713386,38776484,Ph1/Ph2 | treatment,NRG Oncology,Academic/Other,National Cancer Institute (NCI),?,Y,Michael W Sill,Biostatistics (per PubMed affiliation),"Clinical Trials Development Division, NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1022,JCO,2024,Oncology,Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer,https://doi.org/10.1200/jco.24.00144,https://cdn.clinicaltrials.gov/large-docs/23/NCT03839823/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/23/NCT03839823/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03839823,38771995,Ph2 | treatment,Novartis Pharmaceuticals,Industry,,?,Y,,,,,None,,
-1023,JCO,2024,Oncology,First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study,https://doi.org/10.1200/jco.23.01636,https://cdn.clinicaltrials.gov/large-docs/59/NCT03662659/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/59/NCT03662659/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03662659,38723227,Ph2 | treatment,Bristol-Myers Squibb,Industry,,?,Y,,,,,None,,
-1024,JCO,2024,Oncology,"Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116)",https://doi.org/10.1200/jco.23.01100,https://cdn.clinicaltrials.gov/large-docs/73/NCT02822573/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/73/NCT02822573/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02822573,38709986,Ph3 | quadruple | treatment,Wake Forest University Health Sciences,Academic/Other,National Cancer Institute (NCI),?,Y,Emily V Dressler ; W Mark Brown,Biostatistics (per PubMed affiliation),"Department of Biostatistics and Data Sciences, Wake Forest University School of Medicine, Winston-Salem, NC. ; Department of Biostatistics and Data Sciences, Wake Forest University School of Medicine, Winston-Salem, NC.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1025,JCO,2024,Oncology,Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis,https://doi.org/10.1200/jco.23.02394,https://cdn.clinicaltrials.gov/large-docs/42/NCT00116142/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/42/NCT00116142/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT00116142,38691823,Ph3 | treatment,Dana-Farber Cancer Institute,Academic/Other,Sanofi,?,Y,Ming-Hui Chen,Biostatistics (per PubMed affiliation),"Department of Statistics, University of Connecticut, Storrs, CT.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1026,JCO,2024,Oncology,"RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer",https://doi.org/10.1200/jco.23.02110,https://cdn.clinicaltrials.gov/large-docs/13/NCT03088813/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/13/NCT03088813/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03088813,38648575,Ph3 | treatment,Ipsen,Industry,,?,Y,,,,,None,,
-1027,JCO,2024,Oncology,CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy,https://doi.org/10.1200/jco.23.02166,https://cdn.clinicaltrials.gov/large-docs/28/NCT04471428/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/28/NCT04471428/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04471428,38552197,Ph3 | treatment,Hoffmann-La Roche,Industry,Exelixis,?,Y,Alessandra Bearz,Department of Epidemiology and Biostatistics,Centro di Riferimento Oncologico of Aviano,https://pubmed.ncbi.nlm.nih.gov/23154558/,Medium,Web-search,Alessandra Bearz is affiliated with the Department of Epidemiology and Biostatistics at CRO Aviano.
-1028,JCO,2024,Oncology,Randomized Controlled Trial of Virtually Delivered Cognitive Behavioral Therapy for Insomnia to Address Perceived Cancer-Related Cognitive Impairment in Cancer Survivors,https://doi.org/10.1200/jco.23.02330,https://cdn.clinicaltrials.gov/large-docs/48/NCT04026048/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/48/NCT04026048/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04026048,38552188,NA | treatment,Memorial University of Newfoundland,Academic/Other,Canadian Institutes of Health Research (CIHR),?,Y,,,,,None,,
-1029,JCO,2024,Oncology,"Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study",https://doi.org/10.1200/jco.23.01500,https://cdn.clinicaltrials.gov/large-docs/55/NCT04576455/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/55/NCT04576455/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04576455,38537155,Ph2 | treatment,Hoffmann-La Roche,Industry,,?,Y,,,,,None,,
-1030,JCO,2024,Oncology,"Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810",https://doi.org/10.1200/jco.23.01544,https://cdn.clinicaltrials.gov/large-docs/48/NCT01575548/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/48/NCT01575548/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01575548,38531002,Ph3 | double | treatment,National Cancer Institute (NCI),NIH,,?,Y,,,,,None,,
-1031,JCO,2024,Oncology,"PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer",https://doi.org/10.1200/jco.23.01940,https://cdn.clinicaltrials.gov/large-docs/87/NCT03147287/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/87/NCT03147287/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03147287,38513188,Ph2 | treatment,Dana-Farber Cancer Institute,Academic/Other,Pfizer,?,Y,Eric Gauthier,Oncology Clinical Statistics,Pfizer,https://pubmed.ncbi.nlm.nih.gov/42017805/,High,Web-search,"Eric Gauthier is listed with affiliation 'Oncology Clinical Statistics, Pfizer Inc' in a related publication."
-1032,JCO,2024,Oncology,Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>,https://doi.org/10.1200/jco.23.02474,https://cdn.clinicaltrials.gov/large-docs/02/NCT02997202/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/02/NCT02997202/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02997202,38471061,Ph3 | quadruple | treatment,"Astellas Pharma Global Development, Inc.",Industry,"National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network",?,Y,,,,,None,,
-1033,JCO,2024,Oncology,US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer,https://doi.org/10.1200/jco.23.02182,https://cdn.clinicaltrials.gov/large-docs/20/NCT03732820/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/20/NCT03732820/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT03732820, NCT03395197",38452327,Ph3 | quadruple | treatment,AstraZeneca,Industry,Merck Sharp & Dohme LLC,?,Y,Erik Bloomquist,"Senior Principal Scientist, late-development statistics",Merck,https://www.linkedin.com/in/erikbloomquist-stat,High,Web-search,Erik Bloomquist is a Senior Principal Scientist in late-development statistics at Merck.
-1034,JCO,2024,Oncology,Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study,https://doi.org/10.1200/jco.23.02355,https://cdn.clinicaltrials.gov/large-docs/36/NCT03553836/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/36/NCT03553836/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03553836,38452313,Ph3 | double | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,,,,,None,,
-1035,JCO,2024,Oncology,Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression,https://doi.org/10.1200/jco.23.01409,https://cdn.clinicaltrials.gov/large-docs/55/NCT02574455/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/55/NCT02574455/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT02574455,38422473,Ph3 | treatment,Gilead Sciences,Industry,,?,Y,,,,,None,,
-1036,JCO,2024,Oncology,"First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial",https://doi.org/10.1200/jco.23.01601,https://cdn.clinicaltrials.gov/large-docs/16/NCT02872116/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/16/NCT02872116/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02872116,38382001,Ph3 | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,Ming Lei,,Bristol Myers Squibb,https://pubmed.ncbi.nlm.nih.gov/38821718/,Medium,Web-search,Affiliation listed as Global Biostatistics and Data Science at Bristol Myers Squibb in other publications.
-1037,JCO,2024,Oncology,"US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, <i>ESR1</i>-Mutated Advanced or Metastatic Breast Cancer",https://doi.org/10.1200/jco.23.02112,https://cdn.clinicaltrials.gov/large-docs/31/NCT03778931/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/31/NCT03778931/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03778931,38381994,Ph3 | treatment,"Stemline Therapeutics, Inc.",Industry,,?,Y,,,,,None,,
-1038,JCO,2024,Oncology,"Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g<i>BRCA1/2</i> Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer",https://doi.org/10.1200/jco.23.01214,https://cdn.clinicaltrials.gov/large-docs/23/NCT02032823/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/23/NCT02032823/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02032823,38301187,Ph3 | triple | treatment,AstraZeneca,Industry,"Breast International Group; Frontier Science & Technology Research Foundation, Inc.; NRG Oncology; Myriad Genetic Laboratories, Inc.; The Breast Adjuvant Study Team; (+1 more)",?,Y,Hanna Bandos,Senior Biostatistician and the Lead for the Statistics Division,"NRG Oncology SDMC, University of Pittsburgh",https://www.publichealth.pitt.edu/directory/hanna-bandos,High,Web-search,Hanna Bandos is explicitly listed as a Senior Biostatistician and Lead for the Statistics Division at NRG Oncology SDMC.
-1039,JCO,2024,Oncology,Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722,https://doi.org/10.1200/jco.23.01017,https://cdn.clinicaltrials.gov/large-docs/51/NCT02864251/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/51/NCT02864251/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02864251,38252907,Ph3 | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,,,,,None,,
-1040,JCO,2024,Oncology,Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer,https://doi.org/10.1200/jco.23.00137,https://cdn.clinicaltrials.gov/large-docs/27/NCT01740427/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/27/NCT01740427/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT01740427,38252901,Ph3 | quadruple | treatment,Pfizer,Industry,,?,Y,,,,,None,,
-1041,JCO,2024,Oncology,"Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study",https://doi.org/10.1200/jco.23.00795,https://cdn.clinicaltrials.gov/large-docs/67/NCT03943667/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/67/NCT03943667/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03943667,38232341,Ph3 | treatment,UNICANCER,Academic/Other,,?,Y,,,,,None,,
-1042,JCO,2024,Oncology,"Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study",https://doi.org/10.1200/jco.23.01569,https://cdn.clinicaltrials.gov/large-docs/61/NCT02811861/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/61/NCT02811861/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02811861,38227898,Ph3 | treatment,Eisai Inc.,Industry,Merck Sharp & Dohme LLC,?,Y,,,,,None,,
-1043,JCO,2024,Oncology,FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With <i>BRCA</i>-Mutated Metastatic Castration-Resistant Prostate Cancer,https://doi.org/10.1200/jco.23.01868,https://cdn.clinicaltrials.gov/large-docs/20/NCT03732820/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/20/NCT03732820/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03732820,38127780,Ph3 | quadruple | treatment,AstraZeneca,Industry,Merck Sharp & Dohme LLC,?,Y,,,,,None,,
-1044,JCO,2024,Oncology,Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study,https://doi.org/10.1200/jco.23.00838,https://cdn.clinicaltrials.gov/large-docs/68/NCT01332968/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/68/NCT01332968/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT01332968,38096461,Ph3 | treatment,Hoffmann-La Roche,Industry,"German Low Grade Lymphoma Study Group; Institute of Cancer Research, United Kingdom",?,Y,Vindi Jurinovic,Biostatistics (per PubMed affiliation),"Department of Internal Medicine III, University Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1045,JCO,2024,Oncology,CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer,https://doi.org/10.1200/jco.23.02219,https://cdn.clinicaltrials.gov/large-docs/86/NCT04035486/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/86/NCT04035486/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT04035486,38042525,Ph3 | treatment,AstraZeneca,Industry,,?,Y,Xiangning Huang,Biostatistics (per PubMed affiliation),"Department of Oncology Biometrics, AstraZeneca, Cambridge, United Kingdom.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1046,JCO,2024,Oncology,Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial,https://doi.org/10.1200/jco.23.00980,https://cdn.clinicaltrials.gov/large-docs/99/NCT03631199/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/99/NCT03631199/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03631199,38039427,Ph3 | quadruple | treatment,Novartis Pharmaceuticals,Industry,,?,Y,,,,,None,,
-1047,JCO,2024,Oncology,SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer,https://doi.org/10.1200/jco.23.01363,https://cdn.clinicaltrials.gov/large-docs/21/NCT04256421/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/21/NCT04256421/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04256421,37976444,Ph3 | triple | treatment,Hoffmann-La Roche,Industry,,?,Y,,,,,None,,
-1048,JCO,2024,Oncology,Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial,https://doi.org/10.1200/jco.22.02644,https://cdn.clinicaltrials.gov/large-docs/86/NCT02231086/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/86/NCT02231086/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02231086,37922442,Ph3 | prevention,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Academic/Other,ZonMw: The Netherlands Organisation for Health Research and Development; Dutch Health Care Insurance Board,?,Y,,,,,None,,
-1049,JCO,2024,Oncology,Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial,https://doi.org/10.1200/jco.23.02132,https://cdn.clinicaltrials.gov/large-docs/00/NCT04269200/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/00/NCT04269200/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04269200,37864337,Ph3 | quadruple | treatment,AstraZeneca,Industry,GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT),?,Y,Conor Donnelly,Biostatistics (per PubMed affiliation),"Oncology Biometrics, AstraZeneca, Cambridge, United Kingdom.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1050,JCO,2024,Oncology,"Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial",https://doi.org/10.1200/jco.23.00910,https://cdn.clinicaltrials.gov/large-docs/69/NCT03447769/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/69/NCT03447769/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03447769,37788412,Ph3 | quadruple | treatment,Novartis Pharmaceuticals,Industry,,?,Y,Sadhvi Khanna,Associate Director Biostatistics,Novartis,https://fr.linkedin.com/in/sadhvi-khanna-73236926,High,Web-search,Sadhvi Khanna is an Associate Director Biostatistics at Novartis.
-1051,JCO,2024,Oncology,"Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases: A Multicenter, Randomized Phase II Clinical Trial",https://doi.org/10.1200/jco.23.00753,https://cdn.clinicaltrials.gov/large-docs/51/NCT03523351/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/51/NCT03523351/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03523351,37748124,Ph1/Ph2 | supportive care,Memorial Sloan Kettering Cancer Center,Academic/Other,,?,Y,Charlie White ; Zhigang Zhang,Biostatistics (per PubMed affiliation),"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. ; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1052,JCO,2024,Oncology,Effect of a Community Health Worker-Led Intervention Among Low-Income and Minoritized Patients With Cancer: A Randomized Clinical Trial,https://doi.org/10.1200/jco.23.00309,https://cdn.clinicaltrials.gov/large-docs/48/NCT03699748/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/48/NCT03699748/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03699748,37625110,NA | triple | health services research,Stanford University,Academic/Other,National Institutes of Health (NIH); National Institute on Minority Health and Health Disparities (NIMHD),?,Y,,,,,None,,
-1053,JCO,2023,Oncology,Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO),https://doi.org/10.1200/jco.23.00985,https://cdn.clinicaltrials.gov/large-docs/19/NCT03449719/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/19/NCT03449719/Prot_000.pdf,Protocol only,fixed_parallel_superiority,NCT03449719,37733977,NA | treatment,Lorenzo Livi,Academic/Other,,?,Y,,,,,None,,
-1054,JCO,2023,Oncology,Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization,https://doi.org/10.1200/jco.23.00493,https://cdn.clinicaltrials.gov/large-docs/80/NCT02977780/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/80/NCT02977780/Prot_SAP_000.pdf,Protocol+SAP,platform,NCT02977780,37722087,Ph2 | treatment,"Patrick Wen, MD",Academic/Other,"Eli Lilly and Company; Celgene; Puma Biotechnology, Inc.; Accelerate Brain Cancer Cure; Quadriga Biosciences, Inc.",?,Y,,,,,None,,
-1055,JCO,2023,Oncology,Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649,https://doi.org/10.1200/jco.23.00170,https://cdn.clinicaltrials.gov/large-docs/16/NCT02872116/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/16/NCT02872116/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02872116,37713657,Ph3 | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,,,,,None,,
-1056,JCO,2023,Oncology,Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer,https://doi.org/10.1200/jco.23.00296,https://cdn.clinicaltrials.gov/large-docs/38/NCT01101438/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/38/NCT01101438/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT01101438,37695982,Ph3 | triple | treatment,Canadian Cancer Trials Group,Network/Cooperative,"National Cancer Institute (NCI); ETOP IBCSG Partners Foundation; Institute of Cancer Research, United Kingdom",?,Y,Marguerite Ennis,Biostatistics (per PubMed affiliation),"Applied Statistician, Markham, ON, Canada.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1057,JCO,2023,Oncology,"Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial",https://doi.org/10.1200/jco.23.01361,https://cdn.clinicaltrials.gov/large-docs/37/NCT04644237/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/37/NCT04644237/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT04644237,37694347,Ph2 | double | treatment,Daiichi Sankyo,Industry,AstraZeneca,?,Y,Fu-Chih Cheng,"Director, Biostatistics",Daiichi Sankyo,https://www.linkedin.com/in/fu-chih-cheng-009885b,High,Web-search,"Fu-Chih Cheng is listed as Director, Biostatistics at Daiichi Sankyo on LinkedIn."
-1058,JCO,2023,Oncology,"Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results",https://doi.org/10.1200/jco.23.00172,https://cdn.clinicaltrials.gov/large-docs/83/NCT03635983/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/83/NCT03635983/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03635983,37651676,Ph3 | treatment,Bristol-Myers Squibb,Industry,Nektar Therapeutics,?,Y,,,,,None,,
-1059,JCO,2023,Oncology,Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer,https://doi.org/10.1200/jco.22.02630,https://cdn.clinicaltrials.gov/large-docs/16/NCT02395016/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/16/NCT02395016/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02395016,37647576,Ph3 | quadruple | treatment,"Biotech Pharmaceutical Co., Ltd.",Academic/Other,NanJing PLA 81 Hospital; Fudan University,?,Y,,,,,None,,
-1060,JCO,2023,Oncology,Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial,https://doi.org/10.1200/jco.23.00126,https://cdn.clinicaltrials.gov/large-docs/94/NCT02513394/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/94/NCT02513394/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02513394,37556775,Ph3 | treatment,"Alliance Foundation Trials, LLC.",Academic/Other,"Austrian Breast & Colorectal Cancer Study Group; NSABP Foundation Inc; PrECOG, LLC.; Breast International Group; Pfizer",?,Y,Amylou C Dueck,Biostatistics (per PubMed affiliation),"Alliance Statistics and Data Center, Mayo Clinic, Phoenix, AZ.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1061,JCO,2023,Oncology,Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology,https://doi.org/10.1200/jco.23.00045,https://cdn.clinicaltrials.gov/large-docs/67/NCT02180867/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/67/NCT02180867/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02180867,37523624,Ph2/Ph3 | treatment,National Cancer Institute (NCI),NIH,,?,Y,,,,,None,,
-1062,JCO,2023,Oncology,ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma,https://doi.org/10.1200/jco.23.00775,https://cdn.clinicaltrials.gov/large-docs/17/NCT03332017/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/17/NCT03332017/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03332017,37506346,Ph2 | treatment,BeiGene,Industry,,?,Y,Pil Kim,Director,BeiGene,https://www.signalhire.com/profiles/kyungpil-kim%27s-email/8299528,Medium,Web-search,Pil Kim was previously a Senior Biostatistician at Gilead Sciences and is now a Director at BeiGene.
-1063,JCO,2023,Other,Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study,https://doi.org/10.1200/jco.22.02830,https://cdn.clinicaltrials.gov/large-docs/40/NCT03053440/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/40/NCT03053440/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03053440,37478390,Ph3 | treatment,BeiGene,Industry,,?,Y,Jingjing Schneider,Director of Biostatistics,BeiGene,https://stat.osu.edu/stat-50/detailed-program,High,Web-search,Jingjing Schneider is listed as Director of Biostatistics at BeiGene.
-1064,JCO,2023,Oncology,Cluster Randomized Pragmatic Clinical Trial Testing Behavioral Economic Implementation Strategies to Improve Tobacco Treatment for Patients With Cancer Who Smoke,https://doi.org/10.1200/jco.23.00355,https://cdn.clinicaltrials.gov/large-docs/31/NCT04737031/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/31/NCT04737031/Prot_SAP_000.pdf,Protocol+SAP,cluster,NCT04737031,37467454,NA | prevention,Abramson Cancer Center at Penn Medicine,Academic/Other,National Cancer Institute (NCI); University of Pennsylvania,?,Y,Katharine A Rendle ; E Paul Wileyto,Biostatistics (per PubMed affiliation),"Department of Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. ; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1065,JCO,2023,Oncology,Lazertinib Versus Gefitinib as First-Line Treatment in Patients With <i>EGFR</i>-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301,https://doi.org/10.1200/jco.23.00515,https://cdn.clinicaltrials.gov/large-docs/29/NCT04248829/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/29/NCT04248829/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04248829,37379502,Ph3 | quadruple | treatment,Yuhan Corporation,Industry,,?,Y,,,,,None,,
-1066,JCO,2023,Oncology,"Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study",https://doi.org/10.1200/jco.22.02624,https://cdn.clinicaltrials.gov/large-docs/12/NCT03776812/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/12/NCT03776812/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT03776812, NCT05257408, NCT03776812",37364223,Ph2 | treatment,Corcept Therapeutics,Industry,,?,Y,,,,,None,,
-1067,JCO,2023,Oncology,"AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer",https://doi.org/10.1200/jco.22.02746,https://cdn.clinicaltrials.gov/large-docs/84/NCT04059484/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/84/NCT04059484/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT04059484,37348019,Ph2 | single | treatment,Sanofi,Industry,,?,Y,Qianying Liu,"Associate Director, Statistical Project Leader",Sanofi,https://www.zoominfo.com/p/Qianying-Liu/-2040054377,High,Web-search,"Qianying Liu is listed as Associate Director, Statistical Project Leader and Senior Biostatistician at Sanofi."
-1068,JCO,2023,Oncology,Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial,https://doi.org/10.1200/jco.22.01856,https://cdn.clinicaltrials.gov/large-docs/82/NCT00063882/Prot_SAP_ICF_000.pdf,https://cdn.clinicaltrials.gov/large-docs/82/NCT00063882/Prot_SAP_ICF_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT00063882,37315297,Ph3 | treatment,Radiation Therapy Oncology Group,Network/Cooperative,National Cancer Institute (NCI); NRG Oncology,?,Y,Kathryn A Winter ; Jennifer Moughan,Biostatistics (per PubMed affiliation),"NRG Oncology Statistics and Data Management Center/ACR, Philadelphia, PA. ; NRG Oncology Statistics and Data Management Center/ACR, Philadelphia, PA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1069,JCO,2023,Oncology,"Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial",https://doi.org/10.1200/jco.23.00233,https://cdn.clinicaltrials.gov/large-docs/19/NCT03834519/Prot_SAP_002.pdf,https://cdn.clinicaltrials.gov/large-docs/19/NCT03834519/Prot_SAP_002.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03834519,37290035,Ph3 | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Jinchun Zhang,"Associate Principle Scientist, Biostatistics",Merck,https://www.linkedin.com/in/jinchun-zhang-biostat,High,Web-search,"Jinchun Zhang is an Associate Principle Scientist, Biostatistics at Merck."
-1070,JCO,2023,Oncology,Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048),https://doi.org/10.1200/jco.23.00903,https://cdn.clinicaltrials.gov/large-docs/87/NCT01515787/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/87/NCT01515787/Prot_SAP_000.pdf,Protocol+SAP,noninferiority,NCT01515787,37270691,Ph2/Ph3 | treatment,Alliance for Clinical Trials in Oncology,Academic/Other,National Cancer Institute (NCI); Canadian Cancer Trials Group,?,Y,Amylou C Dueck ; Brenda Ginos,Biostatistics (per PubMed affiliation),"Alliance Statistics and Data Management Center, Mayo Clinic, Scottsdale, AZ. ; Alliance Statistics and Data Management Center, Mayo Clinic, Scottsdale, AZ.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1071,JCO,2023,Oncology,"Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse",https://doi.org/10.1200/jco.22.02200,https://cdn.clinicaltrials.gov/large-docs/53/NCT02101853/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/53/NCT02101853/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02101853,37257143,Ph3 | treatment,National Cancer Institute (NCI),NIH,,?,Y,,,,,None,,
-1072,JCO,2023,Oncology,Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML,https://doi.org/10.1200/jco.22.02366,https://cdn.clinicaltrials.gov/large-docs/93/NCT03678493/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/93/NCT03678493/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03678493,37235836,Ph2 | treatment,"Masonic Cancer Center, University of Minnesota",Academic/Other,,?,Y,Qing Cao ; Xianghua Luo,Biostatistics (per PubMed affiliation),"Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN. ; Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1073,JCO,2023,Oncology,Phase II Randomized Trial of Lenalidomide in Children With Pilocytic Astrocytomas and Optic Pathway Gliomas: A Report From the Children's Oncology Group,https://doi.org/10.1200/jco.22.01777,https://cdn.clinicaltrials.gov/large-docs/49/NCT01553149/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/49/NCT01553149/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01553149,37126770,Ph2 | treatment,National Cancer Institute (NCI),NIH,,?,Y,Allen Buxton,Biostatistics (per PubMed affiliation),"Statistics and Data Center, Children's Oncology Group, Monrovia, CA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1074,JCO,2023,Oncology,Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up,https://doi.org/10.1200/jco.22.01792,https://cdn.clinicaltrials.gov/large-docs/32/NCT02603432/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/32/NCT02603432/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02603432,37071838,Ph3 | treatment,Pfizer,Industry,,?,Y,,,,,None,,
-1075,JCO,2023,Oncology,Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775,https://doi.org/10.1200/jco.22.02152,https://cdn.clinicaltrials.gov/large-docs/49/NCT03517449/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/49/NCT03517449/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03517449,37058687,Ph3 | treatment,Eisai Inc.,Industry,Merck Sharp & Dohme LLC,?,Y,Steven Bird,"Senior Principal Scientist, Biostatistics",Merck,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209803,209805,209806Orig1s000AdminCorres.pdf",High,Web-search,"Steven Bird is listed as Senior Principal Scientist, Biostatistics at Merck in an FDA document."
-1076,JCO,2023,Oncology,Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial),https://doi.org/10.1200/jco.22.02394,https://cdn.clinicaltrials.gov/large-docs/37/NCT01949337/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/37/NCT01949337/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01949337,36996380,Ph3 | treatment,Alliance for Clinical Trials in Oncology,Academic/Other,"National Cancer Institute (NCI); Astellas Pharma US, Inc.; Medivation, Inc.; Biologics, Inc.",?,Y,Glenn Heller ; David W Hillman,Biostatistics (per PubMed affiliation),"Alliance Statistics and Data Management Center, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. ; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1077,JCO,2023,Oncology,"Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer",https://doi.org/10.1200/jco.22.01994,https://cdn.clinicaltrials.gov/large-docs/36/NCT03422536/Prot_SAP_003.pdf,https://cdn.clinicaltrials.gov/large-docs/36/NCT03422536/Prot_SAP_003.pdf,Protocol+SAP,adaptive_bayesian,NCT03422536,36977289,Ph2 | treatment,University of Arizona,Academic/Other,National Cancer Institute (NCI),?,Y,Denise Roe ; Kathylynn Saboda,Biostatistics (per PubMed affiliation),"Department of Epidemiology and Biostatistics, UA Mel and Enid Zuckerman College of Public Health, Tucson, AZ. ; Biostatistics and Bioinformatics Shared Resource, UA Comprehensive Cancer Center, Tucson, AZ.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1078,JCO,2023,Oncology,Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer,https://doi.org/10.1200/jco.22.01649,https://cdn.clinicaltrials.gov/large-docs/41/NCT03748641/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/41/NCT03748641/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03748641,36952634,Ph3 | quadruple | treatment,"Janssen Research & Development, LLC",Industry,,?,Y,Gary E Mason,Department of Biostatistics and Health Data Science,Janssen,https://ash.confex.com/ash/2024/webprogram/Session27717.html,High,Web-search,Gary E Mason is affiliated with the Department of Biostatistics and Health Data Science.
-1079,JCO,2023,Oncology,Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study,https://doi.org/10.1200/jco.22.01989,https://cdn.clinicaltrials.gov/large-docs/80/NCT02578680/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/80/NCT02578680/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02578680,36809080,Ph3 | quadruple | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Erin Jensen,Senior Principal Scientist,"Merck & Co., Inc",https://www.researchgate.net/profile/Erin-Jensen-2,High,Web-search,Erin Jensen is identified as a Senior Principal Scientist in Biostatistics at Merck & Co.
-1080,JCO,2023,Oncology,Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial,https://doi.org/10.1200/jco.23.00041,https://cdn.clinicaltrials.gov/large-docs/02/NCT02799602/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/02/NCT02799602/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT02799602,36795843,Ph3 | quadruple | treatment,Bayer,Industry,"Orion Corporation, Orion Pharma",?,Y,Shankar Srinivasan,Biostatistics,Bayer HealthCare,https://pubmed.ncbi.nlm.nih.gov/40165634/,Medium,Web-search,"Shankar Srinivasan is listed with affiliation 'Biostatistics, Bayer HealthCare' in a publication."
-1081,JCO,2023,Oncology,Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow,https://doi.org/10.1200/jco.22.00751,https://cdn.clinicaltrials.gov/large-docs/13/NCT03326713/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/13/NCT03326713/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT03326713,36787512,NA | single | prevention,"Rutgers, The State University of New Jersey",Academic/Other,Colorado Department of Public Health and Environment; University of New Mexico,?,Y,,,,,None,,
-1082,JCO,2023,Oncology,US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer,https://doi.org/10.1200/jco.22.02447,https://cdn.clinicaltrials.gov/large-docs/29/NCT03734029/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/29/NCT03734029/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03734029,36780610,Ph3 | treatment,Daiichi Sankyo,Industry,"Daiichi Sankyo Co., Ltd.; AstraZeneca",?,Y,,,,,None,,
-1083,JCO,2023,Oncology,Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study,https://doi.org/10.1200/jco.22.01990,https://cdn.clinicaltrials.gov/large-docs/35/NCT02775435/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/35/NCT02775435/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02775435,36735893,Ph3 | triple | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Erin Jensen,Biostatistics (per PubMed affiliation),"Biostatistics and Research Decision Sciences, Merck & Co, Inc, Rahway, NJ.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1084,JCO,2023,Oncology,Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial,https://doi.org/10.1200/jco.22.02186,https://cdn.clinicaltrials.gov/large-docs/06/NCT02511106/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/06/NCT02511106/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02511106,36720083,Ph3 | triple | treatment,AstraZeneca,Industry,,?,Y,Xiangning Huang,Biostatistics (per PubMed affiliation),"Oncology Biometrics, AstraZeneca, Cambridge, United Kingdom.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1085,JCO,2023,Oncology,"A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas",https://doi.org/10.1200/jco.22.01285,https://cdn.clinicaltrials.gov/large-docs/82/NCT01877382/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/82/NCT01877382/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01877382,36669146,Ph1 | treatment,Daiichi Sankyo,Industry,,?,Y,Ben Tao,Biostatistician,Daiichi Sankyo,https://www.linkedin.com/in/ben-tao-bb649314,High,Web-search,Ben Tao's LinkedIn profile explicitly lists his title as Biostatistician at Daiichi Sankyo.
-1086,JCO,2023,Oncology,Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group,https://doi.org/10.1200/jco.22.01815,https://cdn.clinicaltrials.gov/large-docs/61/NCT02306161/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/61/NCT02306161/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02306161,36669140,Ph3 | treatment,National Cancer Institute (NCI),NIH,,?,Y,Allen Buxton,Biostatistics (per PubMed affiliation),"Children's Oncology Group Statistics and Data Center, Monrovia, CA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1087,JCO,2023,Oncology,High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538,https://doi.org/10.1200/jco.22.01359,https://cdn.clinicaltrials.gov/large-docs/53/NCT00632853/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/53/NCT00632853/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT00632853,36623230,Ph3 | treatment,Alliance for Clinical Trials in Oncology,Academic/Other,National Cancer Institute (NCI),?,Y,Xiaofei Wang ; Junheng Gao,Biostatistics (per PubMed affiliation),"Alliance Statistics and Data Management Center, Duke University, Durham, NC. ; Alliance Statistics and Data Management Center, Duke University, Durham, NC.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1088,JCO,2023,Pediatrics,Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study,https://doi.org/10.1200/jco.22.00509,https://cdn.clinicaltrials.gov/large-docs/44/NCT02959944/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/44/NCT02959944/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02959944,36608310,Ph3 | quadruple | treatment,Pharmacyclics LLC.,Industry,"Janssen Research & Development, LLC",?,Y,Yihua Lee,"Director, Biostatistics",AbbVie,https://theorg.com/org/abbvie/org-chart/yihua-lee,High,Web-search,Yihua Lee is explicitly listed as Director of Biostatistics at AbbVie (which acquired Pharmacyclics).
-1089,JCO,2023,Oncology,Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma,https://doi.org/10.1200/jco.22.00996,https://cdn.clinicaltrials.gov/large-docs/57/NCT02455557/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/57/NCT02455557/Prot_SAP_000.pdf,Protocol+SAP,single_arm,NCT02455557,36521103,Ph2 | treatment,Roswell Park Cancer Institute,Academic/Other,,?,Y,Alan D Hutson ; Henry G Withers,Biostatistics (per PubMed affiliation),"Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY. ; Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1090,JCO,2023,Oncology,Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials,https://doi.org/10.1200/jco.22.01064,https://cdn.clinicaltrials.gov/large-docs/90/NCT00066690/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/90/NCT00066690/SAP_000.pdf,SAP,fixed_parallel_superiority,"NCT00066703, NCT00066690",36521078,Ph3 | treatment,ETOP IBCSG Partners Foundation,Network/Cooperative,National Cancer Institute (NCI); Breast International Group,?,Y,,,,,None,,
-1091,JCO,2023,Oncology,Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial,https://doi.org/10.1200/jco.22.00972,https://cdn.clinicaltrials.gov/large-docs/78/NCT01658878/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/78/NCT01658878/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01658878,36512738,Ph1/Ph2 | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,,,,,None,,
-1092,JCO,2023,Oncology,Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT,https://doi.org/10.1200/jco.22.01065,https://cdn.clinicaltrials.gov/large-docs/90/NCT00066690/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/90/NCT00066690/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT00066690,36493334,Ph3 | treatment,ETOP IBCSG Partners Foundation,Network/Cooperative,Breast International Group; Cancer and Leukemia Group B; National Cancer Institute (NCI); NSABP Foundation Inc; NCIC Clinical Trials Group; (+2 more),?,Y,Richard D Gelber,Biostatistics (per PubMed affiliation),"International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, Frontier Science Foundation, Boston, MA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1093,JCO,2023,Oncology,Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651,https://doi.org/10.1200/jco.22.00332,https://cdn.clinicaltrials.gov/large-docs/70/NCT02741570/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/70/NCT02741570/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02741570,36473143,Ph3 | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,,,,,None,,
-1094,JCO,2023,Oncology,"Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial",https://doi.org/10.1200/jco.22.00620,https://cdn.clinicaltrials.gov/large-docs/58/NCT03062358/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/58/NCT03062358/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03062358,36455168,Ph3 | double | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,,,,,None,,
-1095,JCO,2023,Oncology,Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial,https://doi.org/10.1200/jco.22.00510,https://cdn.clinicaltrials.gov/large-docs/16/NCT03734016/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/16/NCT03734016/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT03734016,36395435,Ph3 | treatment,BeiGene,Industry,,?,Y,,,,,None,,
-1096,JCO,2023,Oncology,Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial,https://doi.org/10.1200/jco.22.01662,https://cdn.clinicaltrials.gov/large-docs/95/NCT02203695/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/95/NCT02203695/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02203695,36367998,Ph2 | triple | treatment,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Academic/Other,"Astellas Pharma Inc; Medivation, Inc.",?,Y,,,,,None,,
-1097,JCO,2023,Oncology,Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702,https://doi.org/10.1200/jco.22.01637,https://cdn.clinicaltrials.gov/large-docs/45/NCT01150045/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/45/NCT01150045/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01150045,36367997,Ph3 | double | treatment,Alliance for Clinical Trials in Oncology,Academic/Other,National Cancer Institute (NCI),?,Y,Qian Shi,Biostatistics (per PubMed affiliation),"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, USA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1098,JCO,2023,Oncology,Effects of a Geriatric Assessment Intervention on Patient-Reported Symptomatic Toxicity in Older Adults With Advanced Cancer,https://doi.org/10.1200/jco.22.00738,https://cdn.clinicaltrials.gov/large-docs/41/NCT02054741/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/41/NCT02054741/Prot_SAP_000.pdf,Protocol+SAP,cluster,NCT02054741,36356279,NA | supportive care,Supriya Mohile,Academic/Other,National Cancer Institute (NCI); University of Chicago; City of Hope National Medical Center,?,Y,,,,,None,,
-1099,JCO,2023,Oncology,Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial,https://doi.org/10.1200/jco.21.02937,https://cdn.clinicaltrials.gov/large-docs/11/NCT02492711/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/11/NCT02492711/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02492711,36332179,Ph3 | treatment,MacroGenics,Industry,,?,Y,,,,,None,,
-1100,JCO,2023,Oncology,Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study,https://doi.org/10.1200/jco.22.00975,https://cdn.clinicaltrials.gov/large-docs/16/NCT03164616/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/16/NCT03164616/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03164616,36327426,Ph3 | treatment,AstraZeneca,Industry,,?,Y,Lynne Poole,Statistical Scientist,AstraZeneca,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761270Orig1s000AdminCorres.pdf,High,Web-search,FDA document explicitly lists Lynne Poole as Statistical Scientist at AstraZeneca.
-1101,JCO,2023,Oncology,Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study,https://doi.org/10.1200/jco.21.02885,https://cdn.clinicaltrials.gov/large-docs/94/NCT02220894/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/94/NCT02220894/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02220894,36306479,Ph3 | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Jianxin Lin,Principal Statistician,Merck,https://www.linkedin.com/pub/dir/Jianxin/Lin/us-0-United-States,High,Web-search,Jianxin Lin is identified as Principal Statistician at Merck.
-1102,JCO,2023,Oncology,NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma,https://doi.org/10.1200/jco.22.00164,https://cdn.clinicaltrials.gov/large-docs/50/NCT01730950/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/50/NCT01730950/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01730950,36260832,Ph2 | treatment,Radiation Therapy Oncology Group,Network/Cooperative,National Cancer Institute (NCI),?,Y,Stephanie L Pugh,Biostatistics (per PubMed affiliation),"NRG Oncology Statistics and Data Management Center, Philadelphia, PA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1103,JCO,2023,Oncology,Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211),https://doi.org/10.1200/jco.22.01013,https://cdn.clinicaltrials.gov/large-docs/75/NCT01824875/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/75/NCT01824875/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01824875,36260828,Ph2 | treatment,ECOG-ACRIN Cancer Research Group,Network/Cooperative,National Cancer Institute (NCI),?,Y,,,,,None,,
-1104,JCO,2023,Oncology,Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984,https://doi.org/10.1200/jco.21.02947,https://cdn.clinicaltrials.gov/large-docs/17/NCT02893917/Prot_SAP_002.pdf,https://cdn.clinicaltrials.gov/large-docs/17/NCT02893917/Prot_SAP_002.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02893917,36256912,Ph2 | treatment,National Cancer Institute (NCI),NIH,,?,Y,Shilin Zhao ; Yu Shyr,Biostatistics (per PubMed affiliation),"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN. ; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1105,JCO,2023,Oncology,FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on <i>FGFR1</i>/<i>3</i> mRNA Expression,https://doi.org/10.1200/jco.21.02303,https://cdn.clinicaltrials.gov/large-docs/93/NCT03410693/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/93/NCT03410693/SAP_001.pdf,SAP,seamless_2_3,NCT03410693,36240478,Ph2/Ph3 | treatment,Bayer,Industry,,?,Y,Weichao Bao,"Senior Director, Clinical Statistics",Bayer,https://www.linkedin.com/in/weichao-bao-b96b7428,High,Web-search,"Weichao Bao is Senior Director, Clinical Statistics at Bayer."
-1106,JCO,2023,Oncology,A Pragmatic Cluster-Randomized Trial of a Standing Order Entry Intervention for Colony-Stimulating Factor Use Among Patients at Intermediate Risk for Febrile Neutropenia,https://doi.org/10.1200/jco.22.01258,https://cdn.clinicaltrials.gov/large-docs/96/NCT02728596/Prot_SAP_ICF_000.pdf,https://cdn.clinicaltrials.gov/large-docs/96/NCT02728596/Prot_SAP_ICF_000.pdf,Protocol+SAP,cluster,NCT02728596,36228177,NA | health services research,SWOG Cancer Research Network,Network/Cooperative,National Cancer Institute (NCI); Patient-Centered Outcomes Research Institute,?,Y,William E Barlow ; Kathryn B Arnold,Biostatistics (per PubMed affiliation),"Fred Hutchinson Cancer Research Center, Seattle, WA. ; Fred Hutchinson Cancer Research Center, Seattle, WA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1107,JCO,2023,Oncology,Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227,https://doi.org/10.1200/jco.22.01503,https://cdn.clinicaltrials.gov/large-docs/26/NCT02477826/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/26/NCT02477826/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02477826,36223558,Ph3 | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,,,,,None,,
-1108,JCO,2023,Oncology,Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study,https://doi.org/10.1200/jco.21.02508,https://cdn.clinicaltrials.gov/large-docs/31/NCT02358031/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/31/NCT02358031/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02358031,36219809,Ph3 | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Jianxin Lin,"Senior Scientist, Clinical Biostatistics",Merck & Co,https://events.stat.uconn.edu/metapack/about-us/,High,Web-search,"Jianxin Lin is listed as Senior Scientist, Clinical Biostatistics at Merck."
-1109,JCO,2023,Oncology,Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134,https://doi.org/10.1200/jco.22.01763,https://cdn.clinicaltrials.gov/large-docs/81/NCT02224781/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/81/NCT02224781/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02224781,36166727,Ph3 | treatment,National Cancer Institute (NCI),NIH,,?,Y,,,,,None,,
-1110,JCO,2023,Oncology,Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915),https://doi.org/10.1200/jco.22.00533,https://cdn.clinicaltrials.gov/large-docs/55/NCT03068455/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/55/NCT03068455/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03068455,36162037,Ph3 | double | treatment,Bristol-Myers Squibb,Industry,,?,Y,,,,,None,,
-1111,JCO,2023,Oncology,Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial,https://doi.org/10.1200/jco.22.01549,https://cdn.clinicaltrials.gov/large-docs/86/NCT01844986/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/86/NCT01844986/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT01844986,36082969,Ph3 | quadruple | treatment,AstraZeneca,Industry,"GOG Foundation; Myriad Genetic Laboratories, Inc.; Merck Sharp & Dohme LLC",?,Y,John McNamara,Biostatistics (per PubMed affiliation),"Biostatistics, Oncology Biometrics, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1112,JCO,2023,Oncology,"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma",https://doi.org/10.1200/jco.22.00343,https://cdn.clinicaltrials.gov/large-docs/08/NCT02263508/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/08/NCT02263508/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02263508,35998300,Ph3 | double | treatment,Amgen,Industry,Merck Sharp & Dohme LLC,?,Y,James R Anderson,Adjunct Professor of Biostatistics / Distinguished Scientist,Merck,https://www.unmc.edu/publichealth/departments/biostatistics/facultyandstaff/james-anderson.html,High,Web-search,James R. Anderson is an adjunct professor of Biostatistics and previously a distinguished scientist for Merck.
-1113,JCO,2023,Oncology,Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial,https://doi.org/10.1200/jco.21.02815,https://cdn.clinicaltrials.gov/large-docs/32/NCT02654132/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/32/NCT02654132/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02654132,35960908,Ph2 | treatment,Bristol-Myers Squibb,Industry,Celgene; AbbVie,?,Y,Ying-Ming Jou,"Director, Biostatistics",Bristol-Myers Squibb,https://www.zoominfo.com/p/Ying-ming-Jou/-1923116675,High,Web-search,"Ying-Ming Jou is listed as Director, Biostatistics at Bristol-Myers Squibb on ZoomInfo."
-1114,JCO,2023,Oncology,"Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)",https://doi.org/10.1200/jco.22.00205,https://cdn.clinicaltrials.gov/large-docs/46/NCT03459846/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/46/NCT03459846/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03459846,35737919,Ph2 | quadruple | treatment,AstraZeneca,Industry,,?,Y,Kathryn Howells,Statistical Sciences Associate Director,AstraZeneca,https://rocketreach.co/kathryn-howells-email_31225304,High,Web-search,Kathryn Howells is listed as Statistical Sciences Associate Director at AstraZeneca.
-1115,JCO,2022,Oncology,Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer,https://doi.org/10.1200/jco.22.01002,https://cdn.clinicaltrials.gov/large-docs/39/NCT03901339/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/39/NCT03901339/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03901339,36027558,Ph3 | treatment,Gilead Sciences,Industry,,?,Y,Lanjia Lin,Biostatistics (per PubMed affiliation),"Department of Biostatistics, Gilead Sciences Inc, Foster City, CA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1116,JCO,2022,Oncology,"Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial",https://doi.org/10.1200/jco.22.00294,https://cdn.clinicaltrials.gov/large-docs/01/NCT03673501/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/01/NCT03673501/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03673501,35947817,Ph3 | treatment,"Deciphera Pharmaceuticals, LLC",Industry,,?,Y,,,,,None,,
-1117,JCO,2022,Oncology,Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer,https://doi.org/10.1200/jco.21.01604,https://cdn.clinicaltrials.gov/large-docs/95/NCT02184195/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/95/NCT02184195/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT02184195,35834777,Ph3 | quadruple | treatment,AstraZeneca,Industry,"Myriad Genetic Laboratories, Inc.; Merck Sharp & Dohme LLC",?,Y,David McGuinness,Statistician,AstraZeneca,https://www.researchgate.net/profile/David-Mcguinness-8,High,Web-search,David McGuinness is listed as a Statistician at AstraZeneca on ResearchGate.
-1118,JCO,2022,Oncology,Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial,https://doi.org/10.1200/jco.21.02772,https://cdn.clinicaltrials.gov/large-docs/79/NCT03726879/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/79/NCT03726879/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03726879,35763704,Ph3 | double | treatment,Hoffmann-La Roche,Industry,Chugai Pharmaceutical,?,Y,,,,,None,,
-1119,JCO,2022,Oncology,Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study,https://doi.org/10.1200/jco.22.00146,https://cdn.clinicaltrials.gov/large-docs/45/NCT00108745/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/45/NCT00108745/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT00108745,35759733,Ph3 | treatment,GOG Foundation,Network/Cooperative,National Cancer Institute (NCI),?,Y,,,,,None,,
-1120,JCO,2022,Oncology,"A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)",https://doi.org/10.1200/jco.22.01003,https://cdn.clinicaltrials.gov/large-docs/46/NCT03522246/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/46/NCT03522246/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03522246,35658487,Ph3 | quadruple | treatment,pharmaand GmbH,Industry,Bristol-Myers Squibb; Gynecologic Oncology Group; European Network of Gynaecological Oncological Trial Groups (ENGOT); Foundation Medicine,?,Y,Sandra Goble,Biostatistics (per PubMed affiliation),"Biostatistics, Clovis Oncology Inc, Boulder, CO.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1121,JCO,2022,Oncology,Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With <i>ALK</i>-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study,https://doi.org/10.1200/jco.21.02278,https://cdn.clinicaltrials.gov/large-docs/08/NCT03052608/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/08/NCT03052608/SAP_000.pdf,SAP,crossover,NCT03052608,35605188,Ph3 | treatment,Pfizer,Industry,,?,Y,,,,,None,,
-1122,JCO,2022,Oncology,"Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial",https://doi.org/10.1200/jco.22.00338,https://cdn.clinicaltrials.gov/large-docs/31/NCT03778931/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/31/NCT03778931/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03778931,35584336,Ph3 | treatment,"Stemline Therapeutics, Inc.",Industry,,?,Y,,,,,None,,
-1123,JCO,2022,Oncology,AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations,https://doi.org/10.1200/jco.21.02641,https://cdn.clinicaltrials.gov/large-docs/68/NCT03849768/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/68/NCT03849768/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT03849768,35580297,Ph3 | quadruple | treatment,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",Industry,,?,Y,,,,,None,,
-1124,JCO,2022,Oncology,Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial,https://doi.org/10.1200/jco.21.02628,https://cdn.clinicaltrials.gov/large-docs/55/NCT03068455/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/55/NCT03068455/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03068455,35512259,Ph3 | double | treatment,Bristol-Myers Squibb,Industry,,?,Y,,,,,None,,
-1125,JCO,2022,Oncology,"COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer",https://doi.org/10.1200/jco.22.00227,https://cdn.clinicaltrials.gov/large-docs/51/NCT03822351/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/51/NCT03822351/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT03822351,35452273,Ph2 | treatment,MedImmune LLC,Industry,,?,Y,Leanne Winzer,Statistical Science Associate Director,AstraZeneca,https://rocketreach.co/leanne-winzer-email_279921436,High,Web-search,Leanne Winzer is a Statistical Science Associate Director at AstraZeneca.
-1126,JCO,2022,Oncology,"Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216)",https://doi.org/10.1200/jco.21.02517,https://cdn.clinicaltrials.gov/large-docs/91/NCT01809691/Prot_SAP_ICF_000.pdf,https://cdn.clinicaltrials.gov/large-docs/91/NCT01809691/Prot_SAP_ICF_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01809691,35446628,Ph3 | treatment,SWOG Cancer Research Network,Network/Cooperative,"Millennium Pharmaceuticals, Inc.; National Cancer Institute (NCI)",?,Y,Catherine M Tangen ; Melissa Plets,Biostatistics (per PubMed affiliation),"SWOG Statistics and Data Management Center, Seattle, WA. ; SWOG Statistics and Data Management Center, Seattle, WA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1127,JCO,2022,Oncology,Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study,https://doi.org/10.1200/jco.21.01926,https://cdn.clinicaltrials.gov/large-docs/43/NCT03430843/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/43/NCT03430843/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03430843,35442766,Ph3 | treatment,BeiGene,Industry,,?,Y,,,,,None,,
-1128,JCO,2022,Oncology,Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer,https://doi.org/10.1200/jco.22.00193,https://cdn.clinicaltrials.gov/large-docs/96/NCT02677896/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/96/NCT02677896/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT02677896,35420921,Ph3 | quadruple | treatment,"Astellas Pharma Global Development, Inc.",Industry,"Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",?,Y,Brad Rosbrook,"Sr. Director, Clinical Statistics",Pfizer,https://rocketreach.co/brad-rosbrook-email_32052524,High,Web-search,"Brad Rosbrook is a Sr. Director, Clinical Statistics at Pfizer."
-1129,JCO,2022,Oncology,"Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial",https://doi.org/10.1200/jco.21.01829,https://cdn.clinicaltrials.gov/large-docs/61/NCT02606461/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/61/NCT02606461/SAP_001.pdf,SAP,crossover,NCT02606461,35394800,Ph2/Ph3 | double | treatment,Karyopharm Therapeutics Inc,Industry,,?,Y,,,,,None,,
-1130,JCO,2022,Oncology,Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score,https://doi.org/10.1200/jco.21.02198,https://cdn.clinicaltrials.gov/large-docs/31/NCT02358031/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/31/NCT02358031/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02358031,35333599,Ph3 | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Joy Ge,statistician,Merck,https://scispace.com/pdf/applied-statistics-in-biomedicine-and-clinical-trials-design-28oib263jt.pdf,High,Web-search,"Joy Ge is identified as a statistician at Merck in multiple sources, including a book on Applied Statistics."
-1131,JCO,2022,Oncology,"Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial",https://doi.org/10.1200/jco.21.02011,https://cdn.clinicaltrials.gov/large-docs/00/NCT02446600/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/00/NCT02446600/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02446600,35290101,Ph3 | treatment,National Cancer Institute (NCI),NIH,AstraZeneca; NRG Oncology,?,Y,Mark F Brady ; Austin Miller,Biostatistics (per PubMed affiliation),"NRG Oncology; Clinical Trial Development Division; Biostatistics & Bioinformatics; Roswell Park Comprehensive Cancer Center, Buffalo, NY. ; NRG Oncology; Clinical Trial Development Division; Biostatistics & Bioinformatics; Roswell Park Comprehensive Cancer Center, Buffalo, NY.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1132,JCO,2022,Oncology,Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma,https://doi.org/10.1200/jco.21.02678,https://cdn.clinicaltrials.gov/large-docs/16/NCT02112916/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/16/NCT02112916/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02112916,35271306,Ph3 | treatment,National Cancer Institute (NCI),NIH,,?,Y,Zhiguo Chen ; J Hunter Archer,Biostatistics (per PubMed affiliation),"Department of Biostatistics, University of Florida, Gainesville, FL. ; Department of Biostatistics, University of Florida, Gainesville, FL.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1133,JCO,2022,Oncology,"Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)",https://doi.org/10.1200/jco.21.00714,https://cdn.clinicaltrials.gov/large-docs/62/NCT01843062/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/62/NCT01843062/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT01843062,35192411,Ph3 | quadruple | treatment,AstraZeneca,Industry,,?,Y,Karen So,Biostatistics and Informatics,AstraZeneca,https://pubmed.ncbi.nlm.nih.gov/29381826/,High,Web-search,"Karen So is listed with affiliation 'Biostatistics and Informatics, AstraZeneca' in multiple publications."
-1134,JCO,2022,Oncology,Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer,https://doi.org/10.1200/jco.21.01308,https://cdn.clinicaltrials.gov/large-docs/61/NCT02125461/Prot_004.pdf,https://cdn.clinicaltrials.gov/large-docs/61/NCT02125461/SAP_005.pdf,SAP,fixed_parallel_superiority,NCT02125461,35108059,Ph3 | quadruple | treatment,AstraZeneca,Industry,,?,Y,Helen Mann,"Biostatistics, AstraZeneca",AstraZeneca,https://www.jto.org/article/S1556-0864(26)00017-1/fulltext,High,Web-search,"Helen Mann is listed with affiliation 'Biostatistics, AstraZeneca' in multiple publications and FDA meeting transcripts."
-1135,JCO,2022,Oncology,Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600-Mutant Unresectable or Metastatic Melanoma,https://doi.org/10.1200/jco.21.01601,https://cdn.clinicaltrials.gov/large-docs/92/NCT02967692/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/92/NCT02967692/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT02967692,35030011,Ph3 | quadruple | treatment,Novartis Pharmaceuticals,Industry,,?,Y,Steven Green,Expert Statistician,Novartis,https://ch.linkedin.com/pub/dir/Steve/Green/ch-0-Schweiz,High,Web-search,LinkedIn snippet explicitly lists 'Expert Statistician at Novartis' for Steve Green.
-1136,JCO,2022,Oncology,Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial,https://doi.org/10.1200/jco.21.02050,https://cdn.clinicaltrials.gov/large-docs/74/NCT00954174/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/74/NCT00954174/Prot_SAP_000.pdf,Protocol+SAP,noninferiority,NCT00954174,35007153,Ph3 | treatment,GOG Foundation,Network/Cooperative,National Cancer Institute (NCI),?,Y,Virginia L Filiaci ; Helen Q Huang,Biostatistics (per PubMed affiliation),"NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY. ; NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1137,JCO,2022,Oncology,Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108),https://doi.org/10.1200/jco.21.02006,https://cdn.clinicaltrials.gov/large-docs/00/NCT01242800/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/00/NCT01242800/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01242800,34995128,NA | treatment,Eastern Cooperative Oncology Group,Network/Cooperative,National Cancer Institute (NCI),?,Y,Fengmin Zhao,Biostatistics (per PubMed affiliation),"Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1138,JCO,2022,Oncology,Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03),https://doi.org/10.1200/jco.21.01918,https://cdn.clinicaltrials.gov/large-docs/94/NCT02513394/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/94/NCT02513394/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02513394,34995105,Ph3 | treatment,"Alliance Foundation Trials, LLC.",Academic/Other,"Austrian Breast & Colorectal Cancer Study Group; NSABP Foundation Inc; PrECOG, LLC.; Breast International Group; Pfizer",?,Y,Amylou Dueck,Biostatistics (per PubMed affiliation),"Alliance Statistics and Data Center, Mayo Clinic, Phoenix, AZ.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1139,JCO,2022,Oncology,"BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer",https://doi.org/10.1200/jco.21.01657,https://cdn.clinicaltrials.gov/large-docs/85/NCT02101385/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/85/NCT02101385/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02101385,34910554,Ph2 | treatment,"Bryan Schneider, MD",Academic/Other,Hoosier Cancer Research Network; Vera Bradley Foundation for Breast Cancer; Walther Cancer Institute; Indiana University,?,Y,,,,,None,,
-1140,JCO,2022,Oncology,Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study,https://doi.org/10.1200/jco.21.00896,https://cdn.clinicaltrials.gov/large-docs/71/NCT01966471/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/71/NCT01966471/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT01966471,34890214,Ph3 | treatment,Hoffmann-La Roche,Industry,,?,Y,,,,,None,,
-1141,JCO,2022,Oncology,Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004,https://doi.org/10.1200/jco.21.01473,https://cdn.clinicaltrials.gov/large-docs/94/NCT03180294/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/94/NCT03180294/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03180294,34882500,Ph2 | double | supportive care,NRG Oncology,Academic/Other,National Cancer Institute (NCI),?,Y,Stephanie L Pugh ; Snehal Deshmukh,Biostatistics (per PubMed affiliation),"NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA. ; NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1142,JCO,2022,Oncology,Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03),https://doi.org/10.1200/jco.21.02554,https://cdn.clinicaltrials.gov/large-docs/94/NCT02513394/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/94/NCT02513394/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02513394,34874182,Ph3 | treatment,"Alliance Foundation Trials, LLC.",Academic/Other,"Austrian Breast & Colorectal Cancer Study Group; NSABP Foundation Inc; PrECOG, LLC.; Breast International Group; Pfizer",?,Y,Amylou C Dueck,Biostatistics (per PubMed affiliation),"Alliance Statistics and Data Center and Mayo Clinic, Phoenix, AZ.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1143,JCO,2022,Oncology,Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies,https://doi.org/10.1200/jco.21.02293,https://cdn.clinicaltrials.gov/large-docs/50/NCT02345850/Prot_SAP_ICF_000.pdf,https://cdn.clinicaltrials.gov/large-docs/50/NCT02345850/Prot_SAP_ICF_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02345850,34855460,Ph3 | prevention,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI),?,Y,,,,,None,,
-1144,JCO,2022,Oncology,Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181,https://doi.org/10.1200/jco.21.00601,https://cdn.clinicaltrials.gov/large-docs/63/NCT02564263/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/63/NCT02564263/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT02564263,34730989,Ph3 | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,,,,,None,,
-1145,JCO,2022,Oncology,Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study,https://doi.org/10.1200/jco.21.00838,https://cdn.clinicaltrials.gov/large-docs/97/NCT02165397/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/97/NCT02165397/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02165397,34606378,Ph3 | double | treatment,Pharmacyclics LLC.,Industry,"Janssen Research & Development, LLC",?,Y,Jerry Ping,Director of Biostatistics,"Pharmacyclics, an AbbVie Company",https://magazine.amstat.org/wp-content/uploads/2025/06/5AN_May23_web.pdf,High,Web-search,"Jerry Ping is listed as Director of Biostatistics at Pharmacyclics, an AbbVie Company in AMSTATNEWS."
-1146,JCO,2022,Oncology,Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1,https://doi.org/10.1200/jco.20.03452,https://cdn.clinicaltrials.gov/large-docs/84/NCT02609984/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/84/NCT02609984/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT02609984,34260265,Ph2 | treatment,"Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",Industry,"Genentech, Inc.",?,Y,,,,,None,,
-1147,JCO,2021,Oncology,Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study,https://doi.org/10.1200/jco.21.01181,https://cdn.clinicaltrials.gov/large-docs/42/NCT02242942/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/42/NCT02242942/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT02242942,34709929,Ph3 | treatment,Hoffmann-La Roche,Industry,AbbVie; German CLL Study Group,?,Y,,,,,None,,
-1148,JCO,2021,Oncology,Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report,https://doi.org/10.1200/jco.21.00358,https://cdn.clinicaltrials.gov/large-docs/06/NCT01231906/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/06/NCT01231906/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01231906,34652968,Ph3 | treatment,Children's Oncology Group,Network/Cooperative,National Cancer Institute (NCI),?,Y,,,,,None,,
-1149,JCO,2021,Oncology,Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study,https://doi.org/10.1200/jco.21.00807,https://cdn.clinicaltrials.gov/large-docs/83/NCT02910583/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/83/NCT02910583/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02910583,34618601,Ph2 | triple | treatment,Pharmacyclics LLC.,Industry,"Janssen Research & Development, LLC",?,Y,Cathy Zhou,Biostatistics,"Pharmacyclics LLC, an AbbVie Company",https://pmc.ncbi.nlm.nih.gov/articles/PMC9198904/,High,Web-search,"Cathy Zhou is listed with affiliation 'Biostatistics, Pharmacyclics LLC, an AbbVie Company' in PMC9198904."
-1150,JCO,2021,Oncology,"Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial",https://doi.org/10.1200/jco.21.01839,https://cdn.clinicaltrials.gov/large-docs/27/NCT01483027/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/27/NCT01483027/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT01483027,34541864,NA | treatment,Boston Scientific Corporation,Industry,Biocompatibles UK Ltd,?,Y,,,,,None,,
-1151,JCO,2021,Oncology,Targeting Depressive Symptoms in Younger Breast Cancer Survivors: The Pathways to Wellness Randomized Controlled Trial of Mindfulness Meditation and Survivorship Education,https://doi.org/10.1200/jco.21.00279,https://cdn.clinicaltrials.gov/large-docs/39/NCT03025139/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/39/NCT03025139/Prot_SAP_000.pdf,Protocol+SAP,platform,NCT03025139,34406839,NA | supportive care,Jonsson Comprehensive Cancer Center,Academic/Other,National Cancer Institute (NCI); National Institutes of Health (NIH),?,Y,Catherine M Crespi,Biostatistics (per PubMed affiliation),"UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1152,JCO,2021,Oncology,E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group,https://doi.org/10.1200/jco.21.00944,https://cdn.clinicaltrials.gov/large-docs/82/NCT02115282/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/82/NCT02115282/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02115282,34357781,Ph3 | double | treatment,National Cancer Institute (NCI),NIH,,?,Y,,,,,None,,
-1153,JCO,2021,Oncology,"Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study",https://doi.org/10.1200/jco.21.00217,https://cdn.clinicaltrials.gov/large-docs/32/NCT02508532/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/32/NCT02508532/SAP_001.pdf,SAP,crossover,"NCT02508532, NCT03465722",34343033,Ph1 | treatment,Blueprint Medicines Corporation,Industry,,?,Y,,,,,None,,
-1154,JCO,2021,Oncology,Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial,https://doi.org/10.1200/jco.21.01210,https://cdn.clinicaltrials.gov/large-docs/96/NCT02477696/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/96/NCT02477696/SAP_003.pdf,SAP,noninferiority,NCT02477696,34310172,Ph3 | single | treatment,Acerta Pharma BV,Industry,,?,Y,Priti Patel,Biostatistics,AstraZeneca,https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bcp.15087,Medium,Web-search,Priti Patel is listed with an affiliation to Biostatistics at AstraZeneca in a related paper.
-1155,JCO,2021,Oncology,"Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study",https://doi.org/10.1200/jco.20.03555,https://cdn.clinicaltrials.gov/large-docs/48/NCT02519348/Prot_004.pdf,https://cdn.clinicaltrials.gov/large-docs/48/NCT02519348/SAP_005.pdf,SAP,fixed_parallel_superiority,NCT02519348,34292792,Ph2 | treatment,MedImmune LLC,Industry,,?,Y,Philip He,Biostatistician | Oncology Clinical Trialist / Statistical Science Director at AstraZeneca,AstraZeneca,https://evidence.nejm.org/doi/full/10.1056/EVIDoa2100070,High,Web-search,"Philip He is identified as a statistician/biostatistician at AstraZeneca and Daiichi Sankyo, with a PhD."
-1156,JCO,2021,Oncology,Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial,https://doi.org/10.1200/jco.20.03329,https://cdn.clinicaltrials.gov/large-docs/37/NCT02352337/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/37/NCT02352337/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02352337,34288696,Ph2 | treatment,Federation Francophone de Cancerologie Digestive,Academic/Other,,?,Y,Karine Le Malicot,Biostatistics (per PubMed affiliation),"Biostatistics Department, Fédération Francphone de Cancérologie Digestive, EPICAD INSERM LNC-UMR 1231 University of Burgundy and Franche Comté, Dijon, France.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1157,JCO,2021,Oncology,"Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium",https://doi.org/10.1200/jco.21.00703,https://cdn.clinicaltrials.gov/large-docs/37/NCT02035137/Prot_SAP_ICF_000.pdf,https://cdn.clinicaltrials.gov/large-docs/37/NCT02035137/Prot_SAP_ICF_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02035137,34270348,Ph2 | treatment,New Approaches to Neuroblastoma Therapy Consortium,Academic/Other,,?,Y,,,,,None,,
-1158,JCO,2021,Oncology,Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001,https://doi.org/10.1200/jco.20.03692,https://cdn.clinicaltrials.gov/large-docs/74/NCT01574274/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/74/NCT01574274/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01574274,34228505,Ph2 | treatment,Dana-Farber Cancer Institute,Academic/Other,Shire; National Cancer Institute (NCI),?,Y,,,,,None,,
-1159,JCO,2021,Oncology,Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial,https://doi.org/10.1200/jco.21.00596,https://cdn.clinicaltrials.gov/large-docs/42/NCT00116142/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/42/NCT00116142/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT00116142,34197181,Ph3 | treatment,Dana-Farber Cancer Institute,Academic/Other,Sanofi,?,Y,,,,,None,,
-1160,JCO,2021,Other,"Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis",https://doi.org/10.1200/jco.20.02864,https://cdn.clinicaltrials.gov/large-docs/86/NCT02426086/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/86/NCT02426086/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02426086,34138638,Ph2 | single | treatment,Geron Corporation,Industry,,?,Y,Eugene Zhu,,Janssen Research & Development,https://apps.dtic.mil/sti/trecms/pdf/AD1216906.pdf,Medium,Web-search,"Snippet explicitly states ""Statistical analysis support was provided by Eugene Zhu... of Janssen Research & Development"""
-1161,JCO,2021,Oncology,"PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer",https://doi.org/10.1200/jco.20.02914,https://cdn.clinicaltrials.gov/large-docs/48/NCT01515748/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/48/NCT01515748/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT01515748,34133211,Ph3 | treatment,Sanofi,Industry,,?,Y,,,,,None,,
-1162,JCO,2021,Oncology,"Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",https://doi.org/10.1200/jco.21.00972,https://cdn.clinicaltrials.gov/large-docs/37/NCT01564537/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/37/NCT01564537/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT01564537,34111952,Ph3 | quadruple | treatment,Takeda,Industry,,?,Y,,,,,None,,
-1163,JCO,2021,Oncology,Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131,https://doi.org/10.1200/jco.21.00976,https://cdn.clinicaltrials.gov/large-docs/91/NCT02445391/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/91/NCT02445391/Prot_SAP_000.pdf,Protocol+SAP,noninferiority,NCT02445391,34092112,Ph3 | treatment,ECOG-ACRIN Cancer Research Group,Network/Cooperative,National Cancer Institute (NCI),?,Y,Fengmin Zhao,Biostatistics (per PubMed affiliation),"Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1164,JCO,2021,Oncology,Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial,https://doi.org/10.1200/jco.20.03398,https://cdn.clinicaltrials.gov/large-docs/48/NCT01853748/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/48/NCT01853748/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01853748,34077270,Ph2 | treatment,Dana-Farber Cancer Institute,Academic/Other,,?,Y,,,,,None,,
-1165,JCO,2021,Oncology,Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance),https://doi.org/10.1200/jco.21.00286,https://cdn.clinicaltrials.gov/large-docs/31/NCT00942331/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/31/NCT00942331/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT00942331,33989025,Ph3 | double | treatment,National Cancer Institute (NCI),NIH,,?,Y,Karla A Ballman ; Susan Halabi,Biostatistics (per PubMed affiliation),"Alliance Statistics and Data Center, Weill Medical College of Cornell University, New York, NY. ; Alliance Statistics and Data Center, Duke University, Durham, NC.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1166,JCO,2021,Oncology,"Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study",https://doi.org/10.1200/jco.20.03488,https://cdn.clinicaltrials.gov/large-docs/18/NCT02489318/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/18/NCT02489318/SAP_001.pdf,SAP,crossover,NCT02489318,33914595,Ph3 | triple | treatment,"Aragon Pharmaceuticals, Inc.",Industry,,?,Y,,,,,None,,
-1167,JCO,2021,Oncology,"Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)",https://doi.org/10.1200/jco.21.00306,https://cdn.clinicaltrials.gov/large-docs/00/NCT03038100/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/00/NCT03038100/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03038100,33891472,Ph3 | double | treatment,Hoffmann-La Roche,Industry,GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT),?,Y,Fan Wu,Biostatistics (per PubMed affiliation),"Biostatistics, Roche (China) Holding Ltd, Shanghai, China.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1168,JCO,2021,Oncology,Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50,https://doi.org/10.1200/jco.21.00174,https://cdn.clinicaltrials.gov/large-docs/38/NCT02142738/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/38/NCT02142738/Prot_SAP_000.pdf,Protocol+SAP,crossover,NCT02142738,33872070,Ph3 | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Erin Jensen,Biostatistics and Research Decision Sciences,"Merck & Co., Inc",https://academic.oup.com/ejcts/article/68/3/ezag028/8539922,High,Web-search,Erin Jensen is listed as Biostatistics and Research Decision Sciences at Merck.
-1169,JCO,2021,Oncology,Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial,https://doi.org/10.1200/jco.20.03639,https://cdn.clinicaltrials.gov/large-docs/46/NCT01864746/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/46/NCT01864746/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT01864746,33793299,Ph3 | quadruple | treatment,GBG Forschungs GmbH,Academic/Other,Pfizer; AGO Study Group; NSABP Foundation Inc; Breast International Group,?,Y,,,,,None,,
-1170,JCO,2021,Oncology,Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies,https://doi.org/10.1200/jco.20.02977,https://cdn.clinicaltrials.gov/large-docs/15/NCT02422615/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/15/NCT02422615/SAP_003.pdf,SAP,fixed_parallel_superiority,"NCT01958021, NCT02422615, NCT02278120",33769862,Ph3 | quadruple | treatment,Novartis Pharmaceuticals,Industry,,?,Y,Nadia Solovieff,,Novartis,https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3105,Medium,Web-search,Nadia Solovieff is associated with Biostatistics at Boston University and works at Novartis.
-1171,JCO,2021,Oncology,"Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes",https://doi.org/10.1200/jco.20.02619,https://cdn.clinicaltrials.gov/large-docs/95/NCT01566695/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/95/NCT01566695/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT01566695,33764805,Ph3 | quadruple | treatment,Celgene,Industry,,?,Y,Jianhua Zhong,"Director, Statistics",Bristol-Myers Squibb,https://www.zoominfo.com/p/Weihan-Zhao/-2048775308,High,Web-search,"Jianhua Zhong is listed as Director, Statistics at Bristol-Myers Squibb in ZoomInfo snippets."
-1172,JCO,2021,Oncology,Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451,https://doi.org/10.1200/jco.20.02212,https://cdn.clinicaltrials.gov/large-docs/66/NCT02538666/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/66/NCT02538666/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02538666,33683919,Ph3 | quadruple | treatment,Bristol-Myers Squibb,Industry,"Ono Pharmaceutical Co., Ltd.",?,Y,Wen Hong Lin,Department of Biostatistics,Bristol Myers Squibb,https://aminer.org/profile/wen-hong-lin/65c27e30671a27199836e82a,Medium,Web-search,Wen Hong Lin is associated with Department of Biostatistics in search snippets. Giovanni Selvaggi is an MD/CMO.
-1173,JCO,2021,Oncology,ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma,https://doi.org/10.1200/jco.20.01366,https://cdn.clinicaltrials.gov/large-docs/62/NCT02285062/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/62/NCT02285062/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02285062,33621109,Ph3 | quadruple | treatment,Celgene,Industry,,?,Y,Steve Wade,Biostatistics (per PubMed affiliation),"Department of Statistical Programming, Celgene Corporation, Overland Park, KS.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1174,JCO,2021,Oncology,TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer,https://doi.org/10.1200/jco.20.02759,https://cdn.clinicaltrials.gov/large-docs/21/NCT02286921/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/21/NCT02286921/SAP_001.pdf,SAP,crossover,NCT02286921,33617303,Ph2 | treatment,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Academic/Other,United States Department of Defense,?,Y,Vanessa Bolejack,Biostatistics (per PubMed affiliation),"Cancer Research and Biostatistics, Seattle, WA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1175,JCO,2021,Oncology,Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA),https://doi.org/10.1200/jco.20.02232,https://cdn.clinicaltrials.gov/large-docs/21/NCT02923921/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/21/NCT02923921/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02923921,33555926,Ph3 | treatment,Eli Lilly and Company,Industry,ARMO BioSciences,?,Y,Rebecca R Hozak,oncology statistics group,Eli Lilly,https://biochem.wisc.edu/wp-content/uploads/sites/1394/2023/02/2002BiochemNewsletter.pdf,High,Web-search,Rebecca Hozak has an M.S. in Biostatistics and is mentioned leading oncology statistics group at Eli Lilly.
-1176,JCO,2021,Oncology,"Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study",https://doi.org/10.1200/jco.20.03579,https://cdn.clinicaltrials.gov/large-docs/34/NCT03302234/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/34/NCT03302234/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03302234,33513313,Ph3 | quadruple | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Lu Xu,"Senior Director, Biostatistics",Merck,https://rocketreach.co/lu-xu-email_60027378,High,Web-search,"Lu Xu is Senior Director, Biostatistics at Merck/AstraZeneca. Bilal Piperdi is an MD."
-1177,JCO,2021,Oncology,Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002),https://doi.org/10.1200/jco.20.03128,https://cdn.clinicaltrials.gov/large-docs/78/NCT02254278/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/78/NCT02254278/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02254278,33507809,Ph2 | treatment,NRG Oncology,Academic/Other,National Cancer Institute (NCI),?,Y,Pedro Torres-Saavedra,Biostatistics (per PubMed affiliation),"NRG Oncology Statistics and Data Management Center, Philadelphia, PA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1178,JCO,2021,Oncology,Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study,https://doi.org/10.1200/jco.20.02088,https://cdn.clinicaltrials.gov/large-docs/24/NCT02928224/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/24/NCT02928224/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT02928224,33503393,Ph3 | treatment,Pfizer,Industry,"Merck KGaA, Darmstadt, Germany; Pierre Fabre Medicament; Ono Pharmaceutical Co., Ltd.",?,Y,,,,,None,,
-1179,JCO,2021,Oncology,Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin,https://doi.org/10.1200/jco.20.01691,https://cdn.clinicaltrials.gov/large-docs/13/NCT02048813/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/13/NCT02048813/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,"NCT02048813, NCT00843882",33439748,Ph3 | treatment,National Cancer Institute (NCI),NIH,,?,Y,Zhuoxin Sun,Biostatistics (per PubMed affiliation),"Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1180,JCO,2021,Oncology,"Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)",https://doi.org/10.1200/jco.20.01055,https://cdn.clinicaltrials.gov/large-docs/79/NCT02763579/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/79/NCT02763579/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02763579,33439693,Ph3 | double | treatment,Hoffmann-La Roche,Industry,,?,Y,,,,,None,,
-1181,JCO,2021,Oncology,Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932,https://doi.org/10.1200/jco.20.00494,https://cdn.clinicaltrials.gov/large-docs/30/NCT01190930/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/30/NCT01190930/Prot_SAP_000.pdf,Protocol+SAP,factorial,NCT01190930,33411585,Ph3 | treatment,Children's Oncology Group,Network/Cooperative,National Cancer Institute (NCI),?,Y,John A Kairalla ; Cindy Wang,Biostatistics (per PubMed affiliation),"Department of Biostatistics, Colleges of Medicine and Public Health & Health Professions, University of Florida, Gainesville, FL. ; Department of Biostatistics, Colleges of Medicine and Public Health & Health Professions, University of Florida, Gainesville, FL.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1182,JCO,2021,Oncology,Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406),https://doi.org/10.1200/jco.20.01994,https://cdn.clinicaltrials.gov/large-docs/16/NCT02164916/Prot_SAP_ICF_000.pdf,https://cdn.clinicaltrials.gov/large-docs/16/NCT02164916/Prot_SAP_ICF_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02164916,33356422,Ph2 | treatment,SWOG Cancer Research Network,Network/Cooperative,National Cancer Institute (NCI); Roche-Genentech,?,Y,Katherine A Guthrie ; Shannon L McDonough,Biostatistics (per PubMed affiliation),"SWOG Statistical and Data Management Center, Seattle, WA. ; SWOG Statistical and Data Management Center, Seattle, WA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1183,JCO,2021,Oncology,Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial,https://doi.org/10.1200/jco.20.01370,https://cdn.clinicaltrials.gov/large-docs/72/NCT02252172/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/72/NCT02252172/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT02252172,33326255,Ph3 | treatment,"Janssen Research & Development, LLC",Industry,,?,Y,,,,,None,,
-1184,JCO,2021,Oncology,Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100,https://doi.org/10.1200/jco.20.00892,https://cdn.clinicaltrials.gov/large-docs/10/NCT02625610/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/10/NCT02625610/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02625610,33197226,Ph3 | treatment,"EMD Serono Research & Development Institute, Inc.",Industry,"Merck KGaA, Darmstadt, Germany",?,Y,,,,,None,,
-1185,JCO,2021,Oncology,Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma,https://doi.org/10.1200/jco.20.00290,https://cdn.clinicaltrials.gov/large-docs/53/NCT02684253/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/53/NCT02684253/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02684253,32822275,Ph2 | treatment,Memorial Sloan Kettering Cancer Center,Academic/Other,,?,Y,Zhigang Zhang ; Jessica Flynn,Biostatistics (per PubMed affiliation),"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. ; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1186,JCO,2020,Oncology,Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer,https://doi.org/10.1200/jco.20.01888,https://cdn.clinicaltrials.gov/large-docs/63/NCT02564263/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/63/NCT02564263/SAP_002.pdf,SAP,fixed_parallel_superiority,NCT02564263,33026938,Ph3 | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Shailaja Suryawanshi,"Director, Statistics",Merck,https://www.researchgate.net/profile/Shailaja-Suryawanshi,High,Web-search,Shailaja Suryawanshi is identified as a Director of Statistics at Merck & Co.
-1187,JCO,2020,Oncology,Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403,https://doi.org/10.1200/jco.20.01149,https://cdn.clinicaltrials.gov/large-docs/22/NCT02438722/Prot_SAP_ICF_000.pdf,https://cdn.clinicaltrials.gov/large-docs/22/NCT02438722/Prot_SAP_ICF_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02438722,33021871,Ph2/Ph3 | treatment,SWOG Cancer Research Network,Network/Cooperative,National Cancer Institute (NCI),?,Y,Mary W Redman ; Jieling Miao,Biostatistics (per PubMed affiliation),"SWOG Statistical Center, Seattle, WA. ; SWOG Statistical Center, Seattle, WA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1188,JCO,2020,Oncology,Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial,https://doi.org/10.1200/jco.20.02060,https://cdn.clinicaltrials.gov/large-docs/58/NCT02312258/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/58/NCT02312258/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT02312258,33021870,Ph3 | quadruple | treatment,Takeda,Industry,,?,Y,Bingxia Wang,Statistician,Millennium Pharmaceuticals Inc,https://www.researchgate.net/profile/Bingxia-Wang,High,Web-search,Bingxia Wang is explicitly listed as a Statistician at Millennium Pharmaceuticals Inc.
-1189,JCO,2020,Oncology,Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study,https://doi.org/10.1200/jco.20.00948,https://cdn.clinicaltrials.gov/large-docs/71/NCT02005471/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/71/NCT02005471/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02005471,32986498,Ph3 | treatment,Hoffmann-La Roche,Industry,AbbVie,?,Y,,,,,None,,
-1190,JCO,2020,Oncology,"Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)",https://doi.org/10.1200/jco.20.02514,https://cdn.clinicaltrials.gov/large-docs/97/NCT03155997/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/97/NCT03155997/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT03155997,32954927,Ph3 | treatment,Eli Lilly and Company,Industry,NSABP Foundation Inc,?,Y,,,,,None,,
-1191,JCO,2020,Oncology,Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial,https://doi.org/10.1200/jco.20.02110,https://cdn.clinicaltrials.gov/large-docs/94/NCT02362594/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/94/NCT02362594/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02362594,32946353,Ph3 | double | treatment,Merck Sharp & Dohme LLC,Industry,European Organisation for Research and Treatment of Cancer,?,Y,,,,,None,,
-1192,JCO,2020,Oncology,Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia,https://doi.org/10.1200/jco.20.00256,https://cdn.clinicaltrials.gov/large-docs/05/NCT00408005/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/05/NCT00408005/Prot_SAP_000.pdf,Protocol+SAP,factorial,NCT00408005,32813610,Ph3 | treatment,National Cancer Institute (NCI),NIH,,?,Y,Zhiguo Chen,Biostatistics (per PubMed affiliation),"Department of Biostatistics, Colleges of Medicine and Public Health and Health Professions, University of Florida, Gainesville, FL.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1193,JCO,2020,Oncology,Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial,https://doi.org/10.1200/jco.20.00505,https://cdn.clinicaltrials.gov/large-docs/01/NCT02737501/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/01/NCT02737501/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT02737501,32780660,Ph3 | treatment,Ariad Pharmaceuticals,Industry,,?,Y,,,,,None,,
-1194,JCO,2020,Oncology,"Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer",https://doi.org/10.1200/jco.20.00315,https://cdn.clinicaltrials.gov/large-docs/83/NCT00430183/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/83/NCT00430183/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT00430183,32706639,Ph3 | treatment,Alliance for Clinical Trials in Oncology,Academic/Other,National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; SWOG Cancer Research Network,?,Y,Susan Halabi ; David W Hillman,Biostatistics (per PubMed affiliation),"Department of Biostatistics and Bioinformatics, Duke University, Durham, NC. ; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1195,JCO,2020,Oncology,Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial,https://doi.org/10.1200/jco.20.00147,https://cdn.clinicaltrials.gov/large-docs/73/NCT01808573/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/73/NCT01808573/SAP_001.pdf,SAP,fixed_parallel_superiority,NCT01808573,32678716,Ph3 | treatment,"Puma Biotechnology, Inc.",Industry,,?,Y,,,,,None,,
-1196,JCO,2020,Oncology,Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434,https://doi.org/10.1200/jco.20.00531,https://cdn.clinicaltrials.gov/large-docs/05/NCT00408005/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/05/NCT00408005/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT00408005,32552472,Ph3 | treatment,National Cancer Institute (NCI),NIH,,?,Y,Zhiguo Chen,Biostatistics (per PubMed affiliation),"Department of Biostatistics, College of Medicine and College of Public Health and Health Professions, University of Florida, Gainesville, FL.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1197,JCO,2020,Oncology,Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131,https://doi.org/10.1200/jco.19.02892,https://cdn.clinicaltrials.gov/large-docs/49/NCT02883049/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/49/NCT02883049/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02883049,32496902,Ph3 | treatment,National Cancer Institute (NCI),NIH,,?,Y,Yunfeng Dai ; John A Kairalla,Biostatistics (per PubMed affiliation),"Department of Biostatistics, Colleges of Medicine and Public Health & Health Professions, University of Florida, Gainesville, FL. ; Department of Biostatistics, Colleges of Medicine and Public Health & Health Professions, University of Florida, Gainesville, FL.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1198,JCO,2020,Oncology,"Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study",https://doi.org/10.1200/jco.20.00793,https://cdn.clinicaltrials.gov/large-docs/78/NCT03066778/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/78/NCT03066778/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT03066778,32468956,Ph3 | quadruple | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,,,,,None,,
-1199,JCO,2020,Oncology,Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial,https://doi.org/10.1200/jco.20.00775,https://cdn.clinicaltrials.gov/large-docs/94/NCT02614794/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/94/NCT02614794/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT02614794,32468955,Ph2 | quadruple | treatment,Seagen Inc.,Industry,,?,Y,,,,,None,,
-1200,JCO,2020,Oncology,"ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia",https://doi.org/10.1200/jco.19.03355,https://cdn.clinicaltrials.gov/large-docs/18/NCT02970318/Prot_002.pdf,https://cdn.clinicaltrials.gov/large-docs/18/NCT02970318/SAP_003.pdf,SAP,fixed_parallel_superiority,NCT02970318,32459600,Ph3 | single | treatment,Acerta Pharma BV,Industry,,?,Y,,,,,None,,
-1201,JCO,2020,Oncology,Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer,https://doi.org/10.1200/jco.19.03158,https://cdn.clinicaltrials.gov/large-docs/43/NCT02366143/Prot_001.pdf,https://cdn.clinicaltrials.gov/large-docs/43/NCT02366143/SAP_000.pdf,SAP,fixed_parallel_superiority,NCT02366143,32459597,Ph3 | treatment,Hoffmann-La Roche,Industry,,?,Y,,,,,None,,
-1202,JCO,2020,Oncology,Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer,https://doi.org/10.1200/jco.19.03091,https://cdn.clinicaltrials.gov/large-docs/21/NCT02500121/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/21/NCT02500121/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02500121,32271672,Ph2 | quadruple | treatment,Matthew Galsky,Academic/Other,Hoosier Cancer Research Network; Merck Sharp & Dohme LLC,?,Y,Qianqian Zhao ; Menggang Yu,Biostatistics (per PubMed affiliation),"Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI. ; Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1203,JCO,2020,Oncology,Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer,https://doi.org/10.1200/jco.19.03136,https://cdn.clinicaltrials.gov/large-docs/80/NCT02578680/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/80/NCT02578680/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02578680,32150489,Ph3 | quadruple | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,Jing Yang,Principle Statistician,Merck,https://rocketreach.co/jing-yang-email_2943960,High,Web-search,Jing Yang is listed as a Principle Statistician at Merck on RocketReach and LinkedIn snippets.
-1204,JCO,2020,Oncology,Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia,https://doi.org/10.1200/jco.19.02250,https://cdn.clinicaltrials.gov/large-docs/13/NCT00923013/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/13/NCT00923013/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT00923013,32109194,Ph2 | treatment,National Cancer Institute (NCI),NIH,,?,Y,Seth M Steinberg,Biostatistics (per PubMed affiliation),"Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1205,JCO,2020,Oncology,TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline <i>BRCA</i> Carriers With HER2-Negative Breast Cancer (the INFORM trial),https://doi.org/10.1200/jco.19.03292,https://cdn.clinicaltrials.gov/large-docs/00/NCT01670500/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/00/NCT01670500/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01670500,32097092,Ph2 | treatment,Beth Israel Deaconess Medical Center,Academic/Other,Dana-Farber Cancer Institute,?,Y,,,,,None,,
-1206,JCO,2020,Oncology,"Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study",https://doi.org/10.1200/jco.19.02446,https://cdn.clinicaltrials.gov/large-docs/57/NCT01905657/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/57/NCT01905657/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01905657,32078391,Ph2/Ph3 | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,,,,,None,,
-1207,JCO,2020,Oncology,Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial,https://doi.org/10.1200/jco.19.02745,https://cdn.clinicaltrials.gov/large-docs/20/NCT02282020/Prot_000.pdf,https://cdn.clinicaltrials.gov/large-docs/20/NCT02282020/SAP_001.pdf,SAP,fixed_parallel_superiority,"NCT00628251, NCT02282020",32073956,Ph3 | treatment,AstraZeneca,Industry,,?,Y,,,,,None,,
-1208,JCO,2020,Oncology,Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001,https://doi.org/10.1200/jco.19.02767,https://cdn.clinicaltrials.gov/large-docs/15/NCT02360215/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/15/NCT02360215/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02360215,32058845,Ph3 | supportive care,NRG Oncology,Academic/Other,National Cancer Institute (NCI),?,Y,Stephanie Pugh ; Snehal Deshmukh,Biostatistics (per PubMed affiliation),"NRG Oncology Statistics and Data Management Center, Philadelphia, PA. ; NRG Oncology Statistics and Data Management Center, Philadelphia, PA.",,High,PubMed-affiliation,Author affiliation explicitly identifies biostatistics/statistics group.
-1209,JCO,2020,Oncology,NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2,https://doi.org/10.1200/jco.19.01455,https://cdn.clinicaltrials.gov/large-docs/77/NCT01275677/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/77/NCT01275677/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01275677,31821109,Ph3 | treatment,National Cancer Institute (NCI),NIH,NRG Oncology,?,Y,,,,,None,,
-1210,JCO,2020,Oncology,Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer,https://doi.org/10.1200/jco.19.01348,https://cdn.clinicaltrials.gov/large-docs/35/NCT02775435/Prot_SAP_001.pdf,https://cdn.clinicaltrials.gov/large-docs/35/NCT02775435/Prot_SAP_001.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02775435,31751163,Ph3 | triple | treatment,Merck Sharp & Dohme LLC,Industry,,?,Y,,,,,None,,
-1211,JCO,2020,Oncology,Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma,https://doi.org/10.1200/jco.19.00172,https://cdn.clinicaltrials.gov/large-docs/67/NCT02257567/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/67/NCT02257567/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT02257567,31693429,Ph1/Ph2 | treatment,Hoffmann-La Roche,Industry,,?,Y,,,,,None,,
-1212,JCO,2020,Oncology,Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma,https://doi.org/10.1200/jco.19.01740,https://cdn.clinicaltrials.gov/large-docs/37/NCT01169337/Prot_SAP_000.pdf,https://cdn.clinicaltrials.gov/large-docs/37/NCT01169337/Prot_SAP_000.pdf,Protocol+SAP,fixed_parallel_superiority,NCT01169337,31652094,Ph3 | treatment,National Cancer Institute (NCI),NIH,,?,Y,,,,,None,,
\ No newline at end of file